{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "initial_id",
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:01.501582Z",
     "start_time": "2024-03-22T05:32:01.468967Z"
    }
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "%matplotlib inline\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "plt.style.use('default')"
   ]
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "              drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n2673  Dactinomycin    FARAGE          GCB -5.584391   -7.048384 -0.962114   \n8706  Dactinomycin   OCILY19     DLBCLNOS -7.705546   -7.004467 -2.088626   \n9844     Daporinad  RPMI8402          TLL -7.312357   -6.966440 -1.417415   \n5607     Dasatinib    LAMA84          CML -8.280412   -6.959291 -4.116759   \n6680   Vinblastine    MOLT16          TLL -6.277419   -6.786866 -1.278285   \n\n      prediction_Z  \n2673     -1.739618  \n8706     -1.716294  \n9844     -1.294112  \n5607     -3.548309  \n6680     -1.512218  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>2673</th>\n      <td>Dactinomycin</td>\n      <td>FARAGE</td>\n      <td>GCB</td>\n      <td>-5.584391</td>\n      <td>-7.048384</td>\n      <td>-0.962114</td>\n      <td>-1.739618</td>\n    </tr>\n    <tr>\n      <th>8706</th>\n      <td>Dactinomycin</td>\n      <td>OCILY19</td>\n      <td>DLBCLNOS</td>\n      <td>-7.705546</td>\n      <td>-7.004467</td>\n      <td>-2.088626</td>\n      <td>-1.716294</td>\n    </tr>\n    <tr>\n      <th>9844</th>\n      <td>Daporinad</td>\n      <td>RPMI8402</td>\n      <td>TLL</td>\n      <td>-7.312357</td>\n      <td>-6.966440</td>\n      <td>-1.417415</td>\n      <td>-1.294112</td>\n    </tr>\n    <tr>\n      <th>5607</th>\n      <td>Dasatinib</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-8.280412</td>\n      <td>-6.959291</td>\n      <td>-4.116759</td>\n      <td>-3.548309</td>\n    </tr>\n    <tr>\n      <th>6680</th>\n      <td>Vinblastine</td>\n      <td>MOLT16</td>\n      <td>TLL</td>\n      <td>-6.277419</td>\n      <td>-6.786866</td>\n      <td>-1.278285</td>\n      <td>-1.512218</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_MixedSet_pre = pd.read_csv('../../data/drug_sensitivity_MixedSet_Erlotinib_test&prediction.csv', index_col=0)\n",
    "df_drug_mean_std = pd.read_csv('../../data/gdsc_drug_mean_std.csv')\n",
    "# 将df_MixedSet_pre和df_drug_mean_std合并，以df_MixedSet_pre的drug，df_drug_mean_std的Drug_Name为键\n",
    "df_MixedSet_pre = pd.merge(df_MixedSet_pre, df_drug_mean_std, left_on='drug', right_on='Drug_Name')\n",
    "# 去掉Drug_Name列\n",
    "df_MixedSet_pre = df_MixedSet_pre.drop(columns=['Drug_Name'])\n",
    "# 分别计算IC50和prediction的Z-score\n",
    "df_MixedSet_pre['IC50_Z'] = (df_MixedSet_pre['IC50'] - df_MixedSet_pre['IC50_mean']) / df_MixedSet_pre['IC50_std']\n",
    "df_MixedSet_pre['prediction_Z'] = (df_MixedSet_pre['prediction'] - df_MixedSet_pre['IC50_mean']) / df_MixedSet_pre['IC50_std']\n",
    "# 去掉IC50_mean, IC50_std列\n",
    "df_MixedSet_pre = df_MixedSet_pre.drop(columns=['IC50_mean', 'IC50_std'])\n",
    "# 按照prediction从小到大排序\n",
    "df_MixedSet_pre = df_MixedSet_pre.sort_values(by='prediction')\n",
    "df_MixedSet_pre.head()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:01.566252Z",
     "start_time": "2024-03-22T05:32:01.502639Z"
    }
   },
   "id": "45b7ea31a593b764",
   "execution_count": 2
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "array(['Dactinomycin', 'Daporinad', 'Dasatinib', 'Vinblastine', 'SN-38',\n       'Docetaxel', 'Rapamycin', 'Romidepsin', 'Sepantronium bromide',\n       'Vinorelbine', 'Nilotinib', 'Vincristine', 'Bortezomib',\n       'Paclitaxel', 'Gemcitabine', 'Temsirolimus', 'Camptothecin',\n       'Bosutinib', 'Trametinib', 'BI-2536', 'Dinaciclib', 'Luminespib',\n       'PD0325901', 'LMP744', 'Staurosporine', 'Elesclomol', 'Teniposide',\n       'Mitoxantrone', 'ABT737', 'Navitoclax', 'Epirubicin',\n       'Methotrexate', 'Dactolisib', 'Selumetinib', 'Venetoclax',\n       'AZD5153', 'AZD5991', 'Lestaurtinib', 'Topotecan', 'Afatinib',\n       'Cytarabine', 'Talazoparib', 'Refametinib', 'Alisertib',\n       'Dabrafenib', 'Dihydrorotenone', 'Pictilisib', 'Tanespimycin',\n       'Pevonedistat', 'Tozasertib', 'Podophyllotoxin bromide',\n       'Sabutoclax', 'AZD7762', 'AZD8055', 'Schweinfurthin A', 'OTX015',\n       'AZD5582', 'Uprosertib', 'Taselisib', 'AZD4547', 'MG-132', 'JQ1',\n       'Foretinib', 'GNE-317', 'Sapitinib', 'MK-1775', 'WEHI-539',\n       'BMS-754807', 'Erlotinib', 'Osimertinib', 'Lapatinib', 'SCH772984',\n       'AZD5363', 'Bleomycin (50 uM)', 'Telomerase Inhibitor IX',\n       'AZD3759', 'Nutlin-3a (-)', 'AZ960', 'Afuresertib', 'MK-2206',\n       'Irinotecan', 'Obatoclax Mesylate', 'Axitinib', 'BMS-536924',\n       'AZD2014', 'YK-4-279', 'Ipatasertib', 'VX-11e', 'POMHEX',\n       'Buparlisib', 'Entinostat', 'Mycophenolic acid', 'Wee1 Inhibitor',\n       'Vorinostat', 'VE-822', 'TW 37', 'Gefitinib', 'AZD6738',\n       'Ulixertinib', 'BX795', 'ZM447439', 'Ibrutinib', 'AZD5438',\n       'SB590885', 'Bromosporine', 'GSK2110183B', 'Ribociclib',\n       'Palbociclib', 'I-BET-762', 'MK-8776', 'Bleomycin', 'Crizotinib',\n       'Piperlongumine', 'PLX-4720', 'Acetalax', '5-azacytidine',\n       'Cisplatin', 'NVP-ADW742', 'OSI-027', 'Alpelisib', 'NU7441',\n       '5-Fluorouracil', 'PD173074', 'Savolitinib', 'PRT062607',\n       'SGC0946', 'GSK269962A', 'Fludarabine', 'Cediranib', 'Serdemetan',\n       'Pyridostatin', 'Sorafenib', 'PRIMA-1MET', 'Niraparib', 'IWP-2',\n       'GSK-LSD1', 'AZD1332', 'AZD6482', 'IOX2', 'Oxaliplatin', 'RO-3306',\n       'VE821', 'AZ6102', 'Elephantin', 'UNC0638', 'AT13148', 'UMI-77',\n       'GSK343', 'BMS-345541', 'Olaparib', 'UNC0379', 'CPI-637', 'P22077',\n       'Rucaparib', 'AMG-319', 'Entospletinib', 'Gallibiscoquinazole',\n       'AZD8186', 'GW441756', 'PCI-34051', 'PFI-1', 'Linsitinib',\n       'Sinularin', 'WZ4003', 'PF-4708671', 'MIM1', 'ICL-SIRT078',\n       'Tamoxifen', 'Fulvestrant', 'I-BRD9', 'KRAS (G12C) Inhibitor-12',\n       'MIRA-1', 'AGK2', 'LCL161', 'RVX-208', 'SB505124', 'Doramapimod',\n       'CCT-018159', 'OF-1', 'LGK974', 'GSK2606414', 'GSK591', 'Mirin',\n       'Zoledronate', 'Wnt-C59', 'GSK2830371', 'Motesanib', 'EHT-1864',\n       'LJI308', 'L-Oxonoreleagnine', 'WIKI4', 'SGC-CBP30', 'Ruxolitinib',\n       'XAV939', 'Avagacestat', 'GSK1904529A', 'AGI-6780', 'KU-55933',\n       'Lenalidomide', 'Bicalutamide', 'Vismodegib', 'ML323', 'EPZ004777',\n       'LY2109761', 'GSK2578215A', 'SB216763', 'Veliparib', 'A-366',\n       'GSK2801', 'Tretinoin', 'Leflunomide', 'CHIR-99021', 'Remodelin',\n       'MN-64', 'AZD1208', 'CCT007093', 'CZC24832', 'SL0101', 'AGI-5198',\n       'JNK Inhibitor VIII', 'BIBR-1532', 'PFI3', 'EPZ5676', 'Nelarabine',\n       'GDC0810', 'Picolinici-acid', 'Temozolomide', 'Cyclophosphamide',\n       'Dacarbazine', 'Carmustine', 'alpha-lipoic acid', 'glutathione',\n       'N-acetyl cysteine'], dtype=object)"
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_MixedSet_pre['drug'].unique()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:01.572581Z",
     "start_time": "2024-03-22T05:32:01.566252Z"
    }
   },
   "id": "a5c58e83e77f59c5",
   "execution_count": 3
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "                       drug cell_line OncotreeCode\n12  Podophyllotoxin bromide     22RV1         PRAD\n7                   GNE-317     22RV1         PRAD\n8                     IWP-2     22RV1         PRAD\n3                Crizotinib     22RV1         PRAD\n14                SCH772984     22RV1         PRAD",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>12</th>\n      <td>Podophyllotoxin bromide</td>\n      <td>22RV1</td>\n      <td>PRAD</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>GNE-317</td>\n      <td>22RV1</td>\n      <td>PRAD</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>IWP-2</td>\n      <td>22RV1</td>\n      <td>PRAD</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Crizotinib</td>\n      <td>22RV1</td>\n      <td>PRAD</td>\n    </tr>\n    <tr>\n      <th>14</th>\n      <td>SCH772984</td>\n      <td>22RV1</td>\n      <td>PRAD</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# 取前列\n",
    "df_MixedSet_pre_3cols = df_MixedSet_pre[['drug', 'cell_line','OncotreeCode']]\n",
    "# 按照cell_line排序\n",
    "df_MixedSet_pre_3cols = df_MixedSet_pre_3cols.sort_values(by='cell_line')\n",
    "df_MixedSet_pre_3cols.head()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:01.587829Z",
     "start_time": "2024-03-22T05:32:01.573605Z"
    }
   },
   "id": "e04d88e8f8e3bdb1",
   "execution_count": 4
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'22RV1': {'Entinostat', 'SB216763', 'Podophyllotoxin bromide', 'Crizotinib', 'BMS-754807', 'GNE-317', 'SCH772984', 'PFI-1', 'YK-4-279', 'VE821', 'WIKI4', 'Daporinad', 'IWP-2', 'AZD5582', 'JNK Inhibitor VIII', 'Cediranib', 'Picolinici-acid', 'Schweinfurthin A', 'Doramapimod'}, '2313287': {'Pyridostatin', 'Pictilisib', 'PD173074', 'BI-2536', 'AGI-6780', 'BMS-345541', 'Olaparib', 'RVX-208', 'KU-55933', 'Foretinib', 'JQ1', 'LGK974', 'MK-1775', 'BMS-754807', 'MIRA-1', 'LY2109761', 'IWP-2', 'Gallibiscoquinazole', 'CZC24832'}, '42MGBA': {'MK-2206', 'EHT-1864', 'Nilotinib', 'AZD1332', 'I-BET-762', 'Talazoparib', 'AZD2014', 'ML323', 'AZD8055', 'MIRA-1', 'Obatoclax Mesylate', 'Mirin', 'UMI-77', 'PRIMA-1MET', 'GSK2110183B', 'OSI-027', 'AZD5153', 'AGI-5198', 'AZD3759'}, '5637': {'L-Oxonoreleagnine', 'Pictilisib', 'Bortezomib', 'SB216763', 'Nelarabine', 'Dacarbazine', 'AZD5991', 'BMS-754807', 'Irinotecan', 'Topotecan', 'LJI308', 'OF-1', 'SN-38', 'Picolinici-acid', 'AZD5153', 'Doramapimod', 'Motesanib', 'AZD6738', 'Ulixertinib'}, '639V': {'AZD5438', 'Paclitaxel', 'AZD5363', 'Pevonedistat', 'Taselisib', 'Rucaparib', 'VX-11e', 'Telomerase Inhibitor IX', 'Serdemetan', 'MN-64', 'EPZ004777', 'MK-8776', 'Sabutoclax', 'Dihydrorotenone', 'IWP-2', 'UMI-77', 'Sinularin', 'Dinaciclib', 'UNC0638'}, '647V': {'Entinostat', 'AZD5363', 'I-BET-762', 'RVX-208', 'Romidepsin', 'Docetaxel', 'ZM447439', 'Luminespib', 'Carmustine', 'Epirubicin', 'PCI-34051', 'Sorafenib', 'ABT737', 'WZ4003', 'Bromosporine', 'Mycophenolic acid', 'Teniposide', 'Palbociclib', 'Dactolisib'}, '697': {'L-Oxonoreleagnine', 'Linsitinib', 'Bortezomib', 'Olaparib', 'Staurosporine', 'Pevonedistat', '5-Fluorouracil', 'AZD2014', 'ML323', 'Carmustine', 'Lenalidomide', 'Fulvestrant', 'PFI-1', 'YK-4-279', 'Selumetinib', 'ABT737', 'Vincristine', 'GW441756', 'Dabrafenib'}, '769P': {'MK-2206', 'AZD5438', 'SB590885', 'AZD5363', 'Foretinib', 'BIBR-1532', 'LGK974', 'Sapitinib', 'Wnt-C59', 'Topotecan', 'EPZ5676', 'POMHEX', 'Erlotinib', 'RO-3306', 'Avagacestat', 'Ipatasertib', 'OSI-027', 'AT13148', 'AZD6738'}, '8305C': {'Cyclophosphamide', 'Bortezomib', 'GDC0810', 'AZD1208', 'BIBR-1532', 'Ruxolitinib', 'Uprosertib', 'AZD5991', 'BMS-754807', 'Elephantin', 'alpha-lipoic acid', 'EPZ5676', 'WEHI-539', 'UMI-77', 'Avagacestat', 'Alisertib', 'Vinorelbine', 'Motesanib', 'PD0325901'}, '8505C': {'I-BRD9', 'Dasatinib', 'NVP-ADW742', 'EHT-1864', 'AZD5363', 'AMG-319', '5-Fluorouracil', 'SGC-CBP30', 'Fludarabine', 'Tamoxifen', 'SCH772984', 'Selumetinib', 'WIKI4', 'AGK2', 'GSK1904529A', 'Teniposide', 'Palbociclib', 'KRAS (G12C) Inhibitor-12', 'Vinorelbine'}, '8MGBA': {'SB590885', 'Taselisib', 'Nelarabine', 'Navitoclax', 'AZD8055', 'Irinotecan', 'Temozolomide', 'Sabutoclax', 'POMHEX', 'Vorinostat', 'Vincristine', 'AZD5582', 'Cediranib', 'OSI-027', 'SGC0946', 'Alisertib', 'Methotrexate', 'AZD6738', 'UNC0638'}, 'A101D': {'PLX-4720', 'BI-2536', 'BMS-345541', 'Olaparib', 'VE-822', 'Methotrexate', 'Fludarabine', 'Wnt-C59', 'AZD5991', 'MIRA-1', 'Trametinib', 'N-acetyl cysteine', 'WEHI-539', 'Mirin', 'Bromosporine', 'GSK1904529A', 'GW441756', 'Picolinici-acid', 'Vismodegib'}, 'A172': {'Pyridostatin', 'Alpelisib', 'AZD1208', 'Taselisib', '5-azacytidine', 'Lenalidomide', 'MIRA-1', 'SCH772984', 'Entospletinib', 'alpha-lipoic acid', 'N-acetyl cysteine', 'PCI-34051', 'PRT062607', 'Erlotinib', 'UMI-77', 'LJI308', 'SGC0946', 'Schweinfurthin A', 'PD0325901'}, 'A204': {'Afatinib', 'AGI-6780', 'Talazoparib', 'AZD4547', 'RVX-208', 'Foretinib', 'Romidepsin', 'LGK974', 'Sapitinib', 'Ribociclib', 'Wnt-C59', 'ML323', 'CPI-637', 'POMHEX', 'AGK2', 'PFI3', 'GSK2110183B', 'OSI-027', 'Ulixertinib'}, 'A2058': {'Remodelin', 'GSK2606414', 'Cyclophosphamide', 'GSK2830371', 'Staurosporine', 'Sapitinib', 'Wnt-C59', 'Luminespib', 'Bosutinib', 'MK-8776', 'AGK2', 'Erlotinib', 'Buparlisib', 'BMS-536924', 'Oxaliplatin', 'Avagacestat', 'GW441756', 'Vismodegib', 'Motesanib'}, 'A253': {'L-Oxonoreleagnine', 'BMS-345541', 'RVX-208', 'Tanespimycin', '5-Fluorouracil', 'LGK974', 'Leflunomide', 'Fludarabine', 'Ribociclib', 'Telomerase Inhibitor IX', 'Bleomycin', 'Savolitinib', 'Topotecan', 'Cisplatin', 'Temozolomide', 'PRIMA-1MET', 'OF-1', 'Lestaurtinib', 'Methotrexate'}, 'A2780': {'Lapatinib', 'Dactinomycin', 'AZD5438', 'SB590885', 'AZ6102', 'VE-822', 'JQ1', 'AZD8186', 'Telomerase Inhibitor IX', 'P22077', 'YK-4-279', 'EPZ5676', 'AZD7762', 'Dihydrorotenone', 'UMI-77', 'GSK2110183B', 'AZD5153', 'AGI-5198', 'Ulixertinib'}, 'A375': {'I-BRD9', 'Pictilisib', 'Linsitinib', 'NVP-ADW742', 'Afatinib', 'AGI-6780', 'AZD1208', 'Fludarabine', 'Dacarbazine', 'Cytarabine', 'Wnt-C59', 'Elephantin', 'EPZ004777', 'PCI-34051', 'IWP-2', 'GSK1904529A', 'Teniposide', 'JNK Inhibitor VIII', 'Palbociclib', 'Dactolisib', 'Ulixertinib'}, 'A388': {'Irinotecan', 'RO-3306', 'Rucaparib', '5-Fluorouracil', 'JNK Inhibitor VIII', 'GW441756', 'Uprosertib', 'Axitinib', 'Ibrutinib', 'SN-38', 'SB590885', 'Wnt-C59', 'Osimertinib', 'GSK269962A', 'Savolitinib', 'BMS-536924'}, 'A3KAW': {'CCT007093', 'A-366', 'Talazoparib', 'Olaparib', 'Ruxolitinib', 'Docetaxel', 'SGC-CBP30', 'AZD5991', 'Trametinib', 'WIKI4', 'AZD7762', 'PCI-34051', 'IWP-2', 'GSK2578215A', 'Ibrutinib', 'Picolinici-acid', 'SGC0946', 'AT13148', 'AZD6738'}, 'A427': {'AZD6482', 'Lapatinib', 'Linsitinib', 'AZD5363', 'Pevonedistat', 'Sapitinib', 'BMS-754807', 'Osimertinib', 'Obatoclax Mesylate', 'Irinotecan', 'WIKI4', 'Gallibiscoquinazole', 'GSK1904529A', 'GSK-LSD1', 'Avagacestat', 'AZD3759', 'SN-38', 'Dabrafenib', 'SL0101'}, 'A431': {'Entinostat', 'GSK2578215A', 'JNK Inhibitor VIII', 'Alpelisib', 'Tamoxifen', 'Daporinad', 'SB590885', 'Crizotinib', 'Gemcitabine', 'Rapamycin', 'AZD6738', 'Camptothecin', 'Osimertinib', 'Savolitinib', 'SCH772984', 'Veliparib'}, 'A498': {'Lapatinib', 'MK-2206', 'GSK2830371', 'Cyclophosphamide', 'Nilotinib', 'BMS-345541', 'Taselisib', 'Methotrexate', 'Cytarabine', 'Carmustine', 'Obatoclax Mesylate', 'Bosutinib', 'Trametinib', 'Cisplatin', 'ABT737', 'Mycophenolic acid', 'KRAS (G12C) Inhibitor-12', 'Gefitinib', 'Doramapimod'}, 'A4FUK': {'Entinostat', 'GSK2830371', 'Acetalax', 'Romidepsin', 'Nelarabine', 'Wee1 Inhibitor', '5-azacytidine', 'AZD5991', 'OTX015', 'Lenalidomide', 'PFI-1', 'Obatoclax Mesylate', 'MN-64', 'Sorafenib', 'ABT737', 'PRT062607', 'NU7441', 'Gefitinib', 'Doramapimod'}, 'A549': {'Remodelin', 'AZD5438', 'Linsitinib', 'GDC0810', 'Olaparib', 'BIBR-1532', 'Ruxolitinib', 'Leflunomide', '5-azacytidine', 'ZM447439', 'OTX015', 'Fulvestrant', 'Bleomycin', 'Savolitinib', 'YK-4-279', 'Niraparib', 'GSK2110183B', 'Cediranib', 'Gemcitabine', 'Doramapimod'}, 'A673': {'Pictilisib', 'Refametinib', 'AZD1332', 'SB216763', 'MK-1775', 'VX-11e', 'AZD5991', 'Luminespib', 'BMS-754807', 'Elephantin', 'EPZ5676', 'Sorafenib', 'LJI308', 'GSK2801', 'Ibrutinib', 'SN-38', 'SGC0946', 'Motesanib', 'Dabrafenib'}, 'A704': {'L-Oxonoreleagnine', 'GSK2830371', 'NVP-ADW742', 'VE-822', 'Taselisib', 'Mitoxantrone', 'Vinblastine', 'Irinotecan', 'Bosutinib', 'EPZ004777', 'LMP744', 'Gallibiscoquinazole', 'PFI3', 'Mycophenolic acid', 'GSK343', 'Palbociclib', 'Dactolisib', 'NU7441', 'Ulixertinib'}, 'ABC1': {'SB216763', 'Camptothecin', 'AMG-319', 'Docetaxel', 'Leflunomide', 'ZM447439', 'AZD5991', 'OTX015', 'Fulvestrant', 'GNE-317', 'Bleomycin', 'Savolitinib', 'LMP744', 'PRT062607', 'Vorinostat', 'GSK1904529A', 'JNK Inhibitor VIII', 'GSK343', 'SN-38'}, 'ACHN': {'GSK2606414', 'MK-2206', 'Refametinib', 'NVP-ADW742', 'AMG-319', 'Zoledronate', 'VE-822', 'AZD8055', 'Osimertinib', 'Entospletinib', 'Epirubicin', 'IWP-2', 'GSK2578215A', 'GSK591', 'Sinularin', 'PRIMA-1MET', 'OF-1', 'OSI-027', 'Doramapimod'}, 'AGS': {'Linsitinib', 'Acetalax', 'JQ1', 'Sapitinib', 'Wee1 Inhibitor', 'Navitoclax', 'Vinblastine', 'Ribociclib', 'Selumetinib', 'WIKI4', 'POMHEX', 'GSK2578215A', 'RO-3306', 'BMS-536924', 'Mycophenolic acid', 'GSK591', 'Sinularin', 'Palbociclib', 'AZD5153'}, 'ALLSIL': {'Pyridostatin', 'L-Oxonoreleagnine', 'GDC0810', 'Venetoclax', 'LCL161', 'Ruxolitinib', 'Docetaxel', 'Uprosertib', 'AZD5991', 'GNE-317', 'CPI-637', 'Sabutoclax', 'Veliparib', 'AZ960', 'AZD5582', 'Cediranib', 'KRAS (G12C) Inhibitor-12', 'SGC0946', 'AZD3759'}, 'AM38': {'Refametinib', 'Dasatinib', 'I-BET-762', 'LCL161', 'KU-55933', 'AMG-319', 'Fludarabine', '5-azacytidine', 'MIRA-1', 'Entospletinib', 'EPZ004777', 'POMHEX', 'ABT737', 'WEHI-539', 'GSK2578215A', 'PRIMA-1MET', 'GSK2110183B', 'Gemcitabine', 'PD0325901'}, 'AMO1': {'YK-4-279', 'CCT007093', 'Elephantin', 'Sinularin', 'Ulixertinib', 'Palbociclib', 'AZD7762', 'Telomerase Inhibitor IX', 'Lestaurtinib', 'LY2109761', 'Serdemetan', 'SB590885', 'Ipatasertib', 'Afuresertib', 'Venetoclax', 'Vinorelbine', 'Dinaciclib', 'AZD3759'}, 'AN3CA': {'Pyridostatin', 'Afatinib', 'Talazoparib', 'KU-55933', 'Staurosporine', 'Taselisib', 'AZD8186', 'Cytarabine', 'ML323', 'SCH772984', 'glutathione', 'Entospletinib', 'N-acetyl cysteine', 'Sorafenib', 'Mycophenolic acid', 'Teniposide', 'Temsirolimus', 'Methotrexate', 'Ulixertinib'}, 'ASH3': {'Pyridostatin', 'Lapatinib', 'Dasatinib', 'Acetalax', 'RVX-208', 'BIBR-1532', 'Navitoclax', '5-azacytidine', 'AZD2014', 'XAV939', 'Dihydrorotenone', 'Vorinostat', 'Veliparib', 'GSK2801', 'Lestaurtinib', 'Dactolisib', 'Picolinici-acid', 'Gefitinib', 'Methotrexate'}, 'ASPC1': {'PD173074', 'Venetoclax', 'Tanespimycin', 'Taselisib', 'SGC-CBP30', 'Cytarabine', 'VX-11e', 'BMS-754807', 'Fulvestrant', 'Osimertinib', 'Bleomycin', 'LY2109761', 'PFI-1', 'Trametinib', 'Epirubicin', 'alpha-lipoic acid', 'PFI3', 'Methotrexate', 'PD0325901'}, 'AU565': {'GSK2606414', 'Alpelisib', 'Bortezomib', 'Acetalax', 'LCL161', 'Wnt-C59', 'CPI-637', 'Dihydrorotenone', 'WZ4003', 'Gallibiscoquinazole', 'Mirin', 'GSK2578215A', 'Bromosporine', 'PRIMA-1MET', 'GSK343', 'GSK2801', 'Dactolisib', 'NU7441', 'Alisertib', 'Ulixertinib'}, 'BCPAP': {'CCT007093', 'L-Oxonoreleagnine', 'Afatinib', 'AZD5363', 'SB216763', 'AZD8186', 'Rucaparib', 'UNC0638', 'Wee1 Inhibitor', 'Carmustine', 'MN-64', 'AGK2', 'Dihydrorotenone', 'Rapamycin', 'Niraparib', 'Teniposide', 'Ipatasertib', 'Dinaciclib', 'AGI-5198'}, 'BECKER': {'Refametinib', 'Dasatinib', 'NVP-ADW742', 'SB590885', 'SB216763', 'Zoledronate', 'JQ1', 'Ruxolitinib', 'Leflunomide', 'Navitoclax', 'AZD2014', 'Nutlin-3a (-)', 'Fulvestrant', 'PFI-1', 'Cisplatin', 'ABT737', 'IWP-2', 'GSK2578215A', 'UNC0379'}, 'BEN': {'GSK2606414', 'Entinostat', 'Selumetinib', 'Tozasertib', 'Lapatinib', 'Trametinib', 'GSK2578215A', 'Motesanib', 'Pictilisib', 'Nilotinib', 'Picolinici-acid', 'Afuresertib', 'Vismodegib', 'Osimertinib', 'SCH772984', 'Pevonedistat'}, 'BFTC905': {'GSK2606414', 'Linsitinib', 'EHT-1864', 'Venetoclax', 'Zoledronate', 'Tanespimycin', 'JQ1', 'AZD8186', 'LGK974', 'Wee1 Inhibitor', 'BMS-754807', 'Topotecan', 'Temozolomide', 'TW 37', 'Veliparib', 'PFI3', 'GSK2801', 'Cediranib', 'NU7441'}, 'BFTC909': {'EHT-1864', 'I-BET-762', 'AZD5363', 'Sapitinib', 'Vinblastine', 'Fulvestrant', 'glutathione', 'CPI-637', 'EPZ004777', 'VE821', 'Epirubicin', 'CZC24832', 'Erlotinib', 'GSK2578215A', 'Cediranib', 'SGC0946', 'NU7441', 'Doramapimod', 'AZD6738'}, 'BHT101': {'EHT-1864', 'Nilotinib', 'Foretinib', 'Pevonedistat', 'Zoledronate', 'Ruxolitinib', 'Uprosertib', 'Ribociclib', 'P22077', 'MN-64', 'Selumetinib', 'CPI-637', 'RO-3306', 'Buparlisib', 'OF-1', 'Ipatasertib', 'SGC0946', 'Vinorelbine', 'PD0325901'}, 'BHY': {'YK-4-279', 'Olaparib', 'SB505124', 'Rucaparib', 'Lestaurtinib', 'ZM447439', 'Wnt-C59', 'Afuresertib', 'MK-8776', 'AZ6102', 'ABT737', 'Gefitinib', 'Nutlin-3a (-)', 'Vismodegib', 'Motesanib', 'Dinaciclib'}, 'BICR22': {'Pyridostatin', 'L-Oxonoreleagnine', 'Refametinib', 'Afatinib', 'AZD5363', 'Wee1 Inhibitor', 'Telomerase Inhibitor IX', 'Tamoxifen', 'MN-64', 'Selumetinib', 'alpha-lipoic acid', 'AZD7762', 'AGK2', 'Erlotinib', 'Mycophenolic acid', 'UMI-77', 'Bleomycin (50 uM)', 'KRAS (G12C) Inhibitor-12', 'Vismodegib'}, 'BICR31': {'GSK1904529A', 'EPZ004777', 'Bicalutamide', 'Ruxolitinib', 'Refametinib', 'Sapitinib', 'BX795', 'Sorafenib', 'Afatinib', 'AGK2', 'IWP-2', 'BMS-345541', 'SB216763', 'Erlotinib', 'RO-3306', 'BMS-536924'}, 'BICR78': {'CCT007093', 'LCL161', 'BIBR-1532', 'VX-11e', 'MIRA-1', 'LY2109761', 'Elephantin', 'CPI-637', 'EPZ004777', 'Temozolomide', 'AZD7762', 'Oxaliplatin', 'PRIMA-1MET', 'OF-1', 'Cediranib', 'Gemcitabine', 'KRAS (G12C) Inhibitor-12', 'Doramapimod', 'AGI-5198'}, 'BL41': {'Pyridostatin', 'I-BET-762', 'Talazoparib', 'Zoledronate', 'Taselisib', 'Uprosertib', 'Mitoxantrone', 'AZD8055', 'ICL-SIRT078', 'Irinotecan', 'Selumetinib', 'AGK2', 'Erlotinib', 'GW441756', 'Doramapimod', 'KRAS (G12C) Inhibitor-12', 'SGC0946', 'Vismodegib', 'PD0325901'}, 'BPH1': {'GSK2606414', 'I-BRD9', 'Dasatinib', 'PD173074', 'AZD1332', 'AZD8186', 'Tamoxifen', 'AZD2014', 'MIRA-1', 'Topotecan', 'WIKI4', 'AZD7762', 'Vorinostat', 'Temsirolimus', 'GSK2801', 'Ibrutinib', 'KRAS (G12C) Inhibitor-12', 'Schweinfurthin A', 'AZD3759'}, 'BT20': {'CCT007093', 'A-366', 'Cyclophosphamide', 'Bortezomib', 'EHT-1864', 'SB590885', 'AZD1332', '5-Fluorouracil', 'Uprosertib', 'Wee1 Inhibitor', '5-azacytidine', 'Bleomycin', 'XAV939', 'Bosutinib', 'AZD7762', 'MK-8776', 'PRT062607', 'Vorinostat', 'AZ960', 'SN-38'}, 'BT474': {'CCT007093', 'Lapatinib', 'Pictilisib', 'BIBR-1532', 'LGK974', 'Fludarabine', 'Axitinib', 'Nutlin-3a (-)', 'Lenalidomide', 'Carmustine', 'Elephantin', 'PCI-34051', 'Mirin', 'Bromosporine', 'GSK1904529A', 'Palbociclib', 'Ibrutinib', 'SN-38', 'Picolinici-acid', 'Methotrexate'}, 'BT483': {'Entinostat', 'VE821', 'Temsirolimus', 'MK-1775', 'Dactinomycin', 'Cyclophosphamide', 'P22077', 'Bortezomib', 'ZM447439', 'AZD5363', 'BMS-754807', 'Osimertinib', 'AT13148'}, 'BT549': {'BI-2536', 'AZD1208', 'KU-55933', 'Nelarabine', 'Mitoxantrone', 'Tamoxifen', 'AZD5991', 'Afuresertib', 'Bosutinib', 'CPI-637', 'Trametinib', 'Topotecan', 'Veliparib', 'BMS-536924', 'JNK Inhibitor VIII', 'GSK2801', 'KRAS (G12C) Inhibitor-12', 'PF-4708671', 'Vinorelbine', 'AZD3759'}, 'BV173': {'Tanespimycin', 'Taselisib', 'Lapatinib', 'Alpelisib', 'Axitinib', 'EHT-1864', 'MG-132', 'AZD1208', 'NU7441', 'Afuresertib', 'BMS-754807', 'Vinorelbine', 'UNC0379', 'AMG-319', 'BMS-536924'}, 'BXPC3': {'Lapatinib', 'L-Oxonoreleagnine', 'SB590885', 'Acetalax', 'Talazoparib', 'SB216763', 'AZD8186', 'Wee1 Inhibitor', 'Crizotinib', 'SCH772984', 'Obatoclax Mesylate', 'PFI-1', 'MK-8776', 'Dihydrorotenone', 'GSK591', 'Avagacestat', 'GSK2110183B', 'AZD5153', 'PD0325901'}, 'C2BBE1': {'GDC0810', 'AMG-319', '5-Fluorouracil', 'MK-1775', 'P22077', 'BMS-754807', 'XAV939', 'Topotecan', 'alpha-lipoic acid', 'N-acetyl cysteine', 'Gallibiscoquinazole', 'GSK1904529A', 'Mycophenolic acid', 'Teniposide', 'NU7441', 'Dabrafenib', 'AZD5153', 'UNC0638', 'Ulixertinib'}, 'C32': {'Alpelisib', 'SB590885', 'AZ6102', 'Tozasertib', 'Tanespimycin', 'MIM1', 'Axitinib', 'Carmustine', 'Osimertinib', 'GNE-317', 'GSK269962A', 'Trametinib', 'EPZ004777', 'POMHEX', 'AGK2', 'Dihydrorotenone', 'WEHI-539', 'Vorinostat', 'Erlotinib', 'OF-1', 'Cediranib'}, 'C33A': {'Refametinib', 'AZD5438', 'Camptothecin', 'RVX-208', 'AMG-319', 'Tanespimycin', 'MIM1', 'VX-11e', 'Epirubicin', 'Sabutoclax', 'RO-3306', 'Niraparib', 'JNK Inhibitor VIII', 'Palbociclib', 'Dactolisib', 'Schweinfurthin A', 'Methotrexate', 'PD0325901', 'Dabrafenib'}, 'C4I': {'Entinostat', 'BI-2536', 'SB590885', 'I-BET-762', 'Uprosertib', 'MK-1775', 'Wee1 Inhibitor', 'Navitoclax', 'Podophyllotoxin bromide', 'Wnt-C59', 'Osimertinib', 'Obatoclax Mesylate', 'EPZ5676', 'AZD7762', 'Sorafenib', 'ABT737', 'CZC24832', 'Avagacestat', 'NU7441'}, 'CA46': {'Remodelin', 'L-Oxonoreleagnine', 'Linsitinib', 'NVP-ADW742', 'Afatinib', 'AZD1332', 'Zoledronate', 'MIM1', 'Dacarbazine', 'Navitoclax', 'ML323', 'BMS-754807', 'Trametinib', 'Dihydrorotenone', 'GSK2110183B', 'Lestaurtinib', 'NU7441', 'Vinorelbine', 'Dinaciclib'}, 'CA922': {'Lapatinib', 'Pictilisib', 'AZD5438', 'BI-2536', 'AZD1208', 'Taselisib', 'BIBR-1532', 'Fludarabine', 'VX-11e', 'OTX015', 'ICL-SIRT078', 'Entospletinib', 'PRT062607', 'Buparlisib', 'Mycophenolic acid', 'Teniposide', 'SN-38', 'Motesanib', 'UNC0638'}, 'CADOES1': {'Dactinomycin', 'Afatinib', 'Romidepsin', 'Taselisib', 'Serdemetan', 'AZD5991', 'MN-64', 'Elephantin', 'Selumetinib', 'Entospletinib', 'Temozolomide', 'LMP744', 'Vorinostat', 'Temsirolimus', 'Lestaurtinib', 'OSI-027', 'SGC0946', 'AZD6738', 'AGI-5198'}, 'CAKI1': {'GSK1904529A', 'Entinostat', 'AZ960', 'AZD8186', 'CHIR-99021', 'WIKI4', 'Ribociclib', 'Tamoxifen', 'SN-38', 'Crizotinib', 'WEHI-539', 'Venetoclax', 'KU-55933', 'Rapamycin', 'AMG-319', 'Ulixertinib'}, 'CAL120': {'CCT007093', 'AZD6482', 'L-Oxonoreleagnine', 'MK-2206', 'Paclitaxel', 'AZ6102', 'Ruxolitinib', 'Docetaxel', 'P22077', 'BMS-754807', 'Fulvestrant', 'GSK269962A', 'Elephantin', 'PCI-34051', 'CZC24832', 'Veliparib', 'GW441756', 'Ibrutinib', 'Dactolisib', 'SGC0946'}, 'CAL12T': {'Entinostat', 'Oxaliplatin', 'AZD8186', 'BX795', 'Linsitinib', 'OF-1', 'NVP-ADW742', 'EHT-1864', 'SB590885', 'ABT737', 'Gefitinib', 'CZC24832', 'Lenalidomide', 'Methotrexate', 'Osimertinib', 'GSK2578215A'}, 'CAL148': {'GSK1904529A', 'Lapatinib', '5-Fluorouracil', 'Alpelisib', 'Navitoclax', 'Crizotinib', 'Gefitinib', 'PF-4708671', 'Camptothecin', 'MIRA-1', 'Savolitinib', 'UNC0379', 'UNC0638', 'AZD3759'}, 'CAL27': {'I-BRD9', 'NVP-ADW742', 'Tanespimycin', 'JQ1', 'MK-1775', 'ZM447439', 'AZD5991', 'AZD8055', 'BMS-754807', 'N-acetyl cysteine', 'ABT737', 'WZ4003', 'RO-3306', 'GSK1904529A', 'GSK591', 'Picolinici-acid', 'Alisertib', 'Schweinfurthin A', 'Dabrafenib'}, 'CAL29': {'Lapatinib', 'Linsitinib', 'Cyclophosphamide', 'Olaparib', 'Leflunomide', 'Podophyllotoxin bromide', 'Wnt-C59', 'AZD5991', 'AZD8055', 'XAV939', 'SCH772984', 'alpha-lipoic acid', 'EPZ5676', 'LMP744', 'Oxaliplatin', 'GSK591', 'Bleomycin (50 uM)', 'Lestaurtinib', 'MG-132'}, 'CAL33': {'AZD5438', 'PD173074', 'Paclitaxel', 'I-BET-762', 'Foretinib', 'AMG-319', 'Leflunomide', 'Sapitinib', 'Uprosertib', 'Nutlin-3a (-)', 'Lenalidomide', 'PFI-1', 'CPI-637', 'Epirubicin', 'Rapamycin', 'GSK2801', 'Cediranib', 'AZD5153', 'Ulixertinib'}, 'CAL51': {'AZD6482', 'Cyclophosphamide', 'Talazoparib', 'VE-822', 'Sapitinib', 'Navitoclax', 'VX-11e', 'Podophyllotoxin bromide', 'P22077', 'OTX015', 'MN-64', 'EPZ5676', 'POMHEX', 'ABT737', 'WEHI-539', 'GSK-LSD1', 'PRIMA-1MET', 'Palbociclib', 'Gemcitabine', 'AGI-5198'}, 'CAL54': {'L-Oxonoreleagnine', 'Cyclophosphamide', 'Nilotinib', 'Telomerase Inhibitor IX', 'Podophyllotoxin bromide', 'AZD5991', 'GNE-317', 'EPZ5676', 'N-acetyl cysteine', 'AZD7762', 'LMP744', 'Rapamycin', 'CZC24832', 'AZD5582', 'GSK2801', 'OF-1', 'Lestaurtinib', 'SGC0946', 'Motesanib'}, 'CAL62': {'CCT007093', 'MK-2206', 'A-366', 'EHT-1864', 'Afatinib', 'Tanespimycin', 'JQ1', 'MIM1', 'LGK974', 'Leflunomide', 'Tamoxifen', 'BMS-754807', 'Entospletinib', 'AZD7762', 'ABT737', 'IWP-2', 'Erlotinib', 'Veliparib', 'Vinorelbine'}, 'CAL72': {'GSK2606414', 'Pictilisib', 'PLX-4720', 'EHT-1864', 'GDC0810', 'Talazoparib', 'Pevonedistat', 'Dacarbazine', 'Axitinib', 'Tamoxifen', 'ML323', 'XAV939', 'glutathione', 'LMP744', 'Niraparib', 'SN-38', 'Gemcitabine', 'KRAS (G12C) Inhibitor-12', 'Methotrexate'}, 'CAL78': {'L-Oxonoreleagnine', 'Linsitinib', 'GDC0810', 'KU-55933', 'MK-1775', 'Uprosertib', 'Axitinib', 'ZM447439', 'Luminespib', 'Afuresertib', 'Fulvestrant', 'PRT062607', 'WEHI-539', 'CZC24832', 'Avagacestat', 'GW441756', 'Picolinici-acid', 'NU7441', 'AGI-5198'}, 'CAL851': {'CCT007093', 'Pyridostatin', 'Lapatinib', 'L-Oxonoreleagnine', 'SB590885', 'AZD1208', 'VE-822', 'Romidepsin', 'Tamoxifen', 'AZD5991', 'Afuresertib', 'BMS-754807', 'YK-4-279', 'TW 37', 'Mirin', 'Buparlisib', 'Veliparib', 'Oxaliplatin', 'Niraparib', 'Dactolisib'}, 'CALU3': {'GSK2606414', 'MK-2206', 'Alpelisib', 'Refametinib', 'Nilotinib', 'Talazoparib', 'MIM1', 'SGC-CBP30', 'Dacarbazine', 'Vinblastine', 'AZD5991', 'Osimertinib', 'MIRA-1', 'YK-4-279', 'WZ4003', 'Gallibiscoquinazole', 'RO-3306', 'SN-38', 'Gemcitabine'}, 'CALU6': {'Pictilisib', 'GSK2830371', 'Bortezomib', 'PLX-4720', 'BI-2536', 'BMS-345541', 'RVX-208', 'Foretinib', 'BIBR-1532', 'Leflunomide', 'LGK974', 'Axitinib', 'Tamoxifen', 'Trametinib', 'Sabutoclax', 'IWP-2', 'Vorinostat', 'Gefitinib', 'Dinaciclib'}, 'CAMA1': {'CCT007093', 'I-BRD9', 'Dactinomycin', 'Linsitinib', 'GDC0810', 'KU-55933', 'RVX-208', 'Tozasertib', 'JQ1', 'Fludarabine', 'Wee1 Inhibitor', 'MIRA-1', 'Obatoclax Mesylate', 'Sepantronium bromide', 'Temozolomide', 'AZD5582', 'PRIMA-1MET', 'Methotrexate', 'PD0325901', 'AZD6738'}, 'CAOV3': {'MN-64', 'Irinotecan', 'Oxaliplatin', 'Taselisib', 'MK-2206', 'PRIMA-1MET', 'Sorafenib', 'Osimertinib', 'Serdemetan', 'Wnt-C59', 'SB590885', 'ZM447439', 'Lenalidomide', 'LCL161', 'Erlotinib', 'Staurosporine'}, 'CAOV4': {'CCT007093', 'CPI-637', 'GSK591', 'Sepantronium bromide', 'Epirubicin', 'Temozolomide', 'Linsitinib', 'Uprosertib', 'Camptothecin', 'Bortezomib', 'Serdemetan', 'Ipatasertib', 'Doramapimod', 'Staurosporine'}, 'CAPAN1': {'GSK2606414', 'NVP-ADW742', 'GDC0810', 'Acetalax', 'Venetoclax', 'Romidepsin', 'JQ1', 'LGK974', 'Axitinib', 'ZM447439', 'Luminespib', 'Nutlin-3a (-)', 'XAV939', 'SCH772984', 'Dihydrorotenone', 'AZ960', 'Lestaurtinib', 'AGI-5198', 'AZD3759'}, 'CAPAN2': {'GSK591', 'Romidepsin', 'Niraparib', 'Lapatinib', 'Dacarbazine', 'OF-1', 'Axitinib', 'Telomerase Inhibitor IX', 'Talazoparib', 'Daporinad', 'Afatinib', 'ML323', 'Dactolisib', 'ABT737', 'Schweinfurthin A', 'MIRA-1', 'Savolitinib', 'Buparlisib'}, 'CAS1': {'Foretinib', 'Sapitinib', 'AZD8055', 'Nutlin-3a (-)', 'ICL-SIRT078', 'PFI-1', 'Elephantin', 'Cisplatin', 'alpha-lipoic acid', 'Temozolomide', 'IWP-2', 'PRT062607', 'WZ4003', 'Vorinostat', 'GSK1904529A', 'Mycophenolic acid', 'Doramapimod', 'AT13148', 'AZD3759'}, 'CASKI': {'A-366', 'GSK2830371', 'Pevonedistat', 'Docetaxel', 'Cytarabine', 'glutathione', 'Irinotecan', 'PCI-34051', 'CZC24832', 'AZ960', 'GSK591', 'PRIMA-1MET', 'JNK Inhibitor VIII', 'GSK2801', 'Ipatasertib', 'SN-38', 'OSI-027', 'Picolinici-acid', 'Dinaciclib'}, 'CCK81': {'AZD5438', 'Dactinomycin', 'PD173074', 'Afatinib', 'AGI-6780', 'LCL161', 'VE-822', 'JQ1', 'Cytarabine', 'Lenalidomide', 'SCH772984', 'MN-64', 'Selumetinib', 'EPZ5676', 'LMP744', 'TW 37', 'Avagacestat', 'Temsirolimus', 'Cediranib', 'SN-38'}, 'CFPAC1': {'GSK2606414', 'AZD5438', 'Bortezomib', 'AZD1208', 'SB216763', 'Camptothecin', 'BIBR-1532', '5-Fluorouracil', 'Osimertinib', 'Savolitinib', 'PFI-1', 'CPI-637', 'WIKI4', 'Temozolomide', 'WEHI-539', 'GSK2578215A', 'GSK2801', 'Vismodegib', 'AGI-5198'}, 'CHAGOK1': {'I-BRD9', 'JQ1', 'SB505124', 'Leflunomide', 'Avagacestat', 'Epirubicin', 'GSK343', 'Wee1 Inhibitor', 'Ribociclib', 'Sabutoclax', 'OTX015', 'Rapamycin', 'Olaparib', 'Motesanib', 'SCH772984', 'BMS-536924'}, 'CHP126': {'Tanespimycin', 'Taselisib', 'Alpelisib', 'BMS-536924', 'Temsirolimus', 'Cyclophosphamide', 'PCI-34051', 'NVP-ADW742', 'OF-1', 'Lestaurtinib', 'SN-38', 'PFI3', 'Afuresertib', 'KU-55933', 'AT13148', 'SL0101'}, 'CHP134': {'Mycophenolic acid', 'Entinostat', 'AZD5582', 'MK-1775', 'Dacarbazine', 'Tamoxifen', 'Vinblastine', 'Telomerase Inhibitor IX', 'Wnt-C59', 'Bromosporine', 'BMS-345541', 'PD0325901', 'Venetoclax', 'AT13148', 'GSK2578215A', 'Dabrafenib'}, 'CHP212': {'Entinostat', 'I-BRD9', 'Pyridostatin', 'Pictilisib', 'PLX-4720', 'AZD5363', 'AZ6102', 'Olaparib', 'RVX-208', 'Nelarabine', 'MK-1775', 'Axitinib', 'Cytarabine', 'Ribociclib', 'ML323', 'Carmustine', 'Topotecan', 'POMHEX', 'JNK Inhibitor VIII'}, 'CL11': {'Entinostat', 'PLX-4720', 'AGI-6780', 'SB216763', 'KU-55933', 'RVX-208', 'Nelarabine', 'SB505124', 'Navitoclax', 'alpha-lipoic acid', 'Temozolomide', 'Vorinostat', 'Oxaliplatin', 'Mycophenolic acid', 'Vincristine', 'Cediranib', 'Lestaurtinib', 'Doramapimod', 'AGI-5198'}, 'CMLT1': {'Entinostat', 'AZD5438', 'SB590885', 'JQ1', 'BIBR-1532', '5-Fluorouracil', 'MK-1775', 'Mitoxantrone', 'Wnt-C59', 'Sepantronium bromide', 'Vorinostat', 'Veliparib', 'RO-3306', 'PFI3', 'GW441756', 'SN-38', 'Ipatasertib', 'Dactolisib', 'OSI-027'}, 'COLO668': {'Afatinib', 'BI-2536', 'JQ1', 'SGC-CBP30', 'Uprosertib', 'Ribociclib', 'AZD2014', 'AZD8055', 'Afuresertib', 'XAV939', 'SCH772984', 'YK-4-279', 'Topotecan', 'PFI3', 'Palbociclib', 'Gemcitabine', 'Picolinici-acid', 'SGC0946', 'AZD5153'}, 'COLO678': {'Pyridostatin', 'GDC0810', 'AZD5363', 'RVX-208', 'Pevonedistat', 'Leflunomide', 'Tamoxifen', 'AZD2014', 'Serdemetan', 'AZD5991', 'Selumetinib', 'CPI-637', 'Topotecan', 'PRT062607', 'GSK-LSD1', 'GSK2801', 'OF-1', 'Palbociclib', 'SGC0946'}, 'COLO679': {'AZD1332', 'Paclitaxel', 'Talazoparib', 'LCL161', 'Leflunomide', 'LGK974', 'Tamoxifen', 'Telomerase Inhibitor IX', 'ML323', 'Crizotinib', 'Carmustine', 'Savolitinib', 'PFI-1', 'CPI-637', 'VE821', 'WEHI-539', 'Mirin', 'UMI-77', 'Cediranib'}, 'COLO680N': {'Entinostat', 'MK-2206', 'Refametinib', 'Bortezomib', 'PD173074', 'AZD4547', 'Zoledronate', 'Axitinib', 'Podophyllotoxin bromide', 'Serdemetan', 'Luminespib', 'Lenalidomide', 'VE821', 'MK-8776', 'WEHI-539', 'Mycophenolic acid', 'JNK Inhibitor VIII', 'Palbociclib', 'Ibrutinib'}, 'COLO684': {'Lapatinib', 'PLX-4720', 'PD173074', 'AZD1208', 'Leflunomide', 'Mitoxantrone', 'Wee1 Inhibitor', 'Vinblastine', 'Lenalidomide', 'GSK2578215A', 'RO-3306', 'GSK-LSD1', 'UMI-77', 'GW441756', 'OSI-027', 'AZD5153', 'Doramapimod', 'AT13148', 'AZD6738'}, 'COLO783': {'GSK591', 'Sepantronium bromide', 'Epirubicin', 'WEHI-539', 'Axitinib', 'PCI-34051', 'Osimertinib', 'SB590885', 'Gemcitabine', 'Nilotinib', 'Piperlongumine', 'AZ6102', 'BI-2536', 'RVX-208', 'Pevonedistat', 'PFI3'}, 'COLO792': {'Entinostat', 'MK-2206', 'Dactinomycin', 'LCL161', 'JQ1', 'Vinblastine', 'Podophyllotoxin bromide', 'Luminespib', 'MIRA-1', 'CPI-637', 'Trametinib', 'Temozolomide', 'Erlotinib', 'Bromosporine', 'GSK591', 'Sinularin', 'Vincristine', 'MG-132', 'Gemcitabine'}, 'COLO800': {'Tretinoin', 'AZD5582', 'Sapitinib', 'Linsitinib', 'Tamoxifen', 'Afatinib', 'BI-2536', 'OTX015', 'AGI-6780', 'SB590885', 'AZ6102', 'MG-132', 'Venetoclax', 'PD0325901', 'GSK2578215A', 'AZD3759'}, 'COLO824': {'Paclitaxel', 'AZD1208', 'MIM1', 'Docetaxel', 'Sapitinib', 'BMS-754807', 'MIRA-1', 'Bleomycin', 'Savolitinib', 'Obatoclax Mesylate', 'CPI-637', 'Topotecan', 'Sabutoclax', 'IWP-2', 'Gallibiscoquinazole', 'Veliparib', 'OF-1', 'NU7441', 'Dinaciclib', 'UNC0638'}, 'COLO829': {'Lapatinib', 'MK-2206', 'Refametinib', 'Linsitinib', 'PD173074', 'BI-2536', 'RVX-208', 'Romidepsin', 'SGC-CBP30', 'Vinblastine', 'Telomerase Inhibitor IX', 'Osimertinib', 'AZD7762', 'Sabutoclax', 'AGK2', 'ABT737', 'Erlotinib', 'Cediranib', 'SGC0946'}, 'CORL105': {'CCT007093', 'NVP-ADW742', 'EHT-1864', 'Venetoclax', 'Staurosporine', 'Ruxolitinib', 'Uprosertib', 'Telomerase Inhibitor IX', 'Crizotinib', 'Afuresertib', 'Osimertinib', 'Entospletinib', 'Epirubicin', 'PRIMA-1MET', 'GSK2110183B', 'Cediranib', 'Picolinici-acid', 'UNC0638', 'AZD3759'}, 'CORL23': {'Paclitaxel', 'VE-822', 'Nelarabine', 'MIM1', 'SGC-CBP30', 'Docetaxel', 'VX-11e', 'Wnt-C59', 'Bleomycin', 'Bosutinib', 'Sorafenib', 'Vinorelbine', 'BMS-536924', 'Niraparib', 'SN-38', 'SGC0946', 'Doramapimod', 'AZD6738', 'AGI-5198'}, 'CORL279': {'Selumetinib', 'Trametinib', 'VE821', 'Cisplatin', 'Avagacestat', 'Obatoclax Mesylate', 'MK-1775', 'BIBR-1532', 'Bortezomib', 'POMHEX', 'Crizotinib', 'Alisertib', 'UNC0379', 'glutathione'}, 'CORL311': {'Cyclophosphamide', 'Bortezomib', 'BI-2536', 'Acetalax', 'AZ6102', 'Staurosporine', 'Ruxolitinib', 'LY2109761', 'Topotecan', 'EPZ5676', 'PRT062607', 'Bromosporine', 'Sinularin', 'Avagacestat', 'GW441756', 'Bleomycin (50 uM)', 'AT13148', 'AZD6738', 'Ulixertinib'}, 'CORL88': {'AZD8186', 'LGK974', 'EPZ5676', 'Ribociclib', 'Cediranib', 'ZM447439', 'Crizotinib', 'AZD8055', 'Talazoparib', 'Nutlin-3a (-)', 'ICL-SIRT078', 'Doramapimod', 'Vorinostat', 'Buparlisib'}, 'CORL95': {'Mycophenolic acid', 'Selumetinib', 'Trametinib', 'alpha-lipoic acid', 'Refametinib', 'AZD8055', 'Rapamycin', 'AZD3759'}, 'CW2': {'AZD5438', 'AZD5363', 'Camptothecin', 'Foretinib', 'LGK974', 'Podophyllotoxin bromide', 'AZD5991', 'CPI-637', 'Trametinib', 'Topotecan', 'EPZ5676', 'N-acetyl cysteine', 'Bromosporine', 'GSK-LSD1', 'Sinularin', 'LJI308', 'Vincristine', 'OSI-027', 'Dabrafenib', 'AZD3759'}, 'D283MED': {'Lapatinib', 'NVP-ADW742', 'SB590885', 'AZD5363', 'Olaparib', 'LCL161', 'Foretinib', 'Pevonedistat', 'Cytarabine', 'Crizotinib', 'GNE-317', 'Obatoclax Mesylate', 'Entospletinib', 'CZC24832', 'Mycophenolic acid', 'Vincristine', 'Lestaurtinib', 'AZD5153', 'Vinorelbine'}, 'DANG': {'CCT007093', 'Linsitinib', 'Bortezomib', 'Paclitaxel', 'AGI-6780', 'Olaparib', 'SCH772984', 'glutathione', 'Sorafenib', 'ABT737', 'Erlotinib', 'Bromosporine', 'GSK1904529A', 'Mycophenolic acid', 'GSK-LSD1', 'GSK2801', 'OSI-027', 'AZD5153', 'Vismodegib'}, 'DAOY': {'Remodelin', 'I-BRD9', 'Afatinib', 'VE-822', 'Sapitinib', 'Dacarbazine', 'Navitoclax', 'Cytarabine', '5-azacytidine', 'OTX015', 'Savolitinib', 'glutathione', 'Trametinib', 'WIKI4', 'MK-8776', 'MG-132', 'Gemcitabine', 'Picolinici-acid', 'Doramapimod'}, 'DAUDI': {'Bortezomib', 'GDC0810', 'AZD1208', 'Acetalax', 'Romidepsin', 'Cytarabine', 'Crizotinib', 'AZD5991', 'Carmustine', 'Nutlin-3a (-)', 'Obatoclax Mesylate', 'Selumetinib', 'PRT062607', 'Bromosporine', 'GSK1904529A', 'Niraparib', 'GW441756', 'Schweinfurthin A', 'PD0325901'}, 'DB': {'AZD5438', 'GSK2830371', 'Zoledronate', 'Tanespimycin', 'Romidepsin', 'AZD8186', 'BIBR-1532', 'Cytarabine', 'Wee1 Inhibitor', 'Telomerase Inhibitor IX', 'Navitoclax', 'Temozolomide', 'Sorafenib', 'TW 37', 'WZ4003', 'Vorinostat', 'Palbociclib', 'Gefitinib', 'Ulixertinib'}, 'DBTRG05MG': {'Pyridostatin', 'PD173074', 'AZD1208', 'Taselisib', 'JQ1', 'LGK974', 'ML323', 'LY2109761', 'Selumetinib', 'N-acetyl cysteine', 'Temozolomide', 'Vinorelbine', 'AZ960', 'UMI-77', 'GSK343', 'Doramapimod', 'OSI-027', 'Methotrexate', 'AGI-5198'}, 'DEL': {'I-BRD9', 'Pyridostatin', 'Dactinomycin', 'Bortezomib', 'PD173074', 'AZ6102', 'Staurosporine', 'JQ1', 'AZD8186', 'Mitoxantrone', 'Bleomycin', 'EPZ004777', 'alpha-lipoic acid', 'Mirin', 'Veliparib', 'GSK2801', 'SN-38', 'Methotrexate', 'UNC0638'}, 'DETROIT562': {'Refametinib', 'Talazoparib', 'KU-55933', 'AZD8186', 'Rucaparib', 'BIBR-1532', '5-Fluorouracil', '5-azacytidine', 'Nutlin-3a (-)', 'SCH772984', 'Epirubicin', 'Sabutoclax', 'IWP-2', 'PRT062607', 'RO-3306', 'UMI-77', 'Dactolisib', 'KRAS (G12C) Inhibitor-12', 'Motesanib'}, 'DKMG': {'Entinostat', 'Afatinib', 'Uprosertib', 'MK-1775', 'Wee1 Inhibitor', 'AZD2014', 'Crizotinib', 'MIRA-1', 'Savolitinib', 'PFI-1', 'YK-4-279', 'Dihydrorotenone', 'Gallibiscoquinazole', 'Erlotinib', 'RO-3306', 'AZ960', 'Niraparib', 'Vismodegib', 'Ulixertinib'}, 'DMS114': {'Bortezomib', 'AZD5363', 'BMS-345541', 'Pevonedistat', 'Tanespimycin', 'Mitoxantrone', 'Cytarabine', 'Vinblastine', 'ICL-SIRT078', 'Osimertinib', 'Obatoclax Mesylate', 'Irinotecan', 'Epirubicin', 'EPZ5676', 'GSK2578215A', 'RO-3306', 'UMI-77', 'Dactolisib', 'Gefitinib'}, 'DMS273': {'BI-2536', '5-Fluorouracil', 'Cytarabine', 'Podophyllotoxin bromide', 'AZD5991', 'Bleomycin', 'Savolitinib', 'EPZ004777', 'Cisplatin', 'AZD7762', 'IWP-2', 'GSK-LSD1', 'Mycophenolic acid', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'Temsirolimus', 'Schweinfurthin A', 'Motesanib', 'UNC0638'}, 'DMS53': {'Afatinib', 'GDC0810', 'AGI-6780', 'Acetalax', 'KU-55933', 'AZD8186', 'Dacarbazine', 'MIRA-1', 'XAV939', 'CPI-637', 'Cisplatin', 'WEHI-539', 'PD0325901', 'GSK1904529A', 'Mycophenolic acid', 'JNK Inhibitor VIII', 'GSK2110183B', 'GSK2801', 'Dinaciclib'}, 'DMS79': {'MK-2206', 'PD173074', 'Afatinib', 'AMG-319', 'Zoledronate', 'Navitoclax', 'MIRA-1', 'Osimertinib', 'GSK269962A', 'PCI-34051', 'MK-8776', 'PRT062607', 'GSK-LSD1', 'Niraparib', 'Lestaurtinib', 'SN-38', 'Picolinici-acid', 'SGC0946', 'AZD3759'}, 'DND41': {'A-366', 'Refametinib', 'Dactinomycin', 'NVP-ADW742', 'Bortezomib', 'BI-2536', 'AZD5363', 'VX-11e', 'AZD8055', 'ICL-SIRT078', 'Epirubicin', 'N-acetyl cysteine', 'Erlotinib', 'GSK1904529A', 'GSK591', 'Sinularin', 'Bleomycin (50 uM)', 'Schweinfurthin A', 'AT13148'}, 'DOHH2': {'PD173074', 'PLX-4720', 'Olaparib', 'Camptothecin', 'RVX-208', 'Tanespimycin', 'Nelarabine', 'Ribociclib', 'AZD2014', 'Wnt-C59', 'AZD5991', 'EPZ004777', 'LMP744', 'Dihydrorotenone', 'Rapamycin', 'GSK-LSD1', 'AZD5582', 'Cediranib', 'Methotrexate'}, 'DOTC24510': {'I-BRD9', 'Alpelisib', 'AZD1332', 'Acetalax', 'Staurosporine', 'AMG-319', 'SGC-CBP30', 'MN-64', 'Gallibiscoquinazole', 'Vorinostat', 'Bromosporine', 'BMS-536924', 'Oxaliplatin', 'LJI308', 'Cediranib', 'Picolinici-acid', 'Methotrexate', 'Dabrafenib', 'AZD3759'}, 'DU4475': {'L-Oxonoreleagnine', 'Dasatinib', 'AGI-6780', 'I-BET-762', 'SB216763', 'Rucaparib', 'Vinblastine', 'Nutlin-3a (-)', 'ICL-SIRT078', 'EPZ004777', 'WIKI4', 'AZD7762', 'Dihydrorotenone', 'Buparlisib', 'PFI3', 'GSK591', 'Teniposide', 'AZD5153', 'Motesanib', 'AZD6738'}, 'EBC1': {'Remodelin', 'GSK2606414', 'Refametinib', 'Nilotinib', 'Paclitaxel', 'Acetalax', 'Staurosporine', 'AZD8186', 'Axitinib', 'AZD5991', 'BMS-754807', 'Bleomycin', 'Obatoclax Mesylate', 'EPZ5676', 'WZ4003', 'Bromosporine', 'UNC0379', 'GSK591', 'GSK343'}, 'ECC10': {'Entinostat', 'AZD1208', 'RVX-208', 'JQ1', 'LGK974', 'Axitinib', 'ZM447439', 'Serdemetan', 'Osimertinib', 'XAV939', 'Bosutinib', 'Topotecan', 'PCI-34051', 'POMHEX', 'CZC24832', 'Vorinostat', 'Palbociclib', 'Ibrutinib', 'Doramapimod'}, 'ECC12': {'SB216763', 'GSK591', 'AZD8186', 'WIKI4', 'EPZ5676', 'Linsitinib', 'Wee1 Inhibitor', 'Telomerase Inhibitor IX', 'Afuresertib', 'SB590885', 'NU7441', 'SL0101', 'WEHI-539', 'CCT-018159', 'Erlotinib', 'GNE-317', 'BMS-536924'}, 'ECGI10': {'Entinostat', 'Alpelisib', 'AZD4547', 'Olaparib', 'Foretinib', 'AMG-319', 'Navitoclax', 'Bleomycin', 'Obatoclax Mesylate', 'Elephantin', 'Bosutinib', 'Entospletinib', 'Trametinib', 'EPZ004777', 'Rapamycin', 'Erlotinib', 'GW441756', 'Palbociclib', 'Ipatasertib'}, 'EFM19': {'Lapatinib', 'Alpelisib', 'AZD1332', 'AZ6102', 'KU-55933', 'AZD8186', 'Luminespib', 'WIKI4', 'Epirubicin', 'Temozolomide', 'AZD7762', 'GSK2578215A', 'PFI3', 'Niraparib', 'LJI308', 'Bleomycin (50 uM)', 'GSK343', 'GSK2801', 'Lestaurtinib', 'PD0325901'}, 'EFM192A': {'I-BRD9', 'A-366', 'EHT-1864', 'SB216763', 'KU-55933', 'JQ1', 'BIBR-1532', 'Nelarabine', 'LGK974', 'ML323', 'Nutlin-3a (-)', 'Elephantin', 'Entospletinib', 'Dihydrorotenone', 'Mycophenolic acid', 'GSK591', 'Niraparib', 'Gefitinib', 'Vismodegib', 'UNC0638'}, 'EFO21': {'Entinostat', 'A-366', 'Dasatinib', 'AZD5438', 'AZD1332', 'BMS-345541', 'SB216763', 'Zoledronate', 'Luminespib', 'MN-64', 'Irinotecan', 'Bosutinib', 'Entospletinib', 'VE821', 'AGK2', 'GSK-LSD1', 'Mycophenolic acid', 'AZD5153', 'AZD3759'}, 'EFO27': {'Schweinfurthin A', 'Refametinib', 'Bortezomib', 'AZD1332', 'AZ6102', 'LCL161', 'Foretinib', 'P22077', 'LMP744', 'MK-8776', 'GSK1904529A', 'LJI308', 'AZD5582', 'Lestaurtinib', 'MG-132', 'Gemcitabine', 'NU7441', 'Gefitinib', 'PF-4708671'}, 'EJM': {'I-BRD9', 'Pictilisib', 'NVP-ADW742', 'PD173074', 'I-BET-762', 'Ruxolitinib', 'MK-1775', 'Dacarbazine', '5-azacytidine', 'AZD2014', 'AZD8055', 'Lenalidomide', 'Bleomycin', 'Epirubicin', 'POMHEX', 'Sinularin', 'Gemcitabine', 'Alisertib', 'SGC0946'}, 'EKVX': {'CCT007093', 'CHIR-99021', 'EHT-1864', 'Talazoparib', 'SB216763', 'AZD8186', 'Luminespib', 'LY2109761', 'Epirubicin', 'alpha-lipoic acid', 'Dihydrorotenone', 'Erlotinib', 'GSK2578215A', 'GSK343', 'Cediranib', 'MG-132', 'Ipatasertib', 'Alisertib', 'NU7441', 'Ulixertinib'}, 'EM2': {'Alpelisib', 'Nilotinib', 'Acetalax', 'Foretinib', 'Nelarabine', 'UNC0638', 'ML323', 'OTX015', 'AZD8055', 'LY2109761', 'AZD7762', 'Sorafenib', 'Buparlisib', 'Niraparib', 'MG-132', 'Dactolisib', 'Picolinici-acid', 'Vinorelbine', 'AGI-5198'}, 'EN': {'Bortezomib', 'AMG-319', 'BIBR-1532', 'P22077', 'Obatoclax Mesylate', 'Selumetinib', 'Temozolomide', 'Rapamycin', 'RO-3306', 'Sinularin', 'UMI-77', 'Vincristine', 'AZD5582', 'GSK2110183B', 'Picolinici-acid', 'OSI-027', 'Schweinfurthin A', 'AZD6738', 'Dabrafenib'}, 'EPLC272H': {'Pyridostatin', 'I-BET-762', 'AGI-6780', 'LCL161', 'Zoledronate', 'Ribociclib', 'Axitinib', 'Wee1 Inhibitor', 'ML323', 'Osimertinib', 'Obatoclax Mesylate', 'alpha-lipoic acid', 'Temozolomide', 'CZC24832', 'AZ960', 'GSK591', 'SN-38', 'Gemcitabine', 'NU7441'}, 'ES2': {'CCT007093', 'Lapatinib', 'MK-2206', 'Dactinomycin', 'GSK2830371', 'Paclitaxel', 'AMG-319', 'Zoledronate', 'Ribociclib', 'P22077', 'MN-64', 'CPI-637', 'AGK2', 'Gallibiscoquinazole', 'GSK-LSD1', 'Mycophenolic acid', 'Vincristine', 'GSK2801', 'OF-1'}, 'ESO26': {'I-BRD9', 'L-Oxonoreleagnine', 'Refametinib', 'Pictilisib', 'GSK2830371', 'Nilotinib', 'RVX-208', 'Romidepsin', 'Taselisib', 'SGC-CBP30', 'Podophyllotoxin bromide', 'AZD2014', 'Osimertinib', 'Entospletinib', 'WZ4003', 'Mirin', 'GSK591', 'SN-38', 'Motesanib'}, 'ESO51': {'Lapatinib', 'MK-2206', 'SB216763', 'Romidepsin', 'BIBR-1532', 'MK-1775', 'Axitinib', 'VX-11e', 'BMS-754807', 'ICL-SIRT078', 'LY2109761', 'EPZ004777', 'ABT737', 'Avagacestat', 'GW441756', 'GSK343', 'Ibrutinib', 'Methotrexate', 'PD0325901'}, 'ESS1': {'Entinostat', 'Alpelisib', 'Zoledronate', 'Tanespimycin', 'Leflunomide', 'Dacarbazine', 'Navitoclax', 'Wee1 Inhibitor', 'Topotecan', 'EPZ5676', 'PCI-34051', 'Oxaliplatin', 'JNK Inhibitor VIII', 'GSK2110183B', 'Palbociclib', 'Cediranib', 'KRAS (G12C) Inhibitor-12', 'AZD5153', 'AGI-5198'}, 'FADU': {'I-BRD9', 'Linsitinib', 'AZD5363', 'AZ6102', 'Olaparib', 'RVX-208', 'MK-1775', 'Afuresertib', 'BMS-754807', 'Selumetinib', 'WIKI4', 'AZ960', 'LJI308', 'OF-1', 'Ipatasertib', 'Gemcitabine', 'SGC0946', 'Schweinfurthin A', 'Ulixertinib'}, 'FARAGE': {'Dactinomycin', 'AZD1208', 'Staurosporine', 'Pevonedistat', 'Romidepsin', 'Nelarabine', 'LGK974', 'SGC-CBP30', 'Uprosertib', 'Wee1 Inhibitor', 'VX-11e', 'WIKI4', 'Mirin', 'Niraparib', 'Teniposide', 'GSK2801', 'Ibrutinib', 'Gemcitabine', 'OSI-027'}, 'FLO1': {'A-366', 'AZD5438', 'EHT-1864', 'Talazoparib', 'Olaparib', 'Staurosporine', 'Nelarabine', 'MK-1775', 'Ribociclib', 'Axitinib', 'Podophyllotoxin bromide', 'AZD8055', 'ICL-SIRT078', 'Irinotecan', 'WIKI4', 'Mirin', 'LJI308', 'GSK2110183B', 'Alisertib'}, 'FTC133': {'MN-64', 'Selumetinib', 'CPI-637', 'Ribociclib', 'Telomerase Inhibitor IX', 'Afatinib', 'SB590885', 'AZD5991', 'MG-132', 'Luminespib', 'Gefitinib', 'WEHI-539', 'SB216763', 'Ibrutinib', 'MIRA-1', 'BI-2536', 'SGC0946', 'I-BET-762'}, 'FU97': {'Pevonedistat', 'MIM1', 'MK-2206', 'JNK Inhibitor VIII', 'Dactinomycin', 'Wee1 Inhibitor', 'Nutlin-3a (-)', 'SB590885', 'Crizotinib', 'NU7441', 'WEHI-539', 'MIRA-1', 'AZD6738', 'AMG-319'}, 'FUOV1': {'Bosutinib', 'I-BRD9', 'UNC0638', 'EPZ004777', 'A-366', 'VE821', 'MIM1', 'Dasatinib', 'AMG-319', 'TW 37', 'Luminespib', 'Pevonedistat', 'AZD3759'}, 'G292CLONEA141B1': {'EHT-1864', 'Afatinib', 'BMS-345541', 'Olaparib', 'Camptothecin', 'SGC-CBP30', 'Sapitinib', 'Telomerase Inhibitor IX', 'Luminespib', 'SCH772984', 'glutathione', 'EPZ5676', 'ABT737', 'Buparlisib', 'PFI3', 'GSK591', 'Vincristine', 'Alisertib', 'Motesanib'}, 'G361': {'Remodelin', 'AZD5363', 'AZ6102', 'SB216763', 'Methotrexate', 'Gefitinib', 'Leflunomide', 'Uprosertib', 'Vinblastine', 'Crizotinib', 'AZD5991', 'Bosutinib', 'LMP744', 'GW441756', 'Temsirolimus', 'Schweinfurthin A', 'AZD5153', 'Doramapimod', 'Dinaciclib'}, 'G401': {'CCT007093', 'I-BRD9', 'Pyridostatin', 'Cyclophosphamide', 'PD173074', 'GDC0810', 'I-BET-762', 'JQ1', 'Leflunomide', 'AZD2014', 'Fulvestrant', 'SCH772984', 'Bosutinib', 'Sabutoclax', 'AGK2', 'PRT062607', 'Oxaliplatin', 'Sinularin', 'Temsirolimus'}, 'G402': {'Lapatinib', 'Refametinib', 'Afatinib', 'AGI-6780', 'VE-822', 'Uprosertib', 'Axitinib', 'Podophyllotoxin bromide', 'Luminespib', 'SCH772984', 'Savolitinib', 'Obatoclax Mesylate', 'Trametinib', 'Topotecan', 'BMS-536924', 'GSK1904529A', 'GSK591', 'JNK Inhibitor VIII', 'Vinorelbine'}, 'GA10': {'Dactinomycin', 'Zoledronate', 'Romidepsin', 'Podophyllotoxin bromide', 'Telomerase Inhibitor IX', 'AZD8055', 'Fulvestrant', 'Osimertinib', 'Savolitinib', 'YK-4-279', 'MN-64', 'Elephantin', 'Sorafenib', 'WZ4003', 'PRIMA-1MET', 'Ibrutinib', 'Gemcitabine', 'PD0325901', 'AZD3759'}, 'GAMG': {'Entinostat', 'Staurosporine', 'Taselisib', 'BIBR-1532', 'Rucaparib', 'Uprosertib', 'MK-1775', 'Vinblastine', '5-azacytidine', 'Afuresertib', 'BMS-754807', 'glutathione', 'Entospletinib', 'WZ4003', 'Veliparib', 'Mycophenolic acid', 'Lestaurtinib', 'KRAS (G12C) Inhibitor-12', 'NU7441'}, 'GB1': {'Dasatinib', 'PD173074', 'SB590885', 'RVX-208', '5-Fluorouracil', 'Leflunomide', 'Fludarabine', 'Navitoclax', 'Podophyllotoxin bromide', 'ML323', 'OTX015', 'Luminespib', 'Bleomycin', 'N-acetyl cysteine', 'PFI3', 'GSK-LSD1', 'AZD5582', 'MG-132', 'AT13148'}, 'GCT': {'I-BRD9', 'Dasatinib', 'PLX-4720', 'Camptothecin', 'Ribociclib', 'Telomerase Inhibitor IX', 'Nutlin-3a (-)', 'Fulvestrant', 'PFI-1', 'Topotecan', 'AZD7762', 'MK-8776', 'POMHEX', 'Sinularin', 'Avagacestat', 'GSK2110183B', 'Lestaurtinib', 'Dactolisib', 'Ulixertinib'}, 'GDM1': {'Entinostat', 'LCL161', 'RVX-208', 'Ribociclib', 'VX-11e', 'Vinblastine', 'Serdemetan', 'MN-64', 'Selumetinib', 'Entospletinib', 'VE821', 'Topotecan', 'AZD7762', 'Sorafenib', 'ABT737', 'CZC24832', 'AZ960', 'Mycophenolic acid', 'PD0325901'}, 'GI1': {'Alpelisib', 'Linsitinib', 'AZD5438', 'Acetalax', 'Tanespimycin', 'Dacarbazine', 'Navitoclax', 'Afuresertib', 'Epirubicin', 'Sorafenib', 'AGK2', 'CZC24832', 'Vorinostat', 'UNC0379', 'Buparlisib', 'Veliparib', 'JNK Inhibitor VIII', 'Dinaciclib', 'AZD3759'}, 'GIMEN': {'Alpelisib', 'PLX-4720', 'Staurosporine', 'JQ1', 'AZD8186', 'Sapitinib', 'Mitoxantrone', 'Telomerase Inhibitor IX', 'ML323', 'BMS-754807', 'Nutlin-3a (-)', 'LY2109761', 'PFI-1', 'Bosutinib', 'Trametinib', 'RO-3306', 'NU7441', 'KRAS (G12C) Inhibitor-12', 'AZD6738'}, 'GOTO': {'I-BRD9', 'Bortezomib', 'Acetalax', 'SB216763', 'Venetoclax', 'KU-55933', 'BIBR-1532', 'Docetaxel', 'Fludarabine', 'Wee1 Inhibitor', 'P22077', 'Crizotinib', 'Lenalidomide', 'Bleomycin', 'AGK2', 'Avagacestat', 'AZD5582', 'Palbociclib', 'OSI-027'}, 'GP5D': {'CCT007093', 'Nilotinib', 'AMG-319', 'Romidepsin', 'Uprosertib', 'Fludarabine', 'Carmustine', 'Bleomycin', 'XAV939', 'WIKI4', 'Sabutoclax', 'UNC0379', 'Veliparib', 'Avagacestat', 'Bleomycin (50 uM)', 'GSK2801', 'OF-1', 'Ibrutinib', 'Dinaciclib'}, 'GRANTA519': {'EHT-1864', 'Afatinib', 'I-BET-762', 'Pevonedistat', 'VE-822', '5-Fluorouracil', 'LGK974', 'VX-11e', 'P22077', 'Vinblastine', 'ML323', 'Osimertinib', 'Sepantronium bromide', 'Sabutoclax', 'Vorinostat', 'RO-3306', 'AZD5582', 'SGC0946', 'Gefitinib'}, 'H4': {'BMS-345541', 'Olaparib', 'Pevonedistat', 'Ruxolitinib', 'Docetaxel', 'LGK974', 'Axitinib', 'P22077', 'Telomerase Inhibitor IX', '5-azacytidine', 'AZD8055', 'ICL-SIRT078', 'Elephantin', 'EPZ004777', 'GSK2801', 'Lestaurtinib', 'Ibrutinib', 'MG-132', 'Dinaciclib'}, 'HARA': {'MK-2206', 'NVP-ADW742', 'PD173074', 'Afatinib', 'BI-2536', 'GDC0810', 'Olaparib', 'RVX-208', 'ML323', 'Crizotinib', 'MIRA-1', 'XAV939', 'CPI-637', 'Daporinad', 'Gallibiscoquinazole', 'Cediranib', 'Ibrutinib', 'Dactolisib', 'Dinaciclib'}, 'HCC1143': {'A-366', 'AGI-6780', 'LCL161', 'SGC-CBP30', 'Vinblastine', 'OTX015', 'XAV939', 'EPZ004777', 'Epirubicin', 'Sorafenib', 'POMHEX', 'Gallibiscoquinazole', 'Mirin', 'AZD5582', 'Vincristine', 'Lestaurtinib', 'SN-38', 'AZD5153', 'Doramapimod', 'AGI-5198'}, 'HCC1187': {'A-366', 'Pictilisib', 'Afatinib', 'AZD4547', 'Camptothecin', 'Pevonedistat', 'Zoledronate', 'AZD8186', 'Rucaparib', 'AZD2014', 'Carmustine', 'Lenalidomide', 'Fulvestrant', 'XAV939', 'Entospletinib', 'Temozolomide', 'PRT062607', 'Erlotinib', 'Mirin', 'Bromosporine'}, 'HCC1395': {'JQ1', '5-Fluorouracil', 'MK-2206', 'Pictilisib', 'Sapitinib', 'MIRA-1', 'Osimertinib', 'Afatinib', 'Crizotinib', 'WEHI-539', 'PF-4708671', 'Doramapimod', 'Erlotinib', 'GSK269962A'}, 'HCC1419': {'Dasatinib', 'Tozasertib', 'VE-822', 'Navitoclax', 'P22077', 'AZD2014', 'Crizotinib', 'Luminespib', 'ICL-SIRT078', 'Fulvestrant', 'MN-64', 'Selumetinib', 'Cisplatin', 'IWP-2', 'WEHI-539', 'SN-38', 'PF-4708671', 'AZD6738', 'Dabrafenib'}, 'HCC1428': {'Bortezomib', 'GDC0810', 'AZD1332', 'Docetaxel', 'Cytarabine', 'P22077', 'ZM447439', 'Wnt-C59', 'AZD8055', 'Lenalidomide', 'Osimertinib', 'GNE-317', 'XAV939', 'Bosutinib', 'Epirubicin', 'PRT062607', 'GSK343', 'Dactolisib', 'OSI-027', 'PF-4708671'}, 'HCC15': {'Lapatinib', 'Cyclophosphamide', 'PLX-4720', 'Acetalax', 'Romidepsin', 'JQ1', 'Fludarabine', 'Uprosertib', 'Mitoxantrone', 'Podophyllotoxin bromide', 'Telomerase Inhibitor IX', 'MIRA-1', 'Osimertinib', 'CPI-637', 'ABT737', 'Erlotinib', 'GSK591', 'AZD5582', 'Motesanib'}, 'HCC1500': {'Bortezomib', 'EHT-1864', 'RVX-208', 'SGC-CBP30', 'Sapitinib', 'Podophyllotoxin bromide', 'Cisplatin', 'Epirubicin', 'PCI-34051', 'IWP-2', 'WZ4003', 'Buparlisib', 'Bleomycin (50 uM)', 'GSK2801', 'Cediranib', 'Lestaurtinib', 'Ibrutinib', 'Alisertib', 'PD0325901'}, 'HCC1569': {'Vismodegib', 'Entinostat', 'L-Oxonoreleagnine', 'Paclitaxel', 'Foretinib', 'Docetaxel', 'Uprosertib', 'Navitoclax', 'Elesclomol', 'Irinotecan', 'Sepantronium bromide', 'Cisplatin', 'Rapamycin', 'CZC24832', 'Bromosporine', 'GSK1904529A', 'Bicalutamide', 'SN-38', 'Doramapimod'}, 'HCC1599': {'Tanespimycin', 'VE-822', 'MK-2206', 'Uprosertib', 'PCI-34051', 'Telomerase Inhibitor IX', 'Sorafenib', 'OTX015', 'AGI-6780', 'IWP-2', 'AZ6102', 'Fulvestrant', 'GSK269962A', 'AZD6738', 'Dabrafenib', 'Ulixertinib'}, 'HCC1806': {'Alpelisib', 'GDC0810', 'Nelarabine', 'Rucaparib', 'BIBR-1532', 'LGK974', 'Dacarbazine', 'VX-11e', 'Tamoxifen', 'Vinblastine', 'SCH772984', 'Savolitinib', 'Elephantin', 'Cisplatin', 'Mirin', 'Veliparib', 'RO-3306', 'Cediranib', 'Vismodegib', 'AZD3759'}, 'HCC1937': {'Dactinomycin', 'NVP-ADW742', '5-Fluorouracil', 'Docetaxel', 'Tamoxifen', 'AZD2014', 'XAV939', 'EPZ004777', 'AZD7762', 'MK-8776', 'PRT062607', 'WZ4003', 'RO-3306', 'PFI3', 'AZD5582', 'JNK Inhibitor VIII', 'GW441756', 'GSK2110183B', 'Lestaurtinib', 'Ibrutinib'}, 'HCC1954': {'Pyridostatin', 'Cyclophosphamide', 'AZD1208', 'SB216763', 'RVX-208', 'Foretinib', 'VE-822', 'Rucaparib', 'LGK974', 'Navitoclax', '5-azacytidine', 'Cisplatin', 'Rapamycin', 'Bromosporine', 'Mycophenolic acid', 'Niraparib', 'UMI-77', 'Avagacestat', 'Bleomycin (50 uM)', 'OSI-027'}, 'HCC202': {'MK-2206', 'Vorinostat'}, 'HCC2157': {'YK-4-279', 'GSK2606414', 'LJI308', 'Topotecan', 'PRIMA-1MET', 'Nelarabine', 'Uprosertib', 'GSK2801', 'Cytarabine', 'Axitinib', 'Tamoxifen', 'MK-8776', 'Navitoclax', 'Serdemetan', 'Podophyllotoxin bromide', 'AZD4547', 'GNE-317', 'Buparlisib'}, 'HCC2218': {'Selumetinib', 'GSK591', 'Tretinoin', 'BIBR-1532', 'Cisplatin', 'JNK Inhibitor VIII', 'Nutlin-3a (-)', 'P22077', 'Sorafenib', 'AZ6102', 'Nilotinib', 'BMS-345541', 'Rapamycin', 'Vorinostat', 'Mirin', 'GSK269962A'}, 'HCC33': {'Entinostat', 'AZD8186', 'EPZ004777', 'Pyridostatin', 'Linsitinib', 'AZD7762', 'Ribociclib', 'Axitinib', 'P22077', 'Buparlisib', 'PD173074', 'Nilotinib', 'Paclitaxel', 'Crizotinib', 'Camptothecin', 'Pevonedistat'}, 'HCC366': {'I-BRD9', 'Bortezomib', 'BI-2536', 'Paclitaxel', 'Venetoclax', 'AZD4547', 'Romidepsin', 'Navitoclax', 'ZM447439', 'Epirubicin', 'EPZ5676', 'ABT737', 'GSK591', 'Sinularin', 'Niraparib', 'Vincristine', 'JNK Inhibitor VIII', 'Vismodegib', 'SL0101'}, 'HCC38': {'A-366', 'AZD5438', 'EHT-1864', 'GDC0810', 'AMG-319', 'BIBR-1532', 'MK-1775', 'Ribociclib', 'Tamoxifen', 'ZM447439', 'Irinotecan', 'AZD7762', 'LMP744', 'Daporinad', 'Dihydrorotenone', 'WEHI-539', 'GSK2110183B', 'Cediranib', 'Ipatasertib', 'Doramapimod'}, 'HCC44': {'I-BRD9', 'AZ6102', 'Olaparib', 'Pevonedistat', 'AZD2014', 'Serdemetan', 'AZD5991', 'Afuresertib', 'Savolitinib', 'LY2109761', 'EPZ5676', 'PCI-34051', 'PFI3', 'Vincristine', 'MG-132', 'SN-38', 'AZD5153', 'Doramapimod', 'AZD6738'}, 'HCC70': {'GSK2830371', 'Paclitaxel', 'AZD5363', 'AZD1208', 'BMS-345541', 'Olaparib', 'MK-1775', 'Wee1 Inhibitor', 'Tamoxifen', 'Carmustine', 'PFI-1', 'Entospletinib', 'Topotecan', 'POMHEX', 'Dihydrorotenone', 'Erlotinib', 'BMS-536924', 'GSK343', 'AZD5153', 'Doramapimod'}, 'HCC78': {'AGI-6780', 'Olaparib', 'BIBR-1532', 'Docetaxel', 'Dacarbazine', '5-azacytidine', 'Tamoxifen', 'GNE-317', 'LY2109761', 'MN-64', 'Sepantronium bromide', 'N-acetyl cysteine', 'Sabutoclax', 'Rapamycin', 'Mirin', 'SN-38', 'SGC0946', 'Methotrexate', 'Ulixertinib'}, 'HCC827': {'GSK2606414', 'Pyridostatin', 'Refametinib', 'Bortezomib', 'PD173074', 'Leflunomide', 'Docetaxel', 'Vinblastine', 'ML323', 'glutathione', 'Temozolomide', 'MK-8776', 'Erlotinib', 'Oxaliplatin', 'Sinularin', 'AZD5582', 'GW441756', 'GSK2110183B', 'Palbociclib', 'PD0325901'}, 'HCT116': {'GSK2830371', 'AZD1332', 'BMS-345541', 'VE-822', 'Sapitinib', 'Uprosertib', '5-azacytidine', 'P22077', 'Topotecan', 'EPZ004777', 'IWP-2', 'WZ4003', 'Rapamycin', 'BMS-536924', 'GSK1904529A', 'UMI-77', 'Lestaurtinib', 'Ibrutinib', 'Ipatasertib', 'AGI-5198'}, 'HCT15': {'GSK2606414', 'A-366', 'AZ6102', 'Olaparib', 'Rucaparib', '5-Fluorouracil', 'SGC-CBP30', 'Leflunomide', 'VX-11e', 'Tamoxifen', 'Temozolomide', 'PCI-34051', 'Buparlisib', 'MG-132', 'KRAS (G12C) Inhibitor-12', 'Vinorelbine', 'Motesanib', 'Dinaciclib', 'UNC0638', 'Ulixertinib'}, 'HDLM2': {'AZD5438', 'GDC0810', 'Staurosporine', 'Pevonedistat', 'AMG-319', 'Romidepsin', 'JQ1', 'ML323', 'GNE-317', 'LY2109761', 'Topotecan', 'Daporinad', 'Dihydrorotenone', 'IWP-2', 'Veliparib', 'Temsirolimus', 'GSK343', 'Gefitinib', 'Vinorelbine'}, 'HDQP1': {'Pictilisib', 'Dasatinib', 'I-BET-762', 'Talazoparib', 'KU-55933', 'Foretinib', 'Pevonedistat', 'Rucaparib', '5-Fluorouracil', 'Cytarabine', 'OTX015', 'Afuresertib', 'Sepantronium bromide', 'WIKI4', 'EPZ5676', 'Niraparib', 'LJI308', 'PRIMA-1MET', 'GW441756', 'AT13148'}, 'HEC1': {'Entinostat', 'Refametinib', 'Dasatinib', 'BI-2536', 'Acetalax', 'Pevonedistat', 'VE-822', 'Nelarabine', 'Navitoclax', 'Tamoxifen', 'ML323', 'GNE-317', 'XAV939', 'Topotecan', 'Sepantronium bromide', 'N-acetyl cysteine', 'Avagacestat', 'LJI308', 'Dabrafenib'}, 'HEL': {'GSK2606414', 'I-BRD9', 'Talazoparib', 'Rucaparib', 'Docetaxel', 'Podophyllotoxin bromide', 'ZM447439', 'BMS-754807', 'Obatoclax Mesylate', 'MN-64', 'EPZ004777', 'ABT737', 'WZ4003', 'BMS-536924', 'GSK-LSD1', 'OF-1', 'Ibrutinib', 'AZD6738', 'Dabrafenib'}, 'HELA': {'A-366', 'NVP-ADW742', 'AZD5991', 'Luminespib', 'PFI-1', 'Bosutinib', 'CPI-637', 'WIKI4', 'Temozolomide', 'POMHEX', 'Gallibiscoquinazole', 'Mirin', 'UNC0379', 'AZ960', 'OF-1', 'Picolinici-acid', 'SGC0946', 'Motesanib', 'Dabrafenib'}, 'HEMCSS': {'Entinostat', 'GSK2830371', 'SB590885', 'Romidepsin', 'BIBR-1532', 'OTX015', 'Bleomycin', 'Irinotecan', 'Bosutinib', 'Trametinib', 'Dihydrorotenone', 'WEHI-539', 'Erlotinib', 'GSK1904529A', 'GSK591', 'PRIMA-1MET', 'Palbociclib', 'Lestaurtinib', 'AZD3759'}, 'HEP3B217': {'AZD6482', 'Camptothecin', 'Tozasertib', 'Uprosertib', 'Sapitinib', 'AT13148', 'Tamoxifen', 'Telomerase Inhibitor IX', 'AZD5991', 'Osimertinib', 'WZ4003', 'PRT062607', 'PD0325901', 'Erlotinib', 'AZD5582', 'NU7441', 'Doramapimod', 'Dinaciclib', 'AGI-5198'}, 'HGC27': {'GSK2606414', 'Lapatinib', 'MK-2206', 'L-Oxonoreleagnine', 'Pictilisib', 'Dasatinib', 'Nilotinib', 'I-BET-762', 'Staurosporine', 'Pevonedistat', 'Zoledronate', 'Bosutinib', 'Entospletinib', 'Trametinib', 'Erlotinib', 'AZ960', 'Vincristine', 'Dactolisib', 'Vinorelbine'}, 'HH': {'CCT007093', 'Lapatinib', 'Linsitinib', 'Dasatinib', 'EHT-1864', 'Nilotinib', 'Docetaxel', 'Wnt-C59', 'ML323', 'Osimertinib', 'Cisplatin', 'WZ4003', 'Sinularin', 'Vincristine', 'Teniposide', 'OF-1', 'MG-132', 'Ipatasertib', 'KRAS (G12C) Inhibitor-12'}, 'HL60': {'Remodelin', 'AZ6102', 'KU-55933', 'Pevonedistat', 'Zoledronate', 'Tanespimycin', 'Ruxolitinib', 'Sapitinib', 'Telomerase Inhibitor IX', 'ML323', 'BMS-754807', 'Savolitinib', 'Topotecan', 'Gallibiscoquinazole', 'GSK591', 'OF-1', 'OSI-027', 'SGC0946', 'Vinorelbine'}, 'HMVII': {'BMS-345541', 'Venetoclax', 'AMG-319', 'MIM1', 'SGC-CBP30', 'Navitoclax', 'Wnt-C59', 'BMS-754807', 'ICL-SIRT078', 'Osimertinib', 'EPZ004777', 'WEHI-539', 'GSK591', 'GSK2110183B', 'Palbociclib', 'SN-38', 'OSI-027', 'SGC0946', 'UNC0638'}, 'HO1U1': {'JQ1', 'MIM1', 'A-366', 'Docetaxel', 'P22077', 'Afatinib', 'GDC0810', 'ICL-SIRT078', 'SGC0946', 'SB216763', 'KU-55933', 'UNC0379', 'Dabrafenib', 'PFI-1'}, 'HOP62': {'Entinostat', 'Dasatinib', 'AGI-6780', 'I-BET-762', 'Staurosporine', '5-Fluorouracil', 'Cytarabine', 'VX-11e', 'Lenalidomide', 'XAV939', 'WIKI4', 'Bromosporine', 'RO-3306', 'BMS-536924', 'GSK1904529A', 'PRIMA-1MET', 'Temsirolimus', 'OSI-027', 'Gefitinib'}, 'HOP92': {'Entinostat', 'I-BRD9', 'AZD5363', 'Olaparib', 'Pevonedistat', 'Taselisib', 'JQ1', 'Cytarabine', 'Telomerase Inhibitor IX', 'Osimertinib', 'Entospletinib', 'WIKI4', 'Temozolomide', 'Gallibiscoquinazole', 'Bromosporine', 'GSK591', 'SN-38', 'SGC0946', 'Vinorelbine'}, 'HOS': {'GSK2606414', 'A-366', 'Linsitinib', 'PLX-4720', 'I-BET-762', 'Staurosporine', 'Axitinib', 'Telomerase Inhibitor IX', 'AZD2014', 'Obatoclax Mesylate', 'LMP744', 'MK-8776', 'IWP-2', 'WEHI-539', 'Vorinostat', 'Sinularin', 'Teniposide', 'MG-132', 'AZD5153'}, 'HPAC': {'EHT-1864', 'Paclitaxel', 'AZD1208', 'Dinaciclib', 'Romidepsin', 'Ribociclib', '5-azacytidine', 'AZD2014', 'ML323', 'XAV939', 'MN-64', 'IWP-2', 'RO-3306', 'Lestaurtinib', 'Ibrutinib', 'Gemcitabine', 'KRAS (G12C) Inhibitor-12', 'Methotrexate', 'AT13148'}, 'HPAFII': {'VE821', 'Vincristine', 'Dactinomycin', 'Linsitinib', 'Tamoxifen', 'PD173074', 'Daporinad', 'AZD1332', 'OSI-027', 'AZD5363', 'PRT062607', 'AGI-6780', 'IWP-2', 'LCL161', 'Paclitaxel', 'Bromosporine', 'AGI-5198'}, 'HS578T': {'A-366', 'Refametinib', 'Dactinomycin', 'I-BET-762', 'VE-822', 'LGK974', 'Dacarbazine', 'OTX015', 'Afuresertib', 'Entospletinib', 'Epirubicin', 'N-acetyl cysteine', 'LMP744', 'AGK2', 'Niraparib', 'GSK343', 'Lestaurtinib', 'PD0325901', 'UNC0638', 'Ulixertinib'}, 'HS683': {'CCT007093', 'GSK2606414', 'Oxaliplatin', 'GSK591', 'Ruxolitinib', 'Docetaxel', 'Alpelisib', 'PCI-34051', 'Sabutoclax', 'SN-38', 'OSI-027', 'Piperlongumine', 'Nutlin-3a (-)', 'AZD6738', 'Tozasertib', 'Savolitinib'}, 'HS746T': {'Pyridostatin', 'Dactinomycin', 'EHT-1864', 'PLX-4720', 'Taselisib', 'LGK974', 'Sapitinib', 'Axitinib', 'Serdemetan', 'BMS-754807', 'SCH772984', 'Sorafenib', 'POMHEX', 'Gallibiscoquinazole', 'WEHI-539', 'Bromosporine', 'GSK343', 'AZD6738', 'UNC0638'}, 'HS766T': {'Tanespimycin', 'Vorinostat', 'RO-3306', 'Motesanib', 'MIM1', 'AGI-5198', 'Pictilisib', 'Cediranib', 'Tamoxifen', 'Vinblastine', 'Ipatasertib', 'Vismodegib', 'Erlotinib', 'Buparlisib'}, 'HS939T': {'GSK1904529A', 'Tozasertib', 'AZD8186', 'Temozolomide', 'PCI-34051', 'Telomerase Inhibitor IX', 'Sabutoclax', 'Ibrutinib', 'SCH772984', 'Staurosporine', 'AGI-6780', 'NU7441', 'BMS-345541', 'AZD5363', 'Camptothecin', 'AZD6738'}, 'HS940T': {'IOX2', 'AZD6482', 'Taselisib', 'Entinostat', 'Lapatinib', 'MK-2206', 'Rucaparib', 'SB505124', 'BX795', 'Pevonedistat', 'Bortezomib', 'Daporinad', 'Lenalidomide', 'SCH772984', 'RO-3306', 'LY2109761'}, 'HSC2': {'Dactinomycin', 'LCL161', 'Taselisib', 'Vinblastine', '5-azacytidine', 'OTX015', 'AZD5991', 'Nutlin-3a (-)', 'SCH772984', 'Savolitinib', 'YK-4-279', 'WIKI4', 'Sorafenib', 'POMHEX', 'TW 37', 'Dihydrorotenone', 'GSK2578215A', 'Schweinfurthin A', 'AZD3759'}, 'HSC3': {'I-BRD9', 'Dasatinib', 'NVP-ADW742', 'Paclitaxel', 'AMG-319', 'JQ1', 'Ruxolitinib', 'MN-64', 'Irinotecan', 'PCI-34051', 'WZ4003', 'Bromosporine', 'RO-3306', 'Sinularin', 'Avagacestat', 'Vincristine', 'Picolinici-acid', 'Vinorelbine', 'Ulixertinib'}, 'HSC4': {'Remodelin', 'MK-2206', 'Alpelisib', 'Nilotinib', 'AZD4547', 'KU-55933', 'Zoledronate', 'Docetaxel', 'Telomerase Inhibitor IX', 'Podophyllotoxin bromide', 'OTX015', 'MIRA-1', 'Bosutinib', 'Dihydrorotenone', 'PRT062607', 'GSK1904529A', 'Vincristine', 'GSK2801', 'Gemcitabine'}, 'HT': {'VE-822', 'Bosutinib', 'Lapatinib', 'PRIMA-1MET', 'BX795', 'Dasatinib', 'Cyclophosphamide', 'AT13148', 'Talazoparib', 'Ipatasertib', 'Paclitaxel', 'NU7441', 'SGC0946', 'Osimertinib', 'Dinaciclib', 'GSK269962A'}, 'HT1080': {'Dasatinib', 'Linsitinib', 'Talazoparib', 'KU-55933', 'VE-822', 'Nelarabine', 'Leflunomide', 'MIM1', 'Tamoxifen', 'ML323', 'Carmustine', 'Lenalidomide', 'MIRA-1', 'PCI-34051', 'ABT737', 'Veliparib', 'GSK591', 'KRAS (G12C) Inhibitor-12', 'AZD3759'}, 'HT115': {'Refametinib', 'AZD5438', 'Dasatinib', 'I-BET-762', 'Olaparib', 'Wnt-C59', 'Luminespib', 'MIRA-1', 'YK-4-279', 'Sepantronium bromide', 'WIKI4', 'Temozolomide', 'Dihydrorotenone', 'PFI3', 'Palbociclib', 'Cediranib', 'Gemcitabine', 'SGC0946', 'Motesanib'}, 'HT1197': {'CCT007093', 'GSK1904529A', 'AZ960', 'EPZ004777', 'Leflunomide', 'MIM1', 'AZD4547', 'MK-1775', 'Fludarabine', 'Wee1 Inhibitor', 'Sabutoclax', 'OTX015', 'Luminespib', 'Talazoparib', 'Carmustine', 'SB216763', 'Fulvestrant', 'Buparlisib'}, 'HT1376': {'LJI308', 'Ruxolitinib', 'Obatoclax Mesylate', 'Epirubicin', 'Cediranib', 'Buparlisib', 'AMG-319', 'Lestaurtinib', 'MG-132', 'Luminespib', 'WEHI-539', 'Doramapimod', 'Motesanib', 'Savolitinib', 'AZD3759'}, 'HT144': {'CCT007093', 'MK-2206', 'Bortezomib', 'EHT-1864', 'SB590885', 'AZD1208', 'BMS-345541', 'LCL161', 'Romidepsin', 'Docetaxel', 'Ribociclib', 'Wnt-C59', 'Crizotinib', 'BMS-754807', 'ABT737', 'Bromosporine', 'Mycophenolic acid', 'AZD5153', 'Vismodegib'}, 'HT29': {'Lapatinib', 'Alpelisib', 'GSK2830371', 'RVX-208', 'Podophyllotoxin bromide', 'Fulvestrant', 'PFI-1', 'Obatoclax Mesylate', 'Daporinad', 'AGK2', 'IWP-2', 'CZC24832', 'PD0325901', 'PRIMA-1MET', 'OF-1', 'Lestaurtinib', 'SN-38', 'Dactolisib', 'NU7441', 'Dinaciclib', 'UNC0638'}, 'HT3': {'MK-2206', 'JQ1', 'MIM1', 'Podophyllotoxin bromide', 'Tamoxifen', 'ML323', 'GNE-317', 'XAV939', 'YK-4-279', 'Topotecan', 'CZC24832', 'Veliparib', 'GSK-LSD1', 'Niraparib', 'AZD5582', 'GSK343', 'Schweinfurthin A', 'Doramapimod', 'AZD3759'}, 'HT55': {'CCT007093', 'GSK2606414', 'Alpelisib', 'SB216763', 'Methotrexate', 'Leflunomide', 'Podophyllotoxin bromide', 'Telomerase Inhibitor IX', 'Wnt-C59', 'MN-64', 'Elephantin', 'VE821', 'Temozolomide', 'WZ4003', 'BMS-536924', 'Sinularin', 'Vincristine', 'Cediranib', 'Vinorelbine'}, 'HTCC3': {'MK-2206', 'Refametinib', 'Dasatinib', 'GSK2830371', 'PLX-4720', 'Paclitaxel', 'AZD4547', 'JQ1', 'AT13148', 'Podophyllotoxin bromide', 'Bosutinib', 'alpha-lipoic acid', 'MK-8776', 'Buparlisib', 'Sinularin', 'GSK2110183B', 'Gemcitabine', 'Vinorelbine', 'Dinaciclib'}, 'HUCCT1': {'CCT007093', 'Lapatinib', 'Refametinib', 'Nilotinib', 'SB590885', 'AGI-6780', 'Olaparib', 'JQ1', 'MK-1775', 'Dacarbazine', 'Fulvestrant', 'Entospletinib', 'POMHEX', 'UNC0379', 'GSK1904529A', 'Mycophenolic acid', 'Sinularin', 'Avagacestat', 'SN-38'}, 'HUH1': {'Pyridostatin', 'Alpelisib', 'Nilotinib', 'Nelarabine', 'Uprosertib', 'Crizotinib', 'MN-64', 'EPZ5676', 'Temozolomide', 'AGK2', 'Rapamycin', 'PFI3', 'BMS-536924', 'Vincristine', 'Temsirolimus', 'Cediranib', 'Dactolisib', 'OSI-027', 'UNC0638'}, 'HUH7': {'Pictilisib', 'Nilotinib', 'GDC0810', 'AZD5363', 'AZ6102', 'Taselisib', 'Dacarbazine', 'Axitinib', 'Serdemetan', 'Afuresertib', 'BMS-754807', 'ICL-SIRT078', 'MN-64', 'POMHEX', 'Vorinostat', 'BMS-536924', 'Niraparib', 'Vincristine', 'OSI-027'}, 'HUO9': {'MK-2206', 'AGI-5198', 'AZD5438', 'Cyclophosphamide', 'Olaparib', 'RVX-208', 'Leflunomide', 'Dacarbazine', 'Lenalidomide', 'Osimertinib', 'N-acetyl cysteine', 'AZD7762', 'Temozolomide', 'AZD5582', 'Temsirolimus', 'GSK2110183B', 'Ipatasertib', 'Gemcitabine', 'UNC0638'}, 'HUPT3': {'Olaparib', 'Pevonedistat', 'JQ1', 'Serdemetan', 'AZD8055', 'Carmustine', 'Fulvestrant', 'PFI-1', 'Sepantronium bromide', 'WIKI4', 'ABT737', 'Erlotinib', 'Oxaliplatin', 'Mycophenolic acid', 'AZD5582', 'Teniposide', 'GW441756', 'Dinaciclib', 'UNC0638'}, 'HUPT4': {'CCT007093', 'I-BRD9', 'Dasatinib', 'Cyclophosphamide', 'NVP-ADW742', 'Pevonedistat', 'Nelarabine', 'Telomerase Inhibitor IX', 'AZD8055', 'SCH772984', 'Savolitinib', 'Selumetinib', 'Erlotinib', 'Mirin', 'PFI3', 'GSK-LSD1', 'SGC0946', 'AZD6738', 'Dabrafenib'}, 'HUTU80': {'CCT007093', 'Alpelisib', 'Pictilisib', 'Acetalax', 'SB216763', 'AZD8186', 'Docetaxel', 'BX795', 'Sapitinib', 'Ribociclib', 'Elesclomol', 'Afuresertib', 'Temozolomide', 'Erlotinib', 'Mirin', 'Buparlisib', 'GSK1904529A', 'GSK-LSD1', 'AT13148'}, 'IALM': {'Alpelisib', 'Linsitinib', 'PD173074', 'Paclitaxel', 'Cytarabine', 'Vinblastine', 'Tamoxifen', 'P22077', 'Wnt-C59', 'PFI-1', 'VE821', 'Dihydrorotenone', 'GSK591', 'Vincristine', 'Lestaurtinib', 'Ipatasertib', 'Dactolisib', 'SGC0946', 'Vinorelbine'}, 'IGR1': {'I-BRD9', 'Lapatinib', 'NVP-ADW742', 'EHT-1864', 'Acetalax', 'Talazoparib', 'LGK974', 'Serdemetan', 'Carmustine', 'Lenalidomide', 'Sepantronium bromide', 'PCI-34051', 'AGK2', 'WZ4003', 'OF-1', 'SN-38', 'Alisertib', 'SGC0946', 'AT13148'}, 'IGR37': {'Alpelisib', 'Refametinib', 'Linsitinib', 'Pevonedistat', 'VE-822', 'Nelarabine', 'Axitinib', 'Vinblastine', 'AZD2014', 'ZM447439', 'Carmustine', 'Selumetinib', 'CPI-637', 'N-acetyl cysteine', 'GSK-LSD1', 'Bleomycin (50 uM)', 'GSK2801', 'KRAS (G12C) Inhibitor-12', 'Schweinfurthin A'}, 'IGROV1': {'AZD5438', 'BI-2536', 'Foretinib', 'JQ1', 'LGK974', 'MK-1775', 'BMS-754807', 'Selumetinib', 'AZD7762', 'PCI-34051', 'LMP744', 'Vorinostat', 'PFI3', 'Teniposide', 'GSK343', 'SN-38', 'Gemcitabine', 'Motesanib', 'Ulixertinib'}, 'IHH4': {'Entinostat', 'Alpelisib', 'AZD5438', 'AZD5363', 'Acetalax', 'BMS-345541', 'I-BET-762', 'Venetoclax', 'Foretinib', 'Zoledronate', 'Uprosertib', 'ML323', 'AZD8055', 'ICL-SIRT078', 'Bosutinib', 'PRT062607', 'WEHI-539', 'GSK1904529A', 'Picolinici-acid'}, 'IM95': {'Refametinib', 'SB590885', 'AZD1332', 'Nilotinib', 'BMS-345541', 'KU-55933', 'Foretinib', 'BIBR-1532', 'Ribociclib', 'AZD2014', 'MN-64', 'Trametinib', 'IWP-2', 'CZC24832', 'Vorinostat', 'Avagacestat', 'OF-1', 'Ipatasertib', 'Dabrafenib'}, 'IPC298': {'Foretinib', 'Ruxolitinib', 'Docetaxel', 'JNK Inhibitor VIII', 'BMS-536924', 'PFI-1', 'EHT-1864', 'AGK2', 'OSI-027', 'Gemcitabine', 'Gefitinib', 'Nutlin-3a (-)', 'Paclitaxel', 'Mirin', 'Tozasertib', 'PFI3'}, 'ISTMES1': {'CCT007093', 'MK-2206', 'GSK2830371', 'GDC0810', 'AZD1332', 'Camptothecin', 'VE-822', 'Navitoclax', 'P22077', 'WIKI4', 'Temozolomide', 'GSK2578215A', 'Mycophenolic acid', 'PRIMA-1MET', 'Temsirolimus', 'Cediranib', 'Ipatasertib', 'NU7441', 'Gefitinib'}, 'J82': {'CCT007093', 'Lapatinib', 'Dactinomycin', 'BI-2536', 'Nilotinib', 'Tanespimycin', 'Leflunomide', 'Lenalidomide', 'ICL-SIRT078', 'GNE-317', 'Obatoclax Mesylate', 'Elephantin', 'alpha-lipoic acid', 'GSK343', 'Lestaurtinib', 'MG-132', 'SN-38', 'OSI-027', 'AZD6738'}, 'JAR': {'YK-4-279', 'Taselisib', 'Trametinib', 'Pyridostatin', 'AT13148', 'Axitinib', 'P22077', 'Telomerase Inhibitor IX', 'Paclitaxel', 'ABT737', 'SGC0946', 'BMS-754807', 'Methotrexate', 'Foretinib', 'AZD6738', 'AMG-319'}, 'JEG3': {'SB216763', 'AZ960', 'Taselisib', 'LJI308', 'Cyclophosphamide', 'Axitinib', 'Lestaurtinib', 'SB590885', 'AGK2', 'OSI-027', 'Gefitinib', 'Venetoclax', 'Erlotinib', 'Foretinib', 'Buparlisib', 'Ulixertinib'}, 'JEKO1': {'Selumetinib', 'IOX2', 'I-BRD9', 'Trametinib', 'Entospletinib', 'Bicalutamide', 'Ruxolitinib', 'Linsitinib', 'OF-1', 'PLX-4720', 'ZM447439', 'AGK2', 'NU7441', 'BMS-345541', 'Vorinostat', 'XAV939'}, 'JHH1': {'Remodelin', 'GSK2606414', 'Linsitinib', 'Bortezomib', 'Afatinib', 'Talazoparib', 'AZD4547', 'VE-822', 'Taselisib', 'BIBR-1532', 'Rucaparib', 'Dacarbazine', 'Carmustine', 'SCH772984', 'AZ960', 'OF-1', 'SN-38', 'NU7441', 'AZD5153'}, 'JHH2': {'Entinostat', 'Dasatinib', 'PD173074', 'GDC0810', 'Venetoclax', 'VE-822', 'MIM1', 'ZM447439', 'Serdemetan', 'glutathione', 'LY2109761', 'Irinotecan', 'Entospletinib', 'Sepantronium bromide', 'alpha-lipoic acid', 'PCI-34051', 'POMHEX', 'Sinularin', 'Motesanib'}, 'JHH4': {'GSK2606414', 'Talazoparib', 'Foretinib', 'Zoledronate', 'Tanespimycin', 'Romidepsin', 'Rucaparib', 'ZM447439', 'AZD8055', 'Savolitinib', 'Obatoclax Mesylate', 'CPI-637', 'Cisplatin', 'IWP-2', 'Gallibiscoquinazole', 'AZD5582', 'Teniposide', 'PRIMA-1MET', 'Dactolisib'}, 'JHH6': {'PLX-4720', 'AGI-6780', 'Talazoparib', 'Venetoclax', 'JQ1', 'Docetaxel', 'MK-1775', 'VX-11e', 'ZM447439', 'OTX015', 'Carmustine', 'Lenalidomide', 'LY2109761', 'Epirubicin', 'Sorafenib', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'Ibrutinib', 'Alisertib'}, 'JHH7': {'Schweinfurthin A', 'MK-2206', 'NVP-ADW742', 'EHT-1864', 'KU-55933', 'Zoledronate', 'Dacarbazine', 'BMS-754807', 'Fulvestrant', 'Savolitinib', 'Cisplatin', 'alpha-lipoic acid', 'GSK2578215A', 'BMS-536924', 'GSK-LSD1', 'Temsirolimus', 'Ipatasertib', 'SN-38', 'Gefitinib'}, 'JHOS2': {'Tretinoin', 'Taselisib', 'Entospletinib', 'Trametinib', '5-Fluorouracil', 'Sabutoclax', 'Osimertinib', 'Nilotinib', 'ML323', 'OTX015', 'NU7441', 'BMS-754807', 'Vorinostat', 'Tozasertib', 'Buparlisib', 'PFI3'}, 'JHOS4': {'Alpelisib', 'Pictilisib', 'Cyclophosphamide', 'PCI-34051', 'Nutlin-3a (-)', 'Cediranib', 'Navitoclax', 'EHT-1864', 'MG-132', 'Serdemetan', 'AGK2', 'Rapamycin', 'Camptothecin', 'Motesanib', 'Dabrafenib', 'Ulixertinib'}, 'JIMT1': {'I-BRD9', 'L-Oxonoreleagnine', 'Alpelisib', 'Refametinib', 'Cyclophosphamide', 'AGI-6780', 'BMS-345541', 'RVX-208', '5-Fluorouracil', 'Sapitinib', '5-azacytidine', 'AZD5991', 'Savolitinib', 'VE821', 'Epirubicin', 'N-acetyl cysteine', 'WZ4003', 'GSK2578215A', 'Gemcitabine', 'OSI-027'}, 'JJN3': {'I-BRD9', 'AGI-6780', 'BIBR-1532', 'Mitoxantrone', 'Cytarabine', 'ML323', 'Osimertinib', 'GNE-317', 'CPI-637', 'Sorafenib', 'IWP-2', 'Vinorelbine', 'Bleomycin (50 uM)', 'Palbociclib', 'Lestaurtinib', 'Dactolisib', 'Picolinici-acid', 'Alisertib', 'Methotrexate'}, 'JM1': {'Entinostat', 'Tretinoin', 'Alpelisib', 'Pictilisib', 'WEHI-539', 'Palbociclib', 'VX-11e', 'Wnt-C59', 'SL0101', 'Rapamycin', 'Lenalidomide', 'LCL161', 'Motesanib', 'Dinaciclib', 'SCH772984', 'Ulixertinib'}, 'JURKAT': {'I-BRD9', 'NVP-ADW742', 'Nilotinib', 'Romidepsin', 'Podophyllotoxin bromide', 'GNE-317', 'LY2109761', 'Entospletinib', 'Cisplatin', 'CZC24832', 'PRIMA-1MET', 'Doramapimod', 'Cediranib', 'Lestaurtinib', 'MG-132', 'KRAS (G12C) Inhibitor-12', 'Methotrexate', 'AT13148', 'Dabrafenib'}, 'JURLMK1': {'Bosutinib', 'Nelarabine', 'Topotecan', 'Leflunomide', 'Camptothecin', 'PCI-34051', 'Navitoclax', 'Ribociclib', 'AZD2014', 'Ibrutinib', 'Veliparib', 'Olaparib', 'RVX-208', 'Bleomycin', 'UNC0638', 'ICL-SIRT078'}, 'JVM2': {'Pyridostatin', 'Refametinib', 'AZD1332', 'AMG-319', 'AZD8186', 'Ruxolitinib', 'SGC-CBP30', 'ZM447439', 'OTX015', 'BMS-754807', 'LY2109761', 'MN-64', 'EPZ004777', 'Sorafenib', 'ABT737', 'PFI3', 'BMS-536924', 'GSK-LSD1', 'Schweinfurthin A'}, 'JVM3': {'I-BRD9', 'RVX-208', 'Tanespimycin', 'VE-822', 'Dacarbazine', 'OTX015', 'AZD8055', 'Afuresertib', 'ICL-SIRT078', 'Bosutinib', 'alpha-lipoic acid', 'Daporinad', 'TW 37', 'Mirin', 'Oxaliplatin', 'Avagacestat', 'GSK343', 'Dactolisib', 'NU7441'}, 'K562': {'MK-2206', 'Refametinib', 'Cyclophosphamide', 'I-BET-762', 'Acetalax', 'Olaparib', 'RVX-208', 'KU-55933', 'VE-822', 'P22077', 'MIRA-1', 'Bosutinib', 'WIKI4', 'Sabutoclax', 'TW 37', 'Oxaliplatin', 'Mycophenolic acid', 'Dactolisib', 'PD0325901'}, 'KALS1': {'Alpelisib', 'Refametinib', 'NVP-ADW742', 'MIM1', 'LGK974', 'Fludarabine', 'Wee1 Inhibitor', 'Luminespib', 'glutathione', 'YK-4-279', 'N-acetyl cysteine', 'IWP-2', 'Gallibiscoquinazole', 'CZC24832', 'GSK591', 'Sinularin', 'GSK2801', 'Alisertib', 'AT13148'}, 'KARPAS299': {'YK-4-279', 'Romidepsin', 'JQ1', 'BIBR-1532', 'Vincristine', 'Docetaxel', 'Topotecan', 'GSK2110183B', 'PCI-34051', 'Telomerase Inhibitor IX', 'ZM447439', 'Wnt-C59', 'ML323', 'AGI-6780', 'Acetalax', 'SB216763', 'GSK2578215A', 'Zoledronate'}, 'KARPAS422': {'Talazoparib', 'SB216763', 'Camptothecin', 'AZD8186', 'Leflunomide', 'Vinblastine', 'Crizotinib', 'Nutlin-3a (-)', 'XAV939', 'CPI-637', 'PCI-34051', 'IWP-2', 'GSK2578215A', 'Bromosporine', 'GSK591', 'Ibrutinib', 'AZD5153', 'AZD6738', 'UNC0638'}, 'KARPAS620': {'Alpelisib', 'Refametinib', 'GSK2830371', 'GDC0810', 'KU-55933', 'AMG-319', 'Zoledronate', 'Rucaparib', '5-Fluorouracil', 'Vinblastine', 'XAV939', 'Elephantin', 'EPZ5676', 'Vorinostat', 'RO-3306', 'GSK591', 'LJI308', 'Ibrutinib', 'NU7441'}, 'KASUMI1': {'SB590885', 'Olaparib', 'Tozasertib', '5-Fluorouracil', 'BX795', 'Fludarabine', 'OTX015', 'AZD5991', 'PCI-34051', 'Daporinad', 'ABT737', 'Oxaliplatin', 'GSK-LSD1', 'Niraparib', 'Sinularin', 'AZD5582', 'OSI-027', 'Picolinici-acid', 'SL0101'}, 'KATOIII': {'AZD5438', 'AZD4547', 'VE-822', 'AZD8186', 'Nelarabine', 'Dacarbazine', 'Podophyllotoxin bromide', 'Tamoxifen', 'Crizotinib', 'AZD5991', 'Selumetinib', 'Sepantronium bromide', 'Topotecan', 'BMS-536924', 'GW441756', 'Temsirolimus', 'Cediranib', 'AGI-5198', 'Ulixertinib'}, 'KCL22': {'L-Oxonoreleagnine', 'AZD5438', 'GSK2830371', 'Foretinib', 'Pevonedistat', 'Romidepsin', 'Navitoclax', 'GNE-317', 'Topotecan', 'Epirubicin', 'AZD7762', 'LMP744', 'POMHEX', 'Vincristine', 'Temsirolimus', 'Palbociclib', 'GSK2801', 'Doramapimod', 'AZD6738'}, 'KE37': {'Entinostat', 'MK-2206', 'Dactinomycin', 'Afatinib', 'AZ6102', 'Navitoclax', 'Wnt-C59', 'ML323', 'Fulvestrant', 'MIRA-1', 'Irinotecan', 'Cisplatin', 'Bromosporine', 'GSK2578215A', 'Vincristine', 'Cediranib', 'Vismodegib', 'PD0325901', 'AZD3759'}, 'KELLY': {'AZD5438', 'GSK2830371', 'PD173074', 'AZ6102', 'Staurosporine', 'Pevonedistat', 'Tanespimycin', 'Fludarabine', 'Tamoxifen', 'Luminespib', 'SCH772984', 'N-acetyl cysteine', 'Temozolomide', 'Gallibiscoquinazole', 'Rapamycin', 'Erlotinib', 'MG-132', 'Ipatasertib', 'AZD3759'}, 'KG1': {'Cyclophosphamide', 'AZD5363', 'Venetoclax', 'Staurosporine', 'Mitoxantrone', 'Serdemetan', 'Lenalidomide', 'MN-64', 'Epirubicin', 'Sabutoclax', 'Dihydrorotenone', 'PD0325901', 'Vorinostat', 'Buparlisib', 'Niraparib', 'GSK591', 'GSK2801', 'Schweinfurthin A', 'AT13148'}, 'KLE': {'NVP-ADW742', 'Bortezomib', 'Acetalax', 'Staurosporine', 'AMG-319', 'Leflunomide', 'Serdemetan', 'OTX015', 'AZD5991', 'Selumetinib', 'N-acetyl cysteine', 'Dihydrorotenone', 'GSK1904529A', 'Mycophenolic acid', 'AZ960', 'Lestaurtinib', 'Alisertib', 'Methotrexate', 'Dinaciclib'}, 'KM12': {'EHT-1864', 'AZD1332', 'JQ1', 'SGC-CBP30', 'Uprosertib', 'Axitinib', 'VX-11e', '5-azacytidine', 'ML323', 'Lenalidomide', 'Selumetinib', 'Epirubicin', 'GSK1904529A', 'JNK Inhibitor VIII', 'Doramapimod', 'OF-1', 'KRAS (G12C) Inhibitor-12', 'Vinorelbine', 'AZD6738'}, 'KMH2': {'Tretinoin', 'I-BRD9', 'Alpelisib', 'Pictilisib', 'Tozasertib', 'Cytarabine', 'Telomerase Inhibitor IX', 'Serdemetan', 'OTX015', 'CCT-018159', 'BMS-754807', 'glutathione', 'Topotecan', 'Cisplatin', 'POMHEX', 'Rapamycin', 'Vincristine', 'Ibrutinib', 'Dactolisib', 'Gefitinib', 'Dinaciclib'}, 'KMRC1': {'Taselisib', 'EPZ004777', 'Docetaxel', 'GW441756', 'MIM1', 'Refametinib', 'Vinblastine', 'Alisertib', 'AZ6102', 'Nutlin-3a (-)', 'Venetoclax', 'ABT737', 'Staurosporine', 'PFI-1'}, 'KMRC20': {'Remodelin', 'Entinostat', 'Pictilisib', 'GDC0810', 'Venetoclax', 'JQ1', 'Fludarabine', 'Wee1 Inhibitor', 'Entospletinib', 'WIKI4', 'Temozolomide', 'Buparlisib', 'GSK1904529A', 'Avagacestat', 'Vincristine', 'GSK2110183B', 'Dactolisib', 'Gemcitabine', 'AT13148'}, 'KMS11': {'IOX2', 'AZD6482', 'JQ1', 'SB505124', 'Alpelisib', 'LGK974', 'Temsirolimus', 'Refametinib', 'MK-8776', 'ML323', 'BI-2536', 'Piperlongumine', 'Ulixertinib', 'Nutlin-3a (-)', 'Fulvestrant', 'PFI-1'}, 'KMS12BM': {'MK-2206', 'NVP-ADW742', 'Paclitaxel', 'AMG-319', 'Taselisib', 'MIM1', 'AZD2014', 'Crizotinib', 'Lenalidomide', 'ICL-SIRT078', 'SCH772984', 'VE821', 'alpha-lipoic acid', 'Mycophenolic acid', 'GSK2110183B', 'GSK2801', 'SN-38', 'Alisertib', 'Doramapimod'}, 'KNS42': {'AZ960', 'Selumetinib', 'Niraparib', 'LJI308', 'EPZ004777', 'Bicalutamide', 'Oxaliplatin', 'OF-1', 'PF-4708671', 'Bortezomib', 'WEHI-539', 'Lenalidomide', 'Erlotinib', 'Savolitinib', 'Pevonedistat', 'AZD3759'}, 'KNS62': {'GSK2606414', 'Lapatinib', 'PLX-4720', 'GDC0810', 'VE-822', 'Docetaxel', 'Wee1 Inhibitor', 'Serdemetan', 'LY2109761', 'Trametinib', 'VE821', 'LMP744', 'Avagacestat', 'Bleomycin (50 uM)', 'Palbociclib', 'GSK2801', 'AZD5153', 'UNC0638', 'AZD3759'}, 'KON': {'AZ960', 'Oxaliplatin', 'EPZ004777', 'Alpelisib', 'BX795', 'Dactinomycin', 'Cediranib', 'Serdemetan', 'Gemcitabine', 'OTX015', 'IWP-2', 'BMS-345541', 'AZD6738', 'Fulvestrant', 'GSK2578215A', 'BMS-536924'}, 'KOPN8': {'Vismodegib', 'Entinostat', 'Afatinib', 'AZ6102', 'AMG-319', 'Vinblastine', 'LY2109761', 'alpha-lipoic acid', 'AZD7762', 'POMHEX', 'Vincristine', 'GW441756', 'Lestaurtinib', 'Ibrutinib', 'Dactolisib', 'Schweinfurthin A', 'AZD5153', 'Doramapimod', 'UNC0638'}, 'KOSC2': {'VE-822', 'GSK591', 'VE821', 'Sepantronium bromide', '5-Fluorouracil', 'PCI-34051', 'Serdemetan', 'ML323', 'Gemcitabine', 'Nilotinib', 'OTX015', 'GDC0810', 'Vorinostat', 'XAV939', 'Dabrafenib', 'PFI-1'}, 'KP2': {'GSK2606414', 'A-366', 'Nilotinib', 'AZD1208', 'KU-55933', 'Dacarbazine', 'VX-11e', 'Telomerase Inhibitor IX', 'MIRA-1', 'XAV939', 'MN-64', 'WIKI4', 'Dihydrorotenone', 'Erlotinib', 'UNC0379', 'RO-3306', 'Ibrutinib', 'Picolinici-acid', 'UNC0638'}, 'KP3': {'A-366', 'Dasatinib', 'GDC0810', 'Olaparib', 'AZD4547', 'AMG-319', 'Ribociclib', 'Navitoclax', 'Fulvestrant', 'Bleomycin', 'Sepantronium bromide', 'Sorafenib', 'Sabutoclax', 'MK-8776', 'AGK2', 'Teniposide', 'Doramapimod', 'Dabrafenib', 'AZD3759'}, 'KP4': {'PLX-4720', 'I-BET-762', 'Acetalax', 'SB216763', 'AZD8186', 'Ruxolitinib', 'Uprosertib', 'Sapitinib', 'Navitoclax', 'Ribociclib', 'Podophyllotoxin bromide', 'Afuresertib', 'Fulvestrant', 'Epirubicin', 'N-acetyl cysteine', 'MK-8776', 'AGK2', 'BMS-536924', 'KRAS (G12C) Inhibitor-12'}, 'KPNRTBM1': {'YK-4-279', 'Irinotecan', 'AZD6482', 'CHIR-99021', 'Rucaparib', 'Lapatinib', 'Ribociclib', 'Wee1 Inhibitor', 'EHT-1864', 'Staurosporine', 'Daporinad', 'Gemcitabine', 'OSI-027', 'KU-55933', 'GNE-317', 'AZD6738'}, 'KPNYN': {'YK-4-279', 'GSK1904529A', 'Oxaliplatin', 'I-BRD9', 'Pyridostatin', 'Topotecan', 'Bleomycin (50 uM)', 'Refametinib', 'Dactinomycin', 'LMP744', 'EHT-1864', 'ZM447439', 'MG-132', 'AZD1208', 'Foretinib', 'XAV939', 'Dabrafenib', 'Ulixertinib'}, 'KS1': {'Lapatinib', 'Refametinib', 'Bortezomib', 'PLX-4720', 'Zoledronate', 'Selumetinib', 'Topotecan', 'EPZ5676', 'Daporinad', 'PRT062607', 'Gallibiscoquinazole', 'GSK2578215A', 'RO-3306', 'AZ960', 'GSK-LSD1', 'Bleomycin (50 uM)', 'OF-1', 'Dinaciclib', 'Dabrafenib'}, 'KU1919': {'Remodelin', 'Alpelisib', 'Afatinib', 'AZD5363', 'Tanespimycin', '5-azacytidine', 'Luminespib', 'MIRA-1', 'GNE-317', 'SCH772984', 'Savolitinib', 'Sepantronium bromide', 'PCI-34051', 'Bromosporine', 'PFI3', 'AZ960', 'GSK-LSD1', 'MG-132', 'Motesanib'}, 'KU812': {'PD173074', 'Nilotinib', 'Acetalax', 'KU-55933', 'Pevonedistat', 'VE-822', 'JQ1', 'Ruxolitinib', 'SGC-CBP30', 'Navitoclax', 'Serdemetan', 'BMS-754807', 'Sepantronium bromide', 'PCI-34051', 'MK-8776', 'GSK-LSD1', 'UMI-77', 'AT13148', 'AGI-5198'}, 'KURAMOCHI': {'CCT007093', 'Dasatinib', 'AZD1332', 'AZD1208', 'AZD4547', 'LCL161', 'LGK974', 'Dacarbazine', 'Serdemetan', 'Luminespib', 'Fulvestrant', 'Obatoclax Mesylate', 'IWP-2', 'Teniposide', 'MG-132', 'Gemcitabine', 'SGC0946', 'AZD5153', 'Dabrafenib'}, 'KYM1': {'Venetoclax', 'Docetaxel', 'SGC-CBP30', 'MIM1', 'LGK974', 'Podophyllotoxin bromide', 'Serdemetan', 'ICL-SIRT078', 'MIRA-1', 'Elephantin', 'VE821', 'Epirubicin', 'WZ4003', 'UNC0379', 'Vincristine', 'GSK2110183B', 'GSK2801', 'Methotrexate', 'Dabrafenib'}, 'KYSE140': {'Entinostat', 'Pyridostatin', 'PLX-4720', 'BI-2536', 'Venetoclax', 'Olaparib', 'VE-822', 'Leflunomide', 'Wee1 Inhibitor', 'AZD5991', 'Fulvestrant', 'SCH772984', 'LY2109761', 'Temozolomide', 'WEHI-539', 'AZD5582', 'GSK343', 'OF-1', 'Vinorelbine'}, 'KYSE150': {'alpha-lipoic acid', 'AGI-5198', 'GSK2830371', 'Nutlin-3a (-)', 'Sorafenib', 'Ipatasertib', 'Crizotinib', 'NU7441', 'Rapamycin', 'Lenalidomide', 'Vinorelbine', 'Vorinostat', 'PD0325901', 'AMG-319'}, 'KYSE180': {'Afatinib', 'Nilotinib', 'Pevonedistat', 'OTX015', 'Luminespib', 'Nutlin-3a (-)', 'Savolitinib', 'PFI-1', 'Obatoclax Mesylate', 'Selumetinib', 'CPI-637', 'AZD7762', 'Rapamycin', 'RO-3306', 'Buparlisib', 'GSK343', 'MG-132', 'Ipatasertib', 'Vinorelbine'}, 'KYSE270': {'EHT-1864', 'Paclitaxel', 'GDC0810', 'BMS-345541', '5-Fluorouracil', 'Fludarabine', 'Telomerase Inhibitor IX', 'ICL-SIRT078', 'XAV939', 'MN-64', 'Epirubicin', 'Sorafenib', 'Daporinad', 'Vorinostat', 'RO-3306', 'Oxaliplatin', 'LJI308', 'GSK2110183B', 'Alisertib'}, 'KYSE410': {'NVP-ADW742', 'PD173074', 'SB590885', 'GDC0810', 'Talazoparib', 'Staurosporine', 'Nelarabine', 'Nutlin-3a (-)', 'Epirubicin', 'alpha-lipoic acid', 'Temozolomide', 'Veliparib', 'GSK591', 'Sinularin', 'AZD5582', 'GW441756', 'Dactolisib', 'Schweinfurthin A', 'Methotrexate'}, 'KYSE450': {'GSK2830371', 'NVP-ADW742', 'PD173074', 'BI-2536', 'AZD5363', 'BIBR-1532', 'Uprosertib', 'Lenalidomide', 'Fulvestrant', 'XAV939', 'SCH772984', 'PRT062607', 'WZ4003', 'Buparlisib', 'AZ960', 'Mycophenolic acid', 'Gefitinib', 'Vinorelbine', 'Dinaciclib'}, 'KYSE510': {'PRT062607', 'Bicalutamide', 'JNK Inhibitor VIII', 'Refametinib', 'Uprosertib', 'Mitoxantrone', 'OF-1', 'Dactinomycin', '5-Fluorouracil', 'EHT-1864', 'Dihydrorotenone', 'Acetalax', 'WZ4003', 'AGI-6780', 'AT13148', 'Tozasertib', 'Dabrafenib', 'SL0101'}, 'KYSE520': {'Pictilisib', 'Nilotinib', 'BMS-345541', 'KU-55933', 'Tanespimycin', 'Cytarabine', 'Vinblastine', 'Carmustine', 'LY2109761', 'Irinotecan', 'Trametinib', 'VE821', 'LMP744', 'MK-8776', 'Dihydrorotenone', 'Gallibiscoquinazole', 'RO-3306', 'JNK Inhibitor VIII', 'Ulixertinib'}, 'KYSE70': {'GSK2606414', 'Refametinib', 'Ruxolitinib', 'SGC-CBP30', 'Wnt-C59', 'Fulvestrant', 'MIRA-1', 'GNE-317', 'PFI-1', 'Entospletinib', 'POMHEX', 'AGK2', 'Rapamycin', 'WEHI-539', 'UMI-77', 'SN-38', 'Picolinici-acid', 'Vismodegib', 'AZD3759'}, 'L1236': {'MK-2206', 'Acetalax', 'BMS-345541', 'Venetoclax', 'VX-11e', 'Podophyllotoxin bromide', '5-azacytidine', 'Luminespib', 'MN-64', 'Sabutoclax', 'Daporinad', 'IWP-2', 'Erlotinib', 'Vorinostat', 'GSK2578215A', 'Veliparib', 'UMI-77', 'AZD5582', 'Dinaciclib'}, 'L363': {'Nilotinib', 'BI-2536', 'Acetalax', 'KU-55933', 'Taselisib', 'MIM1', 'SGC-CBP30', 'AZD2014', 'Nutlin-3a (-)', 'Obatoclax Mesylate', 'Sepantronium bromide', 'N-acetyl cysteine', 'AGK2', 'GSK591', 'Doramapimod', 'Palbociclib', 'Cediranib', 'GSK2801', 'Vinorelbine'}, 'L428': {'Dactinomycin', 'Bortezomib', 'I-BET-762', 'Talazoparib', 'Romidepsin', 'Mitoxantrone', 'Vinblastine', 'AZD5991', 'OTX015', 'Luminespib', 'Savolitinib', 'Cisplatin', 'Buparlisib', 'GSK-LSD1', 'GSK343', 'OF-1', 'OSI-027', 'AT13148', 'Dabrafenib'}, 'L540': {'AZD5363', 'Zoledronate', 'MIM1', 'Fulvestrant', 'Osimertinib', 'Entospletinib', 'Trametinib', 'Epirubicin', 'N-acetyl cysteine', 'Daporinad', 'Vorinostat', 'Bromosporine', 'BMS-536924', 'GSK1904529A', 'Bleomycin (50 uM)', 'Palbociclib', 'Alisertib', 'KRAS (G12C) Inhibitor-12', 'Dinaciclib'}, 'LAMA84': {'Dasatinib', 'Afatinib', 'SB590885', 'Romidepsin', 'Nelarabine', 'OTX015', 'MIRA-1', 'Entospletinib', 'Sepantronium bromide', 'Cisplatin', 'EPZ5676', 'Dihydrorotenone', 'Rapamycin', 'Mirin', 'PFI3', 'GSK591', 'Teniposide', 'Doramapimod', 'Methotrexate'}, 'LCLC103H': {'A-366', 'Pictilisib', 'Dasatinib', 'PLX-4720', 'Afatinib', 'Olaparib', 'Foretinib', 'LGK974', 'Sapitinib', 'Navitoclax', 'ZM447439', 'Crizotinib', 'Elephantin', 'EPZ004777', 'Epirubicin', 'Rapamycin', 'Motesanib', 'AZD6738', 'AGI-5198'}, 'LCLC97TM1': {'Pyridostatin', 'AZD5438', 'SB590885', 'BMS-345541', 'RVX-208', 'Ruxolitinib', 'Serdemetan', 'AZD8055', 'Carmustine', 'Osimertinib', 'glutathione', 'Bosutinib', 'Epirubicin', 'Sorafenib', 'Mirin', 'AZ960', 'Sinularin', 'SGC0946', 'Dabrafenib'}, 'LK2': {'Entinostat', 'Dactinomycin', 'KU-55933', 'Foretinib', 'Zoledronate', 'Tanespimycin', 'Taselisib', '5-Fluorouracil', 'LGK974', 'Sapitinib', 'Ribociclib', 'Podophyllotoxin bromide', 'glutathione', 'Erlotinib', 'Sinularin', 'JNK Inhibitor VIII', 'OF-1', 'Lestaurtinib', 'Vinorelbine'}, 'LN18': {'Remodelin', 'A-366', 'AZD1332', 'AZD5363', 'JQ1', 'MIM1', 'Mitoxantrone', 'Axitinib', '5-azacytidine', 'Lenalidomide', 'MN-64', 'Elephantin', 'Sorafenib', 'Dihydrorotenone', 'Gallibiscoquinazole', 'AZ960', 'Lestaurtinib', 'AT13148', 'AZD3759'}, 'LN229': {'Linsitinib', 'EHT-1864', 'AZD4547', 'LCL161', 'Ruxolitinib', 'Podophyllotoxin bromide', 'ML323', 'YK-4-279', 'Trametinib', 'LMP744', 'Mycophenolic acid', 'GSK591', 'Vincristine', 'Teniposide', 'GSK2110183B', 'Cediranib', 'Gemcitabine', 'Gefitinib', 'PD0325901'}, 'LNCAPCLONEFGC': {'CCT007093', 'Lapatinib', 'EHT-1864', 'Acetalax', 'Docetaxel', 'AT13148', 'Osimertinib', 'Dihydrorotenone', 'ABT737', 'Vorinostat', 'Erlotinib', 'GSK2578215A', 'GSK591', 'Vincristine', 'Temsirolimus', 'Alisertib', 'Gefitinib', 'Dinaciclib', 'Dabrafenib'}, 'LOUCY': {'A-366', 'GSK2830371', 'GDC0810', 'I-BET-762', 'SB216763', 'Olaparib', 'Staurosporine', 'Taselisib', 'Methotrexate', 'SGC-CBP30', 'P22077', 'OTX015', 'Sabutoclax', 'Veliparib', 'GSK1904529A', 'GSK591', 'GSK2801', 'Vismodegib', 'AZD3759'}, 'LOUNH91': {'Venetoclax', 'AMG-319', 'Wee1 Inhibitor', 'AZD2014', 'AZD5991', 'SCH772984', 'YK-4-279', 'Entospletinib', 'WEHI-539', 'Rapamycin', 'Sinularin', 'Avagacestat', 'Teniposide', 'GSK343', 'Cediranib', 'Lestaurtinib', 'Gemcitabine', 'Gefitinib', 'Dabrafenib'}, 'LOVO': {'MK-2206', 'Nilotinib', 'AZD1332', 'AZ6102', 'Taselisib', 'Leflunomide', 'Navitoclax', 'Wnt-C59', 'AZD5991', 'Crizotinib', 'XAV939', 'Bosutinib', 'alpha-lipoic acid', 'PCI-34051', 'Erlotinib', 'Sinularin', 'GW441756', 'GSK2110183B', 'SN-38', 'Doramapimod'}, 'LOXIMVI': {'GSK2606414', 'L-Oxonoreleagnine', 'AZD5438', 'GDC0810', 'AZD5363', 'KU-55933', 'Docetaxel', 'Wee1 Inhibitor', '5-azacytidine', 'Epirubicin', 'POMHEX', 'TW 37', 'AZ960', 'Palbociclib', 'Cediranib', 'MG-132', 'NU7441', 'Doramapimod', 'AZD6738'}, 'LP1': {'Dasatinib', 'Dactinomycin', 'NVP-ADW742', 'AZD1332', 'Zoledronate', 'Ruxolitinib', 'Sapitinib', 'Fludarabine', 'BMS-754807', 'YK-4-279', 'MK-8776', 'CZC24832', 'GSK2578215A', 'Oxaliplatin', 'Teniposide', 'OSI-027', 'PF-4708671', 'Vismodegib', 'Dinaciclib'}, 'LS1034': {'Entinostat', 'AZD1332', 'AZD5363', 'AMG-319', 'Docetaxel', '5-Fluorouracil', 'Telomerase Inhibitor IX', 'Luminespib', 'Nutlin-3a (-)', 'MIRA-1', 'EPZ004777', 'N-acetyl cysteine', 'AZD7762', 'IWP-2', 'PFI3', 'GSK591', 'Temsirolimus', 'MG-132', 'Picolinici-acid', 'Doramapimod'}, 'LS123': {'GSK2606414', 'Entinostat', 'Pyridostatin', 'Refametinib', 'AGI-6780', 'LCL161', 'VE-822', 'Nelarabine', 'Fludarabine', 'Mitoxantrone', 'Navitoclax', 'Podophyllotoxin bromide', 'Luminespib', 'AZD8055', 'ICL-SIRT078', 'glutathione', 'PFI-1', 'EPZ5676', 'IWP-2', 'PFI3'}, 'LS180': {'GSK2606414', 'L-Oxonoreleagnine', 'Dactinomycin', 'PLX-4720', 'KU-55933', 'LGK974', 'AZD2014', 'Serdemetan', 'Afuresertib', 'Osimertinib', 'Entospletinib', 'Epirubicin', 'Sorafenib', 'Gallibiscoquinazole', 'WEHI-539', 'RO-3306', 'Avagacestat', 'Picolinici-acid', 'NU7441', 'Ulixertinib'}, 'LS411N': {'AZD5438', 'Dactinomycin', 'AGI-6780', 'Camptothecin', 'KU-55933', 'JQ1', 'Leflunomide', 'Bleomycin', 'MN-64', 'Elephantin', 'Trametinib', 'PCI-34051', 'Sorafenib', 'Rapamycin', 'PFI3', 'BMS-536924', 'Sinularin', 'Picolinici-acid', 'Dabrafenib'}, 'LS513': {'GSK2606414', 'Trametinib', 'A-366', 'GW441756', 'Alpelisib', 'Sabutoclax', 'Daporinad', 'Lestaurtinib', 'AZD5991', 'AZ6102', 'AZD4547', 'Motesanib', 'XAV939', 'RO-3306', 'LY2109761'}, 'LU134A': {'Bosutinib', 'GSK591', 'Leflunomide', 'BX795', 'Uprosertib', 'NVP-ADW742', 'Bortezomib', 'Elesclomol', 'Nilotinib', 'Gemcitabine', 'GDC0810', 'IWP-2', 'PRT062607', 'Venetoclax', 'Osimertinib', 'Staurosporine'}, 'LU135': {'Alpelisib', 'Cyclophosphamide', 'Camptothecin', 'Taselisib', 'JQ1', 'Leflunomide', 'Tamoxifen', 'Vinblastine', 'Serdemetan', 'Wnt-C59', 'Afuresertib', 'ICL-SIRT078', 'GNE-317', 'MN-64', 'Gallibiscoquinazole', 'PFI3', 'UMI-77', 'Vincristine', 'OSI-027'}, 'LU165': {'L-Oxonoreleagnine', 'Dactinomycin', 'Paclitaxel', 'Pevonedistat', 'Rucaparib', 'Ribociclib', 'Podophyllotoxin bromide', 'Wnt-C59', 'AZD5991', 'SCH772984', 'EPZ004777', 'LMP744', 'MK-8776', 'Sorafenib', 'ABT737', 'PFI3', 'Teniposide', 'Lestaurtinib', 'Dinaciclib'}, 'LU65': {'GSK2606414', 'Entinostat', 'MK-2206', 'GSK2830371', 'PLX-4720', 'SB590885', 'Taselisib', 'JQ1', 'Docetaxel', '5-Fluorouracil', 'Wee1 Inhibitor', 'XAV939', 'LY2109761', 'Irinotecan', 'Topotecan', 'RO-3306', 'Niraparib', 'AZD5582', 'Temsirolimus'}, 'LXF289': {'Entinostat', 'Lapatinib', 'MK-2206', 'Cyclophosphamide', 'PD173074', 'Zoledronate', 'Taselisib', 'Nelarabine', 'Ruxolitinib', 'Mitoxantrone', 'Axitinib', 'Fulvestrant', 'Selumetinib', 'Epirubicin', 'Bromosporine', 'GSK-LSD1', 'UMI-77', 'Dactolisib', 'KRAS (G12C) Inhibitor-12'}, 'MC116': {'Pyridostatin', 'EPZ004777', 'PRT062607', 'Alpelisib', 'Dactinomycin', 'Dinaciclib', 'Nilotinib', 'Gemcitabine', 'SN-38', 'CCT-018159', 'Dabrafenib', 'WEHI-539', 'Ipatasertib', 'Foretinib', 'GSK2578215A', 'RO-3306'}, 'MCF7': {'CCT007093', 'Cyclophosphamide', 'PD173074', 'BI-2536', 'Tozasertib', 'Zoledronate', 'BIBR-1532', 'LGK974', 'Dacarbazine', 'VX-11e', 'OTX015', 'AZD8055', 'Irinotecan', 'Entospletinib', 'Sabutoclax', 'WEHI-539', 'UNC0379', 'Veliparib', 'JNK Inhibitor VIII', 'Schweinfurthin A'}, 'MDAMB157': {'L-Oxonoreleagnine', 'Dactinomycin', 'NVP-ADW742', 'I-BET-762', 'Sapitinib', 'Mitoxantrone', 'Uprosertib', 'AZD8055', 'glutathione', 'YK-4-279', 'Elephantin', 'N-acetyl cysteine', 'WEHI-539', 'RO-3306', 'PFI3', 'Mycophenolic acid', 'Ipatasertib', 'AZD5153', 'Dinaciclib', 'AZD3759'}, 'MDAMB175VII': {'Irinotecan', 'Trametinib', 'WIKI4', 'Obatoclax Mesylate', 'Pictilisib', 'AZD7762', 'Buparlisib', 'AZ6102', 'TW 37', 'Talazoparib', 'WEHI-539', 'Vinorelbine', 'Pevonedistat', 'PFI-1'}, 'MDAMB231': {'SB590885', 'Staurosporine', 'Nelarabine', 'Docetaxel', 'MK-1775', 'Uprosertib', 'Wee1 Inhibitor', 'Afuresertib', 'Carmustine', 'MIRA-1', 'YK-4-279', 'Gallibiscoquinazole', 'WEHI-539', 'Oxaliplatin', 'Bleomycin (50 uM)', 'MG-132', 'Ibrutinib', 'NU7441', 'PF-4708671', 'Dinaciclib'}, 'MDAMB361': {'AZD6482', 'MK-2206', 'GDC0810', 'AGI-6780', 'JQ1', 'Telomerase Inhibitor IX', 'Wnt-C59', 'Serdemetan', 'Crizotinib', 'Lenalidomide', 'ICL-SIRT078', 'CPI-637', 'Topotecan', 'VE821', 'Vincristine', 'GSK2801', 'Ibrutinib', 'Schweinfurthin A', 'Vismodegib', 'UNC0638'}, 'MDAMB415': {'Lapatinib', 'PLX-4720', 'GDC0810', 'Paclitaxel', 'Acetalax', 'Camptothecin', 'Foretinib', 'Docetaxel', 'Uprosertib', 'VX-11e', 'Telomerase Inhibitor IX', 'Obatoclax Mesylate', 'LY2109761', 'CPI-637', 'LMP744', 'Mycophenolic acid', 'Ipatasertib', 'Vinorelbine', 'AT13148', 'Ulixertinib'}, 'MDAMB436': {'MK-2206', 'NVP-ADW742', 'AZD1208', 'BMS-345541', 'SB216763', 'AZD4547', 'VE-822', 'Docetaxel', 'MIM1', '5-Fluorouracil', 'LGK974', 'Podophyllotoxin bromide', 'PFI-1', 'Trametinib', 'Gallibiscoquinazole', 'PFI3', 'Sinularin', 'Lestaurtinib', 'Dactolisib', 'Picolinici-acid'}, 'MDAMB453': {'AZD6482', 'Alpelisib', 'MK-2206', 'BMS-345541', 'KU-55933', 'RVX-208', 'Tozasertib', 'JQ1', 'Fludarabine', 'AZD8055', 'Afuresertib', 'MIRA-1', 'Elephantin', 'VE821', 'Erlotinib', 'GSK591', 'Avagacestat', 'Teniposide', 'Vismodegib', 'Ulixertinib'}, 'MDAMB468': {'CCT007093', 'Taselisib', 'Ruxolitinib', 'LGK974', 'Axitinib', 'Cytarabine', 'AZD2014', 'Lenalidomide', 'Osimertinib', 'GSK269962A', 'Sepantronium bromide', 'EPZ5676', 'AGK2', 'Vorinostat', 'BMS-536924', 'Oxaliplatin', 'GSK-LSD1', 'Bleomycin (50 uM)', 'GW441756', 'AZD3759'}, 'MDST8': {'Refametinib', 'Cyclophosphamide', 'GDC0810', 'AZD1208', 'Olaparib', 'JQ1', 'AZD8186', 'Ruxolitinib', 'Lenalidomide', 'Bleomycin', 'Obatoclax Mesylate', 'Trametinib', 'Temozolomide', 'GSK2578215A', 'GSK343', 'Ibrutinib', 'KRAS (G12C) Inhibitor-12', 'Alisertib', 'Motesanib'}, 'ME1': {'CCT007093', 'Dasatinib', 'AZD5438', 'I-BET-762', 'AZ6102', 'Dinaciclib', 'Docetaxel', 'Fludarabine', 'Podophyllotoxin bromide', '5-azacytidine', 'Crizotinib', 'MN-64', 'POMHEX', 'TW 37', 'Bromosporine', 'Picolinici-acid', 'NU7441', 'Motesanib', 'AT13148'}, 'MEG01': {'Dactinomycin', 'Afatinib', 'Paclitaxel', 'Tanespimycin', 'SGC-CBP30', 'Mitoxantrone', 'AZD2014', 'Nutlin-3a (-)', 'Lenalidomide', 'MIRA-1', 'Bleomycin', 'SCH772984', 'Savolitinib', 'Irinotecan', 'EPZ5676', 'PCI-34051', 'POMHEX', 'UMI-77', 'GSK2801'}, 'MELHO': {'Tanespimycin', 'Selumetinib', 'Sepantronium bromide', 'PRIMA-1MET', 'Axitinib', 'P22077', 'ZM447439', 'PD173074', 'Nilotinib', 'OTX015', 'OSI-027', 'Serdemetan', 'Methotrexate', 'Dinaciclib', 'SCH772984', 'AGI-5198'}, 'MELJUSO': {'PD173074', 'SB216763', 'Zoledronate', 'VE-822', 'Rucaparib', 'Sapitinib', 'Wee1 Inhibitor', 'ZM447439', 'Serdemetan', 'OTX015', 'AZD8055', 'Osimertinib', 'GNE-317', 'Obatoclax Mesylate', 'Selumetinib', 'Erlotinib', 'Bleomycin (50 uM)', 'Methotrexate', 'AZD6738'}, 'MESSA': {'Remodelin', 'CCT007093', 'Linsitinib', 'Cyclophosphamide', 'Acetalax', 'AZ6102', 'Zoledronate', 'Dacarbazine', 'Nutlin-3a (-)', 'Entospletinib', 'Sepantronium bromide', 'WEHI-539', 'GSK2578215A', 'UNC0379', 'PFI3', 'GSK591', 'Niraparib', 'Gemcitabine', 'Motesanib'}, 'MEWO': {'BIBR-1532', 'Epirubicin', 'Dasatinib', 'Cyclophosphamide', 'Cediranib', 'Telomerase Inhibitor IX', 'SB590885', 'Dabrafenib', 'Afuresertib', 'BMS-754807', 'Camptothecin', 'MIRA-1', 'AGI-5198', 'Obatoclax Mesylate'}, 'MFE280': {'I-BRD9', 'Lapatinib', 'L-Oxonoreleagnine', 'Dactinomycin', 'Dasatinib', 'AZ6102', 'SB216763', 'LCL161', 'VX-11e', 'ZM447439', 'Wnt-C59', 'AZD5991', 'Afuresertib', 'GNE-317', 'AZD7762', 'WEHI-539', 'LJI308', 'AZD5582', 'SN-38'}, 'MFE296': {'Entinostat', 'Pyridostatin', 'I-BET-762', 'LCL161', 'KU-55933', 'Foretinib', 'Tanespimycin', 'MIM1', 'Cytarabine', 'OTX015', 'YK-4-279', 'Cisplatin', 'PCI-34051', 'Dihydrorotenone', 'AZ960', 'Teniposide', 'Gemcitabine', 'Picolinici-acid', 'Gefitinib'}, 'MFE319': {'GSK2606414', 'Nilotinib', 'BI-2536', 'AZD4547', 'AMG-319', 'Zoledronate', 'JQ1', 'OTX015', 'Nutlin-3a (-)', 'ICL-SIRT078', 'Fulvestrant', 'Osimertinib', 'PFI-1', 'Topotecan', 'Gallibiscoquinazole', 'Rapamycin', 'GSK2110183B', 'Vinorelbine', 'AZD3759'}, 'MFM223': {'Entinostat', 'Lapatinib', 'PD173074', 'Nilotinib', 'GDC0810', 'Talazoparib', 'Tozasertib', 'BIBR-1532', 'MIM1', 'AZD2014', 'Bleomycin', 'PFI-1', 'Irinotecan', 'Epirubicin', 'ABT737', 'Vorinostat', 'Buparlisib', 'Ipatasertib', 'KRAS (G12C) Inhibitor-12', 'Dinaciclib'}, 'MG63': {'Pictilisib', 'AZD5438', 'Cyclophosphamide', 'Nilotinib', 'AZD8186', '5-Fluorouracil', 'Carmustine', 'Osimertinib', 'Obatoclax Mesylate', 'Elephantin', 'Bosutinib', 'Temozolomide', 'AZD7762', 'Vorinostat', 'GSK2801', 'SN-38', 'Vismodegib', 'AT13148', 'AGI-5198'}, 'MHHCALL2': {'Remodelin', 'GSK1904529A', 'Irinotecan', 'GSK591', 'BIBR-1532', 'EPZ004777', '5-Fluorouracil', 'SGC-CBP30', 'AZD5438', 'Palbociclib', 'Navitoclax', 'Mitoxantrone', 'Podophyllotoxin bromide', 'Ibrutinib', 'Dihydrorotenone', 'Gallibiscoquinazole', 'Carmustine'}, 'MHHCALL4': {'Lapatinib', 'Docetaxel', 'GSK2578215A', 'Dasatinib', 'Wee1 Inhibitor', 'PCI-34051', 'Telomerase Inhibitor IX', 'Navitoclax', 'Daporinad', 'Ibrutinib', 'Bortezomib', 'Alisertib', 'PD0325901', 'Foretinib', 'XAV939', 'AGI-5198'}, 'MHHES1': {'A-366', 'Refametinib', 'Dasatinib', 'Paclitaxel', 'AZD1332', 'SB216763', 'AZD4547', 'Dacarbazine', 'Osimertinib', 'SCH772984', 'Irinotecan', 'Sorafenib', 'Sabutoclax', 'Temsirolimus', 'Palbociclib', 'OSI-027', 'Alisertib', 'NU7441', 'Dinaciclib', 'Dabrafenib', 'SL0101'}, 'MHHNB11': {'Bosutinib', 'VE821', 'Bicalutamide', 'WIKI4', 'EPZ004777', 'Dactinomycin', 'AZD7762', 'LGK974', 'Axitinib', 'Daporinad', 'MG-132', 'Nilotinib', 'ML323', 'Ipatasertib', 'Alisertib', 'Vismodegib'}, 'MIAPACA2': {'Entinostat', 'Dasatinib', 'Dactinomycin', 'Camptothecin', 'Telomerase Inhibitor IX', 'ML323', 'Bleomycin', 'Sepantronium bromide', 'alpha-lipoic acid', 'Sorafenib', 'Vinorelbine', 'WZ4003', 'Buparlisib', 'Avagacestat', 'LJI308', 'Vincristine', 'Gemcitabine', 'Vismodegib', 'AZD3759'}, 'MKN1': {'Irinotecan', 'Mycophenolic acid', 'Avagacestat', 'GNE-317', 'JNK Inhibitor VIII', 'Temsirolimus', 'WEHI-539', 'Palbociclib', 'Wee1 Inhibitor', 'Podophyllotoxin bromide', 'Sabutoclax', 'MK-8776', 'Afatinib', 'AZD5991', 'Carmustine', 'CZC24832', 'PD0325901', 'RO-3306'}, 'MKN45': {'Dactinomycin', 'AZD1208', 'Foretinib', 'AZD8186', 'Uprosertib', 'Mitoxantrone', 'Dacarbazine', 'Wee1 Inhibitor', 'P22077', 'AZD8055', 'CPI-637', 'alpha-lipoic acid', 'LMP744', 'CZC24832', 'Erlotinib', 'AZ960', 'PRIMA-1MET', 'SN-38', 'Ulixertinib'}, 'MKN7': {'GSK1904529A', 'VE-822', 'Selumetinib', 'AZD8186', 'EPZ004777', 'WIKI4', 'Pictilisib', 'Sapitinib', 'Linsitinib', 'P22077', 'Tamoxifen', 'Elesclomol', 'Serdemetan', 'AZD5363', 'Picolinici-acid', 'PRT062607', 'AMG-319'}, 'ML1': {'Fulvestrant', 'Methotrexate', 'PRIMA-1MET', 'Leflunomide', 'GSK343', 'Sapitinib', 'GW441756', 'EHT-1864', 'Wnt-C59', 'Gemcitabine', 'I-BET-762', 'NU7441', 'BMS-345541', 'Vismodegib', 'RO-3306', 'KU-55933'}, 'MM1S': {'MK-2206', 'Venetoclax', 'SB216763', 'BIBR-1532', 'Methotrexate', 'MK-1775', 'Lenalidomide', 'Bleomycin', 'Irinotecan', 'Sepantronium bromide', 'WIKI4', 'alpha-lipoic acid', 'POMHEX', 'Mirin', 'Bromosporine', 'GSK591', 'Doramapimod', 'GSK2801', 'Vismodegib'}, 'MOLM13': {'Vismodegib', 'GSK2830371', 'Paclitaxel', 'AZD1208', 'Talazoparib', 'Taselisib', 'Rucaparib', 'MK-1775', 'Axitinib', 'Navitoclax', 'Serdemetan', 'AZD8055', 'Savolitinib', 'PFI-1', 'YK-4-279', 'IWP-2', 'Bleomycin (50 uM)', 'SGC0946', 'Methotrexate'}, 'MOLM16': {'EPZ004777', 'WIKI4', 'Epirubicin', 'Ruxolitinib', 'Refametinib', 'Palbociclib', 'Alpelisib', 'Sorafenib', 'PLX-4720', 'Ipatasertib', 'BI-2536', 'Dabrafenib', 'Piperlongumine', 'AZD4547', 'GSK2578215A', 'Pevonedistat'}, 'MOLP8': {'CCT007093', 'A-366', 'Cyclophosphamide', 'Acetalax', 'AZD4547', 'KU-55933', 'Leflunomide', 'P22077', 'AZD8055', 'MIRA-1', 'MN-64', 'Irinotecan', 'POMHEX', 'AGK2', 'ABT737', 'Vorinostat', 'MG-132', 'Dinaciclib', 'Dabrafenib'}, 'MOLT16': {'Entinostat', 'PD173074', 'BI-2536', 'AZD1332', 'I-BET-762', 'BMS-345541', 'LCL161', 'RVX-208', 'KU-55933', 'MK-1775', 'Wee1 Inhibitor', 'Podophyllotoxin bromide', '5-azacytidine', 'Vinblastine', 'Luminespib', 'Mirin', 'GSK2578215A', 'Oxaliplatin', 'Teniposide'}, 'MONOMAC6': {'Tanespimycin', 'LJI308', 'AZD4547', 'GW441756', 'Ribociclib', 'Navitoclax', 'Sorafenib', 'GDC0810', 'SGC0946', 'NU7441', 'Doramapimod', 'Erlotinib', 'Foretinib', 'Veliparib'}, 'MPP89': {'Lapatinib', 'Refametinib', 'EHT-1864', 'Afatinib', 'Paclitaxel', 'Venetoclax', 'Foretinib', 'Docetaxel', 'MK-1775', 'Mitoxantrone', 'Topotecan', 'alpha-lipoic acid', 'PRT062607', 'Mirin', 'GSK2578215A', 'GSK343', 'Ipatasertib', 'Gefitinib', 'AZD5153'}, 'MS751': {'Entinostat', 'SB590885', 'AZD5363', 'RVX-208', 'Foretinib', '5-Fluorouracil', 'Sapitinib', 'AZD2014', 'SCH772984', 'YK-4-279', 'EPZ5676', 'AZD7762', 'Sorafenib', 'UNC0379', 'LJI308', 'PRIMA-1MET', 'Palbociclib', 'Ibrutinib', 'SGC0946'}, 'MSTO211H': {'L-Oxonoreleagnine', 'Bortezomib', 'I-BET-762', 'Nelarabine', 'Fludarabine', 'Mitoxantrone', 'OTX015', 'Carmustine', 'MIRA-1', 'Bosutinib', 'Trametinib', 'Sepantronium bromide', 'EPZ5676', 'N-acetyl cysteine', 'Dihydrorotenone', 'Vorinostat', 'Erlotinib', 'Sinularin', 'SGC0946'}, 'MV411': {'Irinotecan', 'Motesanib', 'A-366', 'Temsirolimus', 'Ribociclib', '5-azacytidine', 'AZD1208', 'AZD8055', 'Nutlin-3a (-)', 'Lenalidomide', 'Camptothecin', 'Erlotinib', 'SCH772984', 'Buparlisib'}, 'NALM6': {'I-BRD9', 'Pyridostatin', 'AGI-6780', 'Olaparib', 'Pevonedistat', 'Ribociclib', 'ZM447439', 'ML323', 'Bleomycin', 'VE821', 'EPZ5676', 'AZD7762', 'Rapamycin', 'Sinularin', 'Teniposide', 'JNK Inhibitor VIII', 'Dactolisib', 'Doramapimod', 'UNC0638'}, 'NAMALWA': {'Entinostat', 'AZD5438', 'GDC0810', 'BIBR-1532', 'AZD8186', 'Telomerase Inhibitor IX', 'ZM447439', 'Wnt-C59', 'ML323', 'Luminespib', 'BMS-754807', 'Sepantronium bromide', 'EPZ5676', 'Temozolomide', 'MK-8776', 'AZD5582', 'Temsirolimus', 'GSK2801', 'UNC0638'}, 'NB1': {'Taselisib', 'Cisplatin', 'Bleomycin (50 uM)', 'GSK343', 'Linsitinib', 'Dasatinib', 'MK-1775', 'Vinblastine', 'AZD5363', 'SB216763', 'Osimertinib', 'AZD6738', 'Dabrafenib'}, 'NB4': {'VE-822', 'Tretinoin', 'BIBR-1532', 'PRIMA-1MET', 'Alpelisib', 'Linsitinib', 'Lenalidomide', 'LCL161', 'Elesclomol', 'Dactolisib', 'AGI-6780', 'KRAS (G12C) Inhibitor-12', 'Nutlin-3a (-)', 'PF-4708671', 'Vismodegib', 'GSK2578215A'}, 'NCCIT': {'UMI-77', 'Lapatinib', 'A-366', 'Docetaxel', 'Cyclophosphamide', 'Navitoclax', 'VX-11e', 'Tamoxifen', 'EHT-1864', 'Ipatasertib', 'AZD5363', 'Camptothecin', 'Buparlisib', 'Obatoclax Mesylate'}, 'NCIH1048': {'L-Oxonoreleagnine', 'Afatinib', 'AZD1332', 'AZ6102', 'Olaparib', 'LGK974', 'Uprosertib', 'Sapitinib', 'Navitoclax', 'Wnt-C59', 'Afuresertib', 'Entospletinib', 'Trametinib', 'Mycophenolic acid', 'Bleomycin (50 uM)', 'Cediranib', 'OF-1', 'Picolinici-acid', 'UNC0638'}, 'NCIH1092': {'Refametinib', 'GDC0810', 'Acetalax', 'BIBR-1532', 'Dacarbazine', 'Serdemetan', 'ML323', 'AZD5991', 'Lenalidomide', 'SCH772984', 'Savolitinib', 'Irinotecan', 'AZD7762', 'PRT062607', 'CZC24832', 'Niraparib', 'LJI308', 'Picolinici-acid', 'AT13148'}, 'NCIH1105': {'Tanespimycin', 'AZ960', 'Pyridostatin', 'AZD8186', 'GSK343', 'Uprosertib', 'Palbociclib', 'Axitinib', 'Tamoxifen', 'Daporinad', 'Ibrutinib', 'Serdemetan', 'Crizotinib', 'IWP-2', 'SCH772984', 'AZD3759'}, 'NCIH1155': {'AZD1332', 'Paclitaxel', 'AZD1208', 'Taselisib', 'Axitinib', 'ML323', 'glutathione', 'Entospletinib', 'VE821', 'Epirubicin', 'AZD7762', 'MK-8776', 'AGK2', 'Vinorelbine', 'Rapamycin', 'LJI308', 'Doramapimod', 'AGI-5198', 'Ulixertinib'}, 'NCIH1299': {'Bortezomib', 'AZD1332', 'Foretinib', 'Pevonedistat', 'Zoledronate', 'Ruxolitinib', 'Lenalidomide', 'Savolitinib', 'EPZ004777', 'alpha-lipoic acid', 'LMP744', 'AGK2', 'Gallibiscoquinazole', 'BMS-536924', 'AZ960', 'Niraparib', 'Teniposide', 'Motesanib', 'AT13148'}, 'NCIH1341': {'Remodelin', 'MIM1', 'GW441756', 'GSK343', 'WEHI-539', 'VX-11e', 'Tamoxifen', 'PLX-4720', 'PD173074', 'Gemcitabine', 'OSI-027', 'AZ6102', 'BMS-754807', 'Lenalidomide'}, 'NCIH1355': {'MK-2206', 'PLX-4720', 'Paclitaxel', 'I-BET-762', 'Acetalax', 'LCL161', 'RVX-208', 'Tanespimycin', 'Navitoclax', 'Telomerase Inhibitor IX', 'Vinblastine', 'Luminespib', 'AZD7762', 'IWP-2', 'Bromosporine', 'Mycophenolic acid', 'Cediranib', 'Ibrutinib', 'Doramapimod'}, 'NCIH1435': {'GSK2606414', 'Lapatinib', 'Refametinib', 'Bortezomib', 'AZD5363', 'Ribociclib', 'VX-11e', 'Podophyllotoxin bromide', 'Nutlin-3a (-)', 'BMS-754807', 'Bleomycin', 'Selumetinib', 'EPZ5676', 'Sabutoclax', 'AGK2', 'Dihydrorotenone', 'CZC24832', 'LJI308', 'Ibrutinib'}, 'NCIH1436': {'Oxaliplatin', 'Bosutinib', 'JQ1', 'Trametinib', 'Refametinib', 'MK-1775', 'Linsitinib', 'Cediranib', 'Talazoparib', 'P22077', 'PCI-34051', 'SGC0946', 'Gefitinib', 'GSK269962A', 'Pevonedistat', 'PFI-1'}, 'NCIH1437': {'Tretinoin', 'LGK974', 'Temsirolimus', 'Uprosertib', 'AZD7762', 'Cediranib', 'Dasatinib', 'Sabutoclax', 'Serdemetan', 'SN-38', 'Ibrutinib', 'AGI-6780', 'NU7441', 'SB216763', 'Fulvestrant', 'SCH772984'}, 'NCIH146': {'YK-4-279', 'GSK1904529A', 'IOX2', 'JQ1', 'EPZ004777', 'PRIMA-1MET', 'Navitoclax', 'Sorafenib', 'Elesclomol', 'PLX-4720', 'ZM447439', 'Crizotinib', 'Afatinib', 'PFI3', 'Mirin', 'BMS-536924'}, 'NCIH1563': {'Linsitinib', 'BMS-345541', 'UNC0638', 'MK-1775', '5-azacytidine', 'Vinblastine', 'Carmustine', 'Nutlin-3a (-)', 'BMS-754807', 'Lenalidomide', 'Trametinib', 'PCI-34051', 'Dihydrorotenone', 'IWP-2', 'Buparlisib', 'AZD5582', 'GW441756', 'Gemcitabine', 'AGI-5198'}, 'NCIH1568': {'L-Oxonoreleagnine', 'AZD5438', 'GSK2830371', 'SB590885', 'GDC0810', 'Pevonedistat', 'Tanespimycin', 'Taselisib', 'BIBR-1532', 'VX-11e', 'Wnt-C59', 'AZD8055', 'MIRA-1', 'Osimertinib', 'Obatoclax Mesylate', 'Entospletinib', 'Topotecan', 'WIKI4', 'WZ4003'}, 'NCIH1573': {'Bosutinib', 'Pyridostatin', 'Rucaparib', '5-Fluorouracil', 'Dactinomycin', 'Dasatinib', 'Wee1 Inhibitor', 'Buparlisib', 'Bortezomib', 'PD173074', 'Afuresertib', 'WEHI-539', 'Veliparib', 'glutathione'}, 'NCIH1581': {'MK-2206', 'Pictilisib', 'Linsitinib', 'Camptothecin', 'Uprosertib', 'Dacarbazine', 'Ribociclib', 'Vinblastine', 'AZD5991', 'MIRA-1', 'Epirubicin', 'AZD7762', 'AGK2', 'WZ4003', 'RO-3306', 'Oxaliplatin', 'Ibrutinib', 'SGC0946', 'Vismodegib'}, 'NCIH1623': {'A-366', 'SB590885', 'AZD1208', 'VE-822', 'AZD8186', 'Nelarabine', '5-Fluorouracil', 'Vinblastine', 'Carmustine', 'EPZ5676', 'Temozolomide', 'PCI-34051', 'Dihydrorotenone', 'AZ960', 'MG-132', 'Picolinici-acid', 'Gefitinib', 'Vinorelbine', 'AZD6738'}, 'NCIH1648': {'Tanespimycin', 'Avagacestat', 'Lapatinib', 'Docetaxel', 'JNK Inhibitor VIII', 'Epirubicin', 'Dasatinib', 'N-acetyl cysteine', 'BIBR-1532', 'VX-11e', '5-azacytidine', 'Tamoxifen', 'AZD5363', 'ICL-SIRT078'}, 'NCIH1650': {'Pictilisib', 'Cyclophosphamide', 'GSK2830371', 'AMG-319', 'Zoledronate', 'Romidepsin', 'Leflunomide', 'MIM1', 'Uprosertib', 'Sapitinib', 'Selumetinib', 'Trametinib', 'Gallibiscoquinazole', 'GSK2578215A', 'Oxaliplatin', 'Vincristine', 'Dactolisib', 'Alisertib', 'Dabrafenib'}, 'NCIH1651': {'MK-2206', 'GSK2830371', 'Nilotinib', 'Zoledronate', 'BIBR-1532', 'Serdemetan', 'BMS-754807', 'Nutlin-3a (-)', 'MIRA-1', 'Bleomycin', 'Savolitinib', 'VE821', 'WIKI4', 'Sepantronium bromide', 'CZC24832', 'Erlotinib', 'UMI-77', 'MG-132', 'Vismodegib'}, 'NCIH1666': {'PLX-4720', 'SB590885', 'BI-2536', 'I-BET-762', 'AZD5363', 'Ruxolitinib', 'Mitoxantrone', 'Navitoclax', 'AZD5991', 'AZD8055', 'PFI-1', 'MN-64', 'Selumetinib', 'Sepantronium bromide', 'POMHEX', 'CZC24832', 'GSK591', 'GW441756', 'AZD6738'}, 'NCIH1693': {'Pictilisib', 'AZD5438', 'Camptothecin', 'Pevonedistat', 'Zoledronate', 'Tanespimycin', 'Rucaparib', 'Serdemetan', 'Luminespib', 'Carmustine', 'Lenalidomide', 'Bosutinib', 'EPZ5676', 'Temozolomide', 'Vorinostat', 'GSK-LSD1', 'GSK591', 'AZ960', 'JNK Inhibitor VIII'}, 'NCIH1694': {'Irinotecan', 'AZ960', 'Elephantin', 'Taselisib', 'Oxaliplatin', 'LGK974', 'Uprosertib', 'Cytarabine', 'Tamoxifen', 'Bortezomib', 'MG-132', 'AZD5363', 'Dihydrorotenone', 'Talazoparib', 'PD0325901', 'SB216763', 'Mirin', 'XAV939'}, 'NCIH1703': {'Tanespimycin', 'Selumetinib', 'UNC0638', 'Bleomycin (50 uM)', 'GSK343', 'Cyclophosphamide', 'AMG-319', 'MG-132', 'SN-38', 'AGK2', 'Talazoparib', 'Osimertinib', 'GNE-317', 'Savolitinib'}, 'NCIH1734': {'Vismodegib', 'LJI308', 'AZD4547', 'CHIR-99021', 'JNK Inhibitor VIII', 'SB505124', 'Uprosertib', 'MK-1775', 'Sorafenib', 'SB590885', 'Picolinici-acid', 'AZD5363', 'AGI-6780', 'Camptothecin', 'AMG-319', 'SL0101'}, 'NCIH1755': {'GSK2606414', 'EHT-1864', 'Tanespimycin', 'Axitinib', 'VX-11e', 'ZM447439', 'ICL-SIRT078', 'SCH772984', 'alpha-lipoic acid', 'PCI-34051', 'MK-8776', 'Sabutoclax', 'AGK2', 'Vorinostat', 'RO-3306', 'BMS-536924', 'Sinularin', 'UMI-77', 'AGI-5198'}, 'NCIH1781': {'Venetoclax', 'JQ1', 'AZD8186', 'MIM1', 'Navitoclax', 'AZD8055', 'MIRA-1', 'Trametinib', 'MK-8776', 'Sorafenib', 'POMHEX', 'WEHI-539', 'Rapamycin', 'Erlotinib', 'Mycophenolic acid', 'GSK2110183B', 'MG-132', 'Dactolisib', 'UNC0638'}, 'NCIH1792': {'Refametinib', 'Bortezomib', 'Romidepsin', 'Mitoxantrone', 'ML323', 'Afuresertib', 'Nutlin-3a (-)', 'PFI-1', 'Obatoclax Mesylate', 'WZ4003', 'Ulixertinib', 'UNC0379', 'UMI-77', 'AZD5582', 'Temsirolimus', 'Lestaurtinib', 'Alisertib', 'Vinorelbine', 'AZD3759'}, 'NCIH1793': {'GSK2606414', 'Pictilisib', 'AZD5438', 'AGI-6780', 'Venetoclax', 'Camptothecin', 'Foretinib', 'VE-822', 'UNC0638', 'ZM447439', 'Serdemetan', 'AZD8055', 'Nutlin-3a (-)', 'EPZ5676', 'LMP744', 'Cediranib', 'NU7441', 'Doramapimod', 'AGI-5198'}, 'NCIH1836': {'Entinostat', 'IOX2', 'GSK591', 'Oxaliplatin', 'VE821', 'Bicalutamide', 'GW441756', 'Pictilisib', 'Dasatinib', 'Cediranib', 'Tamoxifen', 'Wnt-C59', 'AZD5363', 'IWP-2', 'Foretinib', 'Veliparib'}, 'NCIH1838': {'VE821', 'MIM1', 'Dasatinib', 'Linsitinib', 'Vinblastine', 'Tamoxifen', 'P22077', 'AZD5363', 'OSI-027', 'ABT737', 'BMS-754807', 'Vinorelbine', 'AT13148', 'Staurosporine'}, 'NCIH1869': {'AZ960', 'Entospletinib', 'Sepantronium bromide', 'Topotecan', 'SGC-CBP30', 'LGK974', 'Vincristine', 'Axitinib', 'PD173074', 'AGK2', 'IWP-2', 'BMS-345541', 'Rapamycin', 'Vinorelbine', 'Olaparib', 'GNE-317'}, 'NCIH1876': {'Bortezomib', 'PD173074', 'AGI-6780', 'BIBR-1532', 'Sapitinib', 'VX-11e', 'Tamoxifen', 'Podophyllotoxin bromide', 'Crizotinib', 'Savolitinib', 'Gallibiscoquinazole', 'GSK-LSD1', 'Sinularin', 'AZD5582', 'JNK Inhibitor VIII', 'GSK2110183B', 'Gemcitabine', 'KRAS (G12C) Inhibitor-12', 'Methotrexate'}, 'NCIH1915': {'GSK2606414', 'L-Oxonoreleagnine', 'NVP-ADW742', 'BI-2536', 'AZD4547', 'Camptothecin', 'BIBR-1532', 'Navitoclax', 'Entospletinib', 'WIKI4', 'Cisplatin', 'WEHI-539', 'RO-3306', 'Veliparib', 'Teniposide', 'Palbociclib', 'Picolinici-acid', 'Gefitinib', 'AT13148'}, 'NCIH1944': {'Bortezomib', 'PLX-4720', 'AZD1332', 'AZD5363', 'GDC0810', 'Talazoparib', 'UNC0638', 'LGK974', 'Fludarabine', 'XAV939', 'PFI-1', 'Sepantronium bromide', 'WZ4003', 'Mirin', 'GSK2578215A', 'UNC0379', 'Oxaliplatin', 'KRAS (G12C) Inhibitor-12', 'AGI-5198'}, 'NCIH196': {'CCT007093', 'PLX-4720', 'AZD1332', '5-Fluorouracil', 'SGC-CBP30', 'Uprosertib', 'MK-1775', 'Osimertinib', 'WIKI4', 'alpha-lipoic acid', 'Sorafenib', 'Dihydrorotenone', 'UMI-77', 'LJI308', 'Palbociclib', 'OF-1', 'Ipatasertib', 'Methotrexate', 'AZD6738'}, 'NCIH1963': {'CCT007093', 'Avagacestat', 'Trametinib', 'Teniposide', 'WIKI4', 'WEHI-539', 'Tamoxifen', 'Ibrutinib', 'Afatinib', 'Paclitaxel', 'AZD5363', 'IWP-2', 'I-BET-762', 'BMS-754807', 'SB216763', 'RVX-208', 'AZD6738', 'Pevonedistat'}, 'NCIH1975': {'GSK2830371', 'AZD1208', 'Acetalax', 'Camptothecin', 'Foretinib', 'AZD8186', 'Podophyllotoxin bromide', 'P22077', 'ZM447439', 'Afuresertib', 'SCH772984', 'LY2109761', 'Bosutinib', 'MK-8776', 'RO-3306', 'Vincristine', 'Ipatasertib', 'AZD5153', 'AT13148'}, 'NCIH2009': {'UMI-77', 'Docetaxel', 'Temozolomide', 'Dactinomycin', 'Cytarabine', 'MK-1775', 'Tamoxifen', 'ZM447439', 'Gemcitabine', 'Paclitaxel', 'AZD4547', 'AZD6738', 'Dabrafenib', 'Ulixertinib'}, 'NCIH2023': {'RVX-208', 'AZD8186', 'Methotrexate', '5-Fluorouracil', 'Wee1 Inhibitor', 'Tamoxifen', 'ZM447439', 'Bosutinib', 'Topotecan', 'VE821', 'Epirubicin', 'PCI-34051', 'TW 37', 'ABT737', 'Rapamycin', 'GSK2110183B', 'OF-1', 'Gefitinib', 'Doramapimod'}, 'NCIH2029': {'Alpelisib', 'PD173074', 'PLX-4720', 'LCL161', 'Pevonedistat', 'Rucaparib', 'LGK974', 'P22077', 'PFI-1', 'Topotecan', 'Temozolomide', 'AZD7762', 'WEHI-539', 'GSK2578215A', 'Oxaliplatin', 'Bicalutamide', 'AZD3759', 'AZD5153', 'Ulixertinib'}, 'NCIH2030': {'Selumetinib', 'Niraparib', 'Trametinib', 'LGK974', 'Pictilisib', 'MK-1775', 'P22077', 'Sorafenib', 'Elesclomol', 'Wnt-C59', 'SB590885', 'AZD5363', 'SB216763', 'AZD4547', 'GSK269962A', 'BMS-536924'}, 'NCIH2052': {'Remodelin', 'MK-2206', 'PD173074', 'GDC0810', 'RVX-208', 'Staurosporine', 'VE-822', '5-Fluorouracil', 'Navitoclax', 'Tamoxifen', 'Wnt-C59', 'Epirubicin', 'IWP-2', 'WEHI-539', 'UNC0379', 'OSI-027', 'KRAS (G12C) Inhibitor-12', 'Motesanib', 'Dabrafenib'}, 'NCIH2081': {'CCT007093', 'GSK2606414', 'AZD4547', 'WIKI4', 'MK-1775', 'Cyclophosphamide', 'VX-11e', 'Elesclomol', 'Alisertib', 'Luminespib', 'CZC24832', 'PF-4708671', 'Methotrexate', 'BMS-754807', 'AMG-319', 'LY2109761'}, 'NCIH2085': {'AZD5438', 'Cyclophosphamide', 'Romidepsin', 'Taselisib', 'BIBR-1532', 'Leflunomide', 'Wee1 Inhibitor', 'Wnt-C59', 'AZD5991', 'Lenalidomide', 'GNE-317', 'LY2109761', 'glutathione', 'PFI-1', 'VE821', 'RO-3306', 'Picolinici-acid', 'Schweinfurthin A', 'AGI-5198'}, 'NCIH2087': {'Lapatinib', 'Nilotinib', 'Talazoparib', 'LCL161', 'Leflunomide', 'Fludarabine', 'Navitoclax', 'Podophyllotoxin bromide', 'Tamoxifen', 'Afuresertib', 'Lenalidomide', 'MN-64', 'Irinotecan', 'CPI-637', 'Gallibiscoquinazole', 'UNC0379', 'Buparlisib', 'GSK1904529A', 'Teniposide'}, 'NCIH209': {'MK-2206', 'Linsitinib', 'Paclitaxel', 'Venetoclax', 'Tanespimycin', 'ZM447439', 'Fulvestrant', 'Savolitinib', 'PFI-1', 'YK-4-279', 'Trametinib', 'Sepantronium bromide', 'WIKI4', 'AZD7762', 'Gallibiscoquinazole', 'Lestaurtinib', 'Doramapimod', 'Motesanib', 'UNC0638'}, 'NCIH211': {'Romidepsin', 'Niraparib', 'GNE-317', 'Lapatinib', 'Sinularin', 'Bleomycin (50 uM)', 'EPZ5676', 'Uprosertib', 'Mitoxantrone', 'JNK Inhibitor VIII', 'PD173074', 'Serdemetan', 'Nilotinib', 'OTX015', 'I-BET-762', 'PD0325901', 'Staurosporine', 'Ulixertinib'}, 'NCIH2110': {'AZD6482', 'AZD8186', 'Sapitinib', 'Navitoclax', 'VX-11e', 'Nutlin-3a (-)', 'Nilotinib', 'Gemcitabine', 'Vinorelbine', 'SGC0946', 'Rapamycin', 'SB216763', 'Methotrexate', 'Vorinostat', 'Foretinib', 'Staurosporine'}, 'NCIH2122': {'Bortezomib', 'PD173074', 'SB590885', 'AZD5363', 'RVX-208', 'AMG-319', 'Tanespimycin', 'Taselisib', 'Dacarbazine', 'Luminespib', 'BMS-754807', 'Irinotecan', 'EPZ004777', 'IWP-2', 'Erlotinib', 'Bromosporine', 'Teniposide', 'Ipatasertib', 'Dactolisib'}, 'NCIH2170': {'AZD5438', 'GSK2830371', 'PD173074', 'Camptothecin', 'Tanespimycin', 'AZD8186', 'Rucaparib', 'MIM1', 'BIBR-1532', 'Sapitinib', 'Ribociclib', 'Axitinib', 'Sepantronium bromide', 'alpha-lipoic acid', 'CZC24832', 'Bromosporine', 'GSK-LSD1', 'JNK Inhibitor VIII', 'Alisertib'}, 'NCIH2171': {'GSK1904529A', 'IOX2', 'Niraparib', 'BIBR-1532', 'Ruxolitinib', 'Telomerase Inhibitor IX', 'Sorafenib', 'Bortezomib', 'Daporinad', 'Paclitaxel', 'Picolinici-acid', 'Afuresertib', 'Nutlin-3a (-)', 'AZD4547', 'Buparlisib', 'SL0101'}, 'NCIH2172': {'Avagacestat', 'VE821', 'MK-2206', 'Temsirolimus', 'Sapitinib', 'EPZ5676', 'VX-11e', 'Ipatasertib', 'ML323', 'AGI-6780', 'Dactolisib', 'Lenalidomide', 'LCL161', 'Mirin', 'Tozasertib', 'Dabrafenib'}, 'NCIH2196': {'SL0101', 'Avagacestat', 'PRT062607', 'PFI-1', 'OF-1', 'Telomerase Inhibitor IX', 'EHT-1864', 'Serdemetan', 'Ibrutinib', 'SCH772984', 'Talazoparib', 'Fulvestrant', 'GSK269962A', 'GSK2578215A', 'Dabrafenib', 'AZD3759'}, 'NCIH2227': {'Tretinoin', 'Pyridostatin', 'Sapitinib', 'Mitoxantrone', 'AZD2014', 'CCT-018159', 'Carmustine', 'MIRA-1', 'GSK269962A', 'Irinotecan', 'EPZ004777', 'VE821', 'GSK-LSD1', 'Niraparib', 'Bicalutamide', 'JNK Inhibitor VIII', 'MG-132', 'Dactolisib', 'Dinaciclib'}, 'NCIH2228': {'Schweinfurthin A', 'A-366', 'Refametinib', 'GSK2830371', 'NVP-ADW742', 'Paclitaxel', 'AZ6102', 'LCL161', 'ZM447439', 'Wnt-C59', 'AZD5991', 'Afuresertib', 'Entospletinib', 'VE821', 'Erlotinib', 'GSK-LSD1', 'Sinularin', 'OF-1', 'Cediranib', 'Gefitinib'}, 'NCIH226': {'PLX-4720', 'Talazoparib', 'Venetoclax', 'Tanespimycin', 'VE-822', 'Romidepsin', 'LGK974', 'Uprosertib', 'Mitoxantrone', 'Serdemetan', 'GNE-317', 'XAV939', 'Elephantin', 'CPI-637', 'PCI-34051', 'Vorinostat', 'RO-3306', 'Veliparib', 'UNC0638'}, 'NCIH2291': {'Vismodegib', 'IOX2', 'Sepantronium bromide', 'Docetaxel', 'Dasatinib', 'MK-1775', 'Ribociclib', 'Axitinib', 'PFI-1', 'Osimertinib', 'LY2109761', 'GDC0810', 'Doramapimod', 'Erlotinib', 'SCH772984', 'BMS-536924'}, 'NCIH23': {'CCT007093', 'A-366', 'Dactinomycin', 'GSK2830371', 'AZD5438', 'BI-2536', 'JQ1', 'Rucaparib', 'MIM1', 'Uprosertib', 'Wnt-C59', 'alpha-lipoic acid', 'AZD7762', 'Gallibiscoquinazole', 'GSK591', 'Ipatasertib', 'Picolinici-acid', 'NU7441', 'Gefitinib'}, 'NCIH2342': {'Oxaliplatin', 'LJI308', 'Docetaxel', 'GW441756', 'Pictilisib', 'Palbociclib', 'PD173074', 'Serdemetan', 'BI-2536', 'Paclitaxel', 'Ipatasertib', 'Rapamycin', 'Vinorelbine', 'Osimertinib'}, 'NCIH2347': {'LJI308', 'MIM1', 'Uprosertib', 'AZD7762', 'Cytarabine', 'Telomerase Inhibitor IX', 'POMHEX', 'PLX-4720', 'AZD8055', 'WEHI-539', 'Lenalidomide', 'Camptothecin', 'Foretinib', 'AGI-5198'}, 'NCIH2405': {'Bortezomib', 'Olaparib', 'Pevonedistat', 'Tanespimycin', 'BIBR-1532', 'Sapitinib', 'Mitoxantrone', 'Uprosertib', 'WIKI4', 'ABT737', 'WEHI-539', 'Vorinostat', 'Bromosporine', 'RO-3306', 'Teniposide', 'OF-1', 'Lestaurtinib', 'OSI-027', 'Methotrexate'}, 'NCIH2444': {'IOX2', 'Niraparib', 'JQ1', 'GSK591', 'Rucaparib', 'Bicalutamide', 'GSK343', 'MG-132', 'Nilotinib', 'Crizotinib', 'OSI-027', 'ABT737', 'MIRA-1', 'SCH772984', 'Savolitinib', 'BMS-536924'}, 'NCIH2452': {'Vorinostat', 'Oxaliplatin', 'UMI-77', 'I-BRD9', 'BIBR-1532', 'Dactinomycin', 'Vinblastine', 'ZM447439', 'SN-38', 'Dactolisib', 'Alisertib', 'AZ6102', 'AZD4547', 'Osimertinib'}, 'NCIH28': {'Alpelisib', 'L-Oxonoreleagnine', 'Pictilisib', 'Dactinomycin', 'Bortezomib', 'PLX-4720', 'Paclitaxel', 'Pevonedistat', 'Zoledronate', 'MK-1775', 'Fludarabine', 'Wnt-C59', 'AZD8055', 'Osimertinib', 'AZD7762', 'Bromosporine', 'Sinularin', 'Ibrutinib', 'Motesanib'}, 'NCIH292': {'Bosutinib', 'Taselisib', 'Ruxolitinib', 'PRIMA-1MET', 'GSK2578215A', 'Dasatinib', 'NVP-ADW742', 'Staurosporine', 'SCH772984', 'SN-38', 'CCT-018159', 'Talazoparib', 'IWP-2', 'Foretinib', 'XAV939', 'PFI-1'}, 'NCIH3122': {'Lapatinib', 'PD173074', 'Acetalax', 'SB216763', 'Romidepsin', 'SGC-CBP30', 'Sapitinib', 'Mitoxantrone', 'Cytarabine', 'XAV939', 'Bosutinib', 'Daporinad', 'AGK2', 'TW 37', 'Niraparib', 'AZD5582', 'SGC0946', 'Motesanib', 'Ulixertinib'}, 'NCIH358': {'Pevonedistat', 'SGC-CBP30', 'Podophyllotoxin bromide', 'ZM447439', 'AZD5991', 'AZD8055', 'Lenalidomide', 'Epirubicin', 'EPZ5676', 'AZD7762', 'Dihydrorotenone', 'WEHI-539', 'Rapamycin', 'Bromosporine', 'RO-3306', 'GSK1904529A', 'GSK-LSD1', 'MG-132', 'KRAS (G12C) Inhibitor-12'}, 'NCIH441': {'Pyridostatin', 'AZD5438', 'Acetalax', 'Staurosporine', 'Zoledronate', 'Taselisib', 'Leflunomide', 'Uprosertib', 'VX-11e', 'BMS-754807', 'Fulvestrant', 'SCH772984', 'Epirubicin', 'Dihydrorotenone', 'BMS-536924', 'Temsirolimus', 'Ipatasertib', 'SGC0946', 'KRAS (G12C) Inhibitor-12'}, 'NCIH446': {'BI-2536', 'Pevonedistat', 'Tanespimycin', 'Uprosertib', '5-azacytidine', 'Serdemetan', 'AZD5991', 'PFI-1', 'LY2109761', 'glutathione', 'Obatoclax Mesylate', 'Bosutinib', 'Elephantin', 'IWP-2', 'Erlotinib', 'Veliparib', 'BMS-536924', 'AZ960', 'Sinularin'}, 'NCIH460': {'I-BRD9', 'Docetaxel', 'GW441756', 'EPZ5676', 'Temozolomide', 'Palbociclib', 'Ribociclib', 'NVP-ADW742', 'Dactolisib', 'I-BET-762', 'GDC0810', 'AZ6102', 'SB216763', 'AZD4547', 'Staurosporine', 'LY2109761'}, 'NCIH508': {'PRT062607', 'Gefitinib', 'BX795', 'Dactinomycin', 'Sapitinib', 'Linsitinib', 'NVP-ADW742', 'Dactolisib', 'AZD5363', 'Piperlongumine', 'IWP-2', 'Picolinici-acid', 'PF-4708671', 'Vismodegib', 'GSK2578215A', 'Ulixertinib'}, 'NCIH520': {'LCL161', 'Staurosporine', 'Zoledronate', 'BIBR-1532', 'P22077', 'AZD8055', 'Savolitinib', 'N-acetyl cysteine', 'AZD7762', 'TW 37', 'IWP-2', 'PRT062607', 'ABT737', 'UNC0379', 'GSK591', 'LJI308', 'Cediranib', 'Lestaurtinib', 'Ulixertinib'}, 'NCIH522': {'EHT-1864', 'LCL161', 'KU-55933', 'Crizotinib', 'AZD8055', 'Selumetinib', 'Sepantronium bromide', 'N-acetyl cysteine', 'LMP744', 'MK-8776', 'WZ4003', 'UNC0379', 'AZ960', 'Sinularin', 'Avagacestat', 'Cediranib', 'Picolinici-acid', 'AZD6738', 'UNC0638'}, 'NCIH524': {'GSK2606414', 'Pyridostatin', 'Alpelisib', 'Pictilisib', 'SB216763', 'Nelarabine', 'Ruxolitinib', 'Mitoxantrone', 'Afuresertib', 'Fulvestrant', 'Elephantin', 'Bosutinib', 'EPZ004777', 'AZD7762', 'Sabutoclax', 'Buparlisib', 'UMI-77', 'LJI308', 'MG-132'}, 'NCIH526': {'Entinostat', 'Alpelisib', 'Dasatinib', 'Cyclophosphamide', 'Bortezomib', 'Romidepsin', 'Taselisib', 'Gefitinib', 'Telomerase Inhibitor IX', 'MIRA-1', 'Selumetinib', 'N-acetyl cysteine', 'Daporinad', 'Dihydrorotenone', 'Veliparib', 'RO-3306', 'Gemcitabine', 'Schweinfurthin A', 'PD0325901'}, 'NCIH596': {'NVP-ADW742', 'PLX-4720', 'Taselisib', 'Ruxolitinib', 'VX-11e', 'ZM447439', 'ML323', 'Luminespib', 'AZD8055', 'BMS-754807', 'Bleomycin', 'CPI-637', 'WEHI-539', 'CZC24832', 'Erlotinib', 'Sinularin', 'GSK2110183B', 'Methotrexate', 'AZD3759'}, 'NCIH647': {'Vorinostat', 'AZD6482', 'I-BRD9', 'Sepantronium bromide', 'EPZ004777', 'AZD5582', 'JNK Inhibitor VIII', 'ZM447439', 'PLX-4720', 'BI-2536', 'Paclitaxel', 'Afatinib', 'Venetoclax', 'Motesanib', 'GSK269962A', 'LY2109761'}, 'NCIH650': {'Remodelin', 'Entinostat', 'A-366', 'AZD5363', 'AZD4547', 'Camptothecin', 'Taselisib', 'Sapitinib', 'Tamoxifen', 'Podophyllotoxin bromide', 'Trametinib', 'alpha-lipoic acid', 'Sabutoclax', 'Rapamycin', 'LJI308', 'Avagacestat', 'PRIMA-1MET', 'MG-132', 'Vismodegib'}, 'NCIH660': {'Taselisib', 'JQ1', 'LJI308', 'AZD5582', 'Lenalidomide', 'Sapitinib', 'NVP-ADW742', 'Bortezomib', 'MG-132', 'SN-38', 'Ipatasertib', 'AGK2', 'Venetoclax', 'Osimertinib', 'GSK2578215A', 'Dabrafenib'}, 'NCIH661': {'Paclitaxel', 'RVX-208', 'UNC0638', '5-Fluorouracil', 'SGC-CBP30', 'ZM447439', 'Elephantin', 'Entospletinib', 'Sorafenib', 'Dihydrorotenone', 'WEHI-539', 'Vorinostat', 'Mirin', 'Bromosporine', 'GSK591', 'Avagacestat', 'Vincristine', 'PRIMA-1MET', 'Dabrafenib'}, 'NCIH69': {'Pevonedistat', 'Trametinib', 'EPZ004777', 'Rucaparib', 'Bleomycin (50 uM)', 'MIM1', 'Linsitinib', 'Refametinib', 'Sorafenib', 'Nilotinib', 'Crizotinib', 'Doramapimod', 'Erlotinib', 'Dabrafenib'}, 'NCIH716': {'L-Oxonoreleagnine', 'AZ6102', 'Olaparib', 'Ruxolitinib', 'Leflunomide', '5-Fluorouracil', 'Uprosertib', '5-azacytidine', 'OTX015', 'ICL-SIRT078', 'Fulvestrant', 'MN-64', 'PCI-34051', 'Vincristine', 'GSK2110183B', 'MG-132', 'Ipatasertib', 'Gemcitabine', 'SGC0946'}, 'NCIH727': {'Afatinib', 'Nilotinib', 'Talazoparib', 'Camptothecin', 'Ruxolitinib', '5-Fluorouracil', 'Telomerase Inhibitor IX', 'Podophyllotoxin bromide', 'P22077', 'Luminespib', 'PCI-34051', 'Sorafenib', 'TW 37', 'RO-3306', 'UMI-77', 'JNK Inhibitor VIII', 'GSK2801', 'Lestaurtinib', 'Ulixertinib'}, 'NCIH747': {'EHT-1864', 'SB590885', 'Rucaparib', 'Docetaxel', 'P22077', 'ML323', 'Irinotecan', 'Epirubicin', 'Erlotinib', 'GSK2578215A', 'GSK-LSD1', 'AZ960', 'GSK2110183B', 'GSK2801', 'Alisertib', 'Gefitinib', 'AZD5153', 'AT13148', 'UNC0638'}, 'NCIH810': {'Refametinib', 'NVP-ADW742', 'GDC0810', 'LCL161', 'Telomerase Inhibitor IX', 'Podophyllotoxin bromide', 'Wnt-C59', 'OTX015', 'Fulvestrant', 'VE821', 'Sorafenib', 'TW 37', 'Vorinostat', 'Bromosporine', 'OF-1', 'Picolinici-acid', 'KRAS (G12C) Inhibitor-12', 'SGC0946', 'Methotrexate'}, 'NCIH82': {'Entinostat', 'AZD5363', 'Venetoclax', 'AMG-319', 'Dacarbazine', 'P22077', 'ZM447439', 'AZD8055', 'Afuresertib', 'GNE-317', 'Bleomycin', 'EPZ004777', 'alpha-lipoic acid', 'AZD7762', 'PCI-34051', 'Teniposide', 'Palbociclib', 'AZD5153', 'PD0325901'}, 'NCIH838': {'Bosutinib', 'Alpelisib', 'Temsirolimus', 'Linsitinib', 'PCI-34051', 'Afatinib', 'BI-2536', 'AGK2', 'AZD5363', 'Piperlongumine', 'CCT-018159', 'KRAS (G12C) Inhibitor-12', 'AZD4547', 'Foretinib', 'Tozasertib', 'Buparlisib'}, 'NCIH841': {'GSK2606414', 'I-BRD9', 'Lapatinib', 'NVP-ADW742', 'PLX-4720', 'AZD1332', 'GDC0810', 'Foretinib', 'VE-822', 'Cytarabine', 'Wnt-C59', 'Irinotecan', 'Epirubicin', 'Gallibiscoquinazole', 'UNC0379', 'AZD5582', 'GSK2110183B', 'Schweinfurthin A', 'Ulixertinib'}, 'NCIH929': {'Pictilisib', 'PLX-4720', 'AZD5363', 'Tanespimycin', 'VE-822', 'Uprosertib', 'Cytarabine', 'LY2109761', 'Selumetinib', 'Sepantronium bromide', 'AZD7762', 'Rapamycin', 'Mycophenolic acid', 'Niraparib', 'GSK2801', 'OF-1', 'Lestaurtinib', 'AT13148', 'AGI-5198'}, 'NCIN87': {'CCT007093', 'GSK591', 'Nelarabine', 'AZD8186', 'Docetaxel', 'MIM1', 'Palbociclib', 'Axitinib', 'VX-11e', 'Mitoxantrone', 'PD173074', 'Dihydrorotenone', 'Luminespib', 'Rapamycin', 'SB216763', 'Dinaciclib', 'Dabrafenib', 'Zoledronate'}, 'NH12': {'Entinostat', 'Nilotinib', 'Venetoclax', 'RVX-208', 'Pevonedistat', 'Sapitinib', 'Uprosertib', 'AZD5991', 'Nutlin-3a (-)', 'Savolitinib', 'YK-4-279', 'Sepantronium bromide', 'BMS-536924', 'Mycophenolic acid', 'GSK591', 'Palbociclib', 'Gefitinib', 'Vismodegib', 'AZD3759'}, 'NMCG1': {'VE-822', 'Vorinostat', 'CHIR-99021', 'GW441756', 'Dasatinib', 'N-acetyl cysteine', 'Navitoclax', 'EHT-1864', 'GDC0810', 'Picolinici-acid', 'I-BET-762', 'WZ4003', 'WEHI-539', 'Erlotinib', 'XAV939', 'BMS-536924'}, 'NO10': {'YK-4-279', 'Taselisib', 'Epirubicin', 'Palbociclib', 'Wee1 Inhibitor', 'Elesclomol', 'Afatinib', 'ZM447439', 'OTX015', 'I-BET-762', 'GDC0810', 'Afuresertib', 'Paclitaxel', 'Olaparib', 'GSK269962A', 'PFI3'}, 'NOMO1': {'Entinostat', 'Lapatinib', 'PLX-4720', 'BMS-345541', 'Talazoparib', 'SB216763', 'RVX-208', 'MK-1775', 'Dacarbazine', 'ICL-SIRT078', 'Lenalidomide', 'LY2109761', 'Elephantin', 'Cisplatin', 'LMP744', 'Bromosporine', 'JNK Inhibitor VIII', 'Gefitinib', 'Dinaciclib'}, 'NOS1': {'Lapatinib', 'L-Oxonoreleagnine', 'Pictilisib', 'LGK974', 'Wnt-C59', 'ML323', 'AZD5991', 'Luminespib', 'Osimertinib', 'Bleomycin', 'LY2109761', 'Entospletinib', 'IWP-2', 'Mycophenolic acid', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'GW441756', 'GSK343', 'AZD5153'}, 'NTERA2CLD1': {'GSK591', 'BIBR-1532', 'Cisplatin', 'WIKI4', 'Dactinomycin', 'Uprosertib', 'Cediranib', 'VX-11e', 'Nilotinib', 'Crizotinib', 'TW 37', 'ICL-SIRT078', 'Savolitinib', 'Veliparib'}, 'NUDUL1': {'GSK2606414', 'Bosutinib', 'PRIMA-1MET', 'EPZ5676', 'Uprosertib', 'Tamoxifen', 'MK-8776', 'P22077', 'Wnt-C59', 'SB590885', 'Picolinici-acid', 'LCL161', 'AT13148', 'XAV939', 'AMG-319', 'PFI-1'}, 'NUGC3': {'MK-2206', 'Acetalax', 'BMS-345541', 'Olaparib', 'Taselisib', '5-Fluorouracil', 'Mitoxantrone', 'VX-11e', 'AZD2014', 'BMS-754807', 'XAV939', 'YK-4-279', 'PRT062607', 'RO-3306', 'GSK2801', 'Ipatasertib', 'Schweinfurthin A', 'Vinorelbine', 'Motesanib'}, 'NUGC4': {'EHT-1864', 'I-BET-762', 'SB216763', 'LCL161', 'VE-822', '5-Fluorouracil', 'MIM1', 'SGC-CBP30', 'AZD5991', 'Bosutinib', 'CPI-637', 'MK-8776', 'Rapamycin', 'Veliparib', 'AZ960', 'Teniposide', 'KRAS (G12C) Inhibitor-12', 'Methotrexate', 'Dinaciclib'}, 'OACM51': {'Lapatinib', 'Bortezomib', 'Paclitaxel', 'AGI-6780', 'AZD4547', 'Pevonedistat', 'Leflunomide', 'Vinblastine', 'ICL-SIRT078', 'Fulvestrant', 'glutathione', 'CPI-637', 'Sabutoclax', 'Dihydrorotenone', 'Rapamycin', 'GSK-LSD1', 'Teniposide', 'MG-132', 'AGI-5198'}, 'OAW42': {'GSK2606414', 'EPZ004777', 'L-Oxonoreleagnine', 'Alpelisib', 'Sapitinib', 'Palbociclib', 'Dactinomycin', 'PCI-34051', 'Podophyllotoxin bromide', 'Wnt-C59', 'Crizotinib', 'Dihydrorotenone', 'SGC0946', 'Nutlin-3a (-)', 'SB216763', 'Erlotinib', 'Staurosporine'}, 'OC314': {'Tanespimycin', 'Bosutinib', 'I-BRD9', 'Avagacestat', 'EPZ004777', 'GSK343', 'Lestaurtinib', 'Daporinad', 'OSI-027', 'ABT737', 'Luminespib', 'ICL-SIRT078', 'Olaparib', 'UNC0379'}, 'OCIAML2': {'I-BRD9', 'L-Oxonoreleagnine', 'PLX-4720', 'Nilotinib', 'RVX-208', 'Zoledronate', 'Ruxolitinib', '5-Fluorouracil', 'Cytarabine', 'BMS-754807', 'Bleomycin', 'Epirubicin', 'WZ4003', 'Veliparib', 'LJI308', 'Picolinici-acid', 'AZD5153', 'Vinorelbine', 'Dabrafenib'}, 'OCIAML3': {'Nelarabine', 'Teniposide', 'Docetaxel', 'GSK343', 'MK-1775', 'Linsitinib', 'Navitoclax', 'RVX-208', 'Dactolisib', 'AGK2', 'IWP-2', 'WZ4003', 'Dihydrorotenone', 'Lenalidomide', 'Olaparib', 'Motesanib', 'GSK2578215A', 'UNC0638'}, 'OCIAML5': {'Oxaliplatin', 'Selumetinib', 'Romidepsin', 'Topotecan', 'MK-2206', 'Teniposide', 'Dasatinib', 'POMHEX', 'Serdemetan', 'PLX-4720', 'KRAS (G12C) Inhibitor-12', 'BMS-345541', 'WEHI-539', 'AZD5153', 'Motesanib', 'Ulixertinib'}, 'OCILY19': {'Tanespimycin', 'BIBR-1532', 'Leflunomide', 'MK-2206', 'EPZ5676', 'Dactinomycin', 'Ribociclib', 'RVX-208', 'OTX015', 'AGI-6780', 'OSI-027', 'AZ6102', 'Nutlin-3a (-)', 'Vismodegib', 'Vorinostat', 'AGI-5198'}, 'OCILY7': {'Irinotecan', 'Selumetinib', 'AZ960', 'Bosutinib', 'Dasatinib', 'AZD7762', 'Sapitinib', 'Sorafenib', 'Lestaurtinib', 'Wnt-C59', 'AZD5363', 'Erlotinib', 'GNE-317', 'XAV939', 'Veliparib', 'BMS-536924'}, 'OCIM1': {'CCT007093', 'L-Oxonoreleagnine', 'Dactinomycin', 'SB590885', 'Olaparib', 'BIBR-1532', 'Docetaxel', 'Serdemetan', 'Luminespib', 'Osimertinib', 'Savolitinib', 'VE821', 'WZ4003', 'Gallibiscoquinazole', 'AZ960', 'LJI308', 'Vincristine', 'Gefitinib', 'Vismodegib'}, 'OCUM1': {'Lapatinib', 'LCL161', 'Tanespimycin', 'VE-822', 'JQ1', 'Ruxolitinib', 'Dacarbazine', 'Podophyllotoxin bromide', 'Luminespib', 'XAV939', 'TW 37', 'CZC24832', 'Mirin', 'Bromosporine', 'Buparlisib', 'GSK1904529A', 'Gemcitabine', 'Alisertib', 'Doramapimod'}, 'OE19': {'Linsitinib', 'PLX-4720', 'AZD5363', 'Acetalax', 'RVX-208', 'Foretinib', 'VE-822', 'BIBR-1532', 'Ruxolitinib', 'Cytarabine', 'Serdemetan', 'AZD8055', 'Lenalidomide', 'LY2109761', 'YK-4-279', 'Bosutinib', 'Sepantronium bromide', 'AGK2', 'Alisertib'}, 'OE21': {'Remodelin', 'MK-2206', 'Pictilisib', 'AZD5438', 'GSK2830371', 'EHT-1864', 'AGI-6780', 'SB216763', 'AZD4547', 'Zoledronate', 'AZD5991', 'Bleomycin', 'XAV939', 'Topotecan', 'AZD7762', 'MK-8776', 'CZC24832', 'Bromosporine', 'Ipatasertib'}, 'OE33': {'GSK2606414', 'MK-2206', 'AZD1332', 'AMG-319', 'JQ1', 'Rucaparib', 'MK-1775', '5-azacytidine', 'LY2109761', 'PFI-1', 'Elephantin', 'EPZ004777', 'EPZ5676', 'MK-8776', 'WEHI-539', 'Teniposide', 'Dactolisib', 'Schweinfurthin A', 'Motesanib'}, 'ONS76': {'Entinostat', 'L-Oxonoreleagnine', 'Pictilisib', 'Cyclophosphamide', 'JQ1', 'BIBR-1532', 'MK-1775', 'Cytarabine', 'P22077', 'MIRA-1', 'Savolitinib', 'LY2109761', 'Bosutinib', 'EPZ5676', 'Daporinad', 'ABT737', 'UMI-77', 'Gemcitabine', 'AZD3759'}, 'OPM2': {'Dactinomycin', 'Dasatinib', 'GDC0810', 'Olaparib', 'Axitinib', 'ZM447439', 'Nutlin-3a (-)', 'Fulvestrant', 'SCH772984', 'VE821', 'MK-8776', 'ABT737', 'Gallibiscoquinazole', 'Veliparib', 'PFI3', 'GSK343', 'Palbociclib', 'Dactolisib', 'Gefitinib'}, 'OSC19': {'RO-3306', 'GW441756', 'Refametinib', 'Camptothecin', 'Dactinomycin', 'Elesclomol', 'Ibrutinib', 'ML323', 'PD173074', 'I-BET-762', 'BMS-345541', 'CZC24832', 'Doramapimod', 'RVX-208', 'Staurosporine', 'AGI-5198'}, 'OSC20': {'NVP-ADW742', 'Paclitaxel', 'Acetalax', 'KU-55933', '5-Fluorouracil', 'Navitoclax', 'P22077', 'AZD2014', 'AZD8055', 'Nutlin-3a (-)', 'Irinotecan', 'Epirubicin', 'AGK2', 'CZC24832', 'GSK591', 'UMI-77', 'LJI308', 'Teniposide', 'Gemcitabine'}, 'OSRC2': {'GSK2606414', 'SB590885', 'AGI-6780', 'BMS-345541', 'AZD4547', 'AMG-319', 'Tanespimycin', 'AZD8186', '5-azacytidine', 'Savolitinib', 'LMP744', 'MK-8776', 'GSK2578215A', 'GSK591', 'OF-1', 'Ipatasertib', 'Dactolisib', 'NU7441', 'Doramapimod'}, 'OV17R': {'YK-4-279', 'Avagacestat', 'MK-2206', 'Epirubicin', 'Leflunomide', 'AT13148', 'EHT-1864', 'Serdemetan', 'Dactolisib', 'Piperlongumine', 'Alisertib', 'PF-4708671', 'Erlotinib', 'Foretinib', 'Staurosporine', 'AZD3759'}, 'OV56': {'Remodelin', 'PLX-4720', 'GDC0810', 'AZD5363', 'Staurosporine', 'Pevonedistat', 'Tanespimycin', 'VE-822', 'Taselisib', 'Podophyllotoxin bromide', 'Nutlin-3a (-)', 'Selumetinib', 'alpha-lipoic acid', 'GSK2578215A', 'AZ960', 'LJI308', 'Vismodegib', 'Motesanib', 'AGI-5198'}, 'OV7': {'Niraparib', 'Trametinib', 'Lapatinib', 'Pictilisib', 'Palbociclib', 'Ribociclib', 'OF-1', 'ZM447439', 'Ibrutinib', 'BI-2536', 'OTX015', 'AGI-6780', 'ABT737', 'Gemcitabine', 'PD173074', 'Dabrafenib'}, 'OV90': {'Pictilisib', 'Camptothecin', 'AZD2014', 'ZM447439', 'Carmustine', 'Fulvestrant', 'XAV939', 'glutathione', 'Elephantin', 'PCI-34051', 'CZC24832', 'GSK1904529A', 'GSK591', 'GSK2801', 'OF-1', 'Alisertib', 'Gefitinib', 'Dinaciclib', 'AZD3759'}, 'OVCAR4': {'CCT007093', 'Bortezomib', 'AZD5363', 'AZ6102', 'Venetoclax', 'Pevonedistat', 'Ribociclib', 'ICL-SIRT078', 'MN-64', 'Sepantronium bromide', 'Sabutoclax', 'Rapamycin', 'Erlotinib', 'Mycophenolic acid', 'Avagacestat', 'Temsirolimus', 'MG-132', 'OSI-027', 'Ulixertinib'}, 'OVCAR5': {'Pyridostatin', 'GSK2830371', 'NVP-ADW742', 'AZD5363', 'Olaparib', 'SGC-CBP30', 'Dacarbazine', 'Vinblastine', 'P22077', 'Afuresertib', 'MK-8776', 'Sorafenib', 'Dihydrorotenone', 'Vorinostat', 'Erlotinib', 'GSK1904529A', 'AZ960', 'Doramapimod', 'AT13148'}, 'OVCAR8': {'L-Oxonoreleagnine', 'Romidepsin', 'Nelarabine', 'Wee1 Inhibitor', 'Telomerase Inhibitor IX', 'Irinotecan', 'Dihydrorotenone', 'PRT062607', 'Gallibiscoquinazole', 'UNC0379', 'Veliparib', 'Bromosporine', 'Buparlisib', 'BMS-536924', 'GSK-LSD1', 'LJI308', 'Lestaurtinib', 'OSI-027', 'Schweinfurthin A'}, 'OVISE': {'Talazoparib', 'AZD8186', 'LGK974', 'SGC-CBP30', 'Podophyllotoxin bromide', 'P22077', 'ML323', 'Nutlin-3a (-)', 'SCH772984', 'Trametinib', 'Epirubicin', 'MK-8776', 'GSK591', 'LJI308', 'PRIMA-1MET', 'GSK343', 'OF-1', 'Dinaciclib', 'Dabrafenib'}, 'OVK18': {'I-BRD9', 'Talazoparib', 'Mitoxantrone', 'Tamoxifen', 'AZD2014', 'AZD5991', 'Nutlin-3a (-)', 'Lenalidomide', 'Topotecan', 'MK-8776', 'IWP-2', 'PRT062607', 'WEHI-539', 'Mirin', 'RO-3306', 'LJI308', 'OF-1', 'Gemcitabine', 'Vinorelbine'}, 'OVKATE': {'CPI-637', 'AZD8186', 'GSK2578215A', 'GSK343', 'Cytarabine', 'Daporinad', 'Serdemetan', 'Afatinib', 'TW 37', 'Afuresertib', 'AZD6738', 'Methotrexate', 'MIRA-1', 'SCH772984'}, 'OVTOKO': {'Lapatinib', 'PLX-4720', 'Talazoparib', 'AZD4547', 'VE-822', 'Wee1 Inhibitor', 'ML323', 'Crizotinib', 'Dihydrorotenone', 'Rapamycin', 'Veliparib', 'UMI-77', 'LJI308', 'PRIMA-1MET', 'Palbociclib', 'SGC0946', 'Gefitinib', 'AZD5153', 'Dabrafenib'}, 'P12ICHIKAWA': {'WIKI4', 'GW441756', 'Docetaxel', 'Uprosertib', 'PCI-34051', 'P22077', 'Tamoxifen', 'Nilotinib', 'SCH772984', 'I-BET-762', 'Vinorelbine', 'AZD5363', 'Venetoclax', 'KU-55933', 'MIRA-1', 'Staurosporine', 'AMG-319'}, 'P30OHK': {'Dactinomycin', 'GDC0810', 'VE-822', 'Romidepsin', 'Rucaparib', 'Navitoclax', 'Cytarabine', 'AZD2014', 'Serdemetan', 'AZD8055', 'Irinotecan', 'Entospletinib', 'N-acetyl cysteine', 'Temozolomide', 'IWP-2', 'Niraparib', 'GW441756', 'GSK343', 'Ibrutinib'}, 'P31FUJ': {'CCT007093', 'Pevonedistat', 'MIM1', 'Doramapimod', 'Pictilisib', 'GSK2830371', 'Navitoclax', 'Lestaurtinib', 'SGC0946', 'Nutlin-3a (-)', 'Vismodegib', 'PD0325901', 'AZD6738', 'AMG-319'}, 'PA1': {'Talazoparib', 'Venetoclax', 'Staurosporine', 'Ruxolitinib', '5-Fluorouracil', 'Afuresertib', 'Osimertinib', 'Savolitinib', 'PFI-1', 'EPZ004777', 'Topotecan', 'Temozolomide', 'IWP-2', 'GSK1904529A', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'JNK Inhibitor VIII', 'Schweinfurthin A', 'Doramapimod'}, 'PANC0203': {'Linsitinib', 'SB216763', 'Docetaxel', 'MK-1775', 'Axitinib', 'ZM447439', 'Obatoclax Mesylate', 'Topotecan', 'WIKI4', 'PFI3', 'Vincristine', 'Teniposide', 'OF-1', 'MG-132', 'Alisertib', 'Schweinfurthin A', 'AZD5153', 'Vinorelbine', 'AZD6738'}, 'PANC0327': {'YK-4-279', 'BIBR-1532', 'WIKI4', 'Refametinib', 'N-acetyl cysteine', 'Camptothecin', 'Cytarabine', 'ZM447439', 'OSI-027', 'Luminespib', 'Afuresertib', 'Vismodegib', 'AT13148', 'BMS-536924'}, 'PANC0403': {'YK-4-279', 'Pyridostatin', 'WIKI4', 'Dasatinib', 'Uprosertib', 'Cediranib', 'VX-11e', 'MK-8776', 'POMHEX', 'Serdemetan', 'Afatinib', 'ABT737', 'Vorinostat', 'UNC0379'}, 'PANC0813': {'SB590885', 'Acetalax', 'Olaparib', 'AZD8186', 'SGC-CBP30', 'Mitoxantrone', '5-azacytidine', 'AZD2014', 'GNE-317', 'XAV939', 'EPZ004777', 'N-acetyl cysteine', 'POMHEX', 'IWP-2', 'UNC0379', 'Buparlisib', 'SGC0946', 'Schweinfurthin A', 'Dabrafenib'}, 'PANC1005': {'Refametinib', 'GSK2830371', 'BI-2536', 'Olaparib', 'KU-55933', 'Rucaparib', 'Selumetinib', 'Topotecan', 'Cisplatin', 'Daporinad', 'TW 37', 'Dihydrorotenone', 'PRT062607', 'WEHI-539', 'Mycophenolic acid', 'AZD5582', 'SN-38', 'Dactolisib', 'AZD5153'}, 'PATU8902': {'A-366', 'Dactinomycin', 'Linsitinib', 'PD173074', 'Nilotinib', 'I-BET-762', 'AZ6102', 'Camptothecin', 'Docetaxel', 'Navitoclax', 'Cytarabine', 'Luminespib', 'Fulvestrant', 'Topotecan', 'Cisplatin', 'ABT737', 'GW441756', 'Ipatasertib', 'Gefitinib'}, 'PATU8988T': {'Dasatinib', 'NVP-ADW742', 'AZD1208', 'AZ6102', 'AMG-319', 'Tanespimycin', 'Serdemetan', 'AZD8055', 'glutathione', 'Topotecan', 'N-acetyl cysteine', 'LMP744', 'WZ4003', 'WEHI-539', 'Oxaliplatin', 'JNK Inhibitor VIII', 'MG-132', 'OSI-027', 'Ulixertinib'}, 'PC14': {'Nilotinib', 'GDC0810', 'JQ1', 'SB505124', 'LGK974', 'Navitoclax', 'P22077', 'Crizotinib', 'BMS-754807', 'ICL-SIRT078', 'Cisplatin', 'EPZ5676', 'ABT737', 'Vorinostat', 'Erlotinib', 'Niraparib', 'UMI-77', 'Avagacestat', 'LJI308', 'JNK Inhibitor VIII', 'GSK2801', 'Picolinici-acid'}, 'PC3': {'L-Oxonoreleagnine', 'Linsitinib', 'Dasatinib', 'PLX-4720', 'Nilotinib', 'Paclitaxel', 'Romidepsin', 'Uprosertib', 'Navitoclax', 'P22077', 'Telomerase Inhibitor IX', 'OTX015', 'Fulvestrant', 'GNE-317', 'Topotecan', 'Temozolomide', 'POMHEX', 'AZ960', 'Methotrexate'}, 'PECAPJ15': {'Irinotecan', 'Tretinoin', 'Lapatinib', 'Sapitinib', 'Temozolomide', 'Cyclophosphamide', 'Buparlisib', 'Sabutoclax', 'ZM447439', 'AGK2', 'Gemcitabine', 'SGC0946', 'Camptothecin', 'Erlotinib', 'Tozasertib', 'AGI-5198'}, 'PEO1': {'Alpelisib', 'L-Oxonoreleagnine', 'AZD1208', 'BMS-345541', 'Sapitinib', 'Cytarabine', 'OTX015', 'Afuresertib', 'Fulvestrant', 'MIRA-1', 'Osimertinib', 'GNE-317', 'Elephantin', 'AGK2', 'Buparlisib', 'GSK591', 'GSK343', 'MG-132', 'KRAS (G12C) Inhibitor-12'}, 'PF382': {'MK-2206', 'L-Oxonoreleagnine', 'AZD5438', 'Afatinib', 'Talazoparib', 'BIBR-1532', 'Uprosertib', 'Navitoclax', 'SCH772984', 'glutathione', 'Topotecan', 'EPZ5676', 'MK-8776', 'ABT737', 'CZC24832', 'JNK Inhibitor VIII', 'OF-1', 'Dactolisib', 'Alisertib'}, 'PFSK1': {'GSK2606414', 'VE-822', 'LJI308', 'Nelarabine', 'EPZ004777', 'MK-2206', 'GSK343', 'Sapitinib', 'Fludarabine', 'Cediranib', 'NVP-ADW742', 'Wnt-C59', 'AZD5991', 'Schweinfurthin A', 'Vorinostat', 'AZD6738'}, 'PL21': {'MN-64', 'Pevonedistat', 'AZ960', 'Lapatinib', 'GW441756', 'GSK343', 'Linsitinib', 'Dasatinib', 'Cediranib', 'Ribociclib', 'Axitinib', 'Lestaurtinib', 'AZD5363', 'Afuresertib', 'Dinaciclib', 'RO-3306'}, 'PSN1': {'Pictilisib', 'AZD1332', 'I-BET-762', 'SB216763', 'Foretinib', 'VE-822', 'MIM1', 'LGK974', 'glutathione', 'Topotecan', 'EPZ004777', 'PFI3', 'Oxaliplatin', 'Mycophenolic acid', 'Vincristine', 'PRIMA-1MET', 'JNK Inhibitor VIII', 'GW441756', 'Picolinici-acid'}, 'QGP1': {'CCT007093', 'Lapatinib', 'Alpelisib', 'Pictilisib', 'Cyclophosphamide', 'SB590885', 'AGI-6780', 'SB216763', 'LCL161', 'Foretinib', 'Tanespimycin', 'Epirubicin', 'Sabutoclax', 'Sinularin', 'AZD5582', 'Teniposide', 'OF-1', 'SN-38', 'Dinaciclib'}, 'RAJI': {'CCT007093', 'Entinostat', 'BI-2536', 'GDC0810', 'BMS-345541', 'Camptothecin', 'Vinblastine', 'ML323', 'Carmustine', 'Selumetinib', 'Cisplatin', 'POMHEX', 'ABT737', 'Vinorelbine', 'GSK-LSD1', 'Teniposide', 'NU7441', 'Gefitinib', 'Methotrexate'}, 'RCC10RGB': {'Refametinib', 'Cyclophosphamide', 'PLX-4720', 'AZD5363', 'Romidepsin', 'Nelarabine', 'MK-1775', 'Nutlin-3a (-)', 'ICL-SIRT078', 'Savolitinib', 'Trametinib', 'Sabutoclax', 'Gallibiscoquinazole', 'Bromosporine', 'AZ960', 'UMI-77', 'JNK Inhibitor VIII', 'GSK2110183B', 'GSK2801'}, 'RCHACV': {'Vorinostat', 'I-BRD9', 'AZD5582', 'GSK343', 'Palbociclib', 'VX-11e', 'Lestaurtinib', 'PLX-4720', 'SB590885', 'Dactolisib', 'GDC0810', 'Piperlongumine', 'KU-55933', 'Osimertinib', 'AGI-5198', 'PFI-1'}, 'RCK8': {'YK-4-279', 'Irinotecan', 'Niraparib', 'EPZ004777', 'WIKI4', 'JNK Inhibitor VIII', 'Pictilisib', 'PCI-34051', 'Navitoclax', 'Ribociclib', 'Acetalax', 'IWP-2', 'CZC24832', 'ICL-SIRT078', 'Vinorelbine', 'Vorinostat', 'Erlotinib'}, 'RCM1': {'GSK2606414', 'I-BRD9', 'Cyclophosphamide', 'Taselisib', 'Rucaparib', 'Sapitinib', 'Cytarabine', 'Wee1 Inhibitor', 'AZD2014', 'Wnt-C59', 'MIRA-1', 'Obatoclax Mesylate', 'MN-64', 'PCI-34051', 'POMHEX', 'TW 37', 'Vorinostat', 'UNC0379', 'RO-3306', 'Ulixertinib'}, 'RD': {'Entinostat', 'Bortezomib', 'Nilotinib', 'AZD1332', 'AZ6102', 'RVX-208', 'Ruxolitinib', 'MIM1', 'Docetaxel', 'Uprosertib', 'Telomerase Inhibitor IX', 'AZD2014', 'AZD8055', 'Fulvestrant', 'Osimertinib', 'WIKI4', 'UNC0379', 'Gefitinib', 'AGI-5198'}, 'REH': {'GSK2606414', 'Cyclophosphamide', 'GDC0810', 'Camptothecin', 'AZD4547', 'Tanespimycin', 'AZD8186', 'BIBR-1532', 'Docetaxel', 'LGK974', 'MIM1', 'Wnt-C59', 'Afuresertib', 'BMS-754807', 'alpha-lipoic acid', 'AGK2', 'TW 37', 'CZC24832', 'Dabrafenib'}, 'RERFGC1B': {'Remodelin', 'Paclitaxel', 'JQ1', 'VX-11e', 'AZD2014', 'MIRA-1', 'Bleomycin', 'PFI-1', 'YK-4-279', 'MN-64', 'alpha-lipoic acid', 'Epirubicin', 'UNC0379', 'Oxaliplatin', 'Gemcitabine', 'Picolinici-acid', 'NU7441', 'OSI-027', 'AZD3759'}, 'RERFLCKJ': {'Pyridostatin', 'Refametinib', 'Cyclophosphamide', 'SB590885', 'AZD5363', 'Sapitinib', 'Dacarbazine', 'Navitoclax', 'AZD2014', 'Fulvestrant', 'SCH772984', 'Savolitinib', 'MK-8776', 'Mirin', 'GSK2578215A', 'GSK-LSD1', 'Niraparib', 'KRAS (G12C) Inhibitor-12', 'AZD5153'}, 'RERFLCMS': {'Tretinoin', 'AZD6482', 'VE821', '5-Fluorouracil', 'Pictilisib', 'MK-1775', 'Dasatinib', 'Navitoclax', 'Ribociclib', 'Tamoxifen', 'MK-8776', 'CCT-018159', 'Afuresertib', 'Lenalidomide', 'Fulvestrant', 'AMG-319'}, 'RERFLCSQ1': {'I-BRD9', 'Refametinib', 'Nilotinib', 'AZD1332', 'Taselisib', 'BIBR-1532', 'Ruxolitinib', 'MIM1', 'Leflunomide', 'Methotrexate', 'Fludarabine', 'Mitoxantrone', 'Axitinib', 'P22077', 'Serdemetan', 'UNC0379', 'GSK2110183B', 'Dactolisib', 'Vismodegib'}, 'RH18': {'NU7441'}, 'RH41': {'Lapatinib', 'L-Oxonoreleagnine', 'Cyclophosphamide', 'Venetoclax', 'AZD4547', 'KU-55933', 'JQ1', 'LGK974', 'Cytarabine', 'AZD8055', 'Savolitinib', 'MN-64', 'Irinotecan', 'Bosutinib', 'Epirubicin', 'PCI-34051', 'CZC24832', 'GSK2578215A', 'Doramapimod'}, 'RKN': {'Lapatinib', 'Linsitinib', 'Afatinib', 'Paclitaxel', 'AGI-6780', 'AZD4547', 'KU-55933', 'Zoledronate', 'Sapitinib', 'Wee1 Inhibitor', '5-azacytidine', 'P22077', 'Carmustine', 'PCI-34051', 'Sabutoclax', 'Buparlisib', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'Lestaurtinib'}, 'RKO': {'L-Oxonoreleagnine', 'Talazoparib', 'SB216763', 'BIBR-1532', 'Leflunomide', 'P22077', 'ML323', 'OTX015', 'Afuresertib', 'GNE-317', 'SCH772984', 'XAV939', 'LY2109761', 'EPZ004777', 'Temozolomide', 'WEHI-539', 'Picolinici-acid', 'AZD6738', 'UNC0638'}, 'RL': {'Irinotecan', 'BIBR-1532', 'Sepantronium bromide', 'Refametinib', 'Temozolomide', 'GSK343', 'P22077', 'EHT-1864', 'SN-38', 'Paclitaxel', 'AZ6102', 'KU-55933', 'Vorinostat', 'GSK2578215A', 'RO-3306', 'LY2109761'}, 'RL952': {'Refametinib', 'Cyclophosphamide', 'NVP-ADW742', 'LCL161', 'Tanespimycin', 'Romidepsin', 'AZD5991', 'PFI-1', 'Elephantin', 'EPZ5676', 'Vorinostat', 'UNC0379', 'UMI-77', 'Doramapimod', 'GSK2110183B', 'Palbociclib', 'Cediranib', 'Methotrexate', 'Dabrafenib'}, 'RMGI': {'Selumetinib', 'Pyridostatin', 'A-366', 'Docetaxel', 'Dactinomycin', 'GSK2830371', 'SN-38', 'SB590885', 'AGK2', 'Luminespib', 'Nutlin-3a (-)', 'KU-55933', 'AZD6738', 'AMG-319'}, 'RO82W1': {'PD173074', 'Paclitaxel', 'I-BET-762', 'Venetoclax', 'Rucaparib', 'Docetaxel', 'MK-1775', 'Tamoxifen', 'Luminespib', 'Lenalidomide', 'SCH772984', 'Savolitinib', 'Irinotecan', 'WIKI4', 'GSK1904529A', 'AZD5582', 'Dactolisib', 'Alisertib', 'Gefitinib'}, 'RPMI7951': {'L-Oxonoreleagnine', 'Afatinib', 'AZD1332', 'Telomerase Inhibitor IX', 'Luminespib', 'Nutlin-3a (-)', 'PFI-1', 'CPI-637', 'Topotecan', 'PCI-34051', 'IWP-2', 'Gallibiscoquinazole', 'RO-3306', 'BMS-536924', 'Bleomycin (50 uM)', 'SN-38', 'Ipatasertib', 'Vismodegib', 'Motesanib'}, 'RPMI8226': {'I-BRD9', 'Lapatinib', 'Dasatinib', 'AZD5363', 'Staurosporine', 'MIM1', 'Uprosertib', 'Dacarbazine', 'Ribociclib', 'Wnt-C59', 'GNE-317', 'YK-4-279', 'LMP744', 'PRT062607', 'Oxaliplatin', 'Avagacestat', 'AZD5582', 'Ipatasertib', 'OSI-027'}, 'RPMI8402': {'CCT007093', 'Tanespimycin', 'LJI308', 'Lapatinib', 'EPZ5676', 'Pictilisib', 'Ribociclib', 'Daporinad', 'Paclitaxel', 'Ulixertinib', 'WEHI-539', 'Vinorelbine', 'Erlotinib', 'BMS-536924'}, 'RS411': {'PD173074', 'SB590885', 'Paclitaxel', 'Dinaciclib', 'Nelarabine', 'Rucaparib', 'AZD5991', 'BMS-754807', 'PFI-1', 'Sepantronium bromide', 'VE821', 'EPZ5676', 'Sabutoclax', 'POMHEX', 'GSK2578215A', 'GSK591', 'Dactolisib', 'AZD5153', 'PD0325901'}, 'RT112': {'AZD5438', 'AZD1332', 'BMS-345541', 'LCL161', 'Taselisib', 'Dacarbazine', 'Ribociclib', 'Nutlin-3a (-)', 'BMS-754807', 'AZD7762', 'Daporinad', 'CZC24832', 'Vorinostat', 'Avagacestat', 'Bleomycin (50 uM)', 'Ibrutinib', 'Ipatasertib', 'Alisertib', 'AZD3759'}, 'RT4': {'MK-2206', 'Alpelisib', 'Dactinomycin', 'I-BET-762', 'AZD5363', 'KU-55933', 'BIBR-1532', 'Ruxolitinib', 'Axitinib', 'AZD5991', 'Afuresertib', 'Nutlin-3a (-)', 'Lenalidomide', 'Fulvestrant', 'Sabutoclax', 'LJI308', 'GSK2801', 'Ibrutinib', 'AZD5153'}, 'RVH421': {'Tanespimycin', 'VE-822', 'I-BRD9', 'Tozasertib', 'AZD5582', 'CHIR-99021', 'Sepantronium bromide', 'Temsirolimus', 'Nutlin-3a (-)', 'RVX-208', 'Afatinib', 'Ipatasertib', 'Rapamycin', 'Motesanib', 'AT13148', 'AZD6738'}, 'SAOS2': {'EHT-1864', 'BI-2536', 'AZD1332', 'AZD1208', 'Nelarabine', 'Docetaxel', 'Crizotinib', 'Nutlin-3a (-)', 'SCH772984', 'YK-4-279', 'Epirubicin', 'PRT062607', 'Mirin', 'AZ960', 'LJI308', 'GSK343', 'Cediranib', 'Dactolisib', 'UNC0638'}, 'SAS': {'Bortezomib', 'SB590885', 'AZD4547', 'LCL161', 'KU-55933', 'Zoledronate', 'Leflunomide', 'Uprosertib', 'Podophyllotoxin bromide', 'CPI-637', 'WZ4003', 'Erlotinib', 'UNC0379', 'GSK-LSD1', 'GW441756', 'Temsirolimus', 'GSK2801', 'Gemcitabine', 'KRAS (G12C) Inhibitor-12'}, 'SAT': {'AZD5438', 'Linsitinib', 'I-BET-762', 'Talazoparib', 'AZ6102', 'BMS-345541', 'VE-822', 'MIM1', 'LGK974', 'MK-1775', 'AZD5991', 'glutathione', 'N-acetyl cysteine', 'Bromosporine', 'Teniposide', 'Temsirolimus', 'Palbociclib', 'Ibrutinib', 'SN-38'}, 'SBC5': {'CCT007093', 'Romidepsin', 'MK-1775', 'Mitoxantrone', 'ZM447439', 'Serdemetan', 'Crizotinib', 'Lenalidomide', 'XAV939', 'VE821', 'Temozolomide', 'Sorafenib', 'Erlotinib', 'UNC0379', 'Bromosporine', 'Oxaliplatin', 'JNK Inhibitor VIII', 'Palbociclib', 'AZD3759'}, 'SCC15': {'Remodelin', 'AZD5363', 'Talazoparib', 'Venetoclax', 'KU-55933', 'Zoledronate', 'SGC-CBP30', 'AZD2014', 'Osimertinib', 'Elephantin', 'CPI-637', 'Sepantronium bromide', 'Cisplatin', 'alpha-lipoic acid', 'WIKI4', 'AZD7762', 'Mirin', 'Oxaliplatin', 'Niraparib'}, 'SCC25': {'Vismodegib', 'GSK591', 'BIBR-1532', 'Temsirolimus', 'Linsitinib', 'Uprosertib', 'Buparlisib', 'Ibrutinib', 'SN-38', 'SB590885', 'Gefitinib', 'Vinorelbine', 'Vorinostat', 'Dinaciclib', 'Staurosporine', 'RO-3306'}, 'SCC3': {'Entinostat', 'A-366', 'AGI-6780', 'AZ6102', 'RVX-208', 'Taselisib', 'LGK974', 'Fludarabine', 'VX-11e', 'Serdemetan', 'Bleomycin', 'Bosutinib', 'Topotecan', 'N-acetyl cysteine', 'Sabutoclax', 'JNK Inhibitor VIII', 'Lestaurtinib', 'SGC0946', 'Schweinfurthin A'}, 'SCC4': {'GSK2830371', 'GDC0810', 'AZD4547', 'Romidepsin', 'JQ1', 'Docetaxel', 'VX-11e', 'Tamoxifen', 'Lenalidomide', 'Bleomycin', 'LY2109761', 'Sepantronium bromide', 'EPZ5676', 'POMHEX', 'Erlotinib', 'Veliparib', 'RO-3306', 'GSK1904529A', 'Ipatasertib'}, 'SCC9': {'Entinostat', 'AGI-6780', 'AMG-319', 'Ruxolitinib', 'Rucaparib', '5-azacytidine', 'AZD2014', 'Tamoxifen', 'Wnt-C59', 'Carmustine', 'Nutlin-3a (-)', 'SCH772984', 'EPZ004777', 'RO-3306', 'GSK591', 'PRIMA-1MET', 'GSK343', 'MG-132', 'AZD5153'}, 'SF126': {'VE-822', 'AZD6482', 'Rucaparib', '5-Fluorouracil', 'Docetaxel', 'Cyclophosphamide', 'Axitinib', 'VX-11e', 'Daporinad', 'BI-2536', 'Gemcitabine', 'I-BET-762', 'Crizotinib', 'Gefitinib', 'OSI-027', 'GSK269962A'}, 'SF268': {'Vismodegib', 'Pyridostatin', 'Cyclophosphamide', 'PD173074', 'SB590885', 'AZD1332', 'Talazoparib', 'SB216763', 'AMG-319', 'Dacarbazine', 'Ribociclib', 'Carmustine', 'Sepantronium bromide', 'alpha-lipoic acid', 'MK-8776', 'Erlotinib', 'GSK591', 'Gemcitabine', 'Methotrexate'}, 'SF295': {'Tanespimycin', 'Tretinoin', 'I-BRD9', 'BIBR-1532', 'Ruxolitinib', 'AZD8186', 'Linsitinib', 'Temozolomide', 'MK-1775', 'NVP-ADW742', 'EHT-1864', 'Wnt-C59', 'Picolinici-acid', 'Afuresertib', 'PF-4708671', 'Mirin'}, 'SF539': {'Alpelisib', 'Cyclophosphamide', 'PLX-4720', 'AGI-6780', 'AZD5363', 'SB216763', 'LCL161', 'VE-822', 'AZD8186', 'AT13148', 'Telomerase Inhibitor IX', 'Nutlin-3a (-)', 'MIRA-1', 'ABT737', 'PD0325901', 'GSK2801', 'Motesanib', 'Dinaciclib', 'Dabrafenib'}, 'SH4': {'Linsitinib', 'AZD5438', 'Afatinib', 'Nilotinib', 'SB590885', 'Taselisib', 'JQ1', 'Uprosertib', 'Axitinib', 'SCH772984', 'WIKI4', 'N-acetyl cysteine', 'PCI-34051', 'Vorinostat', 'GSK591', 'AZD5582', 'GSK2801', 'Dabrafenib', 'AZD3759'}, 'SHP77': {'MK-2206', 'AZD5438', 'LCL161', 'Taselisib', '5-Fluorouracil', 'Fludarabine', 'Sapitinib', 'VX-11e', 'Luminespib', 'Lenalidomide', 'Fulvestrant', 'Trametinib', 'Mirin', 'UNC0379', 'AZ960', 'Sinularin', 'Temsirolimus', 'SN-38', 'Alisertib'}, 'SIGM5': {'VE-822', 'AZ960', 'Taselisib', 'I-BRD9', 'LJI308', 'IOX2', 'Leflunomide', 'GW441756', 'SB505124', 'Temozolomide', 'Uprosertib', 'Axitinib', 'Nutlin-3a (-)', 'Lenalidomide', 'Doramapimod', 'AGI-5198'}, 'SIHA': {'NVP-ADW742', 'PLX-4720', 'AZ6102', 'Venetoclax', 'RVX-208', 'MIM1', 'Sapitinib', '5-azacytidine', 'GNE-317', 'glutathione', 'LY2109761', 'Sorafenib', 'CZC24832', 'Buparlisib', 'Oxaliplatin', 'PRIMA-1MET', 'GSK343', 'Schweinfurthin A', 'Doramapimod'}, 'SIMA': {'A-366', 'AZD5438', 'Foretinib', 'AMG-319', 'Ruxolitinib', 'Uprosertib', 'Crizotinib', 'Luminespib', 'Osimertinib', 'Irinotecan', 'Selumetinib', 'Vorinostat', 'Mirin', 'Veliparib', 'GSK591', 'AZD5582', 'Bleomycin (50 uM)', 'GSK2801', 'NU7441'}, 'SISO': {'Alpelisib', 'MK-2206', 'Refametinib', 'A-366', 'GSK2830371', 'AZD1332', 'AZD8186', 'Nelarabine', 'Navitoclax', 'Ribociclib', 'ML323', 'Sepantronium bromide', 'N-acetyl cysteine', 'POMHEX', 'AGK2', 'Niraparib', 'GSK591', 'Dinaciclib', 'AGI-5198'}, 'SJSA1': {'Taselisib', '5-Fluorouracil', 'Wee1 Inhibitor', 'Ribociclib', 'AMG-319', 'Afatinib', 'SN-38', 'Dactolisib', 'Paclitaxel', 'Afuresertib', 'AZD4547', 'Motesanib', 'SCH772984', 'Veliparib'}, 'SKCO1': {'GSK2606414', 'Cyclophosphamide', 'Bortezomib', 'PD173074', 'BMS-345541', 'Camptothecin', 'RVX-208', 'Zoledronate', 'Leflunomide', 'SGC-CBP30', 'Fludarabine', 'P22077', 'AZD8055', 'BMS-754807', 'Vorinostat', 'Erlotinib', 'Mycophenolic acid', 'LJI308', 'Bleomycin (50 uM)', 'Lestaurtinib'}, 'SKES1': {'CCT007093', 'Bortezomib', 'AGI-6780', 'Tanespimycin', 'JQ1', 'Nelarabine', 'Rucaparib', 'SGC-CBP30', 'LGK974', 'Cytarabine', 'Serdemetan', 'YK-4-279', 'Bosutinib', 'WIKI4', 'PRT062607', 'RO-3306', 'GSK-LSD1', 'AT13148', 'Ulixertinib'}, 'SKGIIIA': {'Lapatinib', 'AZD1332', 'Romidepsin', 'Dacarbazine', 'Navitoclax', 'Axitinib', 'Vinblastine', 'AZD2014', 'Crizotinib', 'glutathione', 'CPI-637', 'WZ4003', 'RO-3306', 'Vincristine', 'SN-38', 'Dactolisib', 'Motesanib', 'AT13148', 'AGI-5198'}, 'SKGT2': {'NVP-ADW742', 'BMS-345541', 'Lenalidomide', 'Obatoclax Mesylate', 'Entospletinib', 'Cisplatin', 'alpha-lipoic acid', 'Vorinostat', 'Erlotinib', 'UNC0379', 'PFI3', 'GSK-LSD1', 'GSK591', 'Niraparib', 'AZD5582', 'GSK2110183B', 'MG-132', 'KRAS (G12C) Inhibitor-12', 'Methotrexate'}, 'SKGT4': {'Refametinib', 'NVP-ADW742', 'AGI-6780', 'AZ6102', 'Taselisib', 'Rucaparib', 'LGK974', 'SGC-CBP30', 'Fludarabine', 'Dacarbazine', 'P22077', 'Luminespib', 'Sepantronium bromide', 'Dihydrorotenone', 'WZ4003', 'Vorinostat', 'AZD5582', 'AZD5153', 'Vinorelbine'}, 'SKHEP1': {'I-BRD9', 'Refametinib', 'Afatinib', 'Olaparib', 'Camptothecin', 'JQ1', 'BIBR-1532', 'Navitoclax', '5-azacytidine', 'Serdemetan', 'Lenalidomide', 'MIRA-1', 'GNE-317', 'Elephantin', 'MK-8776', 'Daporinad', 'Veliparib', 'Niraparib', 'Dactolisib'}, 'SKLMS1': {'MK-2206', 'GDC0810', 'I-BET-762', 'Camptothecin', 'Foretinib', 'Romidepsin', 'Leflunomide', 'Wee1 Inhibitor', 'MIRA-1', 'LY2109761', 'Sepantronium bromide', 'Cisplatin', 'Sinularin', 'AZD5582', 'PRIMA-1MET', 'Lestaurtinib', 'Dactolisib', 'AT13148', 'AGI-5198'}, 'SKM1': {'I-BRD9', 'CHIR-99021', 'Refametinib', 'Afatinib', 'Venetoclax', 'JQ1', '5-Fluorouracil', 'Fludarabine', 'Navitoclax', 'Elesclomol', 'Luminespib', 'Selumetinib', 'Entospletinib', 'Sepantronium bromide', 'PCI-34051', 'Sinularin', 'OF-1', 'Ipatasertib', 'SL0101'}, 'SKMEL1': {'Lapatinib', 'A-366', 'BMS-536924', 'Refametinib', 'Cediranib', 'Navitoclax', 'ZM447439', 'EHT-1864', 'BI-2536', 'AZD5363', 'Gefitinib', 'Doramapimod', 'Buparlisib', 'KU-55933'}, 'SKMEL2': {'L-Oxonoreleagnine', 'Refametinib', 'GSK2830371', 'Docetaxel', 'Leflunomide', 'Vinblastine', 'Fulvestrant', 'Elephantin', 'Topotecan', 'Cisplatin', 'Epirubicin', 'EPZ5676', 'PCI-34051', 'Bromosporine', 'Mycophenolic acid', 'Dactolisib', 'Schweinfurthin A', 'AZD5153', 'Vismodegib'}, 'SKMEL24': {'Refametinib', 'Cyclophosphamide', 'AZD1208', 'MIM1', 'Fludarabine', '5-azacytidine', 'Crizotinib', 'Luminespib', 'MIRA-1', 'GNE-317', 'MN-64', 'Cisplatin', 'LMP744', 'Sorafenib', 'Gallibiscoquinazole', 'CZC24832', 'Bleomycin (50 uM)', 'Schweinfurthin A', 'AT13148'}, 'SKMEL28': {'YK-4-279', 'Irinotecan', 'Niraparib', 'JQ1', 'Pyridostatin', 'Avagacestat', 'Bicalutamide', 'EPZ5676', 'PCI-34051', 'Cediranib', 'Tamoxifen', 'OSI-027', 'I-BET-762', 'PD0325901', 'Doramapimod', 'Mirin'}, 'SKMEL3': {'JQ1', 'AZD5582', 'CHIR-99021', 'AZD7762', 'PCI-34051', 'Mirin', 'EHT-1864', 'SB590885', 'AGK2', 'AZD5363', 'Nilotinib', 'ML323', 'Methotrexate', 'PD0325901', 'Veliparib', 'BMS-536924'}, 'SKMEL30': {'Oxaliplatin', 'Bosutinib', 'I-BRD9', 'Epirubicin', 'Pictilisib', 'BX795', 'Elesclomol', 'PD173074', 'Daporinad', 'OSI-027', 'SGC0946', 'AZ6102', 'KRAS (G12C) Inhibitor-12', 'Erlotinib', 'AT13148', 'SL0101'}, 'SKMEL31': {'VE-822', 'Irinotecan', 'Pyridostatin', 'Docetaxel', 'JNK Inhibitor VIII', 'EPZ5676', 'Bicalutamide', 'AZD7762', 'Cyclophosphamide', 'P22077', 'Tamoxifen', 'Crizotinib', 'Picolinici-acid', 'WZ4003', 'Doramapimod', 'RO-3306'}, 'SKMEL5': {'L-Oxonoreleagnine', 'Alpelisib', 'MK-2206', 'Tanespimycin', 'VE-822', 'Docetaxel', 'Uprosertib', 'Dacarbazine', 'Fulvestrant', 'YK-4-279', 'Bosutinib', 'Selumetinib', 'Trametinib', 'GSK1904529A', 'OSI-027', 'Schweinfurthin A', 'Methotrexate', 'Dinaciclib', 'Ulixertinib'}, 'SKMES1': {'Alpelisib', 'GSK2830371', 'AZD5363', 'Talazoparib', 'AZD4547', 'LCL161', 'LGK974', 'Ribociclib', 'Serdemetan', 'Luminespib', 'Elephantin', 'Cisplatin', 'Sorafenib', 'WEHI-539', 'BMS-536924', 'JNK Inhibitor VIII', 'Vinorelbine', 'Dinaciclib', 'Ulixertinib'}, 'SKMM2': {'A-366', 'Pictilisib', 'Afatinib', 'BMS-345541', 'JQ1', 'Uprosertib', 'Tamoxifen', '5-azacytidine', 'Savolitinib', 'LY2109761', 'AGK2', 'Bromosporine', 'Vincristine', 'Palbociclib', 'Lestaurtinib', 'MG-132', 'KRAS (G12C) Inhibitor-12', 'Methotrexate', 'AGI-5198'}, 'SKN': {'Dasatinib', 'Linsitinib', 'Pevonedistat', 'Rucaparib', 'Mitoxantrone', 'Luminespib', 'WZ4003', 'Veliparib', 'Oxaliplatin', 'Niraparib', 'Avagacestat', 'Bleomycin (50 uM)', 'Temsirolimus', 'GSK2110183B', 'MG-132', 'OSI-027', 'KRAS (G12C) Inhibitor-12', 'Dabrafenib', 'AZD3759'}, 'SKNAS': {'Dasatinib', 'GDC0810', 'Talazoparib', 'Taselisib', 'Uprosertib', 'Dacarbazine', 'MIRA-1', 'Savolitinib', 'Trametinib', 'AZD7762', 'Dihydrorotenone', 'ABT737', 'Rapamycin', 'Mirin', 'GSK-LSD1', 'PRIMA-1MET', 'MG-132', 'AZD6738', 'AZD3759'}, 'SKNDZ': {'GSK2606414', 'Alpelisib', 'Cyclophosphamide', 'Paclitaxel', 'AGI-6780', 'JQ1', 'Cytarabine', 'Telomerase Inhibitor IX', 'AZD2014', 'Crizotinib', 'BMS-754807', 'Fulvestrant', 'Irinotecan', 'CZC24832', 'Veliparib', 'GSK-LSD1', 'GSK591', 'GSK2110183B', 'Ibrutinib'}, 'SKNFI': {'JQ1', 'Trametinib', 'WIKI4', 'EPZ5676', 'AZD7762', 'Vinblastine', '5-azacytidine', 'PD173074', 'ZM447439', 'Bortezomib', 'OSI-027', 'AZ6102', 'BMS-754807', 'RO-3306'}, 'SKNSH': {'Tanespimycin', 'Cisplatin', 'Veliparib', 'Sorafenib', 'Staurosporine', 'Gemcitabine', 'NU7441', 'Alisertib', 'Rapamycin', 'SB216763', 'AZD4547', 'Osimertinib', 'GSK2578215A', 'Savolitinib'}, 'SKOV3': {'MK-2206', 'Pictilisib', 'Cyclophosphamide', 'BMS-345541', 'Mitoxantrone', 'Wee1 Inhibitor', 'Osimertinib', 'LY2109761', 'Entospletinib', 'EPZ004777', 'Cisplatin', 'EPZ5676', 'Mycophenolic acid', 'AZ960', 'GW441756', 'Ipatasertib', 'Schweinfurthin A', 'Vinorelbine', 'AT13148'}, 'SKPNDW': {'Lapatinib', 'MK-2206', 'Linsitinib', 'Docetaxel', 'MK-1775', 'Uprosertib', 'Navitoclax', 'VX-11e', 'Telomerase Inhibitor IX', 'ICL-SIRT078', 'MIRA-1', 'Daporinad', 'AGK2', 'Buparlisib', 'AZ960', 'Niraparib', 'Cediranib', 'Gemcitabine', 'AZD6738'}, 'SKUT1': {'GSK2606414', 'AZD1208', 'KU-55933', 'Docetaxel', 'ICL-SIRT078', 'Irinotecan', 'Elephantin', 'Selumetinib', 'Sepantronium bromide', 'Epirubicin', 'EPZ5676', 'AZD7762', 'Sorafenib', 'Mycophenolic acid', 'GSK-LSD1', 'LJI308', 'PRIMA-1MET', 'MG-132', 'Vinorelbine'}, 'SLVL': {'Entinostat', 'Lapatinib', 'EHT-1864', 'Acetalax', 'Staurosporine', 'BIBR-1532', 'Sapitinib', 'Fulvestrant', 'MIRA-1', 'SCH772984', 'YK-4-279', 'PFI3', 'PRIMA-1MET', 'Temsirolimus', 'Palbociclib', 'Cediranib', 'Ipatasertib', 'Gemcitabine', 'PD0325901'}, 'SNB75': {'MK-1775', 'Dasatinib', 'Axitinib', 'Temozolomide', 'Tamoxifen', 'Sabutoclax', 'Elesclomol', 'MG-132', 'Afatinib', 'GDC0810', 'Crizotinib', 'Dabrafenib', 'RVX-208', 'GSK2578215A', 'Erlotinib', 'AZD3759'}, 'SNGM': {'I-BRD9', 'Refametinib', 'EHT-1864', 'SB590885', 'Acetalax', 'Nelarabine', 'Vinblastine', 'Luminespib', 'Elephantin', 'alpha-lipoic acid', 'LMP744', 'CZC24832', 'Erlotinib', 'Bromosporine', 'UNC0379', 'AZD5582', 'NU7441', 'Vismodegib', 'AGI-5198'}, 'SNU1': {'I-BRD9', 'Pyridostatin', 'L-Oxonoreleagnine', 'Romidepsin', 'Wnt-C59', 'OTX015', 'Luminespib', 'Afuresertib', 'BMS-754807', 'EPZ004777', 'alpha-lipoic acid', 'N-acetyl cysteine', 'Sorafenib', 'Rapamycin', 'Veliparib', 'Sinularin', 'Vincristine', 'OF-1', 'NU7441'}, 'SNU1040': {'Elephantin', 'Taselisib', 'AZD5582', 'PRIMA-1MET', 'AZD7762', 'PCI-34051', 'GSK2801', 'Podophyllotoxin bromide', 'I-BET-762', 'PD0325901'}, 'SNU16': {'Foretinib', 'Oxaliplatin', 'Rucaparib', 'Cisplatin', 'Temsirolimus', 'AZD7762', 'Ipatasertib', 'AGK2', 'GDC0810', 'Venetoclax', 'Savolitinib', 'Buparlisib', 'ICL-SIRT078'}, 'SNU175': {'Pictilisib', 'I-BET-762', 'Pevonedistat', 'BIBR-1532', 'MK-1775', 'Navitoclax', 'BMS-754807', 'Lenalidomide', 'YK-4-279', 'Irinotecan', 'EPZ5676', 'Temozolomide', 'CZC24832', 'Mirin', 'GSK-LSD1', 'SN-38', 'NU7441', 'Gefitinib', 'Methotrexate'}, 'SNU283': {'BIBR-1532', 'VE821', 'Rucaparib', 'Temsirolimus', 'Dactinomycin', 'BX795', 'Cediranib', 'Sabutoclax', 'Serdemetan', 'Ibrutinib', 'WZ4003', 'Wnt-C59', 'SGC0946', 'PRT062607', 'Erlotinib', 'AZD6738'}, 'SNU387': {'L-Oxonoreleagnine', 'Afatinib', 'Paclitaxel', 'Talazoparib', 'AZD4547', 'LCL161', 'LGK974', 'Axitinib', 'ML323', 'Nutlin-3a (-)', 'Entospletinib', 'Temozolomide', 'IWP-2', 'WEHI-539', 'UNC0379', 'Palbociclib', 'NU7441', 'Dinaciclib', 'AZD6738'}, 'SNU398': {'Paclitaxel', 'KU-55933', 'LCL161', 'Leflunomide', 'MK-1775', 'Sapitinib', '5-azacytidine', 'Podophyllotoxin bromide', 'ZM447439', 'Carmustine', 'LY2109761', 'YK-4-279', 'alpha-lipoic acid', 'Sabutoclax', 'IWP-2', 'PRT062607', 'GSK2578215A', 'Oxaliplatin', 'Bleomycin (50 uM)'}, 'SNU407': {'Lapatinib', 'SB590885', 'BMS-345541', '5-Fluorouracil', 'SGC-CBP30', 'Fludarabine', 'Telomerase Inhibitor IX', 'Osimertinib', 'Buparlisib', 'RO-3306', 'Niraparib', 'AZD5582', 'Teniposide', 'Vincristine', 'PRIMA-1MET', 'GSK2110183B', 'Cediranib', 'Methotrexate', 'AZD3759'}, 'SNU423': {'Alpelisib', 'Refametinib', 'Linsitinib', 'Cyclophosphamide', 'GSK2830371', 'SB590885', 'KU-55933', 'Axitinib', 'Podophyllotoxin bromide', 'Vinblastine', 'Sepantronium bromide', 'Sorafenib', 'CZC24832', 'AZD5582', 'JNK Inhibitor VIII', 'Temsirolimus', 'Palbociclib', 'OF-1', 'KRAS (G12C) Inhibitor-12'}, 'SNU449': {'PLX-4720', 'BMS-345541', 'Pevonedistat', 'JQ1', 'Cytarabine', '5-azacytidine', 'OTX015', 'Crizotinib', 'LY2109761', 'VE821', 'alpha-lipoic acid', 'N-acetyl cysteine', 'MK-8776', 'GSK591', 'UMI-77', 'JNK Inhibitor VIII', 'OF-1', 'SN-38', 'Vismodegib'}, 'SNU5': {'GSK2830371', 'Venetoclax', 'Foretinib', 'Pevonedistat', 'Rucaparib', 'MIM1', 'Cytarabine', 'Luminespib', 'MN-64', 'Bosutinib', 'AZD7762', 'LMP744', 'Dihydrorotenone', 'Buparlisib', 'Mycophenolic acid', 'AZ960', 'GW441756', 'KRAS (G12C) Inhibitor-12', 'AT13148'}, 'SNU61': {'Irinotecan', 'JQ1', 'GNE-317', '5-Fluorouracil', 'SGC-CBP30', 'GSK2110183B', 'LMP744', 'Tamoxifen', 'AZD2014', 'PD0325901', 'PD173074', 'AGI-6780', 'ABT737', 'Gefitinib', 'KRAS (G12C) Inhibitor-12', 'AZD1208', 'Bleomycin', 'Pevonedistat'}, 'SNU81': {'AZD6482', 'Pictilisib', 'AZD1208', 'KU-55933', 'LCL161', 'Tanespimycin', 'VX-11e', 'Tamoxifen', 'MIRA-1', 'SCH772984', 'PCI-34051', 'MK-8776', 'IWP-2', 'GSK2578215A', 'PFI3', 'Sinularin', 'PRIMA-1MET', 'GSK2801', 'AZD5153'}, 'SNUC1': {'CCT007093', 'L-Oxonoreleagnine', 'Refametinib', 'AZD5438', 'Dinaciclib', 'Nelarabine', 'Leflunomide', 'LGK974', 'Cytarabine', 'Telomerase Inhibitor IX', 'Elephantin', 'Trametinib', 'WZ4003', 'Oxaliplatin', 'GSK591', 'NU7441', 'Gefitinib', 'Motesanib', 'AT13148', 'Dabrafenib'}, 'SNUC5': {'Pyridostatin', 'EHT-1864', 'AZD5363', 'VE-822', 'Romidepsin', 'JQ1', 'Telomerase Inhibitor IX', 'AZD5991', 'Nutlin-3a (-)', 'Osimertinib', 'Bosutinib', 'EPZ004777', 'MK-8776', 'CZC24832', 'LJI308', 'AZD5582', 'Ipatasertib', 'SGC0946', 'UNC0638'}, 'ST486': {'UMI-77', 'Trametinib', 'Lapatinib', '5-Fluorouracil', 'A-366', 'Topotecan', 'AZD5438', 'Navitoclax', 'Cytarabine', 'NVP-ADW742', 'PLX-4720', 'Ibrutinib', 'SCH772984', 'ML323', 'I-BET-762', 'KRAS (G12C) Inhibitor-12', 'GSK2578215A', 'AGI-5198'}, 'SU8686': {'AZD5438', 'GSK2830371', 'Nelarabine', 'Fludarabine', 'Mitoxantrone', 'Cytarabine', 'Vinblastine', 'AZD2014', 'AZD8055', 'Afuresertib', 'YK-4-279', 'Rapamycin', 'Erlotinib', 'Mycophenolic acid', 'PRIMA-1MET', 'Lestaurtinib', 'Gemcitabine', 'Gefitinib', 'UNC0638'}, 'SUDHL1': {'GSK1904529A', 'IOX2', 'LJI308', 'LGK974', 'MK-1775', 'Palbociclib', 'Navitoclax', 'Temozolomide', 'Daporinad', 'Serdemetan', 'SB590885', 'Paclitaxel', 'Luminespib', 'AZD6738', 'RO-3306'}, 'SUDHL10': {'A-366', 'SB590885', 'Acetalax', 'Foretinib', 'Nelarabine', '5-Fluorouracil', 'Dacarbazine', 'Axitinib', 'BMS-754807', 'Osimertinib', 'LY2109761', 'VE821', 'MK-8776', 'WEHI-539', 'Rapamycin', 'Vincristine', 'OF-1', 'Picolinici-acid', 'SGC0946'}, 'SUDHL4': {'Bosutinib', 'IOX2', 'JNK Inhibitor VIII', 'Axitinib', 'Bortezomib', 'MK-8776', 'Dactolisib', 'I-BET-762', 'Alisertib', 'NU7441', 'Picolinici-acid', 'SB216763', 'Olaparib', 'Paclitaxel', 'PD0325901', 'BMS-536924'}, 'SUDHL5': {'Pyridostatin', 'Afatinib', 'Talazoparib', 'SB216763', 'VE-822', 'Romidepsin', 'Rucaparib', 'MIM1', 'LGK974', 'Navitoclax', 'VX-11e', 'ZM447439', 'Crizotinib', 'Selumetinib', 'Rapamycin', 'Vorinostat', 'PFI3', 'GSK-LSD1', 'Dinaciclib'}, 'SUDHL6': {'CCT007093', 'Alpelisib', 'SB590885', 'Rucaparib', 'Docetaxel', 'SGC-CBP30', 'Podophyllotoxin bromide', 'P22077', 'Wnt-C59', 'Carmustine', 'SCH772984', 'YK-4-279', 'CPI-637', 'TW 37', 'Dihydrorotenone', 'Gallibiscoquinazole', 'AZD5153', 'Vinorelbine', 'Dinaciclib'}, 'SUDHL8': {'EHT-1864', 'Romidepsin', 'JQ1', 'SGC-CBP30', 'Sapitinib', 'Tamoxifen', 'ZM447439', 'Bleomycin', 'Trametinib', 'Topotecan', 'Cisplatin', 'Rapamycin', 'BMS-536924', 'AZ960', 'JNK Inhibitor VIII', 'GSK2801', 'MG-132', 'Schweinfurthin A', 'AZD5153'}, 'SUIT2': {'AGI-6780', 'RVX-208', 'LGK974', 'Navitoclax', 'VX-11e', 'Telomerase Inhibitor IX', 'Afuresertib', 'Nutlin-3a (-)', 'GNE-317', 'Elephantin', 'alpha-lipoic acid', 'PCI-34051', 'LMP744', 'POMHEX', 'Oxaliplatin', 'UMI-77', 'Temsirolimus', 'OSI-027', 'Vinorelbine'}, 'SUPB15': {'AZD5438', 'PLX-4720', 'I-BET-762', 'AZD8186', 'Docetaxel', 'LGK974', 'Telomerase Inhibitor IX', 'OTX015', 'AZD8055', 'glutathione', 'LY2109761', 'VE821', 'Epirubicin', 'MK-8776', 'GSK1904529A', 'Vincristine', 'GSK2801', 'OSI-027', 'Alisertib'}, 'SUPM2': {'Dactinomycin', 'BI-2536', 'Nilotinib', 'Talazoparib', 'Romidepsin', 'SGC-CBP30', 'LGK974', '5-azacytidine', 'P22077', 'Luminespib', 'Afuresertib', 'Sepantronium bromide', 'EPZ5676', 'Dihydrorotenone', 'Oxaliplatin', 'GSK2110183B', 'Ipatasertib', 'OSI-027', 'UNC0638'}, 'SUPT1': {'Alpelisib', 'NVP-ADW742', 'SB590885', 'Romidepsin', 'AZD8055', 'Luminespib', 'MIRA-1', 'Osimertinib', 'Selumetinib', 'CPI-637', 'Trametinib', 'LMP744', 'WZ4003', 'Rapamycin', 'Buparlisib', 'JNK Inhibitor VIII', 'Gemcitabine', 'Methotrexate', 'PD0325901'}, 'SW1088': {'AZD5438', 'Cyclophosphamide', 'Paclitaxel', 'Taselisib', 'MIM1', 'Mitoxantrone', 'ICL-SIRT078', 'SCH772984', 'YK-4-279', 'EPZ004777', 'IWP-2', 'Bromosporine', 'Buparlisib', 'Sinularin', 'GSK2110183B', 'PD0325901', 'AZD6738', 'AGI-5198', 'Ulixertinib'}, 'SW1116': {'MK-2206', 'Refametinib', 'Paclitaxel', 'Olaparib', 'VE-822', 'Romidepsin', 'LGK974', 'Sapitinib', 'Ribociclib', 'ICL-SIRT078', 'Obatoclax Mesylate', 'Selumetinib', 'Bosutinib', 'Cisplatin', 'Epirubicin', 'PCI-34051', 'Gallibiscoquinazole', 'GSK-LSD1', 'SGC0946', 'KRAS (G12C) Inhibitor-12'}, 'SW1271': {'CCT007093', 'Entinostat', 'Pyridostatin', 'Alpelisib', 'MK-2206', 'Cyclophosphamide', 'PLX-4720', 'GDC0810', 'LCL161', 'Mitoxantrone', 'Wee1 Inhibitor', 'AZD8055', 'MIRA-1', 'Epirubicin', 'alpha-lipoic acid', 'Daporinad', 'Avagacestat', 'OF-1', 'Ulixertinib'}, 'SW13': {'MK-2206', 'AZD1332', 'Romidepsin', 'Taselisib', 'P22077', 'Fulvestrant', 'Savolitinib', 'PFI-1', 'LY2109761', 'Trametinib', 'Gallibiscoquinazole', 'PRT062607', 'Erlotinib', 'GSK1904529A', 'Mycophenolic acid', 'AZD5582', 'OF-1', 'Cediranib', 'AZD3759'}, 'SW1417': {'Entinostat', 'Refametinib', 'Linsitinib', 'BI-2536', 'BIBR-1532', 'MK-1775', 'glutathione', 'PFI-1', 'CPI-637', 'EPZ004777', 'VE821', 'Sorafenib', 'Dihydrorotenone', 'Erlotinib', 'Bromosporine', 'Oxaliplatin', 'LJI308', 'JNK Inhibitor VIII', 'GW441756', 'Dinaciclib'}, 'SW1463': {'Entinostat', 'Linsitinib', 'AZD5438', 'Bortezomib', 'SB590885', 'AZ6102', 'LGK974', '5-azacytidine', 'Afuresertib', 'glutathione', 'Trametinib', 'WZ4003', 'WEHI-539', 'Rapamycin', 'RO-3306', 'GSK1904529A', 'GSK591', 'Cediranib', 'SN-38', 'Dactolisib'}, 'SW156': {'VE-822', 'Tretinoin', 'Lapatinib', '5-Fluorouracil', 'JNK Inhibitor VIII', 'Lenalidomide', 'Lestaurtinib', 'Daporinad', 'PLX-4720', 'IWP-2', 'WEHI-539', 'PF-4708671', 'PD0325901', 'AZD6738', 'Dabrafenib', 'AZD3759'}, 'SW1573': {'MK-2206', 'Bortezomib', 'PLX-4720', 'BI-2536', 'Paclitaxel', 'Staurosporine', 'JQ1', 'Telomerase Inhibitor IX', 'Serdemetan', 'Fulvestrant', 'Sorafenib', 'POMHEX', 'Vorinostat', 'Mirin', 'Palbociclib', 'MG-132', 'Dactolisib', 'KRAS (G12C) Inhibitor-12', 'SGC0946'}, 'SW1710': {'Entinostat', 'Cyclophosphamide', 'NVP-ADW742', 'Talazoparib', 'SB216763', 'AZD4547', 'Rucaparib', 'Uprosertib', 'OTX015', 'Fulvestrant', 'Savolitinib', 'glutathione', 'Elephantin', 'TW 37', 'IWP-2', 'Rapamycin', 'Veliparib', 'JNK Inhibitor VIII', 'GSK2801'}, 'SW1783': {'YK-4-279', 'LJI308', 'Sepantronium bromide', 'EPZ004777', '5-Fluorouracil', 'MK-1775', 'Temozolomide', 'Axitinib', 'Camptothecin', 'ZM447439', 'SB590885', 'Doramapimod', 'Savolitinib', 'Pevonedistat'}, 'SW1990': {'Oxaliplatin', 'GSK591', '5-Fluorouracil', 'Cyclophosphamide', 'AZD7762', 'Wee1 Inhibitor', 'Telomerase Inhibitor IX', 'GSK2830371', 'Nilotinib', 'AGK2', 'Talazoparib', 'GNE-317', 'GSK2578215A', 'AZD3759'}, 'SW48': {'MK-2206', 'L-Oxonoreleagnine', 'AZD5438', 'GDC0810', 'AZD5363', 'LCL161', 'Cytarabine', 'Bleomycin', 'LY2109761', 'YK-4-279', 'Elephantin', 'MK-8776', 'Sorafenib', 'Dihydrorotenone', 'Niraparib', 'GW441756', 'Cediranib', 'Ipatasertib', 'Picolinici-acid'}, 'SW620': {'Tretinoin', 'I-BET-762', 'Acetalax', 'Olaparib', 'Rucaparib', 'MIM1', 'Cytarabine', 'VX-11e', 'P22077', 'Afuresertib', 'Obatoclax Mesylate', 'LY2109761', 'MN-64', 'EPZ5676', 'Sorafenib', 'Daporinad', 'MK-8776', 'Vorinostat', 'Buparlisib', 'Schweinfurthin A', 'Vinorelbine'}, 'SW626': {'CCT007093', 'Lapatinib', 'Bortezomib', 'PLX-4720', 'Nilotinib', 'Venetoclax', 'Taselisib', 'Fludarabine', 'Tamoxifen', 'Wnt-C59', 'Luminespib', 'Cisplatin', 'MK-8776', 'Dihydrorotenone', 'UMI-77', 'JNK Inhibitor VIII', 'Schweinfurthin A', 'AZD6738', 'UNC0638'}, 'SW756': {'Alpelisib', 'EHT-1864', 'Paclitaxel', 'LCL161', 'Camptothecin', 'Dinaciclib', 'Romidepsin', 'AZD8186', 'Dacarbazine', 'Telomerase Inhibitor IX', 'OTX015', 'Afuresertib', 'EPZ5676', 'AGK2', 'Dihydrorotenone', 'Bromosporine', 'Veliparib', 'Methotrexate', 'AT13148'}, 'SW780': {'Afatinib', 'GDC0810', 'RVX-208', 'Leflunomide', 'Docetaxel', 'MK-1775', 'Sepantronium bromide', 'Epirubicin', 'EPZ5676', 'MK-8776', 'WZ4003', 'CZC24832', 'Niraparib', 'UMI-77', 'Lestaurtinib', 'Gemcitabine', 'OSI-027', 'AZD5153', 'Vinorelbine'}, 'SW837': {'Refametinib', 'Nilotinib', 'AZD1332', 'Acetalax', 'BMS-345541', 'AZ6102', 'AZD4547', 'Pevonedistat', '5-Fluorouracil', 'Navitoclax', 'Serdemetan', 'Bosutinib', 'Entospletinib', 'EPZ5676', 'MK-8776', 'Gallibiscoquinazole', 'Vorinostat', 'BMS-536924', 'GSK343', 'OSI-027'}, 'SW948': {'GSK2606414', 'Lapatinib', 'Nilotinib', 'AZD1208', 'AZ6102', 'AZD4547', 'Taselisib', 'Uprosertib', 'AZD8055', 'Nutlin-3a (-)', 'glutathione', 'AZD7762', 'PCI-34051', 'Sorafenib', 'Daporinad', 'Rapamycin', 'Palbociclib', 'Ibrutinib', 'PD0325901'}, 'SW954': {'Irinotecan', 'Sepantronium bromide', 'Sapitinib', 'Cyclophosphamide', 'Navitoclax', 'Axitinib', 'P22077', 'Telomerase Inhibitor IX', 'Ipatasertib', 'OSI-027', 'KRAS (G12C) Inhibitor-12', 'Luminespib', 'Methotrexate', 'Vorinostat', 'GSK2578215A', 'Savolitinib'}, 'SW982': {'GSK2830371', 'Cyclophosphamide', 'AGI-6780', 'Sapitinib', 'Dacarbazine', 'Savolitinib', 'PFI-1', 'glutathione', 'MN-64', 'Topotecan', 'AZD7762', 'IWP-2', 'UNC0379', 'Niraparib', 'Lestaurtinib', 'Dactolisib', 'Gemcitabine', 'SGC0946', 'Vismodegib'}, 'T24': {'IOX2', 'Avagacestat', 'EPZ004777', 'Dactinomycin', 'NVP-ADW742', 'VX-11e', 'P22077', 'PD173074', 'Serdemetan', 'LY2109761', 'WZ4003', 'Piperlongumine', 'CCT-018159', 'Camptothecin', 'GSK2578215A', 'PFI3'}, 'T47D': {'Remodelin', 'NVP-ADW742', 'AGI-6780', 'BMS-345541', 'BIBR-1532', 'UNC0638', 'LGK974', 'Fludarabine', 'Dacarbazine', 'Tamoxifen', 'ML323', 'LY2109761', 'GSK2578215A', 'Veliparib', 'PFI3', 'LJI308', 'Palbociclib', 'AZD5153', 'Dabrafenib', 'Ulixertinib'}, 'T84': {'I-BRD9', 'PLX-4720', 'KU-55933', 'Romidepsin', 'BIBR-1532', 'Rucaparib', 'Ruxolitinib', 'Serdemetan', 'BMS-754807', 'Nutlin-3a (-)', 'PFI-1', 'Selumetinib', 'Entospletinib', 'Epirubicin', 'Dihydrorotenone', 'Mycophenolic acid', 'LJI308', 'OF-1', 'PD0325901', 'Ulixertinib'}, 'T98G': {'CCT007093', 'Entinostat', 'Camptothecin', 'Olaparib', 'Tanespimycin', 'UNC0638', 'Rucaparib', 'Uprosertib', 'Ribociclib', 'Bromosporine', 'Mycophenolic acid', 'AZD5582', 'Temsirolimus', 'GSK343', 'Ipatasertib', 'KRAS (G12C) Inhibitor-12', 'Schweinfurthin A', 'Dabrafenib', 'AZD3759'}, 'TALL1': {'Selumetinib', 'VE821', '5-Fluorouracil', 'Sepantronium bromide', 'Bicalutamide', 'Sapitinib', 'WEHI-539', 'PCI-34051', 'OF-1', 'RVX-208', 'AZD5363', 'Gefitinib', 'BMS-754807', 'Vismodegib', 'MIRA-1', 'GSK2578215A'}, 'TC71': {'L-Oxonoreleagnine', 'Cytarabine', 'Wnt-C59', 'Luminespib', 'PFI-1', 'glutathione', 'MN-64', 'Obatoclax Mesylate', 'Selumetinib', 'Sabutoclax', 'AGK2', 'Dihydrorotenone', 'Gallibiscoquinazole', 'Vorinostat', 'JNK Inhibitor VIII', 'Palbociclib', 'SN-38', 'AZD5153', 'Vismodegib'}, 'TCCSUP': {'CCT007093', 'GSK2606414', 'Entinostat', 'AZ6102', 'Taselisib', 'Rucaparib', 'Wee1 Inhibitor', 'VX-11e', 'Vinblastine', 'ICL-SIRT078', 'MN-64', 'Topotecan', 'AGK2', 'Erlotinib', 'UNC0379', 'BMS-536924', 'GSK-LSD1', 'GSK591', 'Cediranib'}, 'TE1': {'Venetoclax', 'KU-55933', 'Zoledronate', 'Taselisib', 'Methotrexate', '5-Fluorouracil', 'LGK974', 'Uprosertib', 'Vinblastine', 'BMS-754807', 'Nutlin-3a (-)', 'MIRA-1', 'CPI-637', 'AGK2', 'Gallibiscoquinazole', 'OF-1', 'MG-132', 'Alisertib', 'Vismodegib'}, 'TE10': {'MN-64', 'Selumetinib', 'Rucaparib', 'PRIMA-1MET', 'VE821', 'WIKI4', 'OF-1', 'MG-132', 'BI-2536', 'OTX015', 'SB590885', 'ABT737', 'IWP-2', 'Vinorelbine', 'Foretinib', 'Savolitinib'}, 'TE11': {'IOX2', 'LJI308', 'Lapatinib', 'Leflunomide', 'Linsitinib', 'Temozolomide', 'Cediranib', 'PCI-34051', 'Daporinad', 'Luminespib', 'ABT737', 'CZC24832', 'NU7441', 'GNE-317', 'Tozasertib', 'PFI3'}, 'TE15': {'Entinostat', 'CPI-637', 'Trametinib', 'Avagacestat', 'Leflunomide', 'Doramapimod', 'Dactinomycin', 'Mitoxantrone', 'OF-1', 'Dacarbazine', 'MK-8776', 'MG-132', 'Alisertib', 'AZ6102', 'LCL161', 'AZD3759'}, 'TE4': {'AGI-5198', 'Cyclophosphamide', 'AZD1208', 'AGI-6780', 'Camptothecin', 'Mitoxantrone', 'Bleomycin', 'GNE-317', 'Bosutinib', 'Cisplatin', 'POMHEX', 'Gallibiscoquinazole', 'Erlotinib', 'Sinularin', 'Vincristine', 'AZD5582', 'GSK2801', 'AZD6738', 'UNC0638'}, 'TE441T': {'Niraparib', 'JQ1', 'LGK974', 'Doramapimod', 'Refametinib', 'Palbociclib', 'OF-1', 'Cediranib', 'Sorafenib', 'Daporinad', 'Nilotinib', 'OTX015', 'ML323', 'PRT062607', 'LCL161', 'Ulixertinib'}, 'TE5': {'PD173074', 'GDC0810', 'AZD4547', 'Leflunomide', 'LGK974', 'Wee1 Inhibitor', 'Nutlin-3a (-)', 'PFI-1', 'Elephantin', 'EPZ5676', 'PCI-34051', 'POMHEX', 'Veliparib', 'Palbociclib', 'OSI-027', 'NU7441', 'AZD5153', 'Vismodegib', 'AZD6738'}, 'TE6': {'PD173074', 'PLX-4720', 'GDC0810', 'BMS-345541', 'VX-11e', 'Podophyllotoxin bromide', 'Vinblastine', 'ZM447439', 'Afuresertib', 'ICL-SIRT078', 'Bleomycin', 'Selumetinib', 'Bosutinib', 'EPZ5676', 'ABT737', 'Mirin', 'PFI3', 'JNK Inhibitor VIII', 'UNC0638'}, 'TE8': {'A-366', 'PD173074', 'SB590885', 'AGI-6780', 'AZD1208', 'Venetoclax', 'AZD4547', 'KU-55933', 'AZD8186', 'Fludarabine', 'Mitoxantrone', 'Uprosertib', 'AZD2014', 'glutathione', 'WIKI4', 'Temsirolimus', 'Lestaurtinib', 'Dinaciclib', 'AZD6738'}, 'TE9': {'Lapatinib', 'AZD5438', 'Venetoclax', 'Rucaparib', 'Docetaxel', 'ZM447439', 'ICL-SIRT078', 'Epirubicin', 'Sabutoclax', 'ABT737', 'WZ4003', 'Erlotinib', 'BMS-536924', 'Teniposide', 'JNK Inhibitor VIII', 'Bleomycin (50 uM)', 'Ipatasertib', 'Gefitinib', 'AGI-5198'}, 'TGBC11TKB': {'YK-4-279', 'Oxaliplatin', 'RO-3306', 'UNC0638', 'Cisplatin', 'Dactinomycin', 'MG-132', 'SN-38', 'Paclitaxel', 'NU7441', 'IWP-2', 'Nutlin-3a (-)', 'SB216763', 'Buparlisib', 'PFI-1'}, 'TGBC1TKB': {'Docetaxel', 'GSK343', 'N-acetyl cysteine', 'Dasatinib', 'Wee1 Inhibitor', 'VX-11e', '5-azacytidine', 'POMHEX', 'SN-38', 'BI-2536', 'Ipatasertib', 'Talazoparib', 'SCH772984', 'PFI-1'}, 'TGW': {'I-BRD9', 'Pictilisib', 'Dactinomycin', 'AGI-6780', 'I-BET-762', 'Camptothecin', 'Cytarabine', 'ZM447439', 'GNE-317', 'alpha-lipoic acid', 'EPZ5676', 'Veliparib', 'AZ960', 'OSI-027', 'Dabrafenib', 'Vinorelbine', 'Motesanib', 'UNC0638', 'Ulixertinib'}, 'THP1': {'GSK1904529A', 'Tretinoin', 'Niraparib', 'Taselisib', 'BIBR-1532', 'AZ960', 'JNK Inhibitor VIII', 'Doramapimod', 'PCI-34051', 'OSI-027', 'Afuresertib', 'WEHI-539', 'Vismodegib', 'PD0325901', 'Pevonedistat', 'SL0101'}, 'TOV112D': {'CCT007093', 'Dactinomycin', 'PLX-4720', 'Afatinib', 'AZ6102', 'Olaparib', 'Staurosporine', 'AMG-319', 'AZD8186', 'Fludarabine', 'Uprosertib', 'Nutlin-3a (-)', 'Selumetinib', 'CPI-637', 'WIKI4', 'ABT737', 'Erlotinib', 'GSK1904529A', 'AGI-5198'}, 'TOV21G': {'Dasatinib', 'EHT-1864', 'Nilotinib', 'AZD4547', 'JQ1', 'SGC-CBP30', 'Podophyllotoxin bromide', 'Topotecan', 'N-acetyl cysteine', 'MK-8776', 'PFI3', 'AZ960', 'Oxaliplatin', 'GSK2110183B', 'Dactolisib', 'OSI-027', 'Motesanib', 'AT13148', 'UNC0638'}, 'TT': {'Mycophenolic acid', 'Docetaxel', 'GW441756', 'AZD7762', 'Navitoclax', 'Cytarabine', '5-azacytidine', 'Sorafenib', 'Wee1 Inhibitor', 'BI-2536', 'ABT737', 'Afuresertib', 'Olaparib', 'Vorinostat'}, 'TT2609C02': {'Pyridostatin', 'Dasatinib', 'PD173074', 'I-BET-762', 'Talazoparib', 'Venetoclax', 'AMG-319', 'Tanespimycin', 'Rucaparib', 'Docetaxel', 'Crizotinib', 'Nutlin-3a (-)', 'XAV939', 'IWP-2', 'Erlotinib', 'JNK Inhibitor VIII', 'GSK343', 'NU7441', 'Ulixertinib'}, 'TYKNU': {'Entinostat', 'A-366', 'Nilotinib', 'AGI-6780', 'Olaparib', 'AMG-319', 'MIM1', 'Wee1 Inhibitor', 'ZM447439', 'ICL-SIRT078', 'Irinotecan', 'EPZ004777', 'alpha-lipoic acid', 'EPZ5676', 'AZD7762', 'ABT737', 'Mirin', 'BMS-536924', 'GSK1904529A'}, 'U118MG': {'GSK2606414', 'Refametinib', 'Bortezomib', 'GDC0810', 'Paclitaxel', 'Vinblastine', 'Nutlin-3a (-)', 'Savolitinib', 'Obatoclax Mesylate', 'YK-4-279', 'VE821', 'WIKI4', 'Rapamycin', 'Vincristine', 'PRIMA-1MET', 'Bleomycin (50 uM)', 'Lestaurtinib', 'Ipatasertib', 'Schweinfurthin A'}, 'U2OS': {'Remodelin', 'Dasatinib', 'NVP-ADW742', 'PLX-4720', 'Acetalax', 'Staurosporine', 'Tanespimycin', '5-azacytidine', 'Elesclomol', 'OTX015', 'Afuresertib', 'GSK269962A', 'PFI-1', 'Selumetinib', 'VE821', 'Sorafenib', 'POMHEX', 'Erlotinib', 'GW441756', 'Temsirolimus', 'SN-38'}, 'U87MG': {'Entinostat', 'Selumetinib', 'Topotecan', 'MK-2206', 'WIKI4', 'Fludarabine', 'Navitoclax', 'NVP-ADW742', 'Wee1 Inhibitor', 'PLX-4720', 'Wnt-C59', 'SN-38', 'AZD5991', 'OSI-027', 'CZC24832', 'Bromosporine', 'PFI3'}, 'UACC257': {'Remodelin', 'L-Oxonoreleagnine', 'GSK2830371', 'AZD5363', 'Leflunomide', 'MIM1', 'ZM447439', 'GNE-317', 'MK-8776', 'AGK2', 'Mirin', 'Buparlisib', 'RO-3306', 'PFI3', 'UMI-77', 'Avagacestat', 'Lestaurtinib', 'Gefitinib', 'Doramapimod'}, 'UACC62': {'GSK2606414', 'Entinostat', 'GSK2830371', 'AGI-6780', 'LCL161', 'RVX-208', 'Taselisib', 'Rucaparib', 'Docetaxel', 'Fludarabine', 'Ribociclib', 'VX-11e', 'Afuresertib', 'Vinorelbine', 'WZ4003', 'Mycophenolic acid', 'Cediranib', 'Schweinfurthin A', 'Methotrexate'}, 'UACC812': {'AZD8186', 'Pyridostatin', 'A-366', 'N-acetyl cysteine', 'Temozolomide', 'Wee1 Inhibitor', 'Ipatasertib', 'Crizotinib', 'AZD5363', 'WEHI-539', 'Lenalidomide', 'Olaparib', 'glutathione'}, 'UACC893': {'CCT007093', 'GSK1904529A', 'IOX2', 'AZD6482', 'Avagacestat', 'Lapatinib', 'Cisplatin', 'OF-1', 'Navitoclax', 'ZM447439', 'Afatinib', 'BI-2536', 'EHT-1864', 'PD173074', 'Savolitinib', 'AMG-319'}, 'UMUC3': {'Selumetinib', 'BIBR-1532', 'Rucaparib', 'VE821', 'GSK343', 'Uprosertib', 'Palbociclib', 'Ribociclib', 'Telomerase Inhibitor IX', 'P22077', 'PD173074', 'MG-132', 'AZD8055', 'Afuresertib'}, 'UWB1289': {'VE-822', 'Selumetinib', 'Entospletinib', 'Bicalutamide', 'GW441756', 'Sapitinib', 'LCL161', 'Ribociclib', 'Daporinad', 'EHT-1864', 'Crizotinib', 'KRAS (G12C) Inhibitor-12', 'PRT062607', 'AZD4547', 'Osimertinib', 'KU-55933'}, 'VAESBJ': {'Entinostat', 'Afatinib', 'Olaparib', 'AZD4547', 'RVX-208', 'Taselisib', 'JQ1', '5-Fluorouracil', 'XAV939', 'Savolitinib', 'Irinotecan', 'Selumetinib', 'VE821', 'WIKI4', 'WEHI-539', 'Mirin', 'Avagacestat', 'Vincristine', 'Cediranib'}, 'VAL': {'A-366', 'Talazoparib', 'AZD4547', 'Staurosporine', 'Navitoclax', 'VX-11e', 'Vinblastine', 'AZD2014', 'Carmustine', 'Osimertinib', 'CPI-637', 'AZD7762', 'PRT062607', 'Gallibiscoquinazole', 'Mycophenolic acid', 'Sinularin', 'Bleomycin (50 uM)', 'GSK2801', 'AZD5153'}, 'VCAP': {'GSK2606414', 'Pyridostatin', 'L-Oxonoreleagnine', 'Pictilisib', 'AZD1332', 'AZD5363', 'AZ6102', 'MIM1', 'Tamoxifen', 'XAV939', 'Obatoclax Mesylate', 'EPZ004777', 'alpha-lipoic acid', 'POMHEX', 'TW 37', 'BMS-536924', 'PRIMA-1MET', 'OSI-027', 'Dabrafenib'}, 'VMRCRCW': {'Bosutinib', 'BMS-345541', 'LJI308', 'Rucaparib', 'Leflunomide', 'WIKI4', 'Wee1 Inhibitor', 'VX-11e', 'MIRA-1', 'OSI-027', 'AZ6102', 'Rapamycin', 'Methotrexate', 'CZC24832', 'XAV939', 'AMG-319'}, 'VMRCRCZ': {'I-BRD9', 'Pictilisib', 'PLX-4720', 'Camptothecin', 'LCL161', 'Sapitinib', 'AZD5991', 'MIRA-1', 'Osimertinib', 'Sepantronium bromide', 'Cisplatin', 'Gallibiscoquinazole', 'Erlotinib', 'BMS-536924', 'Avagacestat', 'PRIMA-1MET', 'Gemcitabine', 'Motesanib', 'Dabrafenib'}, 'WM115': {'Pictilisib', 'Cyclophosphamide', 'NVP-ADW742', 'SB590885', 'Acetalax', 'Olaparib', 'KU-55933', '5-azacytidine', 'ICL-SIRT078', 'Lenalidomide', 'Fulvestrant', 'LY2109761', 'CPI-637', 'WIKI4', 'IWP-2', 'Rapamycin', 'RO-3306', 'PRIMA-1MET', 'NU7441'}, 'WSUDLCL2': {'Fulvestrant', 'Tanespimycin', 'JQ1', 'Sepantronium bromide', 'Dactinomycin', 'Tamoxifen', '5-azacytidine', 'Nilotinib', 'OSI-027', 'NU7441', 'AZ6102', 'KU-55933', 'AZD6738', 'BMS-536924'}, 'YAPC': {'Entinostat', 'Pyridostatin', 'AZD5438', 'AZD1332', 'LCL161', 'Taselisib', 'Nelarabine', 'Tamoxifen', '5-azacytidine', 'AZD2014', 'OTX015', 'Carmustine', 'Irinotecan', 'Selumetinib', 'Avagacestat', 'Palbociclib', 'KRAS (G12C) Inhibitor-12', 'Schweinfurthin A', 'Methotrexate'}, 'YH13': {'SB590885', 'Paclitaxel', 'Acetalax', 'Venetoclax', 'Dinaciclib', 'Zoledronate', 'Axitinib', 'VX-11e', 'AZD8055', 'ICL-SIRT078', 'Sepantronium bromide', 'alpha-lipoic acid', 'WEHI-539', 'CZC24832', 'Avagacestat', 'Lestaurtinib', 'NU7441', 'AT13148', 'UNC0638'}, 'YKG1': {'GSK2606414', 'PRT062607', 'Bicalutamide', 'Temsirolimus', 'Temozolomide', 'Linsitinib', 'ZM447439', 'Wnt-C59', 'SB590885', 'Afatinib', 'ABT737', 'WZ4003', 'Nutlin-3a (-)', 'SB216763', 'GNE-317', 'Pevonedistat'}, 'ZR7530': {'GSK2606414', 'AZD6482', 'AZD5363', 'Foretinib', 'Staurosporine', 'Zoledronate', 'BIBR-1532', 'ICL-SIRT078', 'Osimertinib', 'glutathione', 'Selumetinib', 'N-acetyl cysteine', 'AZD7762', 'UNC0379', 'Bromosporine', 'Oxaliplatin', 'Schweinfurthin A', 'Methotrexate', 'PD0325901', 'UNC0638'}}\n"
     ]
    }
   ],
   "source": [
    "# 将每个细胞系的所有药物名称存储为set\n",
    "cell_line_drug_set = {}\n",
    "for index, row in df_MixedSet_pre_3cols.iterrows():\n",
    "    cell_line = row['cell_line']\n",
    "    drug = row['drug']\n",
    "    if cell_line not in cell_line_drug_set:\n",
    "        cell_line_drug_set[cell_line] = set()\n",
    "    cell_line_drug_set[cell_line].add(drug)\n",
    "\n",
    "print(cell_line_drug_set)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:01.866473Z",
     "start_time": "2024-03-22T05:32:01.589380Z"
    }
   },
   "id": "458407b224e0e9c4",
   "execution_count": 5
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[(('A549', 'NCIH716'), 8), (('BHT101', 'KYSE180'), 8), (('HCC1187', 'NCIH1693'), 8), (('2313287', 'CALU6'), 7), (('5637', 'A673'), 7)]\n"
     ]
    }
   ],
   "source": [
    "def find_max_drug_intersections(data):\n",
    "    # 将数据转换为字典的字典形式\n",
    "    cell_line_to_drugs = data\n",
    "\n",
    "    # 计算每对细胞系的药物交集大小\n",
    "    intersections = {}\n",
    "    cell_lines = list(cell_line_to_drugs.keys())\n",
    "    for i in range(len(cell_lines)):\n",
    "        for j in range(i + 1, len(cell_lines)):\n",
    "            cell_line1 = cell_lines[i]\n",
    "            cell_line2 = cell_lines[j]\n",
    "            drugs1 = set(cell_line_to_drugs[cell_line1])\n",
    "            drugs2 = set(cell_line_to_drugs[cell_line2])\n",
    "            intersection = len(drugs1 & drugs2)\n",
    "            intersections[(cell_line1, cell_line2)] = intersection\n",
    "\n",
    "    # 找出两个交集最大的细胞系\n",
    "    max_intersections = sorted(intersections.items(), key=lambda x: x[1], reverse=True)[:5]\n",
    "    return max_intersections\n",
    "\n",
    "max_intersections = find_max_drug_intersections(cell_line_drug_set)\n",
    "print(max_intersections)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.443300Z",
     "start_time": "2024-03-22T05:32:01.867531Z"
    }
   },
   "id": "7d97a1182d058331",
   "execution_count": 6
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "              drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n461    Gemcitabine      A549         LUAD -3.595753   -2.828816 -0.939695   \n465         OTX015      A549         LUAD  1.100080    0.752748 -0.642728   \n455      Bleomycin      A549         LUAD  0.997003    1.329773 -1.147677   \n453        AZD5438      A549         LUAD  1.391646    1.415604 -0.644783   \n470       YK-4-279      A549         LUAD  1.604431    1.543394 -0.389218   \n456      Cediranib      A549         LUAD  2.035846    1.653974 -0.197324   \n471       ZM447439      A549         LUAD  2.007056    1.952309 -0.334005   \n452  5-azacytidine      A549         LUAD  1.847137    2.271099 -0.820443   \n469    Savolitinib      A549         LUAD  3.832341    2.738345  0.917173   \n463     Linsitinib      A549         LUAD  3.200767    3.286070 -0.577650   \n\n     prediction_Z  \n461     -0.684943  \n465     -0.828676  \n455     -0.915692  \n453     -0.629001  \n470     -0.426176  \n456     -0.517586  \n471     -0.366096  \n452     -0.515613  \n469     -0.001801  \n463     -0.513134  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>461</th>\n      <td>Gemcitabine</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>-3.595753</td>\n      <td>-2.828816</td>\n      <td>-0.939695</td>\n      <td>-0.684943</td>\n    </tr>\n    <tr>\n      <th>465</th>\n      <td>OTX015</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>1.100080</td>\n      <td>0.752748</td>\n      <td>-0.642728</td>\n      <td>-0.828676</td>\n    </tr>\n    <tr>\n      <th>455</th>\n      <td>Bleomycin</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>0.997003</td>\n      <td>1.329773</td>\n      <td>-1.147677</td>\n      <td>-0.915692</td>\n    </tr>\n    <tr>\n      <th>453</th>\n      <td>AZD5438</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>1.391646</td>\n      <td>1.415604</td>\n      <td>-0.644783</td>\n      <td>-0.629001</td>\n    </tr>\n    <tr>\n      <th>470</th>\n      <td>YK-4-279</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>1.604431</td>\n      <td>1.543394</td>\n      <td>-0.389218</td>\n      <td>-0.426176</td>\n    </tr>\n    <tr>\n      <th>456</th>\n      <td>Cediranib</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>2.035846</td>\n      <td>1.653974</td>\n      <td>-0.197324</td>\n      <td>-0.517586</td>\n    </tr>\n    <tr>\n      <th>471</th>\n      <td>ZM447439</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>2.007056</td>\n      <td>1.952309</td>\n      <td>-0.334005</td>\n      <td>-0.366096</td>\n    </tr>\n    <tr>\n      <th>452</th>\n      <td>5-azacytidine</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>1.847137</td>\n      <td>2.271099</td>\n      <td>-0.820443</td>\n      <td>-0.515613</td>\n    </tr>\n    <tr>\n      <th>469</th>\n      <td>Savolitinib</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>3.832341</td>\n      <td>2.738345</td>\n      <td>0.917173</td>\n      <td>-0.001801</td>\n    </tr>\n    <tr>\n      <th>463</th>\n      <td>Linsitinib</td>\n      <td>A549</td>\n      <td>LUAD</td>\n      <td>3.200767</td>\n      <td>3.286070</td>\n      <td>-0.577650</td>\n      <td>-0.513134</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_A549 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'A549']\n",
    "df_A549.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.455977Z",
     "start_time": "2024-03-22T05:32:02.444578Z"
    }
   },
   "id": "31831bb7425a341b",
   "execution_count": 7
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "               drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n8285         MG-132   NCIH716         COAD -1.684555   -1.358844 -0.553978   \n8293    Vincristine   NCIH716         COAD -0.935523   -0.314834  0.259996   \n8292     Uprosertib   NCIH716         COAD  2.508591    1.914536 -0.208165   \n8287         OTX015   NCIH716         COAD  3.215223    1.931815  0.489633   \n8277         AZ6102   NCIH716         COAD  2.034493    2.027767 -0.562747   \n8291        SGC0946   NCIH716         COAD  3.112222    2.111873  1.262141   \n8279    GSK2110183B   NCIH716         COAD  2.715761    2.477404 -0.375640   \n8282    Ipatasertib   NCIH716         COAD  4.429537    2.669253  0.704720   \n8276  5-azacytidine   NCIH716         COAD  3.519749    2.906970  0.382171   \n8280    Gemcitabine   NCIH716         COAD  3.870440    3.141342  1.540339   \n\n      prediction_Z  \n8285     -0.103174  \n8293      0.496951  \n8292     -0.556112  \n8287     -0.197451  \n8277     -0.568705  \n8291      0.009459  \n8279     -0.528693  \n8282     -0.504786  \n8276     -0.058420  \n8280      1.298155  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>8285</th>\n      <td>MG-132</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>-1.684555</td>\n      <td>-1.358844</td>\n      <td>-0.553978</td>\n      <td>-0.103174</td>\n    </tr>\n    <tr>\n      <th>8293</th>\n      <td>Vincristine</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>-0.935523</td>\n      <td>-0.314834</td>\n      <td>0.259996</td>\n      <td>0.496951</td>\n    </tr>\n    <tr>\n      <th>8292</th>\n      <td>Uprosertib</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>2.508591</td>\n      <td>1.914536</td>\n      <td>-0.208165</td>\n      <td>-0.556112</td>\n    </tr>\n    <tr>\n      <th>8287</th>\n      <td>OTX015</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>3.215223</td>\n      <td>1.931815</td>\n      <td>0.489633</td>\n      <td>-0.197451</td>\n    </tr>\n    <tr>\n      <th>8277</th>\n      <td>AZ6102</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>2.034493</td>\n      <td>2.027767</td>\n      <td>-0.562747</td>\n      <td>-0.568705</td>\n    </tr>\n    <tr>\n      <th>8291</th>\n      <td>SGC0946</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>3.112222</td>\n      <td>2.111873</td>\n      <td>1.262141</td>\n      <td>0.009459</td>\n    </tr>\n    <tr>\n      <th>8279</th>\n      <td>GSK2110183B</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>2.715761</td>\n      <td>2.477404</td>\n      <td>-0.375640</td>\n      <td>-0.528693</td>\n    </tr>\n    <tr>\n      <th>8282</th>\n      <td>Ipatasertib</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>4.429537</td>\n      <td>2.669253</td>\n      <td>0.704720</td>\n      <td>-0.504786</td>\n    </tr>\n    <tr>\n      <th>8276</th>\n      <td>5-azacytidine</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>3.519749</td>\n      <td>2.906970</td>\n      <td>0.382171</td>\n      <td>-0.058420</td>\n    </tr>\n    <tr>\n      <th>8280</th>\n      <td>Gemcitabine</td>\n      <td>NCIH716</td>\n      <td>COAD</td>\n      <td>3.870440</td>\n      <td>3.141342</td>\n      <td>1.540339</td>\n      <td>1.298155</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_NCIH716 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'NCIH716']\n",
    "df_NCIH716.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.465478Z",
     "start_time": "2024-03-22T05:32:02.455977Z"
    }
   },
   "id": "33fad41bf3c46f42",
   "execution_count": 8
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "                 drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n3362        Daporinad     HCC38          IDC -2.693662   -4.197317  0.228936   \n3359          AZD7762     HCC38          IDC -0.461483    0.363624 -0.405722   \n3370           LMP744     HCC38          IDC -1.022948    0.451108 -0.292822   \n3371          MK-1775     HCC38          IDC  0.524407    1.066797 -0.078954   \n3363  Dihydrorotenone     HCC38          IDC  1.216858    2.099088  0.273593   \n3374         WEHI-539     HCC38          IDC  1.310872    2.909636 -1.378893   \n3358          AZD5438     HCC38          IDC  5.364875    3.179700  1.972524   \n3369       Irinotecan     HCC38          IDC  3.417486    3.231059  0.479242   \n3361        Cediranib     HCC38          IDC  2.884132    3.293483  0.514100   \n3368      Ipatasertib     HCC38          IDC  4.780449    4.089010  0.945834   \n\n      prediction_Z  \n3362     -0.307047  \n3359      0.129115  \n3370      0.339534  \n3371      0.303054  \n3363      0.832753  \n3374     -0.447776  \n3358      0.533072  \n3369      0.382862  \n3361      0.857407  \n3368      0.470741  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>3362</th>\n      <td>Daporinad</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>-2.693662</td>\n      <td>-4.197317</td>\n      <td>0.228936</td>\n      <td>-0.307047</td>\n    </tr>\n    <tr>\n      <th>3359</th>\n      <td>AZD7762</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>-0.461483</td>\n      <td>0.363624</td>\n      <td>-0.405722</td>\n      <td>0.129115</td>\n    </tr>\n    <tr>\n      <th>3370</th>\n      <td>LMP744</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>-1.022948</td>\n      <td>0.451108</td>\n      <td>-0.292822</td>\n      <td>0.339534</td>\n    </tr>\n    <tr>\n      <th>3371</th>\n      <td>MK-1775</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>0.524407</td>\n      <td>1.066797</td>\n      <td>-0.078954</td>\n      <td>0.303054</td>\n    </tr>\n    <tr>\n      <th>3363</th>\n      <td>Dihydrorotenone</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>1.216858</td>\n      <td>2.099088</td>\n      <td>0.273593</td>\n      <td>0.832753</td>\n    </tr>\n    <tr>\n      <th>3374</th>\n      <td>WEHI-539</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>1.310872</td>\n      <td>2.909636</td>\n      <td>-1.378893</td>\n      <td>-0.447776</td>\n    </tr>\n    <tr>\n      <th>3358</th>\n      <td>AZD5438</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>5.364875</td>\n      <td>3.179700</td>\n      <td>1.972524</td>\n      <td>0.533072</td>\n    </tr>\n    <tr>\n      <th>3369</th>\n      <td>Irinotecan</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>3.417486</td>\n      <td>3.231059</td>\n      <td>0.479242</td>\n      <td>0.382862</td>\n    </tr>\n    <tr>\n      <th>3361</th>\n      <td>Cediranib</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>2.884132</td>\n      <td>3.293483</td>\n      <td>0.514100</td>\n      <td>0.857407</td>\n    </tr>\n    <tr>\n      <th>3368</th>\n      <td>Ipatasertib</td>\n      <td>HCC38</td>\n      <td>IDC</td>\n      <td>4.780449</td>\n      <td>4.089010</td>\n      <td>0.945834</td>\n      <td>0.470741</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_HCC38 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'HCC38']\n",
    "df_HCC38.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.477389Z",
     "start_time": "2024-03-22T05:32:02.467302Z"
    }
   },
   "id": "b40d39d7865ec774",
   "execution_count": 9
  },
  {
   "cell_type": "markdown",
   "source": [
    "# 选取药物 三种："
   ],
   "metadata": {
    "collapsed": false
   },
   "id": "84f7c0abb072b199"
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "              drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n128   Pevonedistat       697          BLL -1.360520   -2.167114 -1.039244   \n6777  Pevonedistat     NALM6          BLL -1.162747   -1.699618 -0.947159   \n2682  Pevonedistat    FARAGE          GCB -2.107368   -1.540683 -1.386987   \n6638  Pevonedistat    MOLM16          AML -0.992230   -1.492576 -0.867764   \n9435  Pevonedistat      PL21          AML -1.831793   -1.429256 -1.258676   \n85    Pevonedistat      639V          UCU -1.137647   -1.139332 -0.935472   \n2020  Pevonedistat   D283MED          MBL -2.317395   -0.990968 -1.484778   \n7476  Pevonedistat  NCIH1963         SCLC -3.098671   -0.974772 -1.848550   \n9165  Pevonedistat    P31FUJ          AML -0.823622   -0.946451 -0.789258   \n4939  Pevonedistat     KELLY          NBL -0.728914   -0.870961 -0.745161   \n\n      prediction_Z  \n128      -1.414805  \n6777     -1.197133  \n2682     -1.123131  \n6638     -1.100732  \n9435     -1.071249  \n85       -0.936257  \n2020     -0.867176  \n7476     -0.859635  \n9165     -0.846449  \n4939     -0.811300  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>128</th>\n      <td>Pevonedistat</td>\n      <td>697</td>\n      <td>BLL</td>\n      <td>-1.360520</td>\n      <td>-2.167114</td>\n      <td>-1.039244</td>\n      <td>-1.414805</td>\n    </tr>\n    <tr>\n      <th>6777</th>\n      <td>Pevonedistat</td>\n      <td>NALM6</td>\n      <td>BLL</td>\n      <td>-1.162747</td>\n      <td>-1.699618</td>\n      <td>-0.947159</td>\n      <td>-1.197133</td>\n    </tr>\n    <tr>\n      <th>2682</th>\n      <td>Pevonedistat</td>\n      <td>FARAGE</td>\n      <td>GCB</td>\n      <td>-2.107368</td>\n      <td>-1.540683</td>\n      <td>-1.386987</td>\n      <td>-1.123131</td>\n    </tr>\n    <tr>\n      <th>6638</th>\n      <td>Pevonedistat</td>\n      <td>MOLM16</td>\n      <td>AML</td>\n      <td>-0.992230</td>\n      <td>-1.492576</td>\n      <td>-0.867764</td>\n      <td>-1.100732</td>\n    </tr>\n    <tr>\n      <th>9435</th>\n      <td>Pevonedistat</td>\n      <td>PL21</td>\n      <td>AML</td>\n      <td>-1.831793</td>\n      <td>-1.429256</td>\n      <td>-1.258676</td>\n      <td>-1.071249</td>\n    </tr>\n    <tr>\n      <th>85</th>\n      <td>Pevonedistat</td>\n      <td>639V</td>\n      <td>UCU</td>\n      <td>-1.137647</td>\n      <td>-1.139332</td>\n      <td>-0.935472</td>\n      <td>-0.936257</td>\n    </tr>\n    <tr>\n      <th>2020</th>\n      <td>Pevonedistat</td>\n      <td>D283MED</td>\n      <td>MBL</td>\n      <td>-2.317395</td>\n      <td>-0.990968</td>\n      <td>-1.484778</td>\n      <td>-0.867176</td>\n    </tr>\n    <tr>\n      <th>7476</th>\n      <td>Pevonedistat</td>\n      <td>NCIH1963</td>\n      <td>SCLC</td>\n      <td>-3.098671</td>\n      <td>-0.974772</td>\n      <td>-1.848550</td>\n      <td>-0.859635</td>\n    </tr>\n    <tr>\n      <th>9165</th>\n      <td>Pevonedistat</td>\n      <td>P31FUJ</td>\n      <td>AML</td>\n      <td>-0.823622</td>\n      <td>-0.946451</td>\n      <td>-0.789258</td>\n      <td>-0.846449</td>\n    </tr>\n    <tr>\n      <th>4939</th>\n      <td>Pevonedistat</td>\n      <td>KELLY</td>\n      <td>NBL</td>\n      <td>-0.728914</td>\n      <td>-0.870961</td>\n      <td>-0.745161</td>\n      <td>-0.811300</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Pevonedistat = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'Pevonedistat']\n",
    "df_Pevonedistat.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T06:10:17.524382Z",
     "start_time": "2024-03-22T06:10:17.516270Z"
    }
   },
   "id": "44f0ab2cc5b80fbd",
   "execution_count": 57
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "            drug  cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n5607   Dasatinib     LAMA84          CML -8.280412   -6.959291 -4.116759   \n3934   Dasatinib       HSC3         OCSC -0.757893   -1.585665 -0.879977   \n3517   Dasatinib      HDQP1          IDC -2.767405   -1.565570 -1.744628   \n905    Dasatinib       BPH1          NaN -2.678168   -1.215568 -1.706231   \n12065  Dasatinib     TOV21G         CCOV -2.113615   -1.192560 -1.463316   \n3973   Dasatinib         HT     DLBCLNOS -3.338605   -1.133513 -1.990403   \n7974   Dasatinib    NCIH292        LUMEC -0.957758   -0.942573 -0.965974   \n9296   Dasatinib  PATU8988T         PAAD  0.060700   -0.741518 -0.527753   \n10784  Dasatinib      SNB75           GB -0.279140   -0.699759 -0.673979   \n10622  Dasatinib        SKN         ULMS -1.570692   -0.450626 -1.229707   \n2746   Dasatinib      FUOV1        HGSOC -0.650478   -0.081656 -0.833758   \n\n       prediction_Z  \n5607      -3.548309  \n3934      -1.236150  \n3517      -1.227503  \n905       -1.076905  \n12065     -1.067005  \n3973      -1.041598  \n7974      -0.959441  \n9296      -0.872931  \n10784     -0.854963  \n10622     -0.747766  \n2746      -0.589006  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>5607</th>\n      <td>Dasatinib</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-8.280412</td>\n      <td>-6.959291</td>\n      <td>-4.116759</td>\n      <td>-3.548309</td>\n    </tr>\n    <tr>\n      <th>3934</th>\n      <td>Dasatinib</td>\n      <td>HSC3</td>\n      <td>OCSC</td>\n      <td>-0.757893</td>\n      <td>-1.585665</td>\n      <td>-0.879977</td>\n      <td>-1.236150</td>\n    </tr>\n    <tr>\n      <th>3517</th>\n      <td>Dasatinib</td>\n      <td>HDQP1</td>\n      <td>IDC</td>\n      <td>-2.767405</td>\n      <td>-1.565570</td>\n      <td>-1.744628</td>\n      <td>-1.227503</td>\n    </tr>\n    <tr>\n      <th>905</th>\n      <td>Dasatinib</td>\n      <td>BPH1</td>\n      <td>NaN</td>\n      <td>-2.678168</td>\n      <td>-1.215568</td>\n      <td>-1.706231</td>\n      <td>-1.076905</td>\n    </tr>\n    <tr>\n      <th>12065</th>\n      <td>Dasatinib</td>\n      <td>TOV21G</td>\n      <td>CCOV</td>\n      <td>-2.113615</td>\n      <td>-1.192560</td>\n      <td>-1.463316</td>\n      <td>-1.067005</td>\n    </tr>\n    <tr>\n      <th>3973</th>\n      <td>Dasatinib</td>\n      <td>HT</td>\n      <td>DLBCLNOS</td>\n      <td>-3.338605</td>\n      <td>-1.133513</td>\n      <td>-1.990403</td>\n      <td>-1.041598</td>\n    </tr>\n    <tr>\n      <th>7974</th>\n      <td>Dasatinib</td>\n      <td>NCIH292</td>\n      <td>LUMEC</td>\n      <td>-0.957758</td>\n      <td>-0.942573</td>\n      <td>-0.965974</td>\n      <td>-0.959441</td>\n    </tr>\n    <tr>\n      <th>9296</th>\n      <td>Dasatinib</td>\n      <td>PATU8988T</td>\n      <td>PAAD</td>\n      <td>0.060700</td>\n      <td>-0.741518</td>\n      <td>-0.527753</td>\n      <td>-0.872931</td>\n    </tr>\n    <tr>\n      <th>10784</th>\n      <td>Dasatinib</td>\n      <td>SNB75</td>\n      <td>GB</td>\n      <td>-0.279140</td>\n      <td>-0.699759</td>\n      <td>-0.673979</td>\n      <td>-0.854963</td>\n    </tr>\n    <tr>\n      <th>10622</th>\n      <td>Dasatinib</td>\n      <td>SKN</td>\n      <td>ULMS</td>\n      <td>-1.570692</td>\n      <td>-0.450626</td>\n      <td>-1.229707</td>\n      <td>-0.747766</td>\n    </tr>\n    <tr>\n      <th>2746</th>\n      <td>Dasatinib</td>\n      <td>FUOV1</td>\n      <td>HGSOC</td>\n      <td>-0.650478</td>\n      <td>-0.081656</td>\n      <td>-0.833758</td>\n      <td>-0.589006</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Dactolisib = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'Dasatinib']\n",
    "df_Dactolisib.head(11)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.499776Z",
     "start_time": "2024-03-22T05:32:02.489715Z"
    }
   },
   "id": "9fdaeb3c395012bd",
   "execution_count": 11
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "          drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n6756   AZD8055     MV411          AML -2.706919   -2.089222 -1.948221   \n6610   AZD8055    MOLM13          AML -2.200490   -2.027820 -1.578996   \n6648   AZD8055     MOLP8          PCM -2.178997   -1.681825 -1.563327   \n9680   AZD8055      RH41         ARMS -2.673244   -1.652861 -1.923670   \n4738   AZD8055      JVM3         BPLL -1.969494   -1.494076 -1.410584   \n2832   AZD8055      GA10           BL -1.637329   -1.422344 -1.168410   \n3022   AZD8055        H4         ASTR -1.440728   -1.421941 -1.025073   \n12431  AZD8055      YH13           GB -1.541122   -1.342816 -1.098269   \n6171   AZD8055  MDAMB453         BRCA -2.042360   -1.160465 -1.463708   \n8098   AZD8055   NCIH520         LUSC -1.909361   -0.959618 -1.366742   \n\n       prediction_Z  \n6756      -1.497874  \n6610      -1.453107  \n6648      -1.200851  \n9680      -1.179734  \n4738      -1.063968  \n2832      -1.011670  \n3022      -1.011376  \n12431     -0.953688  \n6171      -0.820741  \n8098      -0.674309  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>6756</th>\n      <td>AZD8055</td>\n      <td>MV411</td>\n      <td>AML</td>\n      <td>-2.706919</td>\n      <td>-2.089222</td>\n      <td>-1.948221</td>\n      <td>-1.497874</td>\n    </tr>\n    <tr>\n      <th>6610</th>\n      <td>AZD8055</td>\n      <td>MOLM13</td>\n      <td>AML</td>\n      <td>-2.200490</td>\n      <td>-2.027820</td>\n      <td>-1.578996</td>\n      <td>-1.453107</td>\n    </tr>\n    <tr>\n      <th>6648</th>\n      <td>AZD8055</td>\n      <td>MOLP8</td>\n      <td>PCM</td>\n      <td>-2.178997</td>\n      <td>-1.681825</td>\n      <td>-1.563327</td>\n      <td>-1.200851</td>\n    </tr>\n    <tr>\n      <th>9680</th>\n      <td>AZD8055</td>\n      <td>RH41</td>\n      <td>ARMS</td>\n      <td>-2.673244</td>\n      <td>-1.652861</td>\n      <td>-1.923670</td>\n      <td>-1.179734</td>\n    </tr>\n    <tr>\n      <th>4738</th>\n      <td>AZD8055</td>\n      <td>JVM3</td>\n      <td>BPLL</td>\n      <td>-1.969494</td>\n      <td>-1.494076</td>\n      <td>-1.410584</td>\n      <td>-1.063968</td>\n    </tr>\n    <tr>\n      <th>2832</th>\n      <td>AZD8055</td>\n      <td>GA10</td>\n      <td>BL</td>\n      <td>-1.637329</td>\n      <td>-1.422344</td>\n      <td>-1.168410</td>\n      <td>-1.011670</td>\n    </tr>\n    <tr>\n      <th>3022</th>\n      <td>AZD8055</td>\n      <td>H4</td>\n      <td>ASTR</td>\n      <td>-1.440728</td>\n      <td>-1.421941</td>\n      <td>-1.025073</td>\n      <td>-1.011376</td>\n    </tr>\n    <tr>\n      <th>12431</th>\n      <td>AZD8055</td>\n      <td>YH13</td>\n      <td>GB</td>\n      <td>-1.541122</td>\n      <td>-1.342816</td>\n      <td>-1.098269</td>\n      <td>-0.953688</td>\n    </tr>\n    <tr>\n      <th>6171</th>\n      <td>AZD8055</td>\n      <td>MDAMB453</td>\n      <td>BRCA</td>\n      <td>-2.042360</td>\n      <td>-1.160465</td>\n      <td>-1.463708</td>\n      <td>-0.820741</td>\n    </tr>\n    <tr>\n      <th>8098</th>\n      <td>AZD8055</td>\n      <td>NCIH520</td>\n      <td>LUSC</td>\n      <td>-1.909361</td>\n      <td>-0.959618</td>\n      <td>-1.366742</td>\n      <td>-0.674309</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_AZD8055 = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'AZD8055']\n",
    "df_AZD8055.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.510836Z",
     "start_time": "2024-03-22T05:32:02.499776Z"
    }
   },
   "id": "6ce86299fb6832da",
   "execution_count": 12
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "            drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n10509  PD0325901   SKMEL28         SKCM -4.328333   -4.293523 -2.644394   \n1847   PD0325901   COLO800         SKCM -3.526498   -2.850867 -2.270638   \n4089   PD0325901      HT29         COAD -2.435552   -2.615621 -1.762120   \n801    PD0325901    BHT101         THAP -2.897905   -1.999452 -1.977634   \n3620   PD0325901  HEP3B217          HCC -1.394020   -1.623602 -1.276634   \n12035  PD0325901      THP1          AML -0.095676   -1.519687 -0.671442   \n600    PD0325901      AM38           GB -1.725701   -1.332307 -1.431239   \n11629  PD0325901     SW948         COAD -1.231857   -1.317335 -1.201046   \n2630   PD0325901     ESO51         ESCA -0.516364   -0.752966 -0.867536   \n9164   PD0325901    P31FUJ          AML -0.757547   -0.697964 -0.979957   \n\n       prediction_Z  \n10509     -2.628168  \n1847      -1.955709  \n4089      -1.846054  \n801       -1.558842  \n3620      -1.383648  \n12035     -1.335211  \n600       -1.247868  \n11629     -1.240889  \n2630      -0.977822  \n9164      -0.952184  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>10509</th>\n      <td>PD0325901</td>\n      <td>SKMEL28</td>\n      <td>SKCM</td>\n      <td>-4.328333</td>\n      <td>-4.293523</td>\n      <td>-2.644394</td>\n      <td>-2.628168</td>\n    </tr>\n    <tr>\n      <th>1847</th>\n      <td>PD0325901</td>\n      <td>COLO800</td>\n      <td>SKCM</td>\n      <td>-3.526498</td>\n      <td>-2.850867</td>\n      <td>-2.270638</td>\n      <td>-1.955709</td>\n    </tr>\n    <tr>\n      <th>4089</th>\n      <td>PD0325901</td>\n      <td>HT29</td>\n      <td>COAD</td>\n      <td>-2.435552</td>\n      <td>-2.615621</td>\n      <td>-1.762120</td>\n      <td>-1.846054</td>\n    </tr>\n    <tr>\n      <th>801</th>\n      <td>PD0325901</td>\n      <td>BHT101</td>\n      <td>THAP</td>\n      <td>-2.897905</td>\n      <td>-1.999452</td>\n      <td>-1.977634</td>\n      <td>-1.558842</td>\n    </tr>\n    <tr>\n      <th>3620</th>\n      <td>PD0325901</td>\n      <td>HEP3B217</td>\n      <td>HCC</td>\n      <td>-1.394020</td>\n      <td>-1.623602</td>\n      <td>-1.276634</td>\n      <td>-1.383648</td>\n    </tr>\n    <tr>\n      <th>12035</th>\n      <td>PD0325901</td>\n      <td>THP1</td>\n      <td>AML</td>\n      <td>-0.095676</td>\n      <td>-1.519687</td>\n      <td>-0.671442</td>\n      <td>-1.335211</td>\n    </tr>\n    <tr>\n      <th>600</th>\n      <td>PD0325901</td>\n      <td>AM38</td>\n      <td>GB</td>\n      <td>-1.725701</td>\n      <td>-1.332307</td>\n      <td>-1.431239</td>\n      <td>-1.247868</td>\n    </tr>\n    <tr>\n      <th>11629</th>\n      <td>PD0325901</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-1.231857</td>\n      <td>-1.317335</td>\n      <td>-1.201046</td>\n      <td>-1.240889</td>\n    </tr>\n    <tr>\n      <th>2630</th>\n      <td>PD0325901</td>\n      <td>ESO51</td>\n      <td>ESCA</td>\n      <td>-0.516364</td>\n      <td>-0.752966</td>\n      <td>-0.867536</td>\n      <td>-0.977822</td>\n    </tr>\n    <tr>\n      <th>9164</th>\n      <td>PD0325901</td>\n      <td>P31FUJ</td>\n      <td>AML</td>\n      <td>-0.757547</td>\n      <td>-0.697964</td>\n      <td>-0.979957</td>\n      <td>-0.952184</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_PD0325901 = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'PD0325901']\n",
    "df_PD0325901.head(10)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.522227Z",
     "start_time": "2024-03-22T05:32:02.511415Z"
    }
   },
   "id": "b50adfc873e077b0",
   "execution_count": 13
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "             drug cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n7745   Paclitaxel  NCIH2171         SCLC -5.427479   -5.847473 -1.275236   \n6619   Paclitaxel    MOLM13          AML -5.876668   -5.845653 -1.497970   \n9745   Paclitaxel        RL     DLBCLNOS -5.802949   -5.816971 -1.461416   \n11165  Paclitaxel    SUDHL4     DLBCLNOS -4.967285   -5.635205 -1.047046   \n4463   Paclitaxel       JAR         UCCA -5.569815   -5.619416 -1.345815   \n9849   Paclitaxel  RPMI8402          TLL -4.771135   -5.603816 -0.949783   \n11127  Paclitaxel    SUDHL1     ALCLALKP -6.922022   -5.487307 -2.016316   \n3941   Paclitaxel      HSC3         OCSC -4.808082   -5.214165 -0.968104   \n8202   Paclitaxel   NCIH647         LUAS -4.735895   -5.014444 -0.932309   \n9869   Paclitaxel     RS411          BLL -4.650407   -5.010117 -0.889920   \n5086   Paclitaxel   KMS12BM          PCM -5.479312   -4.903814 -1.300938   \n6476   Paclitaxel    MHHES1           ES -4.559274   -4.887085 -0.844731   \n3981   Paclitaxel        HT     DLBCLNOS -6.109752   -4.843718 -1.613546   \n10672  Paclitaxel     SKNDZ          NBL -2.358520   -4.693530  0.246529   \n7653   Paclitaxel   NCIH209         SCLC -5.104501   -4.682078 -1.115086   \n7475   Paclitaxel  NCIH1963         SCLC -3.832206   -4.591037 -0.484209   \n1279   Paclitaxel     CAL33         OCSC -4.253907   -4.396115 -0.693312   \n6261   Paclitaxel     MEG01   CMLBCRABL1 -2.644057   -4.333789  0.104943   \n3333   Paclitaxel     HCC33         SCLC -4.668903   -4.257956 -0.899091   \n10922  Paclitaxel    SNU398          HCC -3.520420   -4.027184 -0.329608   \n\n       prediction_Z  \n7745      -1.483493  \n6619      -1.482591  \n9745      -1.468369  \n11165     -1.378239  \n4463      -1.370410  \n9849      -1.362674  \n11127     -1.304903  \n3941      -1.169463  \n8202      -1.070430  \n9869      -1.068284  \n5086      -1.015573  \n6476      -1.007278  \n3981      -0.985774  \n10672     -0.911303  \n7653      -0.905624  \n7475      -0.860481  \n1279      -0.763827  \n6261      -0.732922  \n3333      -0.695320  \n10922     -0.580890  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>7745</th>\n      <td>Paclitaxel</td>\n      <td>NCIH2171</td>\n      <td>SCLC</td>\n      <td>-5.427479</td>\n      <td>-5.847473</td>\n      <td>-1.275236</td>\n      <td>-1.483493</td>\n    </tr>\n    <tr>\n      <th>6619</th>\n      <td>Paclitaxel</td>\n      <td>MOLM13</td>\n      <td>AML</td>\n      <td>-5.876668</td>\n      <td>-5.845653</td>\n      <td>-1.497970</td>\n      <td>-1.482591</td>\n    </tr>\n    <tr>\n      <th>9745</th>\n      <td>Paclitaxel</td>\n      <td>RL</td>\n      <td>DLBCLNOS</td>\n      <td>-5.802949</td>\n      <td>-5.816971</td>\n      <td>-1.461416</td>\n      <td>-1.468369</td>\n    </tr>\n    <tr>\n      <th>11165</th>\n      <td>Paclitaxel</td>\n      <td>SUDHL4</td>\n      <td>DLBCLNOS</td>\n      <td>-4.967285</td>\n      <td>-5.635205</td>\n      <td>-1.047046</td>\n      <td>-1.378239</td>\n    </tr>\n    <tr>\n      <th>4463</th>\n      <td>Paclitaxel</td>\n      <td>JAR</td>\n      <td>UCCA</td>\n      <td>-5.569815</td>\n      <td>-5.619416</td>\n      <td>-1.345815</td>\n      <td>-1.370410</td>\n    </tr>\n    <tr>\n      <th>9849</th>\n      <td>Paclitaxel</td>\n      <td>RPMI8402</td>\n      <td>TLL</td>\n      <td>-4.771135</td>\n      <td>-5.603816</td>\n      <td>-0.949783</td>\n      <td>-1.362674</td>\n    </tr>\n    <tr>\n      <th>11127</th>\n      <td>Paclitaxel</td>\n      <td>SUDHL1</td>\n      <td>ALCLALKP</td>\n      <td>-6.922022</td>\n      <td>-5.487307</td>\n      <td>-2.016316</td>\n      <td>-1.304903</td>\n    </tr>\n    <tr>\n      <th>3941</th>\n      <td>Paclitaxel</td>\n      <td>HSC3</td>\n      <td>OCSC</td>\n      <td>-4.808082</td>\n      <td>-5.214165</td>\n      <td>-0.968104</td>\n      <td>-1.169463</td>\n    </tr>\n    <tr>\n      <th>8202</th>\n      <td>Paclitaxel</td>\n      <td>NCIH647</td>\n      <td>LUAS</td>\n      <td>-4.735895</td>\n      <td>-5.014444</td>\n      <td>-0.932309</td>\n      <td>-1.070430</td>\n    </tr>\n    <tr>\n      <th>9869</th>\n      <td>Paclitaxel</td>\n      <td>RS411</td>\n      <td>BLL</td>\n      <td>-4.650407</td>\n      <td>-5.010117</td>\n      <td>-0.889920</td>\n      <td>-1.068284</td>\n    </tr>\n    <tr>\n      <th>5086</th>\n      <td>Paclitaxel</td>\n      <td>KMS12BM</td>\n      <td>PCM</td>\n      <td>-5.479312</td>\n      <td>-4.903814</td>\n      <td>-1.300938</td>\n      <td>-1.015573</td>\n    </tr>\n    <tr>\n      <th>6476</th>\n      <td>Paclitaxel</td>\n      <td>MHHES1</td>\n      <td>ES</td>\n      <td>-4.559274</td>\n      <td>-4.887085</td>\n      <td>-0.844731</td>\n      <td>-1.007278</td>\n    </tr>\n    <tr>\n      <th>3981</th>\n      <td>Paclitaxel</td>\n      <td>HT</td>\n      <td>DLBCLNOS</td>\n      <td>-6.109752</td>\n      <td>-4.843718</td>\n      <td>-1.613546</td>\n      <td>-0.985774</td>\n    </tr>\n    <tr>\n      <th>10672</th>\n      <td>Paclitaxel</td>\n      <td>SKNDZ</td>\n      <td>NBL</td>\n      <td>-2.358520</td>\n      <td>-4.693530</td>\n      <td>0.246529</td>\n      <td>-0.911303</td>\n    </tr>\n    <tr>\n      <th>7653</th>\n      <td>Paclitaxel</td>\n      <td>NCIH209</td>\n      <td>SCLC</td>\n      <td>-5.104501</td>\n      <td>-4.682078</td>\n      <td>-1.115086</td>\n      <td>-0.905624</td>\n    </tr>\n    <tr>\n      <th>7475</th>\n      <td>Paclitaxel</td>\n      <td>NCIH1963</td>\n      <td>SCLC</td>\n      <td>-3.832206</td>\n      <td>-4.591037</td>\n      <td>-0.484209</td>\n      <td>-0.860481</td>\n    </tr>\n    <tr>\n      <th>1279</th>\n      <td>Paclitaxel</td>\n      <td>CAL33</td>\n      <td>OCSC</td>\n      <td>-4.253907</td>\n      <td>-4.396115</td>\n      <td>-0.693312</td>\n      <td>-0.763827</td>\n    </tr>\n    <tr>\n      <th>6261</th>\n      <td>Paclitaxel</td>\n      <td>MEG01</td>\n      <td>CMLBCRABL1</td>\n      <td>-2.644057</td>\n      <td>-4.333789</td>\n      <td>0.104943</td>\n      <td>-0.732922</td>\n    </tr>\n    <tr>\n      <th>3333</th>\n      <td>Paclitaxel</td>\n      <td>HCC33</td>\n      <td>SCLC</td>\n      <td>-4.668903</td>\n      <td>-4.257956</td>\n      <td>-0.899091</td>\n      <td>-0.695320</td>\n    </tr>\n    <tr>\n      <th>10922</th>\n      <td>Paclitaxel</td>\n      <td>SNU398</td>\n      <td>HCC</td>\n      <td>-3.520420</td>\n      <td>-4.027184</td>\n      <td>-0.329608</td>\n      <td>-0.580890</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Paclitaxel = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'Paclitaxel']\n",
    "df_Paclitaxel.head(20)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.533250Z",
     "start_time": "2024-03-22T05:32:02.524221Z"
    }
   },
   "id": "62d3ba5555dc32a1",
   "execution_count": 14
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "            drug    cell_line OncotreeCode      IC50  prediction    IC50_Z  \\\n8067   Docetaxel      NCIH460         LCLC -6.669256   -6.628595 -1.276031   \n4275   Docetaxel       HUTU80           DA -6.385741   -6.507266 -1.164788   \n3834   Docetaxel        HS683          ODG -6.521924   -6.137796 -1.218222   \n11194  Docetaxel       SUDHL6     DLBCLNOS -6.032596   -6.126490 -1.026223   \n10728  Docetaxel       SKPNDW           ES -5.718170   -6.051600 -0.902851   \n5346   Docetaxel         KYM1         ERMS -5.810904   -5.899730 -0.939238   \n366    Docetaxel        A3KAW     DLBCLNOS -5.566962   -5.815369 -0.843522   \n10104  Docetaxel        SF126           GB -5.067891   -5.810888 -0.647700   \n9121   Docetaxel  P12ICHIKAWA          TLL -5.796639   -5.779648 -0.933641   \n3026   Docetaxel           H4         ASTR -6.123808   -5.776226 -1.062012   \n8671   Docetaxel      OCIAML3          AML -5.716216   -5.666280 -0.902085   \n5802   Docetaxel      LOXIMVI          MEL -4.872396   -5.633533 -0.570993   \n6453   Docetaxel     MHHCALL4          BLL -4.792558   -5.572311 -0.539667   \n6839   Docetaxel        NCCIT        EMBCA -5.698790   -5.494185 -0.895247   \n573    Docetaxel       ALLSIL          TLL -5.778017   -5.463391 -0.926334   \n8738   Docetaxel        OCIM1          AML -5.751862   -5.414031 -0.916071   \n4798   Docetaxel    KARPAS299     ALCLALKP -4.806955   -5.333823 -0.545316   \n9596   Docetaxel          REH          BLL -5.250867   -5.142052 -0.719495   \n7135   Docetaxel     NCIH1648         LUAD -5.319868   -5.113674 -0.746569   \n11248  Docetaxel       SUPB15   BLLBCRABL1 -4.520901   -4.955499 -0.433077   \n\n       prediction_Z  \n8067      -1.260077  \n4275      -1.212471  \n3834      -1.067501  \n11194     -1.063065  \n10728     -1.033680  \n5346      -0.974091  \n366       -0.940990  \n10104     -0.939231  \n9121      -0.926974  \n3026      -0.925631  \n8671      -0.882491  \n5802      -0.869642  \n6453      -0.845620  \n6839      -0.814966  \n573       -0.802883  \n8738      -0.783516  \n4798      -0.752044  \n9596      -0.676799  \n7135      -0.665664  \n11248     -0.603601  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>8067</th>\n      <td>Docetaxel</td>\n      <td>NCIH460</td>\n      <td>LCLC</td>\n      <td>-6.669256</td>\n      <td>-6.628595</td>\n      <td>-1.276031</td>\n      <td>-1.260077</td>\n    </tr>\n    <tr>\n      <th>4275</th>\n      <td>Docetaxel</td>\n      <td>HUTU80</td>\n      <td>DA</td>\n      <td>-6.385741</td>\n      <td>-6.507266</td>\n      <td>-1.164788</td>\n      <td>-1.212471</td>\n    </tr>\n    <tr>\n      <th>3834</th>\n      <td>Docetaxel</td>\n      <td>HS683</td>\n      <td>ODG</td>\n      <td>-6.521924</td>\n      <td>-6.137796</td>\n      <td>-1.218222</td>\n      <td>-1.067501</td>\n    </tr>\n    <tr>\n      <th>11194</th>\n      <td>Docetaxel</td>\n      <td>SUDHL6</td>\n      <td>DLBCLNOS</td>\n      <td>-6.032596</td>\n      <td>-6.126490</td>\n      <td>-1.026223</td>\n      <td>-1.063065</td>\n    </tr>\n    <tr>\n      <th>10728</th>\n      <td>Docetaxel</td>\n      <td>SKPNDW</td>\n      <td>ES</td>\n      <td>-5.718170</td>\n      <td>-6.051600</td>\n      <td>-0.902851</td>\n      <td>-1.033680</td>\n    </tr>\n    <tr>\n      <th>5346</th>\n      <td>Docetaxel</td>\n      <td>KYM1</td>\n      <td>ERMS</td>\n      <td>-5.810904</td>\n      <td>-5.899730</td>\n      <td>-0.939238</td>\n      <td>-0.974091</td>\n    </tr>\n    <tr>\n      <th>366</th>\n      <td>Docetaxel</td>\n      <td>A3KAW</td>\n      <td>DLBCLNOS</td>\n      <td>-5.566962</td>\n      <td>-5.815369</td>\n      <td>-0.843522</td>\n      <td>-0.940990</td>\n    </tr>\n    <tr>\n      <th>10104</th>\n      <td>Docetaxel</td>\n      <td>SF126</td>\n      <td>GB</td>\n      <td>-5.067891</td>\n      <td>-5.810888</td>\n      <td>-0.647700</td>\n      <td>-0.939231</td>\n    </tr>\n    <tr>\n      <th>9121</th>\n      <td>Docetaxel</td>\n      <td>P12ICHIKAWA</td>\n      <td>TLL</td>\n      <td>-5.796639</td>\n      <td>-5.779648</td>\n      <td>-0.933641</td>\n      <td>-0.926974</td>\n    </tr>\n    <tr>\n      <th>3026</th>\n      <td>Docetaxel</td>\n      <td>H4</td>\n      <td>ASTR</td>\n      <td>-6.123808</td>\n      <td>-5.776226</td>\n      <td>-1.062012</td>\n      <td>-0.925631</td>\n    </tr>\n    <tr>\n      <th>8671</th>\n      <td>Docetaxel</td>\n      <td>OCIAML3</td>\n      <td>AML</td>\n      <td>-5.716216</td>\n      <td>-5.666280</td>\n      <td>-0.902085</td>\n      <td>-0.882491</td>\n    </tr>\n    <tr>\n      <th>5802</th>\n      <td>Docetaxel</td>\n      <td>LOXIMVI</td>\n      <td>MEL</td>\n      <td>-4.872396</td>\n      <td>-5.633533</td>\n      <td>-0.570993</td>\n      <td>-0.869642</td>\n    </tr>\n    <tr>\n      <th>6453</th>\n      <td>Docetaxel</td>\n      <td>MHHCALL4</td>\n      <td>BLL</td>\n      <td>-4.792558</td>\n      <td>-5.572311</td>\n      <td>-0.539667</td>\n      <td>-0.845620</td>\n    </tr>\n    <tr>\n      <th>6839</th>\n      <td>Docetaxel</td>\n      <td>NCCIT</td>\n      <td>EMBCA</td>\n      <td>-5.698790</td>\n      <td>-5.494185</td>\n      <td>-0.895247</td>\n      <td>-0.814966</td>\n    </tr>\n    <tr>\n      <th>573</th>\n      <td>Docetaxel</td>\n      <td>ALLSIL</td>\n      <td>TLL</td>\n      <td>-5.778017</td>\n      <td>-5.463391</td>\n      <td>-0.926334</td>\n      <td>-0.802883</td>\n    </tr>\n    <tr>\n      <th>8738</th>\n      <td>Docetaxel</td>\n      <td>OCIM1</td>\n      <td>AML</td>\n      <td>-5.751862</td>\n      <td>-5.414031</td>\n      <td>-0.916071</td>\n      <td>-0.783516</td>\n    </tr>\n    <tr>\n      <th>4798</th>\n      <td>Docetaxel</td>\n      <td>KARPAS299</td>\n      <td>ALCLALKP</td>\n      <td>-4.806955</td>\n      <td>-5.333823</td>\n      <td>-0.545316</td>\n      <td>-0.752044</td>\n    </tr>\n    <tr>\n      <th>9596</th>\n      <td>Docetaxel</td>\n      <td>REH</td>\n      <td>BLL</td>\n      <td>-5.250867</td>\n      <td>-5.142052</td>\n      <td>-0.719495</td>\n      <td>-0.676799</td>\n    </tr>\n    <tr>\n      <th>7135</th>\n      <td>Docetaxel</td>\n      <td>NCIH1648</td>\n      <td>LUAD</td>\n      <td>-5.319868</td>\n      <td>-5.113674</td>\n      <td>-0.746569</td>\n      <td>-0.665664</td>\n    </tr>\n    <tr>\n      <th>11248</th>\n      <td>Docetaxel</td>\n      <td>SUPB15</td>\n      <td>BLLBCRABL1</td>\n      <td>-4.520901</td>\n      <td>-4.955499</td>\n      <td>-0.433077</td>\n      <td>-0.603601</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_Docetaxel = df_MixedSet_pre[df_MixedSet_pre['drug'] == 'Docetaxel']\n",
    "\n",
    "df_Docetaxel.head(20)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.546218Z",
     "start_time": "2024-03-22T05:32:02.534909Z"
    }
   },
   "id": "2e01c05acb78df9d",
   "execution_count": 15
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_Dactolisib_10 = df_Dactolisib.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "palette = {\n",
    "    'Ground Truth': '#00B2EE',\n",
    "    'Prediction': '#FF6A6A'\n",
    "}\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='cell_line', y='prediction', data=df_Dactolisib_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线\n",
    "# plt.axhline(0, color='black', linewidth=0.8)\n",
    "# title\n",
    "plt.title('Dactolisib', fontsize=25)\n",
    "plt.xticks(rotation=65, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Cell Line', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(2)\n",
    "plt.gca().spines['left'].set_linewidth(2)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T05:32:02.774666Z",
     "start_time": "2024-03-22T05:32:02.547215Z"
    }
   },
   "id": "9928ee1e3bcdad98",
   "execution_count": 16
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_Pevonedistat_10 = df_Pevonedistat.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='cell_line', y='prediction', data=df_Pevonedistat_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线\n",
    "# plt.axhline(0, color='black', linewidth=1.5, linestyle='--')\n",
    "# title\n",
    "plt.title('Pevonedistat', fontsize=25)\n",
    "plt.xticks(rotation=45, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Cell Line', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(2)\n",
    "plt.gca().spines['left'].set_linewidth(2)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T06:10:59.107903Z",
     "start_time": "2024-03-22T06:10:59.002156Z"
    }
   },
   "id": "50a9cec872207c73",
   "execution_count": 59
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_PD0325901_10 = df_PD0325901.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='cell_line', y='prediction', data=df_PD0325901_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线\n",
    "# plt.axhline(0, color='black', linewidth=0.8)\n",
    "# title\n",
    "plt.title('PD0325901', fontsize=25)\n",
    "plt.xticks(rotation=45, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Cell Line', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(2)\n",
    "plt.gca().spines['left'].set_linewidth(2)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false
   },
   "id": "b094baf015c3d714",
   "execution_count": 132
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "                      drug cell_line OncotreeCode      IC50  prediction  \\\n5607             Dasatinib    LAMA84          CML -8.280412   -6.959291   \n5620            Romidepsin    LAMA84          CML -6.188206   -5.646011   \n5622  Sepantronium bromide    LAMA84          CML -3.909930   -4.352540   \n5614          Methotrexate    LAMA84          CML -3.450255   -2.820328   \n5619             Rapamycin    LAMA84          CML -3.447897   -2.752299   \n5623            Teniposide    LAMA84          CML -1.578937   -1.444662   \n5608       Dihydrorotenone    LAMA84          CML  0.979489   -0.793049   \n5617                OTX015    LAMA84          CML -0.928230    0.916253   \n5606             Cisplatin    LAMA84          CML  1.330546    1.002698   \n5605              Afatinib    LAMA84          CML  0.937092    1.074874   \n5611         Entospletinib    LAMA84          CML  1.822784    2.656175   \n5612                GSK591    LAMA84          CML  2.556025    3.407228   \n5621              SB590885    LAMA84          CML  3.825008    3.427045   \n5615                 Mirin    LAMA84          CML  4.519339    3.774753   \n5613                MIRA-1    LAMA84          CML  4.074805    3.837215   \n5616            Nelarabine    LAMA84          CML  4.655437    4.219542   \n5618                  PFI3    LAMA84          CML  4.379830    4.380861   \n5609           Doramapimod    LAMA84          CML  3.485559    4.661183   \n5610               EPZ5676    LAMA84          CML  4.687593    4.765944   \n\n        IC50_Z  prediction_Z  \n5607 -4.116759     -3.548309  \n5620 -0.944329     -0.404159  \n5622  0.159539     -0.112340  \n5614 -1.526136     -1.273311  \n5619 -0.921220     -0.508036  \n5623 -1.034258     -0.966536  \n5608  0.123148     -1.000293  \n5617 -1.728603     -0.741142  \n5606 -1.026760     -1.203465  \n5605 -0.444000     -0.350968  \n5611 -1.513367     -0.831643  \n5612 -1.501968     -0.799013  \n5621 -0.381626     -0.675231  \n5615 -0.222583     -0.851686  \n5613 -0.941986     -1.134453  \n5616 -1.253426     -1.655683  \n5618 -1.209412     -1.208187  \n5609 -1.223208     -0.233857  \n5610 -0.831487     -0.755322  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>5607</th>\n      <td>Dasatinib</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-8.280412</td>\n      <td>-6.959291</td>\n      <td>-4.116759</td>\n      <td>-3.548309</td>\n    </tr>\n    <tr>\n      <th>5620</th>\n      <td>Romidepsin</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-6.188206</td>\n      <td>-5.646011</td>\n      <td>-0.944329</td>\n      <td>-0.404159</td>\n    </tr>\n    <tr>\n      <th>5622</th>\n      <td>Sepantronium bromide</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-3.909930</td>\n      <td>-4.352540</td>\n      <td>0.159539</td>\n      <td>-0.112340</td>\n    </tr>\n    <tr>\n      <th>5614</th>\n      <td>Methotrexate</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-3.450255</td>\n      <td>-2.820328</td>\n      <td>-1.526136</td>\n      <td>-1.273311</td>\n    </tr>\n    <tr>\n      <th>5619</th>\n      <td>Rapamycin</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-3.447897</td>\n      <td>-2.752299</td>\n      <td>-0.921220</td>\n      <td>-0.508036</td>\n    </tr>\n    <tr>\n      <th>5623</th>\n      <td>Teniposide</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-1.578937</td>\n      <td>-1.444662</td>\n      <td>-1.034258</td>\n      <td>-0.966536</td>\n    </tr>\n    <tr>\n      <th>5608</th>\n      <td>Dihydrorotenone</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>0.979489</td>\n      <td>-0.793049</td>\n      <td>0.123148</td>\n      <td>-1.000293</td>\n    </tr>\n    <tr>\n      <th>5617</th>\n      <td>OTX015</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>-0.928230</td>\n      <td>0.916253</td>\n      <td>-1.728603</td>\n      <td>-0.741142</td>\n    </tr>\n    <tr>\n      <th>5606</th>\n      <td>Cisplatin</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>1.330546</td>\n      <td>1.002698</td>\n      <td>-1.026760</td>\n      <td>-1.203465</td>\n    </tr>\n    <tr>\n      <th>5605</th>\n      <td>Afatinib</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>0.937092</td>\n      <td>1.074874</td>\n      <td>-0.444000</td>\n      <td>-0.350968</td>\n    </tr>\n    <tr>\n      <th>5611</th>\n      <td>Entospletinib</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>1.822784</td>\n      <td>2.656175</td>\n      <td>-1.513367</td>\n      <td>-0.831643</td>\n    </tr>\n    <tr>\n      <th>5612</th>\n      <td>GSK591</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>2.556025</td>\n      <td>3.407228</td>\n      <td>-1.501968</td>\n      <td>-0.799013</td>\n    </tr>\n    <tr>\n      <th>5621</th>\n      <td>SB590885</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>3.825008</td>\n      <td>3.427045</td>\n      <td>-0.381626</td>\n      <td>-0.675231</td>\n    </tr>\n    <tr>\n      <th>5615</th>\n      <td>Mirin</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>4.519339</td>\n      <td>3.774753</td>\n      <td>-0.222583</td>\n      <td>-0.851686</td>\n    </tr>\n    <tr>\n      <th>5613</th>\n      <td>MIRA-1</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>4.074805</td>\n      <td>3.837215</td>\n      <td>-0.941986</td>\n      <td>-1.134453</td>\n    </tr>\n    <tr>\n      <th>5616</th>\n      <td>Nelarabine</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>4.655437</td>\n      <td>4.219542</td>\n      <td>-1.253426</td>\n      <td>-1.655683</td>\n    </tr>\n    <tr>\n      <th>5618</th>\n      <td>PFI3</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>4.379830</td>\n      <td>4.380861</td>\n      <td>-1.209412</td>\n      <td>-1.208187</td>\n    </tr>\n    <tr>\n      <th>5609</th>\n      <td>Doramapimod</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>3.485559</td>\n      <td>4.661183</td>\n      <td>-1.223208</td>\n      <td>-0.233857</td>\n    </tr>\n    <tr>\n      <th>5610</th>\n      <td>EPZ5676</td>\n      <td>LAMA84</td>\n      <td>CML</td>\n      <td>4.687593</td>\n      <td>4.765944</td>\n      <td>-0.831487</td>\n      <td>-0.755322</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_LAMA84 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'LAMA84']\n",
    "df_LAMA84.head(20)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-21T11:38:59.379877Z",
     "start_time": "2024-03-21T11:38:59.370478Z"
    }
   },
   "id": "f7adf46756d16691",
   "execution_count": 93
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "                drug cell_line OncotreeCode       IC50  prediction    IC50_Z  \\\n11622      Daporinad     SW948         COAD  -4.550119   -4.427495 -0.432805   \n11629      PD0325901     SW948         COAD  -1.231857   -1.317335 -1.201046   \n11631      Rapamycin     SW948         COAD  -1.528877   -0.799537  0.218673   \n11621        AZD8055     SW948         COAD  -1.320921    0.069231 -0.937725   \n11620        AZD7762     SW948         COAD  -0.019826    0.259729 -0.119439   \n11633      Taselisib     SW948         COAD  -0.129392    0.646840 -1.119425   \n11634     Uprosertib     SW948         COAD   0.745355    1.025918 -1.240918   \n11632      Sorafenib     SW948         COAD   3.689755    2.622827  0.941704   \n11617         AZ6102     SW948         COAD   1.773897    2.635948 -0.793597   \n11630    Palbociclib     SW948         COAD   4.045131    3.454783  0.361532   \n11626      Nilotinib     SW948         COAD   5.020491    3.579723  0.970648   \n11625      Lapatinib     SW948         COAD   5.095517    3.931162  1.184712   \n11619        AZD4547     SW948         COAD   3.335971    4.519645  0.154778   \n11623     GSK2606414     SW948         COAD   4.483776    5.030071  0.574170   \n11628      PCI-34051     SW948         COAD   5.918300    5.202985  1.183593   \n11624      Ibrutinib     SW948         COAD   5.965032    5.393507  1.053149   \n11627  Nutlin-3a (-)     SW948         COAD   6.362884    5.502699  1.084058   \n11618        AZD1208     SW948         COAD   5.494661    5.602795  0.251777   \n11635    glutathione     SW948         COAD  10.152096    9.419693  1.094248   \n\n       prediction_Z  \n11622     -0.389095  \n11629     -1.240889  \n11631      0.651899  \n11621      0.075799  \n11620      0.061770  \n11633     -0.661245  \n11634     -1.076588  \n11632      0.063853  \n11617     -0.029945  \n11630     -0.010304  \n11626      0.126309  \n11625      0.449373  \n11619      0.894458  \n11623      1.023436  \n11628      0.627426  \n11624      0.737864  \n11627      0.603843  \n11618      0.357876  \n11635      0.276765  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>11622</th>\n      <td>Daporinad</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-4.550119</td>\n      <td>-4.427495</td>\n      <td>-0.432805</td>\n      <td>-0.389095</td>\n    </tr>\n    <tr>\n      <th>11629</th>\n      <td>PD0325901</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-1.231857</td>\n      <td>-1.317335</td>\n      <td>-1.201046</td>\n      <td>-1.240889</td>\n    </tr>\n    <tr>\n      <th>11631</th>\n      <td>Rapamycin</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-1.528877</td>\n      <td>-0.799537</td>\n      <td>0.218673</td>\n      <td>0.651899</td>\n    </tr>\n    <tr>\n      <th>11621</th>\n      <td>AZD8055</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-1.320921</td>\n      <td>0.069231</td>\n      <td>-0.937725</td>\n      <td>0.075799</td>\n    </tr>\n    <tr>\n      <th>11620</th>\n      <td>AZD7762</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-0.019826</td>\n      <td>0.259729</td>\n      <td>-0.119439</td>\n      <td>0.061770</td>\n    </tr>\n    <tr>\n      <th>11633</th>\n      <td>Taselisib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>-0.129392</td>\n      <td>0.646840</td>\n      <td>-1.119425</td>\n      <td>-0.661245</td>\n    </tr>\n    <tr>\n      <th>11634</th>\n      <td>Uprosertib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>0.745355</td>\n      <td>1.025918</td>\n      <td>-1.240918</td>\n      <td>-1.076588</td>\n    </tr>\n    <tr>\n      <th>11632</th>\n      <td>Sorafenib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>3.689755</td>\n      <td>2.622827</td>\n      <td>0.941704</td>\n      <td>0.063853</td>\n    </tr>\n    <tr>\n      <th>11617</th>\n      <td>AZ6102</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>1.773897</td>\n      <td>2.635948</td>\n      <td>-0.793597</td>\n      <td>-0.029945</td>\n    </tr>\n    <tr>\n      <th>11630</th>\n      <td>Palbociclib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>4.045131</td>\n      <td>3.454783</td>\n      <td>0.361532</td>\n      <td>-0.010304</td>\n    </tr>\n    <tr>\n      <th>11626</th>\n      <td>Nilotinib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>5.020491</td>\n      <td>3.579723</td>\n      <td>0.970648</td>\n      <td>0.126309</td>\n    </tr>\n    <tr>\n      <th>11625</th>\n      <td>Lapatinib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>5.095517</td>\n      <td>3.931162</td>\n      <td>1.184712</td>\n      <td>0.449373</td>\n    </tr>\n    <tr>\n      <th>11619</th>\n      <td>AZD4547</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>3.335971</td>\n      <td>4.519645</td>\n      <td>0.154778</td>\n      <td>0.894458</td>\n    </tr>\n    <tr>\n      <th>11623</th>\n      <td>GSK2606414</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>4.483776</td>\n      <td>5.030071</td>\n      <td>0.574170</td>\n      <td>1.023436</td>\n    </tr>\n    <tr>\n      <th>11628</th>\n      <td>PCI-34051</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>5.918300</td>\n      <td>5.202985</td>\n      <td>1.183593</td>\n      <td>0.627426</td>\n    </tr>\n    <tr>\n      <th>11624</th>\n      <td>Ibrutinib</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>5.965032</td>\n      <td>5.393507</td>\n      <td>1.053149</td>\n      <td>0.737864</td>\n    </tr>\n    <tr>\n      <th>11627</th>\n      <td>Nutlin-3a (-)</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>6.362884</td>\n      <td>5.502699</td>\n      <td>1.084058</td>\n      <td>0.603843</td>\n    </tr>\n    <tr>\n      <th>11618</th>\n      <td>AZD1208</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>5.494661</td>\n      <td>5.602795</td>\n      <td>0.251777</td>\n      <td>0.357876</td>\n    </tr>\n    <tr>\n      <th>11635</th>\n      <td>glutathione</td>\n      <td>SW948</td>\n      <td>COAD</td>\n      <td>10.152096</td>\n      <td>9.419693</td>\n      <td>1.094248</td>\n      <td>0.276765</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_SW948 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'SW948']\n",
    "df_SW948.head(20)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-21T11:59:47.669446Z",
     "start_time": "2024-03-21T11:59:47.651826Z"
    }
   },
   "id": "dd4d8abbea4bbc22",
   "execution_count": 114
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "                       drug cell_line OncotreeCode      IC50  prediction  \\\n12401          Dactinomycin  WSUDLCL2     DLBCLNOS -5.120747   -6.007829   \n12408  Sepantronium bromide  WSUDLCL2     DLBCLNOS -5.303559   -4.931552   \n12403                   JQ1  WSUDLCL2     DLBCLNOS -1.865988   -1.264173   \n12410          Tanespimycin  WSUDLCL2     DLBCLNOS -0.319408    0.083619   \n12399               AZD6738  WSUDLCL2     DLBCLNOS  0.851625    0.479403   \n12407               OSI-027  WSUDLCL2     DLBCLNOS  1.042973    0.736231   \n12405                NU7441  WSUDLCL2     DLBCLNOS  1.614159    0.918626   \n12397         5-azacytidine  WSUDLCL2     DLBCLNOS  0.453413    1.283933   \n12406             Nilotinib  WSUDLCL2     DLBCLNOS  1.548980    1.407518   \n12400            BMS-536924  WSUDLCL2     DLBCLNOS  2.118157    1.669458   \n12398                AZ6102  WSUDLCL2     DLBCLNOS  1.448396    1.776287   \n12409             Tamoxifen  WSUDLCL2     DLBCLNOS  1.559998    2.183949   \n12402           Fulvestrant  WSUDLCL2     DLBCLNOS  1.745323    2.186028   \n12404              KU-55933  WSUDLCL2     DLBCLNOS  2.693418    3.102241   \n\n         IC50_Z  prediction_Z  \n12401 -0.715880     -1.186995  \n12408 -0.696516     -0.468006  \n12403 -1.993111     -1.684885  \n12410 -0.150105      0.103743  \n12399 -0.824837     -1.079494  \n12407 -1.032162     -1.237496  \n12405 -1.130054     -1.647646  \n12397 -1.822536     -1.225389  \n12406 -1.063776     -1.146678  \n12400  0.006660     -0.318218  \n12398 -1.081943     -0.791480  \n12409 -1.973404     -1.463779  \n12402 -1.571827     -1.222960  \n12404 -2.083540     -1.720704  ",
      "text/html": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>drug</th>\n      <th>cell_line</th>\n      <th>OncotreeCode</th>\n      <th>IC50</th>\n      <th>prediction</th>\n      <th>IC50_Z</th>\n      <th>prediction_Z</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>12401</th>\n      <td>Dactinomycin</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>-5.120747</td>\n      <td>-6.007829</td>\n      <td>-0.715880</td>\n      <td>-1.186995</td>\n    </tr>\n    <tr>\n      <th>12408</th>\n      <td>Sepantronium bromide</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>-5.303559</td>\n      <td>-4.931552</td>\n      <td>-0.696516</td>\n      <td>-0.468006</td>\n    </tr>\n    <tr>\n      <th>12403</th>\n      <td>JQ1</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>-1.865988</td>\n      <td>-1.264173</td>\n      <td>-1.993111</td>\n      <td>-1.684885</td>\n    </tr>\n    <tr>\n      <th>12410</th>\n      <td>Tanespimycin</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>-0.319408</td>\n      <td>0.083619</td>\n      <td>-0.150105</td>\n      <td>0.103743</td>\n    </tr>\n    <tr>\n      <th>12399</th>\n      <td>AZD6738</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>0.851625</td>\n      <td>0.479403</td>\n      <td>-0.824837</td>\n      <td>-1.079494</td>\n    </tr>\n    <tr>\n      <th>12407</th>\n      <td>OSI-027</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.042973</td>\n      <td>0.736231</td>\n      <td>-1.032162</td>\n      <td>-1.237496</td>\n    </tr>\n    <tr>\n      <th>12405</th>\n      <td>NU7441</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.614159</td>\n      <td>0.918626</td>\n      <td>-1.130054</td>\n      <td>-1.647646</td>\n    </tr>\n    <tr>\n      <th>12397</th>\n      <td>5-azacytidine</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>0.453413</td>\n      <td>1.283933</td>\n      <td>-1.822536</td>\n      <td>-1.225389</td>\n    </tr>\n    <tr>\n      <th>12406</th>\n      <td>Nilotinib</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.548980</td>\n      <td>1.407518</td>\n      <td>-1.063776</td>\n      <td>-1.146678</td>\n    </tr>\n    <tr>\n      <th>12400</th>\n      <td>BMS-536924</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>2.118157</td>\n      <td>1.669458</td>\n      <td>0.006660</td>\n      <td>-0.318218</td>\n    </tr>\n    <tr>\n      <th>12398</th>\n      <td>AZ6102</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.448396</td>\n      <td>1.776287</td>\n      <td>-1.081943</td>\n      <td>-0.791480</td>\n    </tr>\n    <tr>\n      <th>12409</th>\n      <td>Tamoxifen</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.559998</td>\n      <td>2.183949</td>\n      <td>-1.973404</td>\n      <td>-1.463779</td>\n    </tr>\n    <tr>\n      <th>12402</th>\n      <td>Fulvestrant</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>1.745323</td>\n      <td>2.186028</td>\n      <td>-1.571827</td>\n      <td>-1.222960</td>\n    </tr>\n    <tr>\n      <th>12404</th>\n      <td>KU-55933</td>\n      <td>WSUDLCL2</td>\n      <td>DLBCLNOS</td>\n      <td>2.693418</td>\n      <td>3.102241</td>\n      <td>-2.083540</td>\n      <td>-1.720704</td>\n    </tr>\n  </tbody>\n</table>\n</div>"
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_WSUDLCL2 = df_MixedSet_pre[df_MixedSet_pre['cell_line'] == 'WSUDLCL2']\n",
    "df_WSUDLCL2.head(20)"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T06:23:41.492450Z",
     "start_time": "2024-03-22T06:23:41.482059Z"
    }
   },
   "id": "ab818bfed6137e11",
   "execution_count": 64
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkMAAAKGCAYAAABJHJ+cAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMiwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8g+/7EAAAACXBIWXMAAA9hAAAPYQGoP6dpAAC/PElEQVR4nOzddXgU19cH8HPjRhJCILh70eJOcS9OkRanUKBA8JYf7u7F3SnubgWKu0MIwUOChLjsef/IO7c7MTabTXaT/X6eZx/I7uzMnd3ZmTNXzhXMzAQAAABgpiyMXQAAAAAAY0IwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1hAMAQAAgFlDMAQAREQkhJCPmTNnJtt2Ro4cKbfz/fffJ/r9Xbp0ke8vXry4XmV48+YN2djYyPWsWbMmUe//8uUL2dvby/fv3btXr3IQEQUHB9PChQupTp06lClTJrKxsSE3NzeqUKECjR49mt6/f6/3uomItm3bpvpuL1y4kKT1AaRFCIYAIMUwM23cuFH+fePGDbp3757e67t79y4dO3Ys0e9buHAhRURE6L3d7du3U2hoqPx7/fr1eq3n6tWrVLRoUerfvz+dOHGCPnz4QBEREfTp0ye6fPkyTZgwgfLnz0/btm3Tu6zagW3FihWpcuXKeq8LIK1CMAQAKeb06dP08uVL1XP6BhKK2bNnJ2r54OBgWrp0aZK2GbPM+/bto8+fPydqHY8fP6a6devSixcvElwuMDCQ2rdvTwcOHEhsMenMmTN05coV+benp2ei1wFgDhAMAUCKiSvw2bhxI2k0Gr3XeeTIEXrw4IHOy69du5Y+fvyo9/ZevHhB586dUz0XFhZG27dvT9R6BgwYoAqgPDw8aPTo0bRhwwaaNm0aFStWTL6m0WioT58+FBYWlqhtaNcK5c6dm1q2bJmo9wOYCwRDAJAiQkJCaMeOHfJvKysrIiJ69eoVnT59Wu/1MjPNnTtX52XnzZun97aIiDZs2EDMTET/7QNR4mq43r17R0eOHJF/58+fnx48eEDjxo2jjh070rBhw+j69evUpEkTuczLly/pxIkTOm/j4cOHqtqkgQMHkqWlpc7vBzAnCIYAIEXs2bOHAgICiIgoe/bs1LFjR/laUpvK1q9fT35+ft9c7sCBA/To0aMkb0sxbNgw+f9//vmHvL29dVrH9evXZUBFRDR58mRKnz69ahlra2uaP3++6rlr167pXM6ZM2fKbbi4uFD37t11fi+AuUEwBAApQjuIaNOmDbVv317+vWPHDgoJCdF73SEhIbRkyZJvLjdnzhy9t0FEdOXKFRlMWVlZkaenJ1WsWJGIomudNmzYoNN6/P39VX+XKVMmzuXy5MlDbm5u8m9dAj4iovfv36vK0qtXL3JyctLpvQDmCMEQACQ7X19fOnr0qPy7bdu2VLt2bcqQIQMREX39+pV2796dpG0sWrSIwsPD43399u3bdPLkSSIisrDQ79SnHdAp5W/btm2cryckZmASFRUV77Lao97SpUun0/oXLFgg+xdZWVnR77//rtP7AMwVgiEASHabNm2iyMhIIiLKlSsXVaxYkaysrFQdetetW5fo9RYoUICsra2JKLofzubNm+NdVnvUWbNmzRK9rYiICNqyZYv8u127dkQUXcslhCCi6BFily5d+ua6tDtHExFdvnw5zuXu379PX79+jfd9cQkKCqK//vpL/t22bVvKnj37N98HYM4QDAFAstOuMdGuSVECCiKiY8eO0bt37xK13qxZs6rWEV8zWMxASZ+aksOHD9OHDx+IiMjGxoZatGhBRNH9n6pUqSKX06V2qECBAvTDDz/Iv0eNGiXXrQgNDVWVM2PGjNS8efNvrnvVqlWq0XKDBw/+5nsAzB2CIQBIVvfv36fr16/Lv7WDoZo1a1KmTJmIKLqpKKGanfgMGjRI/v/WrVuyKUybdhNa8eLFVYGIrrSDnLp165Krq6v8W3uftm7dqlNCx7/++ks2e3l7e1PRokVp9OjRtHHjRpo2bRqVLl1ajh4TQtCKFSvIzs4uwXVGRUWpRtbVrFlTleV7zJgx1Lp1a2rdujUtWrTom2UEMBcIhgAgWWkHEXnz5qWyZcvKvy0tLalVq1ZxLqur77//nqpXry7/jlk7FBoaqupc3b9//0Rv48uXL7Rv3z75t3ZtFBFR69atZT8kPz8/OnTo0DfXWahQITpx4gTlzp1bvm/ChAnUqVMnGjFiBD18+JCIiFxdXWn79u06Ne3t3LmTvLy85N8xkyyeOXOGduzYQTt27FAlYwQwdwiGACDZxJx+I2YQEfM5fafn0K4dOnDgAD1+/Fj+rT3s3s3NjTp16pTo9WtPv2Fra0s//vij6vUsWbKoAjJdgzpfX18KDAxMcJmwsLBYTWjx0U6yWKhQIVWeIgCIH4IhAEg2Maff0G5OUlSrVo2yZMki/9andqhZs2aUN29eIlInYYyZkLFnz55kb2+f6PVrl6lBgwbk7OwcaxntfdNleo6jR49Ss2bNvjlcPiQkhPr06fPNZJFnz55VdcQeNGiQ7NgNAAlDMAQAyUY7iChYsCCVKlUq1jIWFhbUunVr+bc+03NYWFjQgAED5N/KlBtHjhyh+/fvE1F0k1zfvn0TuQexp9+Iq3aLiKhVq1Yyw/O3puf4+vUrdezYUe6nra0tjRs3jp49e0bh4eH09u1bWr58OWXMmFG+Z+jQoXJf4qJdK+Tu7k6//PKLbjsIAAiGACB5xJx+I74gIuZr+k7P0a1bN3JxcSGi6MlYly1bpuo/1Lx5c8qRI0ei16s9/Ya9vT01bdo0zuUyZcqk6pidUA1XzIzZ27Zto9GjR1PevHnJ2tqaMmfOTD169KB//vmHHB0diSh6aH98tUOPHj2i/fv3y7/79OmjVw0YgLlCMAQAyWL37t1y+g0iogkTJpAQIs5H1apVVe/VJ+eQk5MT9ejRQ/49Y8YMVaJHfRMPagc1ISEhlC5dunj34/jx43LZc+fO0fPnz+Ncp3YH6woVKsTbObpgwYLUpUsX+bd2wKNt1qxZMmCztbXVqwYMwJwhGAKAZJGU+cZ27NhBwcHBiX5f//79ZVOVdq6dUqVKqTo46+ry5ctJmsssvuk5tIOkEiVKJLgO7dffvn0ba9oSX19fVfDYsWNH8vDw0Ke4AGYLwRAAGNz79+9VtTKJFRgYqNf0HLly5VJltVYYolZIH/EFQ9rTb3wrJ5EyrQZRdIdw7QleiYiOHDmiWmbVqlXx1lydOXNGLrd27VoSQtDYsWMTs0sAaZKVsQsAAGnP5s2bVRf8KVOmUOHChb/5PiWrM1F0INKhQ4dEb3vQoEGqzsvu7u6qSWF1FXP6DVtbW9Xf8Vm9ejXt3buXiP6bnqNChQqqZXLmzCnzCJ0+fZqioqJkjVZMx44dU+2Lg4OD6vWE5jUDAN0gGAIAg9OuUSlRogSNGDFCp/cNHTqUZsyYQUT/Tc+ROXPmRG27UqVKVKFCBTlHWK9evb6ZuTkuhw8fVnVy3rx5s07TYdSsWZM8PDxkxuv169fHCoYqV64sa868vb1p2LBhNHPmzFhD4VevXq1K9qg97QcAGA6CIQCIZffu3ZQ/f36dl3dxcZEjqWJOv5HQKLKY2rVrJ4MhZXoO7YSKupo5c6bsbKxvZ2LtgC5dunTUsGFDnd7n6upK9erVk9vfunUrzZkzR04oSxSd72jy5MkyYJo9ezadO3eOOnToQNmzZyd/f3/av39/rA7TcWXPrlWrFu3atUunsmnXvLm4uNCaNWt0qrEDSPMYAICZiUjvR8mSJeV6RowYoXrtyZMniSpHvnz55HtLly4d6/XOnTvL12vUqGGQ/V29erXqtc+fP7OdnZ18vWPHjola97p161Tr37NnT6xlVq5cmajPuH///nrvq6JGjRpyfZ07d07y+gDSCnSgBgCD4RjTb3z//feJqmEiUmdy1nd6jqTSnn6DKHG1W0REP/74I9na2sq/4+qI3a1bN1q1alWc2ay1WVpa0p9//hlrzjUAMBwEQwBgMLpMv/EtMQMPfXIOJZV28OLi4kL169dP1PudnZ1VzWrxTc/RtWtXevjwIU2fPp2qVKlC2bJlIxsbG8qYMSOVLl2aRowYQXfu3KGJEyfG28EaAJJOMMcYpwkAAABgRlAzBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg0ZqL+BmeXs2Q4ODrHS5QMAAEDqhpqhbwgODiYnJydycnKSQREAAACkHQiGAAAAwKwhGAIAAACzhmAIAAAAzBqCIQAAADBrCIYAAADArCEYAgAAALOGYAgAAADMGoIhAAAAMGtpKhjKnTs3CSHifdy8edPYRQQAAAATk6aCoW/BVBoAAAAQU5oMhs6fP08hISEUEhJCV69eJSIiW1tbKlCggJFLBgAAAKYmTU7UamNjQ3Z2dkREdPz4cSIiqlmzJjk4OBizWAAAAGCC0lQwdPDgQQoPD6dChQrJ5/bv309ERI0bNzZWsQAAAMCECWZmYxciuXz69IkyZsxIUVFR9OzZM8qbN2+i1xEUFEROTk5ERBQYGEiOjo6GLiYAAAAYUZqqGYrp0KFDFBUVRYULF/5mIDR79myaPXt2rOc1Gk1yFQ8AAABMQJoOhhLTRBYQEECvX79O8jaZmYKDg5O8Hl05ODhglBwAAEASpJpgKCoqiiIiIuJ8zcrKiqysrGItf+TIESIiatSo0TfX7+zsTNmyZYv1vEajobdv3+pczuDgYNmslhLQdAcAAJA0qabP0Jo1a6hr165xvjZmzBgaO3as6rlz585R9erVydnZmfz8/Mja2lqv7Sa2z5D28ikBwRAAAEDSpJqaocQ6cOAAERHVrVtX70AoqUaMv0M2NoYfzh8eHkxTRxc3+HoBAADMUaoJhrp06UJdunTReXlTGFJvY+NANrbIbQQAAGDK0mQG6hcvXtC9e/dICEENGzY0dnEAAADAhKXJYEipFSpTpgxlzpzZyKUBAAAAU5YmgyGlv5Auo8gAAADAvKWaPkOJcfDgQWMXAQAAAFKJNFkzBAAAAKArBEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1tJsMFSzZk0SQtDkyZONXRQAAAAwYWkyGDp16hSdOXOGMmbMSAMGDDB2cQAAAMCEpclgaMyYMURENGLECHJ0dDRyaQAAAMCUpblg6MSJE3Tu3DnKkiUL9enTx9jFAQAAABOX5oIhpVbozz//JHt7eyOXBgAAAExdmgqGjh07RufPn6ecOXNS165diZmNXSQAAAAwcWkqGFJGjr19+5acnZ3J3t6e2rRpQx8+fPjme2fPnk3Zs2eP9ShQoEByFxsAAACMyMrYBTCU58+f05kzZ4iIKCIigoiIoqKi6O+//6bPnz/TsWPHEnx/QEAAvX79OtnLCQAAAKYlVdQMRUVFUWhoaJyPyMhIIiLatm0bMTNlypSJLly4QJ8/f6a5c+cSEdHx48fp2rVrCW7D2dmZsmXLFuuRJUuW5N49AAAAMKJUEQytX7+e7O3t43xMnDiRiEgGO7/99htVqlSJXFxcaMCAAVSlShUiIrp161aC2/D09KRXr17Fejx58iR5dw4AAACMKlUEQ7r4+PEjERHlz59f9XzhwoWJiOjdu3cpXiYAAAAwfamiz1CXLl2oS5cuCS7j5uZGREQ+Pj6q51++fElERBkyZEiWsgEAAEDqlmZqhqpVq0ZERPPmzaPTp0+Tv78/rVq1SnacrlGjhjGLBwAAACYqVdQM6aJr1660YMECevLkCf3www+q17p06SKbywAAAAC0pZmaIScnJzp79ix17tyZMmbMSNbW1pQvXz4aP348LV++3NjFAwAAABOVZmqGiIgyZ85Ma9asMXYxAAAAIBVJMzVDAAAAAPpAMAQAAABmDcEQAAAAmLU01WcIDIeZKTg4OEW25eDgQEKIFNkWAABATAiGIE7BwcHk5OSUItsKDAwkR0fHFNkWAABATGgmAwAAALOGmiH4phHj75CNjYNB1xkeHkxTRxc36DoBAAD0gWAIvsnGxoFsbA0bDAEAAJgKNJMBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDW9Jqo1d/fn4KDg4mZ413GwcGB3N3d9S4YAAAAQErQORjy9/enP/74g/7++2/6/PmzTu9xdXWlNm3a0KRJkyhDhgz6lhEAAAAg2egUDH38+JEqVqxIXl5eCdYGxfTp0ydavnw5nTx5ki5dukTp06fXu6AAAAAAyUGnYGjq1Kn07NkzEkJQzZo1qXnz5t+s6fH396fdu3fT6dOn6dmzZzR16lSaNm2aQQoNAAAAYCg6BUP79u0jIQTVqFGDTp48qfPKf//9d/rhhx/ozJkztHfvXgRDAAAAYHJ0Gk324sULIiJq0qRJojegvEdZBwAAAIAp0SkYsrCIXiw8PDzRG4iIiFCtI7l4e3uTECLex5IlS5J1+wAAAJA66RSh5M+fn4iItm/fTpGRkTqvPDIykrZt20ZERPny5dOjeAAAAADJS6c+Q23atKHbt2/TzZs3qVixYtSkSRNyc3NL8D0fP36k/fv305MnT0gIQW3atDFIgb/F0dGR/Pz8Yj1vbW2dItsHAACA1EWnYGjw4MG0f/9+unTpEj1+/JjmzJmj08qVYfjly5enIUOG6F/KRLKzs0uxbQEAAEDqplMzmZ2dHZ0+fZomTpxIxYsXJ1tbW2LmBB+2trZUvHhxmjhxIp0+fTrFApTIyEj6+eefycXFhdzd3aljx4705s2bFNk2AAAApD46Z6C2tbWlP/74g/7444/kLE+ShYWF0YYNG+TfmzZtosuXL9ONGzfIycnJiCUDAAAAU5QmJ2r9448/yNfXl44fP04ZM2akp0+f0ooVKxJ8z+zZsyl79uyxHgUKFEihUgMAAIAx6DVRqyny8PCgffv2kYODA9WqVYuIiGrXrk2enp40cuRIOn78OA0cODDe9wcEBNDr169TqLQAAABgKgwWDPn6+pKPjw+FhISQEIJcXV2pUKFCBhnFFRUVJfMVxWRlZUVWVlZkb28fZ1LIkiVLEhF9s9+Qs7MzZcuWLdbzGo2G3r59q0epAQAAIDXQqZmsXr16VK9ePTpy5Eis1/bt20elSpWiLFmyUIUKFahmzZpUo0YNKlmyJDk7O1OXLl3I19c3SYVcv3492dvbx/mYOHFigu+1t7cnom8njPT09KRXr17Fejx58iRJZQcAAADTplMwdPz4cTpx4kSsZqRVq1ZR8+bN6c6dO3GOKAsLC6P169dTpUqVyN/fP1l24FuCg4OJiMjGxsYo2wcAAADTpncH6qCgIBo8eDAxM9nZ2dHQoUNpz549dO7cOTp9+jStX7+eateuTcxM3t7eNGnSJL0L2aVLl3iH8I8dO5aIiA4cOEDu7u70448/qt578+ZNIqI4m8AAAAAA9O4zdP78efry5QsJIWj58uXUoUOHWMt07NiRateuTadOnaK9e/fS7Nmzk1TYhFStWpWCgoJo3759tGjRIvrpp5/oxo0bcpt169ZNtm0DAABA6qV3zdCHDx/k/2PWxmhr2rQpERG9evVK303pxMXFhaZPn07MTP369SN3d3eqW7cu+fv7U5EiRahHjx7Jun0AAABInfQOhooUKSL/7+3tHe9ySudpR0dHfTels/79+9OyZcuoSJEiZG1tTRkzZqSuXbvS6dOnycHBIdm3DwAAAKlPoprJnj59ShcuXJB/FyhQgJ4+fUo9e/akQ4cOkYuLi2r5q1ev0rJly0gIQVWqVDFMib+hZ8+e1LNnzxTZFgAAAKR+iaoZmjZtGlWrVk0+nj59SkREly5doh07dqiWXbJkCVWoUIE+fvxIlpaWNHLkSMOVGgAAAMBAdA6GvjUxa0xBQUHEzOTu7k579uyhSpUqGbTgAAAAAIagUzPZqVOnvrlMoUKFVH9///33tGHDBmrcuHGs5jMAAAAAU6FTMFSjRo1Er/iHH35I9HsAAAAAUlqanLUeAAAAQFd6B0MajUav1wAAAABMSaKCoZCQEBo3bhzlyZOH/v3333iXu3LlCuXOnZvGjRsn5wYDAAAAMEU6B0Pe3t5UqlQpGj9+PPn4+HxzeR8fHxo/fjyVKlUqwaSMAAAAAMakUzAUFhZGDRs2pCdPnhAzU/Xq1SlXrlzxLp8jRw6qXr06MTM9ffqUGjZsSKGhoQYrNAAAAICh6BQMLVq0iB49ekRCCBo/fjydOnUqwVngs2bNSqdPn6bp06cTEdHjx49p4cKFhikxAAAAgAHpFAxt3ryZiIgqVqxIo0aN0nnlQ4YMoSpVqhAz05YtW/QrIQAAAEAy0ikYevLkCQkhqGXLloneQJMmTYiI5NQdAAAAAKZEp2BICEFERFZWiZrXlYiI7OzsVOsAAAAAMCU6BUN58uQhIqIjR44kegNHjx4lIqK8efMm+r0AAAAAyU2nYKh169bEzHTkyBGaNWuWziufM2cOHTp0iIQQ1Lp1a70LCQAAAJBcdGr36tOnDy1dupRevnxJw4YNo40bN1KTJk0ob968ZGNjo1o2IiKCvLy8aP/+/XTz5k0iIsqZMyf16dPH4IUHAAAASCqdgqH06dPT3r176ccffyQfHx+6desW3bp1K8H3MDMREeXKlYv27t1Lrq6uSS4sQGIwc4pmQHdwcEDfOACAVEjnHtElS5akO3fu0OzZs2nLli30+PFjGfDEJISgQoUKUfv27WnQoEGULl06gxUYQFfBwcHk5OSUYtsLDAwkR0fHFNseAAAYRqKGh6VLl47GjBlDY8aMocjISPL19aWIiAjVMtbW1pQpUya9Rp4BAAAApDS9IxYrKyvKmjWrIcsCkGxGjL9DNjYOBl9veHgwTR1d3ODrBQCAlIPqGzALNjYOZGNr+GAIAABSP51nrQcAAABIi3SqGapXr16SNySE0CtpIwAAAEBy0ikYOn78OAkh4h09lhDlfRhyDAAAAKZIp2CoevXqCGYAAAAgTdIpGDp9+nQyF8OwoqKiqECBAvT8+XM6fvw41a5d29hFAgAAABOVJjtQ79q1i54/f04lSpRAIAQAAAAJSpPB0OzZs4mIaODAgcYtCAAAAJi8NBcMXbx4kS5evEiZMmWiDh06GLs4AAAAYOLSXDCk1Ar16dOHbG1tjVwaAAAAMHVpKhjy9vamXbt2ka2tLfXp08fYxQEAAIBUIE0FQ3PnzqWoqCjq0KEDeXh40L1796h169bk6en5zffOnj2bsmfPHutRoECBFCg5AAAAGEuamZvsy5cvtGrVKiL6r+P0hw8faMeOHfTdd9998/0BAQH0+vXr5CwiAAAAmCCTD4aioqIoIiIiztesrKzIyip6F5YvX05fv36lWrVqUYkSJRK9HWdnZ8qWLVus5zUaDb19+zbR6wMAAIDUweSbydavX0/29vZxPiZOnEhERJGRkTR//nwiIho0aJBe2/H09KRXr17Fejx58sRg+wIAAACmx+SDIV1s376dXr58SQUKFKDGjRsbuzgAAACQiujUTGZpaZnkDQkhKDIyMtHv69KlC3Xp0iXBZY4ePUpERE+ePCELi9jx3b179yh37tzk7e2d6O0DAABA2qZTMKTPbPUpycLCIs6ALSoqSv5f6VsEAAAAoE2nCGHChAmJWmlwcDBNmTKFhBAykOrWrVviS6ejlStX0sqVK2M9f/r0afrhhx/ou+++o7t37ybb9gEAACD10ikY+vPPP3Ve4aFDh6hfv34yECpUqBAtXbqUqlevrnchAQAAAJKLwdqO3r17RwMGDKC///6bmJlsbGxo5MiRNHLkSLKxsTHUZhKlZs2aJt/EBwAAAMZlkGBo4cKF9L///Y8CAgKImal69eq0dOlSKlSokCFWDwAAAJBskhQM3bhxg3799Ve6du0aMTOlT5+eZsyYkaz9gwAAAAAMSa88Q0FBQTRo0CCqUKGCDITat29PDx8+RCAEAAAAqUqia4Z27dpFAwYMoNevXxMzU548eeivv/6ievXqJUf5AAAAAJKVzjVDL1++pGbNmlHr1q3p1atXZGlpScOHD6e7d+8iEAIAAIBUS6eaoRkzZtD48eMpODiYmJmEEDRo0CAqXrw47dq1S+eNdejQQe+CAgAAACQHnYKh4cOHkxCCiEj+O3PmzERtSAiBYAgAAABMjs59hpCvBwAAANIinYKh58+fJ3c5AAAAAIxCp2AoV65cyV0OAAAAAKPQK88QAAAAQFqR7MHQtm3bKG/evJQvX77k3hQAAABAohlsotb4fP36lby9veUoNAAAAABTgmYyAAAAMGsIhgAAAMCsIRgCAAAAs4ZgCAAAAMwagiEAAAAwawiGAAAAwKwhGAIAAACzplOeIRsbG703EBUVpfd7AQAAAJKbTsFQZGRkcpcDAAAAwCh0CobGjBmT3OUAAAAAMAoEQwAAAGDW0IEaAAAAzBqCIQAAADBraSoY+vTpE/3++++UN29ecnR0pOLFi9PUqVMpLCzM2EUDAAAAE6VTn6HUICQkhH744Qe6deuWfO7u3bs0cuRIunz5Mu3cudOIpQMAAABTlWZqhubPn0+3bt2ifPny0b///kv+/v60evVqsrCwoF27dtGjR4+MXUQAAAAwQWkmGHr//j3Vrl2bFi9eTBUqVCA3Nzfq0qULlS5dmogIwRAAAADEKc00k82ePTvO55UM2OnTp0/J4gAAAEAqkWaCIW0REREUEhJCu3btolu3blGhQoWoUqVKxi4WAAAAmKA0GQz17NmT1q5dS0REdevWpeXLl5OVVcK7Onv27DhrlzQaTbKUEQAAAEyDTsFQr169krwhIQQtXbo0yetJrBcvXpCXlxflypUrweUCAgLo9evXKVQqAAAAMBU6BUMrVqwgIYTeG2HmJAVDUVFRFBEREedrVlZWsWp91qxZQ0uXLqX9+/dT+/btqUmTJuTl5UUeHh7xbsPZ2ZmyZcsW63mNRkNv377Vq9wAAABg+nQaTZYzZ844Hx4eHsTMxMzk5OSkes3FxYWYmYiIcuXKRTlz5tS7kOvXryd7e/s4HxMnTozzPba2ttSqVStq3bo1BQcH09atWxPchqenJ7169SrW48mTJ3qXGwAAAEyfTjVD3t7esZ4LCgqimjVrUmhoKO3bt4+qVKkSa5lr165RvXr1qHDhwvT3338nubD6yJcvHxHFvQ8AAAAAeucZGjVqFF2/fp1+/fXXOAMhIqIyZcrQr7/+SkePHqURI0boXcguXbrIGqiYj7Fjx1J4eDjlzJmTMmfOHCvoefnyJRER2dnZ6b19AAAASLv0Doa2bdtGRBRnPxttWbJkIWamHTt26Lupb7KxsaGiRYvS+/fvqVu3bnT37l36+PEjbd68mTZv3kxERBUrVky27QMAAEDqpffQ+k+fPhER0ZUrVxJcTnn9y5cv+m5KJzNmzKALFy7QqVOnqHjx4qrXKlasSI0bN07W7QMkF2am4ODgFNueg4NDkgZMAACkNnoHQ4UKFaJbt27Rxo0bqWTJktS5c2fKkCGDfP3jx4+0bt062rRpEwkhqEiRIgYpcHyKFy9OV69epdGjR9PJkyfp8+fPlDVrVmrVqhWNHTuWLC0tk3X7AMklODiYnJycUmx7gYGB5OjomGLbAwAwNr2DoQEDBlC3bt2ImWno0KE0dOhQVcChTIOhDKsfOHBgkgv7LQULFqQtW7Yk+3YAAAAg7dA7GOrSpQv5+fnRmDFjKCQkhIiIIiMjYy1nb29P48ePp06dOulfSgAgIqIR4++QjY2DwdcbHh5MU0cX//aCekJTHwCYsiRNxzFkyBDq0aMHHT9+nLy8vCg0NFTWBNnZ2VHevHmpTp065OrqaqDiApg3GxsHsrE1fDCU3NDUBwCmLMlzk7m6ulLr1q0NURYAAACAFJcmJ2oFANOVWpv6ACDtMkgwxMx0//59evbsGX39+pUqVqwoMz8DAGhLrU19AJB2JSkYCg0NpSlTptDSpUvpw4cP8vnly5fLYGjmzJnk5+dHU6dOTVpJAQAAAJKB3sFQcHAw1alThy5duiQnZCUi1QiOrVu30rBhw0gIQW3atKEyZcokrbQAAAAABqb3dBxTpkyhf//9l4iIRowYQS9evIi1TN26dSlTpkxERDRv3jx9NwUAAACQbPQOhrZu3UpCCGrVqhVNnjyZcuTIEWsZNzc36tq1KzEznTp1KkkFBQAAAEgOegdDPj4+RERUtWrVBJfLnj07EZGqTxEAAACAqdA7GFISqL1+/TrB5Z49e0ZEhMSLAAAAYJL0DobKli1LzEwrV66UtUQxvXnzhtasWUNCCCpfvrzehQQAAABILnoHQ/369SMiok+fPlGxYsWof//+8rVly5bRsGHDqESJEvT582fV8gAAAACmRO9gqEmTJjRq1ChiZgoMDKTFixfLYfVXrlyhWbNm0cePH4mI6I8//qB69eoZpsQAAAAABqR3MERENH78eDpz5gz99NNPlCNHDrK2tiZmJgsLC8qUKRM1a9aMjhw5QhMmTDBUeQEAAAAMKsnTcVSrVo2qVatmiLIAAAAApLgk1QwBAAAApHYIhgAAAMCs6R0MpU+fnjJkyEAbN25McLkNGzaQm5sbZciQQd9NAQAAACQbvfsMffnyhYQQFBYWFu8yzEwPHjygz58/k7W1tb6bAgAAAEg2OtcMTZgwgWxsbORDGUbfs2dP1fMxH1OnTiUhBOXPnz/ZdgIAAABAXzrXDGk0GoqMjJR/K8EQM6uej3MjVlY0btw4PYsIAAAAkHx0DoZq1qyp+nvcuHEkhKBs2bJRjx494nyPpaUlZc6cmerUqUO5c+dOSjkBAAAAkoXOwVCNGjWoRo0a8u9du3aREILGjBlDzZs3T46yAQAAACQ7vTtQ37x504DFAAAAADCOJOUZ8vf3pzdv3iS4zLt37+j9+/dJ2QwAAABAstE7GAoPD6eaNWtSo0aNKCAgIM5l/Pz8qHbt2lS7du0Eh+Abir+/P/Xq1YsyZ85MNjY2lCdPHvL09KSvX78m+7YBAAAgddI7GFq0aBHdu3eP7ty5Qzt27IhzmVWrVtGDBw/owYMHtHDhQr0LqYuwsDCqXbs2LV++nN6/f08RERHk7e1Nc+bMoXr16pFGo0nW7QMAAEDqpHcwtG3bNiIiKleuHHXt2jXOZYYOHUqlS5cmZqbt27fruymdzJs3j27dukXZs2enM2fOkL+/P23dupWsra3p33//pcOHDyfr9gEAACB10jsYevjwIQkhqFWrVvEuI4Sgtm3bEhHRo0eP9N2UTnbv3k1E0UP+q1evTm5ubtS2bVtq2LAhERHdvn07WbcPAAAAqZPeo8lCQ0OJKDqXUIIbsIreRHL3Gdq/fz9pNBpydXVVPR8eHk5ERE5OTsm6fQAAAEid9K4ZypYtGxERnT17NsHlzpw5Q0REWbNm1XdTOnFzcyN3d3cZfBERPXv2jE6ePElERHXq1EnW7QMAAEDqpHcwVLt2bWJm2rdvH02bNi3WlBzh4eE0ceJE2r9/PwkhqF69ekkubGJoNBrq3bs3hYeH048//kiFCxdOcPnZs2dT9uzZYz0KFCiQQiUGAAAAY9C7mWzYsGG0efNmCgoKoj/++INGjx5N2bNnJ0tLS4qMjKRXr15RVFQUERGlS5eOhg4darBC62LSpEl0/Phxcnd3p8WLF39z+YCAAHr9+nUKlAwAAABMid7BUL58+WjPnj3Uvn178vX1pYiICHr+/Hms5TJnzkxbtmyhPHny6F3IqKgoioiIiPM1KysrVdMYEdGpU6fk3Glr1qzRqYnO2dlZNv1p02g09PbtW/0KDgAAACZP72CIiOiHH36g58+f065du+j69ev06dMn0mg0ZGlpSenTp6eyZcvSjz/+SHZ2dkkq5Pr16+Mdvj9mzBgaO3as/Pvdu3fUoUMHioqKIk9PT2rcuLFO2/D09CRPT89YzwcFBaHzNQAAQBqWpGCIiMje3p46dOhAHTp0MER5kkSj0VCHDh3o3bt3VLZsWZo6daqxiwQAAAAmLsnBUEro0qULdenS5ZvLjRkzhk6dOkXOzs60ZcsWsra2Tv7CAQAAQKqWKoIhXRw9epQmT55MRNHZqLNlyyZzIRFF50NCcAQAAAAx6RQMFSxYkIQQNHnyZJlxumDBgonakBAiWbNQT506Vc4/1rVr11h9jDp37kxr1qxJtu0DAABA6qRTMPT06VMSQtCXL19UzyWGECJxJUskTMQKAAAA+tApGPrll19ICKGqDercuXOyFUofp0+fNnYRAAAAIBXSKRiKq3lp9erVhi4LAAAAQIrTezoOAAAAgLQAwRAAAACYNZ2ayZQh60n1xx9/GGQ9AAAAAIaiUzA0atSoJI8GE0IgGAIAAACTo3PSRWZO0oaS+n4AAACA5KBTnyGNRhPrER4eTk2bNiU7Oztav349BQUFqV6Pioqi7du3k4ODA/3666/xzjoPAAAAYEx6T8cxZcoU2r9/P/Xr1486duwY63UhBLVq1YrOnTtHCxYsoEyZMtG4ceOSVFgAAAAAQ9N7NNmqVauIiKhQoUIJLlegQAFiZkyFAQAAACZJ72Do3bt3RER0//79BJe7d+8eERH5+vrquykAAACAZKN3MJQnTx5iZlqxYgXt3LkzzmV2795Nq1atIiEE5c2bV+9CAgAAACQXvfsMdevWjYYNG0YRERHUpk0bcnR0pMyZM8vX379/T4GBgcTMJISgnj17GqTAAAAAAIakdzA0ePBg8vb2psWLFxMRUWBgYLwz2f/22280cOBAfTcFAGASmJmCg4NTbHsODg5JzvEGAN+mdzAkhKCFCxdSv379aP/+/eTl5UWhoaGyJsjOzo7y5s1LTZo0ocKFCxuyzAAARhEcHExOTk4ptr3AwEBydHRMse0BmCu9gyFF4cKFEewAAABAqpXkYAgAwByNGH+HbGwcDL7e8PBgmjq6uMHXCwDxM1gwFBgYSF5eXvT161fKnz8/eXh4GGrVAAAmx8bGgWxsDR8MAUDK03tovWL16tVUtmxZcnV1pdKlS1P16tXpwIED8vWtW7fSokWLkroZAAAAgGShd81QVFQUtWnThvbs2aOahFV75MOBAweoU6dOZGFhQfXq1aMCBQokrbQAAAAABqZ3zdDcuXNp9+7dxMzUrl07OnPmTKxlSpQoQfb29hQZGUmzZ89OUkEBAAAAkoPewdDatWtJCEF169alzZs3U7Vq1WItkyNHDurWrRsxMx05ciRJBQUAAABIDnoHQ0qCxYYNGya4XMGCBYmI6M2bN/puCgAAACDZ6B0M2draEhGRn59fgsu9fPmSiChFE5UBAAAA6ErvYKhEiRLEzLRhwwb68uVLnMt8/fqV1q9fT0IIKl26tN6FBAAAAEguegdD3bp1I6Lomp+SJUvSrFmz5GtHjx6lxYsXU5kyZWTzWI8ePZJYVAAAAADD0zsY6ty5M3Xq1ImYmXx8fGjYsGFyWP327dupf//+sl9Rx44dqV27doYpMQAAAIABJSnp4rp162jt2rVUsWJFsrS0JGaWD6LoprSlS5fSunXrDFLYxPDz86O2bduSEIKEEN/s2wQAAADmKcnTcfz888/0888/U0REBPn7+1NYWBhZWVmRm5sb2dvbG6KMiebv709FixalDx8+GGX7AAAAkHokeToOhbW1NWXOnJly5cpF2bJlM1ogRBTdcdvPz4969uxptDIAAABA6qB3MLRgwQLq2LFjvCPJjMnFxYUuXLhAy5YtM3ZRAAAAwMTpHQytWrWKtmzZQqVLl6bQ0FBDlinJ0qdPTxUrVjR2MQAAACAVSHIG6rp165KdnZ3BCgQAAACQkvTuQJ0xY0Z68eIFFStWzJDlMZrZs2fHOZmsRqMxQmkAAAAgpegdDPXs2ZP+/PNPevTokSHLYzQBAQH0+vVrYxcDAAAAUpjewdDIkSPp8ePHtGLFCqpYsSK1bNmSHBwcDFm2eEVFRVFEREScr1lZWZGVVeJ3y9nZmbJlyxbreY1GQ2/fvk30+gAAACB10LvPkI2NDW3cuJEiIiKoc+fOlC5dOrKxsYn3oUzsagjr168ne3v7OB8TJ07Ua52enp706tWrWI8nT54YrNwAAABgevSuGYqMjNTpOYUyVQcAAACAKdE7GBozZowhy5EoXbp0oS5duhht+wAAAJB2pMpgCAAAAMBQkjw3GQAApC7MTMHBwSmyLQcHB3STAJOX6GAoICCAbt68SR8+fKCMGTNSqVKlyNnZOTnKBgAAySA4OJicnJxSZFuBgYHk6OiYItsC0JfOwVBQUBANHjyY1q9fr5p+w9bWln755ReaNWuWSR7wzGzsIgAAAIAJ0ykYioiIoNq1a9OVK1diBRehoaG0fPlyunnzJp07d46sra2TpaAAAGB4I8bfIRsbw+aICw8Ppqmjixt0nQDJSac8QwsWLKDLly8TEVGdOnXo4MGDdP/+fTp06BDVrVuXmJmuXLlC8+fPT9bCAgCAYdnYOJCNrYEfBg6uAJKbTsHQhg0biIioUqVKdOTIEWrQoAEVLlyY6tevT4cOHaJKlSoRM9PGjRuTtbAAAAAAhqZTMPT06VMSQlDLli1jjQqwsLCgli1byuUAAAAAUhOdgqHAwEAiInJ1dY3zdeX5oKAggxQKAAAAIKXoPTcZAAAAQFqAYAgAAADMGoIhAAAAMGuJykDds2dP2rJlS6znT5w4ITtW16tXL873CiHoyJEjehQRAAAAIPkkKhhiZjp+/HiCy8R8XQhBzIy5aQAAAMAk6RQMVa9eHcEMAAAApEk6BUOnT59O5mIAAAAAGAc6UAMAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZi1NBUMhISE0cuRIyp8/P9nY2JCrqys1bNiQLl26ZOyiAQAAgImyMnYBDKlFixZ05MgR+feXL1/o8OHDdPLkSbpw4QKVKVPGiKUDAAAAU5RmaobOnz9PR44cISsrK9q4cSP5+fnR3bt3qVKlShQeHk6TJk0ydhEBAADABKWZYEhpCmvUqBF16NCBMmTIQN999x1NnTpV9ToAAACAtjQTDH39+pWIiHLkyKF6PmfOnEREFBAQkOJlAgAAANOXZvoMMXOSXtdFUFBQnM9bWlqSnZ1drOcDA/3IJtxB9ZwQFmRt/d+y4eHB8W4v5rIR4SHExKr3KGUSQpCDw3/bCg4OjnefYy4bEhJCGo1GtYz2vmpvLyIilJjVy2qzsflvvZERYaThqDiXi7nfoaGhFBUV97JERA4ODiSEICKisLAwioyM1GlZRVzfBRGRtZUdCYvoe4KoyHCK0sS/3riWjeu7ICKys7MjS0tLIiIKDw+niIiIeNervWxERASFh4erXtdeb2jIf0F9VFQERUXFv14rSxuysIz+iWuiIikyKjzeZbXXExkZGe+xTkRkY2ND1tbW//++KAoNDY13WWtra7KxsVE9F993YWlhRZZW0cuyRkMRkfGvN65l4/surKysyNbWNnpZZgoOjv83961ltdcbHPRJ9VpCv2ULYUlW1rY6LRsRod7vhL4LCwsLsre3/69MifjdK+I8T5Ega5v/1puY331ERCiFhQXGW35HR0f5/2/97hNaNub3o+854lvL2tvbk4WFBTk4OFBERESCv2VlWSLdf/fMTJ8/f07SOUKbra0tWVlZxbus9r5rLxsZGUlhYWHxrlf7dx9z2Zjfhb7nCF2XdXBwIGamkJAQndarE04jxowZw0TEffv2VT3//PlzJiJ2dHRM8P2zZs3ibNmyxXpkyZKFiSjBR6NGjeR6AgMDv7l8cjyKFi2q2p+iRYvGu2yuXLlUy5YtW9YoZVYegYGB3Lp1628uo+jcuXOCy/r6+hr1uyAivnz5sizv9OnTE1z21KlTctmFCxca9bsgIv77778TfH3hwoWyvKdOnUpw2enTpxv9u/jtt99keX19fRNctnPnzkb/LWs/AgMD2d3dPd7Xy5Ytq/ot58qVK95ltc8Rxto3BwcHVXkbNWqU4PLavnWOSInvYsiQIQkuc/fuXVle5ZoU30M5RxjzONu2bZss77Zt2xJcdvXq1XLZ/fv3G/27uHv3boLLDBkyhBMjzdQMJVVAQAC9fv3a2MUAAACAFCaYDdB+ZALGjh1L48aNo759+9LChQvl897e3pQnTx5ydHSkwMDAeN8/e/Zsmj17dqznNRoNvX37loiI3r9/r6q2VWg3kzEzffjwId7txKzWTmoVuFLlaehmMtaq9tTe57iW1aZPFbiDgwOFhYUZvJmMmenTp086VYETfbta+1vLapfRkM1k2t/Ft6rAtelbBW5jY5PgevWpAmdm+vr1q87V5RqNRucq8LiW1f4uDNlMpv1czObxhH7LiVlW+3fv4OCQYHn1bSZjZvLz80vSOUJbQueImM3WhmomCwoKIg8PDyIi8hx1iRwdM8jtREaGkUYT/3qtre11WjY8PJhmT6xARESBgYFkbW1t8GayoKAgcnJykvuh3eSosLKyJQuL6HNEYprHlWW190P7OmaoZrKY34W9vQtZWkYvq9FEUWRk/OvVbvJOaNmY34W9vb1Bm8lQM/T/PD09ydPTM9bz2geqo6NjnMGQNiEEZcqUSeftfmt9+i4bV9+A+GifTLUp+61vGRKzbFx9ruJja2srL1gJEUKQm5ubzutNrn2zsbHR+UdpbW0tTzja4vouklNcZYiLpaWlTp+FEIKcnZ3J2dlZ5zKkS5fO4MsKIXT+7uJbNr7vIrmOn+T43QshKGPGjMlShuT63Se0rJOTO9nY/rfv2v//loSWDQ9TB6KJ+S0nZllFzP0wFO39iO86ZmVlJQOjb0lo2bj3QfffcnzLxvwuLCwsEnWsfUuaGU0Ws8NsYl8HAAAA85RmgiHlbu3ly5eq5318fIgocXeZAAAAYD7STDBUsWJFIiI6ePAgbdq0ifz9/enevXs0YsQIIiKqUKGCMYsHAAAAJirN9BmqUqUK1a9fn44cOUIdO3ZUvWZjY0OjRo0yUskAAADAlKWZmiEiol27dtHw4cMpb968ZG1tTc7OzlS/fn06c+YMJmkFAACAOKWZmiGi6FFRU6dOlfORAQAAAHxLmqoZAgAAAEgsBEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1hAMAQAAgFlDMAQAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg3BEAAAAJg1BEMAAABg1tJ0MOTn50dt27YlIQQJIcjPz8/YRQIAAAATY2XsAiQXf39/Klq0KH348MHYRQEAgGQUHh6cqtYLpifNBkNfv34lPz8/6tmzJy1fvtzYxQEAgGQydXRxYxcBUrk020zm4uJCFy5coGXLlhm7KAAAAGDC0mzNUPr06alixYrGLgYAACQDBwcHCgwMTNHtQdqVZoOhxJo9ezbNnj071vMajcYIpQEAgIQIIcjR0dHYxTAo9H0yHgRD/y8gIIBev35t7GIAAICZQt8n40Ew9P+cnZ0pW7ZssZ7XaDT09u1bI5QIAAAAUgKCof/n6elJnp6esZ4PCgoiJycnI5QIAADSurTW9ym1NvUhGAIAADCStNb3KbU29aXZofUAAAAAukDNEAAAAOgtLTT1IRgCAAAAvaWFpj40kwEAAIBZQzAEAAAAZs0smsmY2dhFAAAAABOFmiEAAAAwawiGAAAAwKwhGAIAAACzhmAIAAAAzBqCIQAAADBrCIYAAADArCEYAgAAALOGYAgAAADMmlkkXUwK7YSNQUFBRiwJAAAA6MPBwYGEEPG+jmDoG4KDg+X/PTw8jFgSAAAA0EdgYGCCk8mimQwAAADMmmBM3JUgjUZDfn5+RPTtajZ9FShQgN6+fUtZsmShJ0+eGHz9KQX7YTrSwj4QpY39SAv7QIT9MCVpYR+IUnY/0EyWRBYWFpQpU6Zk34byb0LVeKYO+2E60sI+EKWN/UgL+0CE/TAlaWEfiExrP9BMBgAAAGYNwRAAAACYNQRDAAAAYNYQDAEAAIBZQzAEAAAAZg2jyUyAp6cnBQQEkLOzs7GLkiTYD9ORFvaBKG3sR1rYByLshylJC/tAZFr7gTxDAAAAYNbQTAYAAABmDcEQAAAAmDUEQwAAAGDWEAwBAACAWUMwBAAAAGYNwRAAAACYNQRDAAAAYNYQDAGkAUq6MI1GY+SSQHLA9wqQvBAMpRHInWl+tL9zIQSFhISQhUXK/qRx3CUv5fO1sLCgoKAgOnnyJN2+fZvevXtHQUFBRi5d2rJ69Wq6ffu2sYuRYvDbVUMGakg1mJmEEMYuhknQ/ix27NhBp0+fpuvXr1PhwoWpQYMGVKJECSpUqFCybzs1Sw37ERUVRZaWlrRu3TpatGgRXbt2jTQaDRUtWpQaNGhAjRo1olq1ahm7mKne4cOHqVGjRtS5c2davnw5WVn9N1NVajhOviWhfdBoNCl+E6Wv58+fU/bs2SkyMpLs7e0Num4EQ6mMclArJ0lvb286c+YMBQYGkpOTE1WpUoXy589v7GIaXHh4ONnY2BBR6vrxJpfIyEiysrKiNWvWULdu3YiIyMnJiaytrSk8PJzq169PkydPpoIFCxpsm8oxFxwcTPfu3aNdu3ZR5syZKWfOnFS0aFGDbsuQUuuFQCnbixcvqECBAhQZGUk//fQTFSpUiJYtW0bv3r2jYcOG0ZQpU4xd1GSjfAbe3t505coVunPnDhUpUoSyZMlCFStWJDs7O4Nsp2jRovTw4UPasGEDdejQIcGypGaXLl2i27dvU1BQEBUoUIAaN25MRP/VEplS0KfRaCgqKoqsra3pxIkTtHDhQjp27BgVLFiQGjVqRHXr1qUyZcqQk5OTYTbIkOqEhYUxM3NQUBAXK1aMhRAshOB06dJx+fLledasWezr62vkUuovMjKSmZnPnj3L/fv355YtW3LXrl15+/btquWioqKMUTyj02g0zMwcHBzMGTNmZCEE//3338zMPHToUBZCcKVKlZJtu4MHD+Z06dLJ487W1parVavG8+bN44iICLmcKVCOkaioKN60aRN37NiR+/Xrx9OmTeNXr17FWs4U9e7dm4UQPGLECGZm9vb2Zmtra3Z2dua7d+8yM/PFixeNWcRkoZwHvL29uXTp0mxtbS2PuTx58nCHDh341q1bSd7O/PnzWQjBzZo1k8/dvn2bV61axTNmzOBdu3apljel41sXERERzMy8a9cuzpAhg/wMhRBct25d1bFjCr+DR48eyWscc/RxkC9fPhZCsKOjI1tZWbGFhQUXLFiQx48fz48ePWLmpH8vCIZSibt37/Ls2bNVB8mQIUNYCMFly5bln3/+mdu1a8e2trbyh3348GFmTl0/XuXH+O7dO3Zzc1P9cIUQ3LhxYz516pRcXqPRpKr9M6R169axEIJbtGghn8uYMSNbWFjwuXPnOCgoiAcMGMBjx45N8ra0A1QhBLu5ufGqVav46tWrXKRIERZCGGQ7hqaUe+zYsfIYsrKyYiEEFyxYkOfPn8+hoaFyeVO4GGj7+PEj16pVi4UQ/OTJE2Zmbtu2LQsh+M8//2Rm5ilTprAQgu/cuWPMoiabli1bshCC27dvz4cPH+YFCxawEIKzZ88uPxN9BQQEcLp06djOzo7//fdfZmbesGEDZ8+eXXXe+f7773n//v3yfaZ2nOgif/788towaNAgzps3r9y/Hj168OvXr+WyxjqnPn36lHPmzMnDhw/n69evMzPz4cOHWQjBDRs25JcvX/Lx48d5+PDhnCdPHraysuLWrVuzt7d3kreNYCiVKFu2LAshuE6dOvJH2adPH3Z2duZ3794xM/Pnz5957969XK9ePRZCcM2aNfn9+/fGLLbe+vXrx0IIbtmyJa9atYpXrlzJxYsXZyEE29vbc58+fZJ8IkxtYp6A9+zZw9bW1ty1a1dmZh42bBgLIbhz587MzHzmzBm2s7Pj33//3WBlaNOmDQshePHixczMfP78eRlYfPz4kb29vXnGjBkmVTP55s0btrS0ZCEEjx49mpcvX84dO3aUF4Lq1avznj17jF1MSQngFD///DMLIXj79u3y8y5cuDC/efOGmZlbtGjB9vb2fOnSJWMUN1ldv36dhRCcO3du+bkox+C4ceOYmXnbtm28e/duvdbftWvXWLVCSiD0yy+/8MSJE7lUqVLyWPn555/5w4cPSd+xFKIENT4+Puzo6MjNmzdXvT59+nRZ4+bq6sqTJ0826s3lxo0b2dHRkW1tbblChQq8cOFCXrZsGQsh+MaNG3K5gIAAPnjwIDdq1IiFEFyrVi0ODAxMUtkRDKUSu3bt4ipVqrAQgi0sLLhr165cpUoVbtKkCTMzh4eHM3P0wf/ixQtu3LgxCyG4X79+xix2oignu8jISB47dixny5ZNddf+6dMnnjJlCqdPn16eIMeMGcORkZFpunbo06dP8v/aNWHKhdHDw4PXrl0r///48WNmZp43bx4LIQwWDH39+pWbNWvGFhYW/PDhQ2b+L0j/66+/mJl51KhRLITgmzdvGmSbhvDixQvOlCkTjxo1SvX8kSNH5G/KxsaGf/zxR75//75RyhgQEMBHjx6Vf2s0Gvmb/uuvv1gIwSVKlOACBQqwEILXrFnDzMz37t1jKysrTp8+Pb99+9YoZU9OR48eZQsLC27Tpg0zM588eZKFEPzdd9/xx48f+f3795w5c2auU6dOotf9+fNnWeuWOXNmHjlyJI8ZM4aFEPzTTz+pll22bJlsYurSpQuHhIQYZP+Sk3I+9fX15RUrVnDOnDl527ZtzMz85csXuZyfnx93795dBnwrV640SnmVspw4cYJ79OjBLi4u7OrqyqVKlWI7O7s4b35v3rzJHh4enCtXLn7+/HmSto1gKBUJCgrixYsXc7Zs2eSBW758efbx8ZHLKM1of//9N1tbW3Pjxo05ODjYWEXWS/fu3blw4cJcv359Zo5u81bavZmZnzx5IvtRVKxY0VjFTDE1atTgcePGxVmNPX36dLazs2M7OzsWQshaomfPnsk73CtXrjCzYar2PT09WQjB48eP5xUrVrAQgmvXri2/nzp16rCFhQWfPXs2ydtKCuVCcO7cOW7Tpg3b2tryhQsXmJk5JCRE1e9qyZIlnDNnThZC8MmTJ41S3tatW7MQgn/99dc4A7KJEyfK/mFWVla8efNmPn78OFetWlXVZJYam28S8uzZM3Zzc+OMGTPylStX+Pvvv2chBC9fvpyZmf/991/ZVKwEj7qKjIzkGzdu8OzZs2VTb+bMmdna2pqnTZvGzNHnXIWXlxcXLFiQLS0tTSrYjynmMVCjRg3Zp3T69Ony+bCwMFW3i0uXLnG7du1SrJwxadeIvn37lrds2cL169dnGxsbWYN76tQp1XKhoaGyO8W1a9eStH0EQybun3/+iXVwv3r1ij09PWX1Zp48eXjlypWq2pHBgwezEIJ79eqV0kVONO39O3TokAz0smTJwseOHVMtp/1DOHnypGwrjtm0kFYcOHBAXgBr1qzJ69atU92V+vj48P/+9z8uXrw4W1tbc4kSJbhatWqcOXNmeXFl1r8PQMxj7/jx42xnZ8e2trbs4ODAQgg+fvw4MzPv27dP1tgl9sJkSNplLlGihDyeBg0apFpOO8B++fIlr169OqWKqKLRaHjatGky2MmSJQtPmDCBP378KJd5/fo1L1myhBs2bMj29vaq/iz16tWT+5KWgiGNRsNBQUHco0cP2UdICMHVqlWTyyj9iWbOnCnfk1iBgYF8/vx5HjhwIOfJk4eFENy6dWtVOZTfnNJfa9++fUncu+QRV9+ZNWvWcJYsWeTx0q9fP1UzdkhISKzzZ0qfT5csWcLNmjXje/fuqcpw7949XrBgAVeuXJmFEFykSBEeO3asDHyUfrONGjVKchkQDJmwly9fshCCK1SowJ8/f471Q7927Rq3atVKHuQ1a9bkNWvW8JQpU9jOzo6zZMli0lXnq1evls0titDQUF6xYgUXLVqUhRBsbW3NgwcPVtV+RUZGpqmTfkKUtvFmzZrJ/lLt27fnI0eOyGUiIiJ4586d3LlzZ9mMkj17dh44cKBsYtP15KZ8rk+fPpXPxQxsjh49ypUqVZLH3YABA3jYsGEyAFOacFLSp0+f5Ig6bcrdrlLW2rVrqz47jUYT67Mx1rHl7e3Nffv2lWUtXbo0r1q1SrXMlStXeOnSpdyjRw+uW7cur169mp89e8bMafeGIDw8nAcNGiSbqcqWLctTpkzh9u3bsxCC8+XLJ78zXYOh8+fPx6ox9/X15d27d3PLli359u3bcb4vR44cLITgq1evJm2nksGkSZNYCMEbNmyI9ZpGo1ENInB3d+cFCxaoltGuJUpJERERXLp0aRZC8OXLl5lZ3TXg69ev/O+///Lw4cM5W7ZsbGFhwRkzZuQCBQqwvb09d+/eXXV90BeCIROl0WjYy8uLCxcuzH369GHm6DZu7U5kzP9dCJWDSTnQO3fuzC9fvjRCyXXz8OFDWYugfQes8PX15XHjxrGjoyMLITh//vyxRv6Yi6ioKPb19eW1a9dyuXLl2MrKiosUKcKDBg1SnbQ/ffrEt27d4tu3b8t+Q8yJv1u+du0aZ8qUif/880/+/Pkz//rrrzxv3jwODAzkqKgojoiI4MuXL/Off/4p76SV/kpDhgwx2H4nRtOmTVkIwcuWLYv1WkREBO/du5fLlCkjA+zu3burmqOM3edMe/uXL1/mXLlysYWFBVtZWXHTpk1VIyiVWqC0Fvwk9B28fPmSN27cKL9n7W4CSs2kdk1fQkaOHClrSO7evRsr+I3ZQXrHjh3s6enJ1apVYyEEd+rUKZF7ljKGDx/OTk5OsjZdGXKu7dWrV/zTTz/Jz69MmTJ88ODBlC6qSlRUFN+6dUt2gg8NDeXatWvzvHnzVEHRhw8f+NChQ/zzzz/LprHvv//eYIEpgqFUQInY69Spw0IIHjhwIPv5+amW+fz5M8+dO5ezZs3KQgguV66cMYqqE41Gw6GhodyjRw+eOHEiMzM/f/48zmaKe/fucadOneSP94cffuCtW7emcIlNw9mzZ1UnMiEElyxZkmfOnClHFCqSUruhdNhVqqWFEFygQIFYy3369Inv37/PmzZt4tmzZ/Pdu3dVfSxS0saNG7lKlSqyE+XmzZtjfSZfvnzhOXPmcKZMmVgIwTly5OD//e9//PnzZyOUWE25kJ87d46bN2/OVlZWnCdPHs6dOzcLIdjBwYF/++03VSfStDpw4Pr167x+/XpevHixqpk8LCyMnzx5wufOneOpU6fyli1bVLmidBESEqJqOvXw8OCpU6fKkXkx3bp1ixs0aMBCCHZycuIff/zRpGvblRvg0NBQWYt2/vz5WMudO3dO3hwYu9N0TMpgEAcHB27WrFmskYLPnz/nDRs2cNWqVdnZ2dlgndkRDJmwmHeAyh1NfNWczNGd/Nq3b8+bN29O0bImVcWKFWWwc+7cOdVrGo2Gjxw5IjsCFi1a1EilTHnKd3/z5k1Onz4929ra8qRJk3jx4sXco0cPmVeqfv36vHHjRp3vjhPy9etXPn/+PHfo0EGOtCpZsiSfP3/+m7URpnBxvn37Ngsh2NnZmefOnRvrdW9vb+7Xr5/MN2RKw+qV5uG1a9eyv78/+/r68qRJk9jV1VX2D5w2bRoHBAQYu6gGpRy3+/fvl82tyqNJkyYGuftXjs1mzZqxs7Mzt2zZkl1cXGQNw5YtW/jr16+q93z8+JFPnDjBO3fu5H/++cdkB6PEDIxv3rypGmjTrVu3OJuSlMEDMffbmPz9/Xnr1q1cvXp1FkJwhgwZ+Ndff1WljggPD+fr16/HailJCgRDqUzMas7SpUsbvZpTH9qZgZmZd+7cyQULFpT71bVr11jNfEFBQTx37lw5UimtNRMkRGkemDVrFjNH77uSV6pmzZqy70RC/R0SS7lDUx4ZM2bk3r17qy5MYWFhJhEAKceCRqNhf39/mX9EqT3TTpinOHPmDPfv3z+lixqvPXv2yLv5mB4+fMi1atWSAVzFihXTZJNx4cKFZafw3r17y5pupVlLu0Zc38B/8ODBXL58eX716hWfO3dO9scTQnDz5s353LlzBrmpSGkxa4PDwsJ45syZ7OHhIWtapkyZEuu4Ud5nSvscGRnJ3t7ePGvWLJkcUsk4/eLFi2TZJoIhE6dcaGJe+GNWc7Zu3ZofPHhgjCIa1OzZs2Vth4ODA0+ePNmsgp64vH37VvYJO336NDP/16k5IiKCT58+zR4eHnJ0oaEyEXt7e/P06dN59+7dvGzZMtlkU6hQIZ44cSJ/+PCBx4wZw3/99ZdJXpjPnz/P5cqVU13otEeraDOFY0wZSVmyZEnZdBcVFSW/640bN7Krqytny5aNhw0bJl9P7ZRznLe3N9vb23Pjxo1Vr48bN05+h5kyZeI5c+YkaXuhoaG8a9cuefEPCwvjVatWcfny5eUghYEDB/Ljx49NItCPj/LdP3v2TPabYo6+NmjfSPr4+HCfPn3kZ1iwYEHesWNHipdXH0FBQXzz5k0eMGCAnAKoWrVqvGjRIoMf+wiGTFTMH+Hbt2/jvOCsWLFCNW1FXCNqTJH2/gUFBalGLH38+JF79eol96lw4cK8ZcsWYxQzxcV3dzZgwAAWQnDbtm1VnQqVE0KVKlW4W7duso+FoU8UQUFBfOPGDe7fvz87OTmxEELm5nF1dTXotpLqxIkTqs9xzZo1cti6EIKHDx+u+gxT2uvXr/nhw4exviN/f3+ZBPDHH39kLy8v1eu7d+9mNzc3OR8Zc+oPhpQg9OPHj7xx40bOnTu3/K1rJwZ8/fq1bLYVQvCKFSv02pZ236CYIwnfvHnDY8eOlcd1rly5eMGCBSafxV+pUe/Tpw+vWrWK06VLx3PmzOHg4GDV7+D8+fOy/5MQ0fMXGrt5TPs6cO3aNV6yZAmvWrUqVmvH58+f+fjx4zL7uJKE05AQDJko5Ue6a9cubt68OZcuXZq/++47XrRoUayhzqGhoTxw4EAWQpjUNAjx0a6W3blzJ1epUkVOFqj947169apsNxbiv0RradWzZ8+4Q4cOcdbsnDhxQmbeLlasmKrD44ULF2SgpN1clFjaF9bAwED+/PlzrKyunz9/5mPHjsmTUpEiRWJNZJnSlH0+ceIEt2jRgsuWLctRUVGq/QkPD1f1ucucObPR+n+UKlWKy5QpI4fEa9u/f7+sgbOzs+MxY8bwmzdv+Ny5c7I/0T///GOEUicvZXCIs7OzquYnLCxMdb47depUrJojXSxcuJCbNGnCBQsW5ObNm8t5yJhjp+q4fv06d+/eXdZElChRIs4Rr8am/ManTJkiy6o0o65bt04uF7OD8caNGzljxoxco0aNlCxunJTz/cqVK2XqBBsbG3Z2dubWrVurjvXIyEh++/Ytr127Nt4O70mBYMgEKT/MN2/eyKHlzs7OqmrOmDO4M7NR73YTQ9m/GTNmsIODA9vb28s08czRB712zouNGzdy8eLFjZYHI6UoOWaULLEx7/pfvHihyitVvnx57tu3r5zReeHChXG+L7FWrlzJ1apVY1dXV65WrRqPGzcuVm2E0qZv7PnhlH39+PEj58qVi4WInqdIezZz7QD76dOnXK1aNZkCIKVrVl68eME1atSQ0+gwRwf92hfbr1+/qvINOTs7y9o4faadSA0WL14sg30hBA8bNkxVMxQSEhLru9K1j8vUqVPlepXzqRCCu3fvrkpBEbOp9MCBA1y+fPlYU3OYqjJlyshszfny5VONuo15Tv369atsijV2X6HAwEDZutG0aVPu1auXzJeWLl06HjBggCqZZHI1aSMYMmFDhw6VnYmvX7/O586dU1Vz1q9fP8kpyFOaciAreYaEEHLk25MnT9jT05NbtGjBU6ZMibN/h7F/uMnp0aNHPHv2bDlSaMCAAbxw4UL++PGjKqnc9u3bVf3FlGNBoU+tkPK5HjhwgK2trdnOzo6zZs3KmTJlYkdHR65bty4vXrzY5CapVPZVCR5+/fVX1f5rX0DjGoJrjGYmX19fOSRc6aQ+cuRIvn79uqrZ4t69e9yuXTvOmzcvFylShDt06CCTYZpCHydDCwsL4+HDh8tjOmvWrLGawxJ7Q6RM0mtjY8P79u3jV69e8fTp02XgnD59ep4yZYrqRlJ7G0FBQSY7goxZPYddw4YN5cg45TOsVauWqhbs+vXrMjWAqfSHunPnDltZWalmS/Dz8+Nx48bJGq+CBQvytGnTknVOOARDJkb7Yr9o0SJ2d3ePtcyGDRtklbkQ0bOUp7ZaE2XWcGXm6devX8smMSsrK3Z0dOT+/fuzRqNJ9f0i9HHv3j35/TZo0ICPHTsWq8/Yrl27eMaMGXzkyBHZYTKpF0nljmz16tUcEREhJ3tVOpa2bt2ad+/ebdTpNmLy8fGRHci1Ox4rPn78yNOnT+dff/3V6M0dMS9A06dPlyOmihcvzgsWLOAnT56ofs9eXl7s5+cnv39TuYgllbIfMffnyZMnquSKVapUUSWdTIzRo0fLmiZtT58+5b59+8opZb777rtYtdOpMeBUEonu3LlTNrcKIbh///68cuVKzpMnj8ztZkzKde758+c8bdo0dnBwkPmQtIPP+/fv8y+//CL349ChQ8lWJgRDJqpGjRpcokQJLly4MH/9+pXDw8NVJ8jAwECZfr1kyZLGK6gevLy8OHfu3JwhQwb5XLdu3ViI6Bmh9+zZI5P9GWpkVGoQ86KwZs0a/uGHH2SA2KtXL757926ynaQPHjwYqykmf/78LITgvn37cuPGjdnKyopz587NAwYMMJmLhY+PD2fJkoWLFCnCX79+5YiICFXfKaUJrWjRouzv72/k0sZ26tQp7tGjB7u7u8tavh07diRLvwhToH2cR0ZG8p07d+QkxNrH1OHDh1U3ffrMHTd58mRV03PMVBBnzpzhJk2ayG106tRJ1TyX2k2dOlX2I7KwsGAh/puuIyWDau1R0drbVUZ7Ojo68tq1a+XzMfv87d+/n3v06JGsZUQwZILOnDmj6i+g3XE4MjJSdVf++PHjVHfSDAgI4AIFCrC7uzsfPHiQ161bJ4dMKne/LVq0YDs7Oz5x4oSRS5vytE8Cfn5+PG3aNFlj4+HhwVOmTFHNYG8o+/fvV/U9mj59uuyYzRydzFBJezBp0iSDb19f/v7+XKRIEba3t1f1k1Cq1F+8eMF2dnZcsGDBWFmpTUVwcDBv3bqVmzRpwra2tuzo6Mjdu3fnc+fOpamLM/N/Ac++ffu4RYsWsq9Qu3bt+MiRI7EC1jlz5rC7u7tefSK3b98um46uXbsmL8Qxa5vXr18vR5HNmDFDvx0zko8fP/KuXbt42bJlcdag+fr68m+//catWrUy6r7FzBYeFRXFc+fOVU3pM3z4cNX1LCIiIt4aRENDMGRkc+bM4R07dsTZeU/JuCyE4BYtWqj60ISHh5vMnXliaTQaOfrNzc2N7e3tOXfu3HIm6Pv373OWLFnYw8Mj1rQj5urevXvcr18/eeEoV64cr1ixwqDNo9evX+c///yTfX19+evXr7JfhZL5dePGjWxtbW2UiVi1aZ8Ulf2fP3++/K307NlTdULt3bs3CxE9oWzM9xvL06dPefLkybx3717V8y9fvuTZs2dzuXLl2NLSMt4s2qmVcs7y8fGRx3LhwoVlrZiDgwP37ds3VloB7bxautAOenr27MlCRGftHz9+vCoHj3ZQdPHiRbaysuJ69eoZbVoZXSmfw9mzZ7lKlSqq/oM//fRTnDXq2v1tUrrrwa+//spCiFjHO3N0v64///xT3mgVKVKElyxZorq+pUR5EQwZkZeXFwsRPUeS0jE15pe+bNkyOVpIaftOLaPG4qKcpD59+sRTpkzh4sWLc/ny5fnAgQNymS5duqj6E6XWoC8xlO/94cOHvHv3bp41axbfu3dP1XmaOXrG+JYtW8ohqElJdpjQCebatWvs6urK5cuXl88pHTONPbRbOR6WLFnCO3fulM/PmzdPjqaxsrLidu3acaVKleRQeuV3Y6w+aMoF7M6dO/IC9r///U++rn2cX7t2jYcPH87Ozs5yuhBTCOIM5eeff2YhoudZDA4O5pcvX/LUqVO5WLFiLET0lDvKCMbEDpoIDQ1VBewvXrzg4cOHy6HbxYoV43Xr1skaNyXQevjwIVtZWXHp0qVNsjlVoX0cKMlYGzRowOPGjZMBZvr06XnUqFGqefeMdfxoNBru1asXW1pa8pUrV5iZ4xwcc+PGDW7durW81tWrVy9FZ1dAMGREQUFBPGXKFNkW/uTJEx41ahS/ePFCdWL09/fnESNGyGGh2bJlS7V3i9r7FRgYyBEREfIHe+LECe7evTsLET3NiCItXQTionwmL1684IIFC7KdnR0LET27eqdOnfjIkSOqGrLw8HBesGCBTLCZ1BF2np6eMj+V8lm/f/9eTmjapk0bOb1F06ZNk7QtQ/n8+TM7OTmxm5ubqmngw4cP3KNHD9Wdcs2aNeVkj6YQWCv9wH755Re+efMmR0VF8ZkzZ/h///ufKj8Mc3RtXVrz7NkzzpgxI7u4uMT6Pm7evMn169dnIYRqdFFidO3alYUQsaalOX36NLdp00b2oWnUqBGfPHlSjt5UsjQPHDhQvx1LIcpvdOnSpSyE4IYNG8rXtPtYCRGdLf6vv/4yVlFVlCbqV69eyd+lEhwpIiMjee/evVy2bFm5D0qLQXJDMGRC2rVrJztEr1mzJlatwO3bt7l9+/YsRHRa+tRAOdm9fv2a16xZw/379+fRo0fHSubHzDxt2jTZgVcZDpqWh9LHpHz/1apV4/bt28uaGHd3dx48eDBfuXLF4Bljd+zYEW9tz8GDB+WduoWFRbyJAo3hy5cv/Pvvv7MQ0fN0xWwWuH//Pm/bto1Pnjyp6nNjrMBa+R1v3LiRhRBcpkwZWRbtIcRCCO7YsWOy9AkzFf7+/pw9e3bOkSMHP3v2TDXlCHN0DY2zszNXrlxZVbOhqz///JOFEDxixAhm5ljNLevXr+fKlSvL2tW6devKvzNlypQq+mhFRUXJLP1K05OST6lNmzb89u1bbtq0qew0vX79eqOVVTuppUaj4UuXLskmMSGiM2fHzPIdEBDA06dPV90UJzcEQ0YUc1b6I0eOcNu2beUcUw0aNODjx4/HynOxY8eOWBG1qWvRooXqjsXZ2ZmHDBki86YwR9+5TZw40Sz7Cfn6+nKhQoU4V65ccv+fPHnC48ePl5NXFi1alOfOnWvQOeiUTtONGjVSXTSUC/Xr16953bp1vHbt2mSbIDEp/ve//7GVlRU3adJENoOZak1iVFSUrGFTJo7dtWsXOzg4cLZs2fivv/7iIkWKsJWVFZ88edLIpU0+ISEhXKdOHbawsFA1Eyr9v+7evcsWFhZcokQJvboEvHz5UnYtUG6qYqbo8PX15alTp3LZsmVlDWi1atVMds6uuGo0e/Towfny5eMvX77w169f2cXFhe3t7eWxM3XqVLa3t+dq1aqldHF1MnnyZBmsubq6ykmotaVkjicEQylMOajj67eg0Wh406ZNXLVqVdn3oXfv3nz37l2Tyu2iC+WipAzZzpEjB0+dOpV79erFWbJkYSEE58+fP85s2ubo559/5uHDhzOz+uR3/vx57t27N2fPnj1WPxND6NixI1tbW8vkl6bQlPQtShm9vb35p59+YiEEt2/fXtaomNpvRaPRcFBQEP/4449sa2vLz54944iICM6XLx+nS5dOTmmi1I6aStNGcjlw4ABnzpyZhRBcoUIFPnHiBAcFBbG/vz+3bduWhRA8atQoZtavj5cyiqx169YcGhqqqpnQPr6fPXvGly5d4itXrphsjZD2IAntsj98+FDeTC5YsICFiE7Qyxzdb+r777/natWqyf5PKVnLrnzed+7c4aNHj8rnb9y4obrZffv2rew/puTaUm4UUhqCISOpXLmyHDK/f/9+HjVqlGqUQ8wh1VmzZuVJkybFGp5oqrTvzpXEfdoH+eXLl7lz587yRzB9+vRUm+hMX9pNiMePH+datWpx3rx54+xcGBoayn///Tc3bdpUpqZP6vxjirNnz7KTkxO3bt2amf87+b58+ZJDQkJkMjRjUk7kr1+/lrmDFJ8/f5YB0fjx441VRJ0MGzaMhRCcPXt22fnV09NTvt68eXMWQsgBBaZay6WPmPty+PBh2cFd6SeYI0cOeZOkHIeJCYa0J35VbihN4fjV18KFC7lw4cKyz5si5meyZMkSFkLw0KFDmTm66VUIwXXr1k2xssZF+T5HjBjBU6dOZScnJ96yZUusOecuXrzIFStWVHWeTsrgEH0gGDIC5a5FqZq1tLRkV1dXOZxUO4K/d+8e9+3bV866PX/+fGMVO1GUk9LOnTu5e/fu7ObmFudyc+fOZSGi08antizaSaGczAIDA7lcuXJypIvSsfbgwYNxNhEofYb0HRGlXJDmz5/PM2bM4MGDB/PYsWPltitXrszVqlXj4sWLc44cOdjS0pILFiyo304aWGhoKFtYWHCBAgW4SZMm3L17d966dSufPXuWT506JZug/vjjD9kp1tSCiXfv3snALUOGDDxw4ED28fFhZuYtW7awvb09lypVysilNBzt41S7dkb7ufnz53PJkiVlzWfHjh359OnTzKx7bYZS26D0MQoPD+cLFy6wnZ0dlyxZko8cOcJhYWH8/PlzDgsL40ePHvHnz5/56dOnfPv2bZPM1abRaOT0S1ZWVtyhQwfV9EtRUVHyszx37pycv1LJ2+Pg4CBH5BnjJjMsLIz/+OMPee1S+glpN0Vq19oxR+d7EkKo5u5LKQiGjGTTpk1coUIFeaDny5ePAwMD5evh4eGqk8b+/fu5U6dOqarmxN/fny0tLeWFdvLkybIqWtk3Pz8/9vDwYBcXlzQ5ciY+yv4r+ZYKFy7M1atX57Jly7KVlRXnzJmThw0bxv/++6/Bg8SjR4/K4075bjJlysQuLi4shOCMGTNy2bJluVixYtykSRO9p0IwtH/++Ydz5crF5cuXV3U4FiJ6Qkel/EWKFIl1J20s8QVjFy9e5AsXLjBzdL+I/fv3y1w7yuedlgYPLF++nH/66ScuWbIkDx8+nA8ePKjqJP7hwwe+desWP3/+PNEB7JcvX7hMmTJcokQJLlKkCBcrVowLFiwo82TZ2dmxm5sbFylShN3c3Dhr1qzs4uIiL9LOzs4mW+MeHBzMK1askPvi5ubGI0eOlPOLMf8XZJ44cYLLly/Pbm5uXK9ePZlewNjTGX39+pULFy4szzeVK1dWTX2i0WhUtUAREREpXivEjGAoxWn/0G/evKk6oTs5OfGUKVNUFz/tE6Kp3eV+y8ePH3nChAlcu3ZtdnJy4ixZsvCYMWP4zp07MqnZtm3bZFuxuVC+R6UPScaMGWXT182bN3n8+PFyOpIyZcrwvHnzVLPGJ9WlS5d47ty5fOHCBT516hR7eXnxsWPH+Mcff2Qh1NMemFrwHR4ezi9fvuS3b9/y5s2becmSJfzrr79yuXLluHz58qrgSOmHYwouXrzIXl5e7O3tHevipDQju7q68tixY41UQsNTjp3Dhw+rznNCRGdS79OnDx8/fjzJfXVmzpzJNjY2nClTJs6XLx/nzZuX8+TJw+XKlZNBhBCCc+bMyZUqVeI6depwmTJluF69elyhQgUePXq0IXY3Wb19+5ZHjBiRYGJChdK/NKUyN39LZGQk16xZU57PlO+jVatW8oaAOXqiaqX52xhlRjBkJOHh4fz+/Xtu2bIljxs3TtYQKLUESg6Zw4cP87Rp00z2zkUX169f52HDhsnq27Jly/KIESN45MiRnD59ek6fPj0fO3aMmdPW3fC3/P3331yyZEn++eefmfm/E0BoaCifPHmSf/vtN9l0oGRPTk5Xr15lW1tbrlWrlklOW5HQCfLz58/8/v17vnv3rux3U6RIETlxZUrTHiHaokULtrS0ZCcnJ65Xrx7PmzePHz9+LJd9/vw5N2/enE+dOiWzBBv7bt6QlAvhpEmT+MCBAzxlyhQuV64cW1hYcKFChXj8+PF848YNvQLvW7ducdWqVfnjx4/87t07Dg0NlQlslX///PNPtrCwkP1plBux1DjxbczEhHXq1FFNXvrgwQOTbCIOCwuTI6BXr14t5zx0cXHh4cOH86xZszhnzpy8atUqo5URwZAJOX36NNerV0/Vn8jBwYHt7e1VJ8/U6tChQ/zLL7/ILKlCCG7ZsmWaHkYcH2VIu5JXKq5g18/Pj7du3cp169aVQ4ST4yIZERHBUVFRHBwczM2bN2cLCws+cuSIwbeTWNodzLdu3crz5s3jmTNnqgYaaE9Lo33yX7NmDQshuHPnzikeYCvf0devX+V8V4UKFeJChQpxhgwZ2M7Ojps1a8b79u3j0NBQjoyM1CufjilTPoNXr15xxYoVVcO7o6Ki+N9//+WhQ4dy7ty52cbGhitVqsTLli1L9PGtTFmkXZsZs0bk6dOnnCdPHk6XLp0qv1lcfZhMVcx+Vnv27JG1LDY2NtyjRw8eP348u7q6pop+pb6+vjx69GiZSFh5GGskGTOCIaN6//59nHdD69at42LFirGFhQU7ODjI4ZKmTjm5hIeHs5eXF585c4YfPnyoyk/z5csXXrduHTdq1EjWCg0YMIAvXrxo8ISCpuzYsWPcpEkTdnNzk8PCDx48GGdbeczs0ImlnVX67NmzvHz5cr569So/evQo1vF37do1GYgb8yKhve26deuqTpjKHFNxNScrI1Rev37Njo6OXKxYsRSv5VLKPnToUNVwZy8vL96yZYscXl+sWDFVM0Faoez/58+fuVevXpwjR444aza/fv3K+/fvl9PvJHYkoJIw9IcffpC/m/iCKSXZ5U8//cQhISEm1/wbl5j7ot2nVPl77ty5MkVBzIDCFIK8gIAA/vvvv3nr1q185syZWK8/ePCAe/bsyfXq1TN6EIdgKAUpP8CbN2/yqFGjuEqVKlyhQoU4s4N+/fqVt27dyleuXDH5SQOZ//vhRkREcLdu3VQd/urWrctTpkxRXZS8vLx46tSpXKJECTmUdvLkyUZr1jCGZ8+e8YoVK7hatWpyFMjQoUMNmlBTOea8vLy4evXq7ODgoKp5HDdunAxWle+wevXqRs9zo5zIV61aJY+P3377jTt27CjLny9fPt60aVOs9zBH52Yy1qgU5ugAVun3pV2TxRzdN6Jv376yD0Vq+H3rY+bMmfK7srCw4EOHDqkmC1W8evWKt2zZIv/W9SKuNLsrGZjjCnCUZIvv37/nUqVKsaOjo6xlTS1mzZrFHTt25JIlS/KIESP48ePHqn19/fo1jxo1ijt27GjUTNMKpWz79++Xg4RsbW05Y8aM/Ouvv/LNmzdjvSckJMTowRuCoRSiXGj8/f1lRmFlDiqlH01qzoeh7N8ff/zBQgguWLAg9+/fX84TlT179jjvgq9cucIDBw7k3LlzyxFn5iQkJISvX7/O48ePl1lzy5Urx3PnzuUnT54YbDuNGzdmIQQ3a9aMly9fzv3795fNNzEv1nHlOTKWwYMHsxBCNaT4zp07XKdOHVVOknPnzsV678OHD402ZDoyMpIrV67M6dKl48uXL8d63d/fn/PkycNFihRRjQxKS+7cucOTJ0/mmjVrsqWlJZcsWZKnTZuW4GAAXS+IEydOlKMgtbPYJ2Tfvn0sRHSSR1Pvg6kEFKtXr47V+Txjxow8duzYWDWeKT3Le1yU7YaGhsrzWYMGDXj48OHs5ubGjo6OXKRIEZ4yZYqs8TYVCIZSiPIj7927t6yu9fHx4R07dqjmaenUqVOqOzkq+/bq1St2cHBgOzs72TY/ZswYFkJwhw4dmDm6/V7Jp6RQJufr2LGjKpleWvX69Wt++vSp6kL98eNHPnnyJP/6669yyG/nzp2TtB3le7lw4YLsmK+crJo2bcpCCJ44cSIzM586dYpv3LiRpO0lh9mzZ3O+fPmYObrWUbv/z86dO2VHTCcnp1j9KoxFqY1o1aqVbAK9e/euqlnP19eXHRwcOHPmzHIkYVoUHh7Op06d4gEDBnC2bNnYysqK69Spw2vWrNE7IHn37p0qZYeHhwePGzfum/O5hYaGcuPGjdnKysqkZ6VXREREyLkBZ86cyceOHeO+ffvK6UO+//57vnTpkrGLycyx+2lNmDBBXs+U55VZB5Qh9jVq1OCVK1cavUZIgWAoBT1//pxdXFw4Xbp0ssPkkCFDWAjBtWvXltW+lpaWPHjwYCOXNvGUaTeaN2/OzNH7K4Tg9OnT87179zggIIBLlCjBjRo1ku/RvmgZI7dESlDu2J49e8aDBw9me3t7zp07NxcrVoynTJmimn/n9evXvGPHDq5ataocUZjUC/vatWtZCMH9+vVj5v++p5IlS/LXr1/5zp077O7uLk9cxqR8Vv7+/nzixAmePn06Fy5cWFVrGvM4GTVqlGweMKXRiE+fPuXatWuzEILLly/PK1as4Lt373JAQICcIb1Hjx7MbBr9Owwhvv3w8/Pjv//+m9u1a8fp0qVjV1dX7tSpE+/ZsyfRx7cyfUOvXr14xIgRMmFpiRIleP369XI0VVzl2rRpE0+dOjXxO5aClM/Dx8eHCxYsyK1atVK9furUKZkGw83NzeTmqQwJCeFmzZqxEIIvXrzIzP9d55o3b86PHj3iGjVqsI2NDQsh5EhiY0MwlIIeP37MVlZW3KZNG2b+r7Nqzpw5Zec4ZfqN7777zphF1UnMC8+9e/fY0dGRixcvzuHh4dypUycW4r/Zox8+fMj29vbcsmVLVSp2jUaTZi4GCVGaqtzd3bl48eLyzrZEiRKq+dk0Go1BZy1XaoaKFy/O3t7ecttKUrbjx4+zEIJ79uxpMkO6f/nlF1XTQNasWeX0NczRF4zUkLH85MmT/Msvv7CLiwtbWVlxnjx5ZM1f1qxZZVNBaujQmxDt3++HDx947dq1vG/fPj58+LCqtvfFixe8dOlSGSRqT0Wii3///Vc2wyvf/7Fjx7hly5aytqhJkyZ8+vRpkwqMdaX8/h4/fswtWrRgV1dXHjRoEDOrz7dhYWFyiP2yZcuY2TgB9e3bt/nEiROxJlRt0aIFf//998wcPa2PhYUFZ8qUiW/dusXM0ZPMOjs7yxtnU4BgKAW9evWKa9SoIZsj2rRpw0JEz8vFHH3Q2NnZce/evVVDQE3NP//8E+fkgb6+vrIzsNKno0iRIvJHPGLEiBTLmWMqlJObMgVLsWLF2MvLi/39/fnff/+VFwUnJyd5UkuqmCfF9+/fy+9DGY5bp04d+bpyF7do0SKDbF9fSrmVJH3u7u7cvXt3madG6e+hnYrBFCZkVb7jyMhIfvPmDd+/f1/VL8bf359Xr17Nbdq04e+++46FiJ5y4uDBg/J9qZ2yDytXruRChQrJ78vBwYGrV68eK3/M9evXecKECXLKGV2D8P/973/s6OgYKwCIjIzktWvXyvmtbG1tuV+/fvzgwQP53tR0wzV8+HBVM+CZM2dkwKGcT5X+mb///rvRyunh4cElSpSQ/baUz/j8+fNyYMbo0aNZCMHDhg1j5uguAfny5ePatWvHOeWQsSAYSmHKydvLy4vz58/Pzs7OcjRJv379WAjBK1euNGYRE+Tr6ys7RMc1AsTb25t/+OEHVefWS5cuyYkErays5FxMplILkRKU/iNKDZB2U8+CBQvYwcGBixYtyu/fv0/ytpTv4tSpUzLx3NOnT7lZs2ZyNFmrVq14w4YNsrlG6ZdjCpTOsdpzGO3bt0+OTBEiev62R48eGbGU/1E+7+nTp3OhQoU4ffr0nDlzZu7SpYvqYvzmzRt+8+YNP3v2LM73p1bK7/jdu3dsb2/PQgju27cv7927V9ZCKrXhcb1Pl/1Xlv3y5QufOHFCPh9zws/379/zxIkTZZeDbNmy8Zw5c1JdP8zHjx/z+PHjZXBXsGBBnj59Oj9+/JijoqI4PDxcToL6zz//MHPKn083bNjAQgiuUqWKfG7Xrl3y/K5Q+g8pzZNKgmEl2aypQDBkJBqNRmbKnThxIs+YMUO2AZtqAjaNRsOvXr2Ss20rfZ20h6pqNBq+ceMG/+9//5OdW5VHunTpZC6JtHA3rAuNRsMRERGy2Ue7fTw8PJwjIiL48+fPXL58eba0tOQ7d+4kaXvK53rnzh328PDgbt26yeHMt27d4jFjxvD333+v+l4KFy5s9HZ75W733Llz/L///Y+zZMkSaxllUk8lbYOtrW2s3CspTbkAXb9+XQ4hz5cvn5w0U4joiWPT6vB5bcOGDWMhBA8cOJCZo/PgODg4sIODA9+8eZO/fv3K+/bt07vDeFBQEG/ZsoVXrVrF8+fPV40ii4iIUJ1Tbt26xb169ZLz1RUtWjRVDs64ePEi9+vXT3Y+rlSpEjdo0IBLlizJ6dKl41GjRjGzcW4sN23aJPsenjt3TtZmxaxh/vvvv+VvQekG4u7ubnIj+hAMJRPl4AwJCeFz585xmzZt5MzKUVFRHBUVxcuWLVPNVu7k5MRr1641ZrF1tmvXLjkcXgjB3bp1U42OevfuHZ88eZLHjRvHtWrV4v79+/OxY8dMZr6clDZ9+nQ5bF7pVKhNCTANlY1bme26e/fuqs86ODiYz507xytXruTffvuNZ8+eraq9MCZ/f39VkLZ582b5mvaF7t27d9y1a1eeNGlSrNeMRbnbnTJlCr9584Y/f/4s0wIIIbhq1aomlbLA0MLDw7l79+4shJDTQyh9BpV+QUuXLmUhBB89ejTR69+xYwfXqlVLdXwogwK0a31i9iM7fPgwV6pUySQGByREu5bs2rVrqpGd4eHhvGvXLm7durXM3p8xY0betGmTUYenBwYGcu/evdnJyYkzZMggawXj+n4PHz7MpUqVYhsbG27YsCFv3brVCCVOGIKhZKJcgCZNmsQZM2ZkDw+POO+ILl++zEOHDuXx48er5pgxVTHvwIYMGcIWFhYsRPTsz0r/p4SYUyCk1PJ5e3tz5cqVZZPU2LFjZYoB5SJRqlSpJG1LOaG+ffuWy5Yty6VLl5YBOLPpf+6vX7/mDh06yPwkJUqU4C1btsjM5MqQ9ZiMtV9K88yHDx942bJlnCNHjljLPH78WH7v48aNS+kipqixY8fK5pAHDx6wENGJRJXjXEkrsnv37kSt18fHR2Zqb9q0KU+cOJH79u0rU5K4uLjwnDlzVNOyaAdFISEhcSZ7NBXKMR0cHMwjR47krFmz8oIFC2It9/btW16wYAHXrl2braysOGvWrDx48GC+fv16iu+f8pvz8vLiVatWyZt65Rpw7dq1ODuw37hxw2QHPiAYSgbKj/Kff/5hIQRbW1vz/PnzOTg4mF+9esVz587loUOHxsq3k9pMnz6dq1Wrxnnz5uWqVavKu7WiRYvyzp07VcuaQkfXlKKcBG7cuMG9e/eWSQ0/fPjAI0aMkHd37u7uXKZMGRlMKvOB6TMKRjsgWLJkCefLl09ObxAVFRUrYDDlGrpDhw7JTt3KcNxz587Jz8WU+ppFRUXJSVjz5s0rf9NKEygz8549e1gIwaVLlzbJCXD1EVdgeubMGXksK/1ZlBGLz58/53Tp0rGVlZX8jHQ99rp27cpCCB4yZIjq+adPn3K3bt1UozK1k29qNBqTqDX8lpgJa3PkyMELFy5k5uhA7vTp06rj5t69ezxmzBjZUb1UqVI8efJko+VO8vHxkRNKZ8+enS0sLLhy5cq8ZMmSVHWNQzCUjJRJBOfOncvMzE+ePOEaNWrIE4a9vb08WaSGHy3zf+Xcu3cvCyE4b968cuTblStXuFKlSvLk1Lhx4zhTr5sLZWTdpEmTZDAYFBTEZ86c4c6dO8sO5ZUrVzbY9BfaUyDkyJEjVrZfUwx+mGOXKywsjFesWMHlypWTv5XBgwcbdbqW0NDQWAHAjRs3VBMPd+vWTTZdKMueO3dO9pcw5RqKb1H2R7ufVsxEmDt27FA1nys5oJTzgtJkpmtA++zZM/bw8FANNIlZO33y5EnVoA1lpJkpBc3xUfbj7t278sZZybZ+/PhxrlevHqdLl47z5s3LS5cuVf1Ozp49y71792YHBwd2dnZO0RoX7VF8QUFBvHbtWt65cydfuHCBf/nlF3Zzc2MHBwdu1aoV79ixQw7kMGUIhpKJMjeSdtOHMpS+S5cuPGjQIBYiOotoaqw1adSokerEoz06au3atbLjohDCJObLSWmXLl2Sd6vx1Qa8e/eOL168yIGBgfLEre8JXDk57d27l3/55RfZUbFdu3a8c+dOVXOZqdDe1xcvXvDFixf55cuX/OXLF/n8q1eveMyYMfIC6+7ubrR9adWqFffv319VPuboptBRo0axq6srCyE4Q4YMvHDhQn779i0/fPhQjghSOpamlhufuHz9+pVLlCjBM2bMYOboEUXLly9XXexu3LjBffv2Vc2DJ0R0/h9leLiux/mLFy84U6ZMXLVq1Vjvi/k5zpw5ky0sLLhq1aqprsO6MlmtMuLq2bNnXLRoUdlpWojovFRXr15VvS8kJITXrVuXYl0sdDl2X716xWvWrOH69euzjY0NZ82alfv3788nT5402ZsxZgRDyebixYvyBBAWFsbLli1jIaLnaVEULlyYCxQoYNA5qFJCaGio7Bw5cuRIZv6vnV45WXXo0EGOgDC1UQPJRTugOXz4MDs5OfGBAweYOXbTV8yLQWJOEsqyMe/KFT4+Prxq1Spu0KAB29jYcJYsWfj333/ns2fPxkqOZizazXQjRoyQVf7fffcdjx8/nq9cuaIq67Vr17hly5Yyi3ZKn1QfPXrEVlZWXKhQIXmhDQgIUH2PDx48kNmRhYhOppojRw6uUqUKz5kzRy5nyheEb1GymQsRnVVbqYFUaryUfQsICOArV67wyJEjeciQIbx7926ZNiIxwaCvry/nzp2b06dPH+/cjdrrUxKbpqYbMH9/f65Tpw5bW1vLWkUloeIff/zBzNFZ1oUQvG7dOmaOu+k7ua1atYrHjBnDixcvZi8vL3706JGqn1ZMt2/f5unTp8vRq0ryXVOFYCiZ+Pr6cpUqVdjS0pJ/+OEHdnR05Ny5c/OpU6eYObrq3NLSksuUKWPSNUMXLlyIM0fHvn372NnZmT08POI88VSrVo2HDBmiqtpO65QTwpAhQzhLlizs4uKiGipv6Gr7kSNH8sqVKzkyMpKvXLnCU6ZMUX3O9+/f52nTpnGpUqVYiOgM1NOmTTOJpkvlJDplyhQ5Oub777+Xnadr167Ny5Yt4ydPnqhOtMbsN3T+/Hk52fDhw4e5bNmyfOjQIQ4KClKV8ciRI7KJVAjBdevWVd3wpIbmm4QcOnRIJgu1sbHhQoUKqQaHxLwwJuW3HxERIXNh/fjjj3z16tU4z5fKNubOnctCmG6uts+fP8f5/ffq1YuFENynTx8eN24cCyG4fv36sklS+QxiJq9MqYBIyS+ndPFQanxKlizJAwYM4MmTJ/Pu3bvZx8eHHz9+rHrv7du32dPT0yRrp7UhGEoGyvQSu3fv5u+//54dHR25ZMmSvG3bNrlM+/btWQihmmLA1Jw9e5YtLS154sSJsU5oHz9+lDOfCyG4Zs2a/M8///D9+/d54cKFLITgypUrG6nkxhMcHMz169eXn0vJkiVj5fAxxMXwxo0bsi9Nt27duHDhwqpO2IqIiAj+559/eNCgQTIRnZIJ1liUE/jbt2/Zzs6OHRwcZPX/b7/9Jj87Gxsbbt26Ne/evVt2QjeVWhWl466NjQ137dqVb968GesivXDhQvmZK3fGpppDLLFOnjypagJzd3fnkSNHqpqEQ0JCDHITFBAQIOfiKlOmDC9fvpx9fHziDJI7duwYZ9BgCry9vblhw4Z8+PDhWOeAffv2yWlalFo3Jbnk7du3OX/+/Ozi4iJzJaX07+Dz58/ympU5c2YeM2YM16lTh11dXVXNoVmyZOHvv/+eq1SpwmPGjOElS5bw+fPnU0XTMIKhZObt7c3nzp2TVcT379+Xmaa1M3eaonXr1nHhwoXlXdbLly/52rVrqgN7+/btXKJECflj8PDwkHME7dmzh5lTdx8Jfbx584Y3bNggh1RnzZqVPT09VZ2Zkzofm7+/P8+YMUPeoQsRndTy1q1bcQZbnz9/5h07dnDLli1NJnOz0nTcq1cvZo7eJ2tra7azs+Np06bJpKQODg4mNyz948ePPGfOHBmEuru78/jx49nHx0d1vH/48IGHDRsmc7DY2trKptPUzNfXl7t168ZTpkzhCRMmyEk3ixYtykuXLmXm6FF069evN8iUC69eveLevXuzq6srW1hYcLNmzXjfvn2qWutjx47J70JJx2BKlBofJT9WeHi4qjP669ev2dPTk8eOHStrVwIDA+XN1ZQpU5jZeOdTjUYjc0kNHz6cmaObj8+ePctbtmzhnj17qgJkZXZ6R0dHo5Q3sRAMGYD2xcfHx4dv3rzJFy5ciPWD/PTpk7xzKVeunEk0VyQkKiqKHz58KP+uUKEClyhRglesWKHK/hoSEsJz5szhChUqcOHChblkyZImPzO0ocUMbEJCQvjx48c8YcIEzpo1q+xMPWvWLINMuaG4efOm7Lir3DnPnz+fnz9/HudJ05Sqqrds2cI2NjZyWhclS7fSD+3MmTNsY2PDOXLkkB1ETaFmSPtzffToEQ8cOJDd3d1ZiOi559atW8efPn1SlfXWrVtyShZTm2XcEK5evSr3T6kRVYI/Q40kioqK4jNnznDdunXZysqKXVxcuFWrVjxgwADu3r07e3h4sBCCV6xYYZDtGZqSk0epHezfvz+PGDGC79+/r+ofpxw3e/bskZ3v69evH+v1lKRc4y5evCj79ymtGspr27ZtkwHxsWPHePXq1ezp6Slvik0dgqEk0j4w//jjDzlVQL58+bhHjx6xmi0mTJjAffv2NemJWJlj/+BevnzJTZs2ZTc3N3ZycuJ27drxrl27VNXivr6+/O7dO/7y5Yu8YKT2/hGJ9fbtW1VzSVBQEF++fJm7d+/Otra2bGNjw2XLlpXzCelL+X5evHjBzZs35/bt23OfPn1k8rMGDRrwjh07OCwsjK9fv26SzbHnzp2ToxGfPn3KlpaWnCVLFpkvZcyYMammM+zJkye5devW8m64Vq1afPbsWY6MjFT9lkz9Big+2vug/D/m9BaRkZG8e/dumQ7B1dVVBraGPA+EhITw6tWruXLlyqppT3Lnzp1qbsJevHghR9xWrlyZ16xZwy9evFB9zvv27ZMpJZSbUlOoZb979y4XLVqUnZ2dZSbpwMBA2VFa6RZgCmVNDARDSaR84UqVf8aMGblq1apcqlQptra25jJlyvAff/yhaiJJrQHCy5cvefXq1Vy3bl22trbmrFmz8qBBg/jMmTNGnyPKWJS+CocOHeK2bdtyuXLluFSpUqqcIBqNhv38/Hj//v1ySgGlD4whaH/269ev50aNGrGNjQ07OTlxp06d5BDdffv2GWybhnb27Fl5B6zRaPjx48ecIUMGdnR0lKMRjVUrpPzG/fz8eMeOHdyvXz+ePn063717V5XoLjIyktetWyc7T2sHoKntwhCTcs76559/uG/fvly+fHn+4YcfeNy4cXHWNh4/fpwvX74sv7PkOOd9/PiRT5w4wcuXL+cdO3boPedZSvDx8eEDBw7wvn37+ODBg8wcPaVRp06dZDLK1q1b8+HDh1XNiqZWi6h8j6tWrWIhBGfKlImvXr0qJ1du0qSJXM4UanETA8FQEihf9tevX2U1+ZkzZ5j5v7molEelSpV43rx5Br0IppSYJ7Lbt2/zlClTZF8hJe/I7du3jVTClKU9PQRz9Ezayvev3ZmwaNGiqiriyMhIfvnyJV++fFn+nVTKaD3tE4+Pjw/PmjWLy5UrJ6csqFatWpK3lZx8fHw4T548bGdnxw0bNpQBnDK02BRuIJREmcojU6ZMPGDAAL506RIHBATI5d6+fWuSNXH6Uo7Tx48fy3QZVlZWsm9g3rx5ZQ0fqIWHh/PUqVNl3zIhBHfu3Fm+/unTJ165ciX/8MMPbGFhwW5ubjxw4EC+cuWKSY8yZo7OdG9raysnjRVC8LNnz5g5dQb/CIYMYNeuXSyE4FatWjFzdB4epR/HvHnzeMCAAWxjY8MODg6qH4Ip0774KD9K7RqIsLAwPn36NA8YMICzZcvG9vb2/P333xs1Q3BKOH/+PJcuXZr37dsn2/lnzJjBQghu3bo1nz9/no8eParKiPvLL78YrK+OcpJ5+fIlr1u3jlu0aME///wzb9y4ke/fv68avXPnzh1eu3Ytb9u2zei5rJTj6fbt27xp0yYeP348X716lT9+/CgDuSNHjsiaM0tLS27Xrp3MqmusYEgpm1Jz5ebmxhMnTuRevXrxd999x0JEZ5aePn06P3z4UJV8lNk0gjhDUXL49O3bl8+cOcMXL17kli1byuO8e/fuqu8T/ssP5ObmxrVq1eLffvuNX79+zczqgOHJkyc8ceJEVb6tsWPHGrR/oaFoT0I+ZMgQ+f0rAyFi/gZSCwRDSaAczIcOHWIhhJxx3tPTk4UQ/NtvvzFz9Fwy1tbW7OHhIZNmmTrlhLZ69Wpu3rw5Fy9enH/77TfetGmTKomin58f79y5kxs3bpzkiUZTA2UkoJWVFXfs2JFv377NixcvZhsbm1gJDVevXi378BhiNJT2RUYZaqw8rK2tuU6dOrxx48Y480IZk/I78fLy4ly5csmRRxYWFtyuXTs+cOCAzOr84MEDvnr1Kv/777+yBs4U7jLnzZvHQgjesGGDfO7ff//lfv36ydqSWrVq8cqVK402R1Ryunr1KgshOH/+/LFe279/P+fJk4ednZ15165dKV84E/Xs2TMWInry0gsXLnBERESsOQFjjiq9d+8e9+/fn11cXNjOzs5kkqTGx9/fnxs0aMBCCO7atauxi5MkCIZ0pH3Axqy+fPz4Ma9evZpDQ0P57du37ObmxnZ2dvzixQtm/u9EqoyaMXUxJ5pVqsMtLS3Z1dVVdp7WHi335MkT9vHxYea0nWAxICCAFy5cyMWLF2choqdeKFeuHDs4OMgRXNoX70OHDrG1tTWXLVs2yaNqlPX+9ddfLET0VC8HDhzghQsXcsuWLTldunTs4uIim5ZMjTLaqFatWty5c2cuX748W1pacvr06Xno0KEGGYJtSMrnffbsWR46dChnzJgx1jLh4eG8Z88ebtOmDVtbW7OVlVWaDIZOnDjBlpaWsvabOXrflfPitGnTZC0oRJswYYJqdGRcNWbKc6dPn+a2bdtyREQEh4aG8qZNm2QKBlO4GYiLUvaXL1/K4f8dOnQwqRGriYFgKBG8vLx44MCB3KBBA27cuDGvWrUq1kSYt27dYnd3dy5XrhwzR4+wypkzJwshVNmIUwNl5vDRo0fzwYMHedmyZVyzZk22sLDgHDly8MCBA+NNkZ8WaTd5eHl58bBhwzhLliyypuPPP/+Uw2aVgPnBgwdsZ2fHmTNnNkh/sZCQENn/4OLFi/L5ly9f8qJFi2QG5z/++CPJuYwMQfnMfH19uUKFCpw/f345CsnLy4snT54sm5vq1KnDb968MWZxY/n69av8foUQPGfOnDjv1j98+MCzZs2SfWdM9QKmL29vb86cOTM7ODiokscqNz5nzpxhIQQ3b97c5Pu6pJTJkyezEII3b97MzLFvorUpaSVSyzD0mE6fPi1rSG/dumXs4ugFwZCO1q5dKzt12tnZyZNjuXLl+K+//uKnT5+yRqPhgIAAzps3r7xzL1asGAsRnWY9NQkPD+emTZuqqsUjIiL43r17skOghYUFFy9enCdOnGg2J8CYoyTOnDnDbdu2lUN869aty0ePHpW1A0oa/e7duzNz0kdEeXt7c4ECBbhAgQJxrkvJ9VGrVq0kbcfQ1q5dy/ny5ZPZr7WDhXPnznHBggVZCNObRuHdu3c8aNAgrlSpEtvZ2XHBggV5/vz5/OzZswQDHmMHoUml3YwTFRXFQUFB/Pvvv7MQQtbk3bt3Ty7fokULFkLw3LlzVe83ZytWrJAdpr9VW75hwwYWQnDDhg1Tbc363r17uW/fvsYuht4QDOnAx8dH5oQYNGgQnzhxgteuXcs///wzu7u7s42NDTdr1ox37tzJGo2GHzx4wE2aNJFZgVu0aGFyTQBxiXkCW7x4Mffs2TPWcoGBgXKKByEEDx48OKWKaDJidozdsmULV69eXTYnVqtWjYsXL84eHh7cqFEjWRuS1BqDwMBAzp49OwsheM2aNbIcygn0y5cv7ObmxoULFzaZocZLly6VNw/Zs2ePM83EokWLWAjB3bp1M8lalZMnT3LPnj3lqMG6devy33//LSfWTGuU72XTpk1yhCwz8+zZs2US0Tx58vBPP/0kO1YXKFBALodgKHq2AScnJ7azs+NZs2Yl2Jfv7du37O7uzjVq1ODg4OBU+flpNJpU23maGcGQTpQREzHndPLz8+MNGzZww4YN2dbWljNkyMAjR46UfWmuXr3K58+fTzU5eJQT4P79+7lr166yyWXu3LlxNg34+vrywYMHZa1QWho5oyvtC/fHjx95xowZXKhQIba0tGRra2tu2bKlbDoz1OezatUqdnFx4WzZsvG8efP4w4cPMhhasmQJCyG4UaNGBtmWIRw4cIDbt28vj6f27dvznj17VH1rlP5EM2fOZGbTuJjG/L6CgoJ4y5Yt3LRpU7a1tWUHBwfu0aMHHz9+3OQ7uiaGckzfunVLJjNUkv6FhYXx5cuXuVevXqoa8ipVqvDp06eZOW33GUys7du3c86cOdnBwYG7d+/OZ8+eVfW1VEZL3r17l4UQXLFiRVWaBkg5CIa+QZmQsFSpUrJjmHbHQeboUQMzZ86UzWjt27dPdSdH5cT/9OlT2UdCyaZrZ2fH7du3jzXhqDZTuHgZi9KUoLh//z7379+fHR0d2dXV1aDb0Wg0/ObNGx4yZIhsmqtUqRL/+eef3KdPH/nd/fvvvwbbriG8ePGCly1bJhN2ZsuWjQcOHMiLFi2SmabLlCkjL8TGOp60v0c/Pz++f/8+v3r1StX5/fXr1zx//nw5VYKzs7NqhGVa0bZtWxZC8MCBA2PV1gUHB/Pz58955cqVfOTIEVUmevhPZGQk79+/nytUqMBCCM6RIwePHTuWb9++rbpJbt26NQsheOzYscxs3udTY0Ew9A1KYkFlSoCoqCh5wox5wB4/flxOx3HhwoUUL6shKBPxdevWjdesWcNLliyRadazZMnCgwYNitVpHKLFrEk4ePCgDEqS4255z5493LBhQ7azs5Mj/rJnz85jxowx+LYM5ebNmzxp0iQuXrw4W1hYyBwsAwYM4AcPHjAzx5rCIqVob3PYsGFyfq18+fJx27ZteenSpaq7+tu3b/Nvv/3Gnp6esd6fWilBz+fPn7l379783XffqY7dtLCPxvDx40eeOHEi586dWyaq7datGw8YMIDr1q0rk7Sacy27sSEYSsCePXtkNXDv3r352rVr8jXtkTraB64ynNJUhzfHRTnZhYaG8vjx4zlPnjyq154+fcoTJkzgbNmyyR+yOXWaTqyknsiU40q5MHl7e/PmzZt58eLFvG/fPjmjNXN0H6LNmzfzggULePz48fzgwQOT+l4uXbrEN27cUHW2DQ0N5ZMnT/KAAQNkR/w2bdrwunXrZEK6lBTz81ayx2fOnJlbtmzJP/74I1taWnLu3Ln57Nmzsd6v/H7S0gXsxx9/5Bw5cqiSxMbcPwRGiff06VPu1auXHGSjPFq2bCn7ZplinzlzgGAoAe/eveNZs2bJocz58+fn8ePHy/xBzP+dIJQL0I4dO1gIwePHjzdKmZOiQYMGnDNnTm7cuDEzq092oaGhfOXKFe7du7cq27a5iHni164hTA7K8eTn58dFixZla2trWYvSoEEDXrJkSbxD9Y15kVJO5BcvXpT9gNzd3blSpUo8ffp09vLyksv6+vry1q1buXXr1uzo6MguLi7cvXt33rt3r6oGJiUon5m/v7/MHn/jxg1m/i/DeNOmTZk5ehh9Wu04zRzdz0W5SFtaWqoSTTKnraDPGKKiovj+/fu8b98+XrRoEZ89e5ZDQkKMXSyzh2DoG6KiovjBgwc8aNAg2UejSpUqvHLlSlWbr3IR+Pnnn1kIwYsWLTJWkfVy4MABeQJMly4db9q0Kc7lPn/+zPv27ZMXg7R+F6MdWISEhPDTp09VKfINeWG4f/8+b9++Xc43xszco0cPFkJwhQoVuG3btty0aVN2cHDgdOnS8U8//cQ7d+40mQ762p9V+fLlZdV/o0aN2MHBgbNkycLNmjXjjRs3qoIdLy8vXrx4MVerVo2trKw4ffr0qqApuSjZw7VnXz948KCqA/qHDx/Y3t6e7e3t+cqVKxwcHMxVqlThli1bJnv5jOXjx4+8bds2btiwIQsh2MXFhX/99Ve+dOmSajkERZCWIBjSkTIXl3K3a2dnx61ateJDhw7Jk8LFixfZ2tqa3d3dU/zO1hAOHDjANWvWlEFRp06d5N0xs3lWiyvB3vr167l69eqcO3du9vDw4OHDh6tqBwxxYShVqhQ7OTnx4MGD+eLFixwQEMD169fnbNmyyW35+Pjw2rVrVckvBw0apBr+bCzKZzB37lxVQBEQEMB58uSRx5WLiwv36NGDDx06pHr/zZs3efDgwdy/f/8UKe93333HGTNmVHU2v3XrFtvb23P58uWZ+b/pV5T8KU+fPmUnJydu0aJFmh41FRERwc+fP+d58+Zx/vz5Zc34uHHjVDXjAGkFgqFECggI4A0bNsg7Xw8PDx44cCDfu3dPBkrz5s0zdjETRTvICQwM5KVLl3KOHDnkdBN//PGHSU4YmNyUi7uPj48cpaX0mxJCsKurK8+dO1dVO6ZvUPTp0yceNWqUzMZcsmRJnjVrFhcrVkzOcaedU0hJfqlMC9KtW7ck7q1hhIaGyrwzp06dYub/+uCUL1+et2/fzkWLFmUnJyd2c3OTw7EVISEhKZKrRJnSpE6dOqrn3759y2XKlGEhBLdp00YOLVfyhE2aNImFEHHm30qLgoKC+Pbt2+zp6SlzrVWtWpUXLFiQ5muFwbwgGNKDRqPhV69e8ZQpU2TQkDlzZhYierbhtOD169c8ZMgQ2VelRIkSqS7IM5TRo0fL2oHnz5/zkydPuEuXLjIoKlGiBB88eDDJ2wkMDOTz58/z77//zu7u7jKPS9myZeOcpkJJfvnrr78afaoX7czcjRo1kgn4Pn36xE5OTuzk5CRHWHbt2pWtrKxk7Qtz7Akrk1NwcDC7uLiwra0tX716lZnVUyXcvHlTjiRTsgJ7eXnxjh072MHBgYUQskN4WgoIvL29ecmSJTxp0qRYmcA/ffrEJ0+e5Hbt2rEQQvYrBEgrEAwlQVRUFN+6dYt/++03TpcuHQsh+MiRI8YuVqI8ffqUV69ezX/++Sdv2rQp1kika9euyXwj5jArvTalJmbJkiXs5uYW6/UTJ06omhVr1aplkP47Hz584N27d3O7du1kP7VOnTrxwYMH46w1MWaT7Nu3b1V9nJiZ16xZw1euXGFm5okTJ8rRmMzRwUPRokW5evXqcuRYSjc3KdNKlCtXTvV5ak+yq8xI7+HhoRr1o50LJi30mVE++127dsmBIsojX758vHPnTrlsVFQU+/r68tq1a2V287QUDIJ5QzBkACEhIbx3795UM4JMOQEeO3ZMNsto13Js3bpVtXxUVBRv375d5hdKy30l4rJ8+XLOnz8/37t3jyMjI2NdBJWM0BUqVDDYNjUaDT9+/JiXL1/OVapUYSEE582bl4cPHy5rM4zpxo0bPGzYMC5WrBhnypSJBw4cGGuCxqioKB4+fLhqQIHSzNSmTRtjFJsfPXqkGinVuHFj3rRpU5zH9OvXr3nPnj3cp08fLlq0KLdr1463bt2aZnLBKDVxYWFhsvm3Q4cOPG3aNK5cubL8nJo3b67q0G6OfQch7UMwZECp4SShXcYCBQqoToDKRVe5WJljPyHm/4K9Q4cOcYsWLbhKlSpsY2PDv/32m2o4u/Zdsb+/v5xeQtdgUbmYrlq1itesWcPh4eHs7+/PBw4ckMuEh4fzrVu3eNy4cXI6i/Lly/O8efP4yZMnSd5XfQQHB8sgOn369PKYyZEjR6ws5cpklY6Ojly7dm0WQrCNjY3RmpkaNGggL/DK/IHOzs7cuXNnPnfuXLzvCw0NVdWapobf+rco+6DMrv7zzz+rXt+4caNs/u/cubOcOgIgLUIwZGaUE+DixYtVuVMUa9askQnB6tatK6cgMRfK5xMcHMyZMmViIQQ7OTnJC37RokV59erVcr4xZk7SFBKvX7+WHdWHDRsm78h37dqlWi4gIIBPnz7NvXr14owZM7IQgnv16qX/jibBgAEDWAjB7dq141evXvHVq1dlX5KKFSuq5hxjZp4/fz7nzJmThRBcrFgxnj9/PjOnfM3Krl27ZAfgwMBA/vTpEy9cuFBOo5M7d27+888/VUFmVFSUDG7TQgAUU3h4OHft2pWFELxnzx5mjp7sV/Hq1SsuWLCgKu8SQFqEYMgMRUVFyQvaunXrmFl9Anz9+jWXLl06VU8rklRKjUbr1q356dOnfPToUW7btq3sUF6/fn0+ceJEku+WX758yaNHj+aqVavKphtLS8t4h8q/e/eOt2/fzlWrVjVIp+3EevjwoRxVp11LFhISwlWrVmUHBwd++vRprPcpNV7v37+XQVBKB0NKoKk0A2s0Go6IiOAHDx7wyJEjOUOGDLIv0eLFi+UIMua03TdGacocN26cfC4yMlJOGNq6dWu2tLTkw4cPG6uIAMkOwZAZ0b74jBs3joUQ/Pvvv8vnwsPDZQfgnj17qi4c5kC54IWFhfHixYvZyspK1VQYGRnJmzZtkoGLnZ0d//TTT6qLpj6ioqL42rVrssbH0tKS69evz8uWLYszp0tkZGS82aeTm9LMNGPGDGaObhJUjivlc5k2bRo/ffqUz58/zx8/fpRNYj4+PsxsvBqWFy9e8Jo1a+Tf2uUIDg7mf/75hzt27MiWlpZsZWXFTZs25b1796bJGiHm//b/+PHjcm47T09P+T0psmbNykIIvn79ujGKCZAiEAyZgbhG/Ny6dUt2mhwyZEisC7oyskSZiymtXhDi0rZtWy5atCjb2trGOWTdz8+PZ8yYwe7u7nIIub6Uz/XNmzf8448/crly5bhTp07s4uLCTk5O/NNPP/Hu3bs5IiKC/f39jTob/e7du1mI/2vvvqOiuva3gT8HHJAqIIgFNIooSqLEGBGvHYOxxd6RKGosuRYSIthbEsu9WEBBJYiColFjwd4SsUSjXrEjzcSCCiIoHQZmv3/4mxO5mPtGRAaY57MWazFzzpmzjwLzzD7fvbckPvjgA/m5nJwcIcTL+ir1XEySJMnBrm7dusLCwkLUqFFDDBkyRFNNL+GveqXS0tLErl27RMeOHeV6Ik9PzypTL/Pq7/GrM0oHBATIUzk0bdpU/Otf/xJ79+6VV1MfNmyYJppLVG4Yhqqw/zXip6ioSKxcuVJ+86pbt67w9/cXO3fuFCNHjpTnV9E2CQkJwtbWVp4qwdPTU8THx7+2KPrGjRvyLaGyGGF379498ezZM5Geni7Wr18vXF1dhUKhEPXq1RPTpk0TnTp1EpIkifDw8Lc+V2moJxp97733RHh4uHjy5Im8rUOHDnIxfpcuXUSvXr1E8+bNxQcffCDq1asnFAqFOHbsmBCi4o/CUqlU4v79+2L16tXC2NhYTJs2TX6+slP3foaGhgpra2v5NrkQQty8eVOu/Xr1q3nz5uLhw4fFjieqahiGqqj/NeLnxIkT8n53794V/fr1K/EH0M7OTty5c0cIoX1/AE+fPi2mT58uj7b7xz/+8c5WVP9fb7DXrl0T3333nWjRooX8/9KgQQO5N6Y8FRUViVOnTglPT0+hq6srFAqF6NWrlzh16pRYu3at/O+kpu5JUfdKanpSyNIoKCiQp1MQouKHuL8rKytLWFpaCkmSxKpVq0rMLXb27FkxYsQI4e7uLlasWCFiYmKEEFXn+oleRxJCCFCVM336dPj7+2PIkCHw8/PDkydP8K9//Qs7duyAs7MzIiMjYWlpCUmSAABRUVHYsGED9PX10bBhQwwcOBDNmzeHSqWCjo6Ohq/m3SoqKoKuri6ePXuGmjVrAgCUSiUOHTqEiIgIHDx4EEqlEv3798e4cePQunVrmJmZlck5s7OzERsbi5MnT8LMzAzNmzdH7dq1YWdnJ7fj8uXLiI6ORlpaGjp16oQOHTq87SWXWnZ2No4cOQJ/f3+cOXMGJiYmyM3NRWFhIW7cuAFHR0cUFhZCCAGFQqGxdlJJQghIkoSEhAR8+OGHGDJkCEJCQv5y//z8fOjr65djC4k0SLNZjN6F0o740Ubqnpn09HTRu3dvERISIt8SEEKIlJQUsX79ermGpE6dOmLcuHGvXR6jNLy8vORZpiXp5SKmAwYMEGFhYRW6TuXJkydi5cqVomnTpkKSJGFoaCj8/PyKTc5XWFhYJW4tVQXq3q2EhAQxb948YWhoKM6ePSuEePl34XX7EmkThqEq6E1G/Pz6668iLS1NriWKi4sTQlSN+og3oZ53ydraWowePVocOHCg2HQDMTExYvHixcLW1lZYWVm91bnUbzbHjh0TkiQJS0tLERwcLA4ePCjPx6P+v1OriLcoioqKxO3bt4W3t7e8iGe7du1ESEhImSxLQm+vqKio2M9O27Zt5ZGQr641qFKpKuTPGFF5YRiqYkoz4qdevXrCwsJCmJmZVagRP+UpISFBBAUFifbt2wsdHR1hZ2cnZs6cKS5cuFDsTeLEiRPi4sWLQoi3L5pWr+6+ceNGIcTLtc7UExNmZGSI5ORksXr16gofLPLz88WpU6fEwIED5TfaIUOGiL1792q6aVrt9u3b8vfqD0Th4eHCyclJ/hvwxRdfiNjYWHm/VxfcJdImDENVjLaM+HkXCgsLxZUrV8T8+fOFvb290NHREc7OzmLVqlVyEWlZefbsmejcubMwMDAQKSkpQgghF0qHhoYKIYSYPHmykCSp2K2niiwjI0Ns2bJFntzQ1dVV003SWhMmTBCSJImvv/5apKWlFduWnp4u/Pz85CJqGxsbsWTJkmI9oQxEpG0YhqoQbRzxU1rqW1V/tQr88ePHxaRJk4SRkZGwsrISgwYNEps2bSpVb9ClS5dKLFEhhBAjRowQkiSJNWvWCH9/fyFJkujZs6e8vW3btsLIyEheAb4yUKlU4uHDh2L+/PnyPDasQSl/c+bMKdYDrF4o91WJiYlyaJIkSTg7O4utW7dqoLVEmscwVAVlZWWVmDhOvYzEqyvP//eQ2qrudZ92J06cKHbu3FliUkohXi5L8uqbxeTJk9/4nBcuXBCWlpbiq6++ElFRUcX+zffs2SOqV68urK2t5Qnvfv75ZyGEED/99JOQJEk0a9asUn5K18aexYrm/v37YsiQIfLPb8uWLV+7hMvp06eFm5ubvN+OHTs00FoizWIYqsI44ud/27Rpk5AkSTRs2FBMnz692Dps6jfzU6dOCWtra+Hn5yev1fQmb/QrVqyQ/+3bt28vlixZUqwHbvPmzeL999+Xa22+/fZbMWvWLPkWxrZt28roaklbFBUVFeuNO3PmjLykhiRJYvDgwcXqhIR42UMaEhIiOnbsWN7NJaoQGIaqOI74eWndunXi/PnzQog/e4iuX78uvvvuO3lyypYtW4qlS5cWe6P48ssvRb169cTly5eLHft3paamyoXS6qHz3bt3Fxs3bpTruU6ePCnGjx8v6tSpI+9Xu3Zt8fXXX5fFpZMWUt/OvX37tpg5c6awsrISbdq0kadx0NHREbNmzSrxN0B967wsZlQnqkwYhrSENo/4OXv2rJAkSfTt27dEjVBGRoY4c+aMmDp1qrCyshIKhUK4uroKb29v4e3tLSRJEk2aNCnVeV8NXeq13mxsbIS5ubkwMTER7u7u4vjx40KpVMrtWL9+vZg9e7a4du2ayMzMfOtrJ+3WtWtXIUmSWLBggcjMzBQZGRni66+/lkO3jY2NCAkJ0XQziTSOYUjLaOOInzt37ogvvvhCLg69evWqWLduXbE6oSdPnoi9e/eKwYMHC0NDQ/nNwtjYWBw5ckQI8XaflkNDQ4WBgYFo0aKF8Pf3F25ubkJXV1fUr19fzJgxQ1y9erVEr5O23r6ksnH69Gl5aZ3/lpiYKK91J0mSaNWq1Wvr5oi0BZfj0EJCCDx69AjBwcHo2bMn2rRpIy8PUVXl5eWhevXqAAAnJydcv34dw4cPh4eHB7p37y7vl5SUhHv37uH48eMwMDBA+/bt0a5duzJpg5eXF1avXo1p06ZhxIgROHz4MLZs2YKEhAS0atUK7u7ucHNzQ/PmzcvkfKTdTp8+jc6dO8POzg5Hjx5Fo0aNoFQqIUkSqlWrhrNnz2Lo0KF48uQJevXqhcjISHnJDiKto9ksRpqkjSN+cnNzxbp16+T5mOrUqSOmT58url69+j+Pe5NeGvW+KpVK/hLi5eg0FxcXYWpqKs/ndOrUKTFx4kRhZWUljI2NhYuLi7h161Ypr47oT9nZ2eLTTz8VOjo6YsyYMfJ8Vq8ODrCxsRFxcXFyryenQSBtxZ4h0jpFRUX4448/sH37dgQFBeHRo0d4//334eHhgVGjRsHa2hoASrVIrfi/T9biLz5hX7lyBV27doW+vj727duHtm3bIikpCefPn8f69etx7949xMXFlcl1knZR9+5mZGQgOTkZ9vb22LNnD3x9fREfHw8LCwssWrQIAwcORGpqKiZOnIhz587h8OHDxXpHibQRwxBprezsbMTExGDDhg0IDw9Hfn4+3Nzc4O7ujqFDh5Zq1fVBgwahdu3aqFmzJszMzODk5ITs7Gy4uLjg+fPnsLOzg5+fH7755hsMGzYM4eHh8u3J2NhYKBQKNGrUqKwvlbTIsGHDYGJiguDgYABAfHw8Fi9ejC1btgAAbGxskJOTg7S0NHzwwQe4du2aJptLVCEwDFGVpu7dUalUSElJgSRJSEtLQ7NmzQC87MlJT0/HhQsXEBAQgKNHjwIAjh07hm7dur3RuSIjI9GvXz8AgEKhgFKphL6+PgoKCmBgYABDQ0PUrFkT77//Pvbt24fCwkJMmDABy5Ytg6mpaZleN2mntLQ0uLm54cqVK/Dx8cGcOXNgZGQEADh58iQCAgJw+/ZtpKSkoEOHDpgzZw6cnZ1RWFiIatWqabj1RJrDMERa4fvvv0d4eDgePnyI+vXro2PHjhg/fjxatWoFACgsLERKSgp2796NEydOYO/evW98jpSUFGzduhWhoaG4efMmAKBmzZpwdHSEo6Mjbt68icTERPlcurq6aNKkCW7dulWWl0pa7siRIxg9ejSePn2K0NBQeHh4FNseHx8PU1NTGBgYMIQT/R+GIaqy1L1CUVFR6NKlC/T09GBpaYmCggKkpqbCwsICEyZMwJQpU1C7dm0AQG5uLoQQMDQ0LNUIO5VKhdjYWISGhuKHH35Abm4uOnfujL59++KLL75AVlYWJEnCpUuXUFBQgPr166N58+alqk8i+iuXLl3CiBEj8PTpU4SHh6NPnz6abhJRhcYwRFXeqFGjsHXrVgQEBKBPnz5QqVQIDAzE6tWroVQq0axZM3h5eWHMmDFlNr1Afn4+Lly4gBUrVmD//v2oVq2aHIg++eQTeb+/KrQm+jv+6uenoKAAYWFh+OKLL2BlZYXw8HC4ublV+Sk0iEqLYYiqJHUNxOPHjxEQEID9+/fjxo0bxfaJjo7Gd999h927dwMAOnXqhEOHDsHAwKDM2pGZmYl9+/YhICAAly5dQq1atTBkyBB4enrCycmpzM5D2kkdbrZt2wZjY2MoFAq0bdsWZmZmAIADBw5g6NChaN26NSIiIlCvXj3NNpiogmIYoiorKysLjRo1QkFBATp06ID9+/cDePkGIkkSdHR0IITA/v378eWXX+Kzzz7D2rVry7y3RvzfJJfh4eEIDAzEw4cP0aJFCwwYMACTJk2ClZVVmZ2LtE9CQgKaNGkiPzY3N4eLiwusrKzQunVrHD9+HJGRkWjbti2CgoLQsmVL3pYl+i8MQ1Rl/fLLL3B1dZUff/PNN5g5c6b8qfnVETRZWVkwMjKCJEnv7I1CpVLh5s2bWLduHcLCwpCTk4PffvsNH3/8cZmfi7THs2fPEBQUhBo1auDUqVOIjY1FVlYW7t+/X2w/U1NTeHp6YsWKFRpqKVHFxTBEVdoff/wBf39/rFq1CgDQqlUrTJs2DaNGjZL3Ke9hxfn5+Th69CiuXLmCBQsWlNt5STs8fvwYOjo6SEhIwOXLl5GdnY2IiAjcvn0bAODp6Qk/Pz/UqFFDwy0lqjgYhkgrnD9/HosXL8aRI0cAAL1798aMGTPQvn17jbWJxdNUFlJSUmBubv7/nSQ0LCwMS5cuxZ07dxAcHIyxY8eWUwuJKj6GIaoy/jtc5OTkwNDQUH5cWFiIXbt2YfHixYiJiYGBgQGGDRuGwMBA6Ovra6LJRH+b+udb3ZN5/PhxhIWFITExEQUFBZg4cSI8PT3lW7zq/V7t+Xz8+DGaNm0KR0dHREZGsl6N6P8wDFGV8GoQOnnyJHbv3o3ExEQ0btwYU6dOLVZgmpaWhuDgYMycORM9evTAwYMHNdVsojeiDjYvXryAvb09UlNTUb16deTl5QEAmjVrhu+//x59+/YF8PL3Qk2SJNy/fx+NGzdGrVq1EB0dzTBE9H84nICqBJVKBQDYsGED+vXrh6CgIBw7dgyBgYFo0aIFfHx8kJ6eDgCwsLCAj48PYmNjERERAeDlCDOiiujs2bPo2rUrrl27JvfwrFq1CqmpqRgwYACOHTuGY8eOoWvXroiJiUH//v3Rp08fXL9+HZIkyV/Ay3Dk5uaGCRMmMAgRvYI9Q1TpqUd/paenw9bWFjk5OViyZAnatm2Lffv2YevWrXj69CkaN26MDRs2oHPnzppuMtHfNmjQIOzevRuSJGHq1KlYsGABdu3aBS8vLzx69AjGxsbyvps2bcKSJUsQHx8P4GWxdGBgIPT09Iq9JofWExXHMERVxsKFC7Fw4UJMnjwZa9askZ+/fPkyFi5ciIMHD+LDDz/EgQMHUKdOHQ22lOjvS09Px6pVq7By5UpkZWWhVq1aaNasGR49eoT//Oc/0NfXhxBCDjwZGRlYuXIlFi5ciAYNGuD333+XX0s9SSOL94mK40cDqhKEEMjOzgYAefHVjIwMAEDr1q0RGRkJV1dXREdHIyYmRmPtJHoTQgiYm5tj4cKFuHjxIkaMGIGUlBRERUUhOTkZO3bsgEKhgJ6eHgoLC6FUKmFqaor58+fjxo0bOHnyJICXtUYA5KU4GISIimMYoipBkiRYW1sDgPwGYGpqCiEEMjMzIUkSbG1tAQBPnjzRWDuJ/q6NGzdi//79KCgogBACDg4O2LJlC/bv3w9nZ2dkZGRg3LhxGDp0KOLi4lCtWjUoFAoolUqoVCo4OjqiUaNGAFCu82gRVUa8TUaV1n8PNb579y569eqF2NhYdOjQAUuWLEG7du0AAM+fP0fDhg3x4sUL3L59Gw4ODrxVQBVWcnIy6tSpA0tLS1y9ehV169YtMTloYGAgli9fjvv370NHRwe+vr7w8fGBiYmJBltOVDkxDFGl9GqQiYiIQO/evWFqaopffvkF//znP+VbYYMGDULDhg3xyy+/4PLly5g0aRLWrl3LAlKq0LKzs+Hn5wcLCwv885//RHJyMkJCQjBq1CjUrVtXvt319OlTLFu2DGvWrEFBQQEaNGiAb775BpMnT9bwFRBVMoKoEiosLBRCCLF8+XIhSZJYtGhRse3Lly8XRkZGQpIk+atHjx7ixYsXQgghioqKyr3NRG+qoKBACCGEp6enkCRJfPTRRyI8PFykp6cLlUol73flyhUxePBgIUmSMDAw0FRziSot9gxRpZWamoqGDRsiOzsbISEhcHd3h46OjvypOT09HWFhYdDX10eDBg3g4uICMzMz9gpRpfDqz+mpU6ewZs0a7NmzB0II9OrVC97e3nB2dkb16tXlY7Zv3w5ra2t06dKl3NfcI6rMGIao0nr+/DmcnJwwaNAg/Pvf/5afF0JApVLJoYiosnj+/Dl+/vln7Nu3Dzdv3oSrqys++eQTdOnSBTo6OtixYwdWr16N3377DXp6ehg/fjy+/PJLNG7cmMGH6C0wDFGlop4n5fTp01i9ejWioqKwadMm9O7dG7m5uTAwMJD3FSyQpkokPz8fY8aMQWRkJHJycuTnTU1N0bdvX4wfPx7t27dHeno6NmzYgHXr1uHevXuwsbHB1KlTMXLkSM6fRVRKDENUKTk5OeH69etQKBTw9PREUFCQvE0dmIgqk1mzZmHp0qVo2bIlxo0bhw8//BDHjh3D0aNHcfHiRdSrVw+jRo2Cp6cn7OzscP36daxZswa7d+9GWloalixZAh8fH01fBlGlxDBElYIQAkIIuYbijz/+gK+vL3bs2AEA+OCDD7B06VL06NEDwJ9rlbE2iCqD2NhYNGvWDGZmZrh06RLs7OzkbVevXsXOnTuxY8cOJCYmwtnZGQsWLED37t0BAAcOHEBoaCg2bdoEExMT9ogSlQLDEFVY6gLSzMxMee4U9Sy76tth586dw/Tp0/Gf//wHADBgwAB8++23cHBwAMBbZVQ59OjRA0ePHsXy5cvh7e2NoqIiSJIkh3mlUomoqChs3boVmzdvhomJCUJCQjBo0CAAf/aGsleUqHT4sZkqLB0dHbx48QLOzs5YunQpAGDr1q0ICwtDSkoKhBD4xz/+gUuXLiE4OBjm5ubYvXs3WrRoAW9vb2RnZzMIUYW3b98+HD16FI6OjvD29gbw8oPAqyvNKxQKdOvWDcuWLYO3tzcyMzMRGhpaYrAAgxBR6bBniCq0sLAwjB49GgDw4YcfIjo6GjY2NkhISICenh7y8vLkocX5+fmYO3euPLJs06ZN8PDw0FTTif4WZ2dnXLp0CQ0aNMDixYvx6aefwtLSEsCfvaPqP9OSJCE7OxtOTk5ITEzEgwcPUK9ePU02n6hKYM8QVWgeHh44duwY3NzcEB0dDT09PRgYGODhw4cAgOrVq6OwsBD5+fnQ19fH8uXLERMTg8mTJzMIUYWnUqmwfPlyjBkzBg8ePICnpyfGjBmDffv2Afiz5k19u7egoABGRkawtraGra2tvDgxEb0d9gxRpfDLL7/A1dVVfmxmZoaxY8fCy8sLdevWBQDk5eVBkiTo6+vL+7GGgiqD7OxsHDlyBP7+/jhz5gzMzc0xaNAgjB07Fm3atAHwsm5IoVAgLi4ODg4OsLOzw/nz5+VeJCIqPYYhqhRSU1MxZ84cNG7cGEVFRViwYAHy8/PRtGlTTJkyBZMnT8aePXuQkZGB3r17o2bNmppuMtEbS05OxrZt27BmzRrcvXsXjRs3xqhRo+Dh4YEGDRoAAMaPH4+QkBDMmzcPCxYs4IzqRGWAYYgqpatXr2Lp0qXy0HpHR0fcunULenp6ePToESwsLDTcQqLSUalUiIuLw4YNGxASEoLMzEy4uLhg+vTpMDIyQt++fWFqaorHjx9DT0+PYYioDDAMUYX06pB49RpLOTk5MDQ0LLbPoUOH8P333+P8+fOwsLDA5MmTsWjRIr5BUKVXUFCA8+fPIyAgALt374a+vj709fWRkZGB4OBgjB07luuPEZURhiGqkNRhJjIyEjt37sS9e/fg4OCATp06oXfv3qhRo0ax/aOiomBiYoJWrVoVO56ossvMzERkZCTWrVuHc+fOoWnTpoiJidF0s4iqFIYhqnDURc8xMTFo0aIFioqKALwcWaOnp4dPPvkEY8eOxWeffabhlhKVDyEEkpKSEBoaik8//RQff/wxe4WIyhDDEFVYI0eOxLZt2zBx4kR06dIFOTk5+OGHH3Du3DlYWFhg8ODBGDduHD766CNNN5WoXLDHk+jdYBiiCkXdK5SZmQkfHx+cOHECcXFx8rakpCTs2rULa9euxe+//w57e3sMGTIE8+bNg0Kh0HDriYioMuJHDKpQ1HMCTZo0CQcPHpTnWFFvq1+/PqZMmYI9e/bAy8sL8fHxSExMZBAiIqJSY88QVTg//fQTBg8eDADQ19fHli1bMHDgwBL7ZWVl4eLFi/joo49Qo0YNTrBIRESlwjBEFU5qaioOHTqE0NBQREVFoWbNmhg5ciQ8PT3RokULTTePiIiqGIYhqpAKCgpw//597Ny5E4GBgUhKSoKjoyM8PDzg4eEBa2trTTeRiIiqCIYhqtCys7Nx584dBAcHIywsDHl5eejWrRuGDRuGMWPGyBMzEhERlRbDEFUYT548wZEjR/Ds2TPY2dmhX79+8ra0tDT89ttvCAoKwoEDB9C9e3ccPnxYc40lIqIqg2GINEo9cdzRo0fh4+OD69evy9u6d++O2bNno3379vK+ycnJiIyMhKurK5o0acKiaSIiemsMQ6Qx6vXHVCoVmjdvjri4OAwePBidOnXC999/j0ePHqF69erw9PSEr68vbGxsAIAz7xIRUZliGCKNUYeh1atXw8vLCwMGDMCuXbsAAHZ2dvj999+hUCigVCphY2ODCRMmwMfHh0GIiIjKFCddJI2RJAlFRUW4desWAGDcuHEAgHnz5uH333+Hh4cHMjMzMXz4cDx69Ahz587Fzp07NdlkIiKqgvgRmzRKV1cXOjo6cHR0RKdOnfDs2TP8+9//homJCSZMmAA9PT04ODjAyMgIXbt2xfDhwzXdZCIiqmIYhkjjZs6cCYVCAQMDA6xbtw55eXkYPXo0XFxckJWVhZ07d8LR0RGhoaEAwKJpIiIqU7xNRhrXoEED1K1bFwBQo0YNSJIkh53Fixfj5s2bsLKygpmZGQAwCBERUZliATWVK3XRtJpSqSy2yOrZs2fRv39/PHv2DJaWlkhNTYW5uTkuXbqERo0asVeIiIjKHMMQlRuVSgUdHR0olUoEBwfj8OHDsLCwQMOGDfH555+jYcOGAIDffvsNc+fOxZ07d+Ds7IyhQ4di0KBB8vFERERliWGIyo06zMycORPLli0DAHnofP369TFhwgR8+eWXMDU1BQDEx8fD3t5ePv6/e5WIiIjKAsMQlaukpCQ0aNAAKpUKS5cuha2tLX7++WeEhIQAeDnrtI+PDzp37iwfwxBERETvEkeTUbkyMjKCjY0N3N3dMWPGDADA8OHD4e7ujgULFuDo0aMwNzdH+/bt5ckVGYSIiOhdYgEGvXNFRUUAgMjISPTs2RPp6elo27YtACA3NxcqlQqdOnXCunXrYGdnh+3bt+PUqVMabDEREWkThiF659Sjv+bPn48LFy4gMzMTERERUCqVMDAwgI6ODvLz89G0aVM0a9YMAPDgwQNNNpmIiLQIwxCVmzNnzmDq1KkAgO3bt6NRo0YIDw8HAOjr6+PmzZs4cOAAdHV10b17dwAv64WIiIjeJRZQU7l4dT6hO3fu4KuvvsKRI0cAAC1btkSfPn2wc+dOCCEwbtw4eHt7c04hIiIqFwxDpDH79++Ht7c34uPjAQC2trbYsWMHnJ2dAQAFBQXQ09PTZBOJiEgLMAzRO6Hu1cnLy0NCQgLi4uKQlZWFbt26wcTEBCYmJvK+fn5+mDVrFpRKJYyMjDB79mx4e3vLo8mIiIjeJYYheqe8vLywceNGZGZmAgCMjY0xevRojBgxAq1atZJ7ftLS0uDj4yPPN9SsWTPMnDkT7u7unGeIiIjeKYYhKnPqXqG9e/diwIABqFevHubOnQulUolZs2YhMzMTq1evxpQpU0ocGx0djW+++QY///wzateujUePHmngCoiISJswDNE707FjR5w9exbbt2/HkCFDcPLkSXzyySdo3bo1Tp8+DUmSsGXLFowcORK6urrQ1dWV1x7bsmUL7Ozs4OLiouGrICKiqo5hiN6J5ORk9OzZEw8ePMDjx4+hq6sLe3t7JCYmIiIiAsOGDUO/fv1w9uxZJCYmokaNGgDAEWRERFTuWKFK74S1tTWEEEhNTcXx48cRExODxMRE9O/fH8OGDQMAxMXFQVdXF0lJSXIYYhAiIqLyxp4hemtKpRJKpRKGhobFnt+2bRsmT54MS0tL3L9/H0qlEufOnYOLiwt+/PFHDB8+HK1bt8bFixc11HIiIiLOQE1vKS4uDlOmTMHJkydLbHNzc8P48eORlpYGlUoFa2trJCUlYf78+Zg4cSIAYO7cuQD+XL+MiIiovLFniErt8OHD8PX1xY0bN9CjRw/s27evxNxARUVFCA0NxebNm3H+/HkIISCEQK1atTBy5Ej4+flpqPVEREQvMQxRqeTm5qJ58+a4d+8eFi1ahIEDB6JZs2YoLCx87WSJjx8/xoEDB5CSkoLk5GR8/vnncHBwgJGREYumiYhIoxiGqFR8fX2xfPlyjB49Ghs3biyx/fjx40hMTMSTJ0/g4eGBRo0aldiHkykSEVFFwDBEb+zx48do1aoVkpOTcffuXbz33nvIz8+Hvr4+UlJSEBYWBh8fH3nFeSMjIyxatAjTpk2DEIK9QEREVKGwgJre2N27d5Gbm4sePXrgvffeQ2FhIfT19QEA3333HWbOnIn69etjypQpmDhxIrKzs7FixQrcuXOHQYiIiCoczjNEb6xmzZrIy8tDfHw84uPjYW9vDwBYu3YtAgICULduXRw+fBgODg4AAB0dHQQGBmLz5s1YtmyZJptORERUAnuG6I0IIWBhYQEnJyckJCRg1apVCA8Px9dffw1fX1+Ym5sjJCQEDg4OyM/PBwC4uLhAkiS594h3ZomIqCJhzxC9EUmSUKtWLaxcuRJfffUVNmzYgKCgIABA06ZN4eXlhe7duwOAPKrs8uXLEEKgevXq8msQERFVFCygplIpKirCr7/+iqioKFy5cgW6urqYN28emjdvDl1dXRQUFEBPTw9xcXFo06YNsrOzcffuXdja2kKlUskLshIREWkae4aoVHR1ddGhQwe0bdsWCoVCnl9IPZO0np4eAMDb2xsZGRnw9fVlECIiogqJPUNUptRhJzIyEjt27EBERATatm2LqKgoKBQKhiEiIqpw2DNEZUpHRwc5OTlYvnw5fv31VwwYMAAzZsyAQqHgTNNERFQhsWeIypxSqURAQABSUlIwe/ZsmJiYaLpJREREf4lhiN4Z9XIbXHaDiIgqMoYhIiIi0mqsZCUiIiKtxjBEREREWo1hiIiIiLQawxARERFpNYYhIiIi0moMQ0RERKTVGIaIiIhIqzEMEVGF1blzZ0iSVOLL2NgYTZo0wZgxY3DhwgVNN5OIKjmGISKqdLKzsxEfH49NmzbBxcUF06ZNA+ePJaLS4kKtRFQpBAcHy9/n5OTgxo0b+PHHH5GZmQl/f39YWlpi7ty5GmwhEVVWXI6DiCqszp07IyoqCq6urjhx4kSJ7Q8fPoSrqyvi4uJgYGCAe/fuwcrKSgMtJaLKjLfJiKjSsrGxwfr16wEAubm5OHz4sIZbRESVEcMQEVVqHTt2hJGREQDg1q1b8vMLFiyAJEmoVq0aVCoVlixZgoYNG8LY2BhOTk7w9/eHSqUC8Gehdrdu3Uq8/sOHD+XC7U2bNpXYfvv2bfTr1w/m5uYwMTGBm5sbLl++XOz8RFSx8beUiCo1HR0d1KxZE9nZ2UhPT3/tPp6enti8ebP8+Nq1azh//jymTp36VudOSEhAu3bt8OLFC/m548eP48yZM2jfvv1bvTYRlR+GISKq9CRJAgC5p+dVRUVFiIiIwMSJE+Hg4ICbN2/i+PHjCAwMfOvzzpkzRw5CTk5OGDp0KKpVq4Zt27a9tsaJiComhiEiqvKCg4Px+eefy49zcnJgaGj4Vq+pUqlw6NAhAEDLli1x6dIl+ZbY1KlTYWZmhtzc3Lc6BxGVD9YMEVGVN3DgwGKP3zYIAcDTp0+RmZkJABg5cmSx2iA9PT2MGzfurc9BROWDYYiIqjRdXV0YGxuX+evm5eXJ39epU6fEdgsLizI/JxG9GwxDRFTpqadL09XVLfdzElHlxzBERJWaSqVCWloaAMDa2rpUr6EuwH7XxxBRxcQwRESV2unTp5GVlQUAsLe3L9VrqGuInj17VmJbRkbGa4+pXr26/P2TJ09KbH91uD0RVWwMQ0RUaT169AiTJk0C8DLQ9O3bt1SvY2dnB+DlBIp//PFHsW379+9/7TFWVlYwMTEBAERERKCwsFDeVlhYiJ9++qlUbSGi8seh9URU4Z08eRI//PCD/Dg3Nxc3b97E9u3b5Z6befPmwdTUtFSv/9lnnyEgIAAFBQXo3r075s2bB1tbW1y8eBG+vr6vPUZHRwc9e/bEjz/+iOjoaLRp0waDBw+Gvr4+tm/fjgcPHpSqLURU/hiGiKhSGD9+/GuflyQJXl5emDFjRqlfu1u3bvjss88QGRmJuLg4uLu7y9t69Ojxl2ueffvttzh69CieP3+O6OhoREdHAwBMTEwwYsQIRERElLpNRFR+eJuMiCodU1NTODg4YMKECTh//jz8/PzeuqB5x44dmD17Nt577z3o6emhQYMGmD9/PoKCgv7ymMaNG+PXX39F//79YW5uDiMjI3Ts2BEnT55Eo0aNAIBrkxFVApLg+FAiojLn7u6OrVu3om7dukhKStJ0c4jof2DPEBHRW9i8eTNiY2OLPZeQkIA9e/YAANq0aaOJZhHRG2D/LRFRKS1btgy+vr4wNjaGp6cn7O3tkZiYiI0bNyInJwcA5NFuRFRxMQwREZVSu3btYGhoiKysLPj7+5fY7uPjAzc3Nw20jIjeBGuGiIjeQmxsLJYsWYITJ04gJSUFpqam+PjjjzF58mT06dNH080jor+BYYiIiIi0GguoiYiISKsxDBEREZFWYxgiIiIircYwRERERFqNYYiIiIi0GsMQERERaTWGISIiItJqDENERESk1f4f7r6CU5sk1pwAAAAASUVORK5CYII="
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_LAMA84_10 = df_LAMA84.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='drug', y='prediction', data=df_LAMA84_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线，虚线\n",
    "plt.axhline(0, color='black', linewidth=1.5, linestyle='--')\n",
    "# title\n",
    "plt.title('LAMA84', fontsize=25)\n",
    "plt.xticks(rotation=60, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Drug', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# plt.gca().spines['bottom'].set_visible(False)\n",
    "# 去除下方的刻度\n",
    "# plt.gca().xaxis.set_ticks_position('none')\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(1.5)\n",
    "plt.gca().spines['left'].set_linewidth(1.5)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-21T12:57:51.865486Z",
     "start_time": "2024-03-21T12:57:51.739160Z"
    }
   },
   "id": "408b646632c16951",
   "execution_count": 136
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_SW948_10 = df_SW948.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='drug', y='prediction', data=df_SW948_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线，虚线\n",
    "plt.axhline(0, color='black', linewidth=1.5, linestyle='--')\n",
    "# title\n",
    "plt.title('SW948', fontsize=25)\n",
    "plt.xticks(rotation=60, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Drug', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# plt.gca().spines['bottom'].set_visible(False)\n",
    "# 去除下方的刻度\n",
    "# plt.gca().xaxis.set_ticks_position('none')\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(1.5)\n",
    "plt.gca().spines['left'].set_linewidth(1.5)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-21T12:56:47.463572Z",
     "start_time": "2024-03-21T12:56:47.344801Z"
    }
   },
   "id": "b90151d3c6d469bf",
   "execution_count": 133
  },
  {
   "cell_type": "code",
   "outputs": [
    {
     "data": {
      "text/plain": "<Figure size 640x480 with 1 Axes>",
      "image/png": "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"
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# 设置全局字体\n",
    "plt.rcParams['font.sans-serif'] = ['Bahnschrift']\n",
    "plt.rcParams['axes.unicode_minus'] = False\n",
    "# 取df_Docetaxel的前10行\n",
    "df_WSUDLCL2_10 = df_WSUDLCL2.head(10)\n",
    "# df_mix_set_drugs_mean画柱状图，每个cell_line的result列的值，按照variable分成两个柱子，使用seaborn画图\n",
    "# 设置画布大小\n",
    "# plt.figure(figsize=(6, 6))\n",
    "# 画柱状图\n",
    "plt.gca().invert_yaxis() # 反转Y轴\n",
    "sns.barplot(x='drug', y='prediction', data=df_WSUDLCL2_10,edgecolor='black',width=0.5,color='#7482F7',linewidth=1.5)\n",
    "# 设计legend样式\n",
    "# plt.legend(fontsize=15,edgecolor='black',loc='best')\n",
    "# 加入Y=0的线，虚线\n",
    "plt.axhline(0, color='black', linewidth=1.5, linestyle='--')\n",
    "# title\n",
    "plt.title('WSUDLCL2', fontsize=25)\n",
    "plt.xticks(rotation=70, fontsize=14)\n",
    "plt.yticks(fontsize=15)\n",
    "plt.xlabel('Drug', fontsize=18)\n",
    "plt.ylabel('Predicted LN IC50', fontsize=18)\n",
    "# 去除上和右边框\n",
    "plt.gca().spines['top'].set_visible(False)\n",
    "plt.gca().spines['right'].set_visible(False)\n",
    "# plt.gca().spines['bottom'].set_visible(False)\n",
    "# 去除下方的刻度\n",
    "# plt.gca().xaxis.set_ticks_position('none')\n",
    "# 加粗横纵坐标\n",
    "plt.gca().spines['bottom'].set_linewidth(1.5)\n",
    "plt.gca().spines['left'].set_linewidth(1.5)\n",
    "# 刻度加粗\n",
    "plt.gca().tick_params(width=2, length=6)\n",
    "# 保存图片\n",
    "# plt.savefig('img/EGFR_Drugs_IC50&Prediction_On_LUAD_MixedSet.png', dpi=300, bbox_inches='tight')\n",
    "plt.show()"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2024-03-22T06:24:45.981107Z",
     "start_time": "2024-03-22T06:24:45.792324Z"
    }
   },
   "id": "a504a2e47593ec5",
   "execution_count": 66
  },
  {
   "cell_type": "code",
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   },
   "id": "8a0b9108d3b8bf1c"
  },
  {
   "cell_type": "markdown",
   "source": [],
   "metadata": {
    "collapsed": false
   },
   "id": "610af5e3ea59331"
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
